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Antibodies specific for donor HLA molecules are seen as a contraindication to renal 
transplantation.  The presence of these antibodies suggests a patient has previously been 
exposed to non-self HLA, with resulting immune response and memory generation.  Immune 
memory allows for a rapid response upon re-exposure, manifesting as rapid acute rejection.  
Antibody removal pre-transplant facilitates transplantation across HLA antibody 
incompatibilities, however there is no rationale as to which patients will benefit from this 
treatment.  I have developed a testing procedure to identify which patients are suitable for 
antibody removal and the amount required to allow transplantation from a specified donor. 
I hypothesised that patients producing HLA specific antibody to previous mismatches will have 
both cellular and humoral memory to those antigens, and therefore be at greater risk of 
rejection and graft failure, compared to patients with HLA specific antibody but no memory of 
the mismatches with which they are presented.  By observing outcomes I have investigated 
the effect that a repeat HLA mismatch with antibody, and therefore presumed memory, has on 
outcome, with patients in this category having reduced graft survival at 5 years and a shorter 
time to rejection. 
Whilst HLA specific antibody is relatively simple to define in the laboratory, donor specific 
memory T cells are not.  I have also developed a novel assay to identify donor specific memory 
T cells pre-transplant, through their production of IL-17 on stimulation.  This predicted T cell 
mediated rejection with 100% accuracy in the patient group tested.  However the presence of 
memory T cells did not correlate with repeat mismatches or the presence of HLA specific 
antibody. 
The conclusions are that repeat mismatches influence humoral memory but are not obviously 
indicative of T cell memory, which cannot in this assay system be predicted based on the 
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1.1 Renal Transplantation 
End stage renal disease (ESRD) is the failure of the kidneys to effectively filter waste from the 
blood and produce biochemically appropriate urine.  It is defined by the Kidney Disease Quality 
and Outcomes Initiative guidelines as a reduction in the estimated glomerular filtration rate 
(GFR) to ≤ 15ml per minute per 1.73m
2
.  ESRD develops due to damage to the kidneys caused 
by various conditions and diseases which may be acquired or congenital, including diabetes 
mellitus, chronic hypertension, renal tumours, polycystic kidney disease, various autoimmune 
diseases and infections.  If untreated renal failure will ultimately prove fatal.  Treatment in the 
form of dialysis can be effective in the medium to long term. However, it is time consuming for 
the patients, expensive for the health care system and does not provide a cure.  Additionally 
there is a significant level of morbidity and mortality associated with long term dialysis, with 
the average life expectancy in the UK on dialysis being 4 – 20 years depending on the age at 
which dialysis commenced and the underlying disease causing renal failure [1]. 
Transplantation of a functioning kidney from either a living or deceased donor is currently the 
only “cure” for ESRD, allowing the patient a relatively normal quality of life.  Over the past 
century renal transplantation has become a common, accepted and viable treatment option, 
with the half-life of a kidney transplanted from a living donor being up to 15.3 years, and 11.9 
years when the organ is from a deceased donor [2]. 
1.2 History of Renal Transplantation 
In the modern era initial interest in kidney transplantation began at the beginning of the 20
th
 
century driven by advances in surgical skills, particularly in vascular surgical techniques [3].  
The first successful experimental organ transplant was reported in 1902 by Ullmann, in which 
he performed an autograft in a dog, moving the kidney from its native position to the neck.  
The organ remained somewhat functional with demonstrated urine output.  Ullmann followed 
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this up by performing dog to goat and then pig to man, all showed short term function but 
ultimate failure [3].  In 1907 Jaboulay attempted xenotransplantation into two patients 
suffering renal failure, one from a goat and another from a pig, both failed by day 3 [3]. 
Continued developments in surgical technique, particularly suturing, allowed further work on 
organ transplants, with a number of auto- and then allo-grafts being reported by Jaboulay and 
then Carrel [4].  Whilst no allografts functioned for long the physical ability to perform the 
transplants had been demonstrated.  Interest in organ transplantation then waned as further 
attempts in both animals and then humans all resulted in failure.  A lack of knowledge and 
understanding of the process of rejection made success unlikely. 
The first human kidney allograft was carried out in the Ukraine by Voronoy in 1936 [4]. This 
was blood group incompatible (B into O) and the kidney never functioned, leading to the death 
of the patient 2 days later.  Voronoy continued to perform human kidney allografts, carrying 
out a total of 6 between 1936 and 1949, without success.   
By the early 1950s interest in renal transplantation had been revived and it had become 
apparent to investigators that immunological mechanisms were involved.  Simonsen in 
Denmark and Dempster in London both studied graft rejection and suggested that humoral 
and cellular mechanisms were likely [5-8].  In 1954 Joseph Murray and J. Hartwell Harrison 
performed the 1
st
 successful kidney transplant in humans between identical twins [4].  The 
kidney functioned well despite a lack of immunosuppression.  Current knowledge tells us this is 
due to the donor and recipient being genetically identical [9].  Further attempts between 
genetically disparate individuals however resulted in failure due to rejection [9]. 
In the 1950s the knowledge that rejection was an immune mediated mechanism led to various 
efforts at immunosuppression with varied success, initially total body irradiation and bone 
marrow transplantation, which had high rates of associated mortality [10, 11].  In the late 
1950s the immunosuppressive effect of 6-mercaptopurine was discovered and its ability to 
prolong the survival of renal transplants in dogs reported [12].  This was closely followed in 
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1960 by the development of the immunosuppressive agent azathioprine, and the use of this, 
together with prednisolone, became a standard regimen following reports of success from 
Starzl et. al. [13].   
In parallel with the improvements in surgical technique and drug treatment the understanding 
of the immune system involvement had been growing with the identification of first the 
mouse, and then the human, major histocompatibility complex (MHC), in humans the Human 
Leucocyte Antigen (HLA) system.  The MHC was first identified in mice following a series of 
experiments by George Snell in the 1930s using inbreeding to achieve pure strains in which 
each individual mouse is genetically identical except at one locus.  Using transplantation of 
tumours between strains the genetic system involved in the acceptance or rejection of a 
tumour graft was identified [14].  Initially called the H locus, this became the H-2 locus 
following the identification of Antigen II, by Peter Gorer.  Initially believed to be involved in the 
blood group antigen system, Antigen II was finally found to be part of the H system identified 
by Snell. The H-2 system is now known to be the mouse MHC, found on chromosome 17. 
Identification of the human MHC followed, aided both by the knowledge gained from the early 
attempts at kidney allograft transplants plus that from skin grafting of burn victims during the 
second world war.  Peter Medawar led the Medical Research Council war wounds committee 
investigation into the use of skin transplantation and concluded that rejection is a systemic 
process, at the time believed to be ‘governed by at least 7 antigens that are freely combined’ 
[14].  He also found that transplant immunity could be adoptively transferred from one 
sensitised patient to another by lymphocytes but not serum. 
The 1
st
 human leucocyte antigen, “mac”, was described by Dausset in 1958.  Identification of 
further antigens followed and in 1965 the first international Histocompatibility and 
Immunogenetics workshop was held, where a standardised nomenclature for these antigens 
was described.  The first full report was published in 1968 for the 1
st
 8 antigens identified.  At 
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this time it was thought that there was only 1 locus for HLA (HL-A), however by 1975 it was 
realised that HL-A was the product of multiple loci and these became HLA-A and HLA-B. 
Techniques in identifying an individual’s HLA antigens, known as tissue typing, became routine 
from 1962 allowing some form of matching between donor and recipient.  Additionally 
crossmatching between donor cells and recipient serum to identify those pairs in which 
hyperacute rejection may occur was introduced routinely from 1966 [15, 16]. 
From this point on kidney transplantation for patients in end stage renal failure became a 
more viable option.  Refinements in HLA typing and crossmatching, plus in organ retrieval, 
continued and in 1976 the immunosuppressive drug cyclosporine was introduced, 
accompanied by a great improvement in graft survival rates [9]. 
In more recent years our knowledge of the immune system involvement has grown 
exponentially.  Typing to a high resolution at multiple HLA loci to allow a greater level of 
matching has become routine, along with the use of highly sensitive methods for detection 
and identification of HLA specific antibodies. 
1.3 The Immune System 
The primary role of the immune system as a whole is to protect an individual from infection.  
Immunity and immune responses can generally be divided into two groups, the innate 
response and the acquired or adaptive response.  Innate immunity is the first line of defence.  
It is comprised of physical barriers such as the skin and mucosal surfaces along with some 
immune cells such as macrophages, neutrophils and NK cells [17].  Innate immunity provides 
rapid, non-specific protection against bacteria, fungi and parasites, relying on a combination of 
secreted anti-microbial proteins and invariant receptors to recognise invading 
microorganisums [18]. 
The acquired immune response is far more specific than the innate, and its activation results in 
the generation of memory to a particular pathogen, allowing for a rapid and specific response 
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upon re-exposure [19].  The central effector cells to the adaptive immune response are the T 
and B cells. 
T cells recognise foreign antigen in the form of peptides derived from pathogens presented in 
the context of a self MHC molecule [20], whereas B cells recognise small antigenic areas on 
larger intact molecules via an immunoglobulin cell surface receptor [21]. 
 Whilst they are seen as separate systems there is in fact much cross talk between the innate 
and adaptive arms, for example the production of cytokines is required for T and B cell 
activation but can also be used to recruit cells such as the macrophages to sites of infection 
[22]. 
In order to avoid the development of auto immune disease, an important aspect of a 
functional immune system is to be able to discriminate between self and non-self [19].  In 
organ transplantation however the transplanted tissues are seen as non-self due to differences 
in the cell surface molecules, principally the MHC but also the ABO blood group antigens,  
minor histocompatibility antigens and the endothelial cell antigens, all of which have been 
reported to elicit an immune response directed at the transplanted tissue [17]. 
1.4 Structure and Function of the MHC 
The major histocompatibility complex (MHC) is a highly polymorphic group of over 200 genes, 
which in humans is located on the short arm of chromosome 6.  Many of the functions 
attributed to the genes in this complex are associated with the immune system and an 
individuals’ ability to combat disease.  The MHC is divided into three regions, or classes, Class I, 
Class II and Class III, represented in figure 1 below, the gene products of which differ in their 






Figure 1 - Representation of the Genetic Structure of the Human MHC region on 
Chromosome 6 [18]. 
 
In humans the MHC class I and II genes encode the cell surface expressed glycoproteins, HLA.  
HLA molecules are central to the adaptive immune system as they enable the discrimination 
between healthy and diseased cells, which is achieved through the presentation of peptides by 
the HLA molecules to T cells [25].  The Class I and Class II molecules differ in their structure, 
patterns of expression and function.  The classical Class I products, HLA A, B and C, are 
expressed at varying densities on the surface of most nucleated cells in the body and present 
cytoplasmic and virally derived peptides to CD8+ cytotoxic T cells.  The Class II products, HLA 
DR, DQ and DP, are generally expressed only on professional antigen presenting cells (APC), 
such as dendritic cells, macrophages, B cells, monocytes, Langerhans cells, dendritic cells, in 
addition to activated T cells, endothelial and epithelial cells [26] and present externally derived 
peptide which has been internalised and processed by the cell prior to presentation to CD4+ 
helper T cells [19].  Interaction between a T cell receptor (TCR) and a complementary HLA 
molecule can, when accompanied by the appropriate co-stimulatory signals, initiate an 
immune response against the presenting cell or against the source of the peptide being 
presented.  Of note, in regards to renal transplantation, expression of HLA Class II molecules 
can be induced on the surface of renal tubular and glomerular epithelial cells, particularly at 
times of stress to the organ, as seen during transplantation and in renal disease [27, 28]. 
The MHC Class I complex is comprised of genes encoding the classical HLA-A, -B and –C which 
are most commonly described, in addition to the non-classical HLA E – F which have more 
limited variability and tissue distribution [17].  Each gene encodes a 45-kd transmembrane 
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Class I α chain, or heavy chain, which is associated with a 12-kd invariant β2 microglobulin or 
light chain, encoded on chromosome 15, plus peptide, prior to expression on the cell surface 
[23].  The Class I α chain is folded into 3 domains, α1, α2 and α3 and then associated with the 
β2 microglobulin chain prior to expression, as represented in figure 2 below.  The majority of 
the variation between Class I molecules is found in the α1 and α2 regions encoded by exons 2 
and 3, whereas the α3 region, encoded by exon 4, is more conserved [25].  The α1 and α2 
regions fold to form the peptide binding groove, and it is this area which dictates the range of 
peptides that can be bound and presented to the cells of the immune system by the HLA 
molecule.  The variation in amino acids in the α1 and α2 regions are at positions that can alter 
the peptide binding site, meaning that different HLA molecules are able to present a different 
range of peptides to the immune system.  The α3 region is the part of the molecule involved in 
both β2 microglobulin association and interaction with the CD8 molecule on the cytotoxic T 


















Figure 2 - Structure of the HLA Class I and II molecules [30]. 
 
The MHC Class II complex is comprised of 3 main regions, HLA-DR, -DQ and –DP.  Each Class II 
molecule is made up of 2 polypeptide chains, α and β, both of which are encoded within the 
Class II region.  Other than the DRα chain, which has only 2 alleles, each of these loci are 
polymorphic, giving rise to even greater variation in the Class II gene products.  Each chain has 
2 domains and here the α1 and β1 regions, encoded by exon 2, create the peptide binding 
groove, seen in figure 2 above.  Again it is the variation in each of these that dictates the range 
of peptides that can be bound and presented. 
An individual will inherit a single set of MHC genes, known as a haplotype, from each parent, 
meaning a complete MHC region will include 2 of each HLA gene.  These are then co-
dominantly expressed so an individual will have the ability to express 2 each of the HLA-A, -B, -
C, -DR, -DQ and –DP molecules, known as heterozygote [31].  In some cases an individual will 
inherit the same gene from each parent at one or more loci, so for example, only 1 type of 
HLA-A molecule will be expressed, known as homozygote.  Throughout evolution it is believed 
27 
 
that heterozygotes have a survival advantage as the possession of multiple HLA alleles 
increased the chances of expressing an HLA molecule capable of presenting a suitable 
pathogen derived peptide to the T cells to fight the infection [25]. 
The genes encoding the HLA molecules are highly polymorphic, by April 2013 there were 7089 
Class I and 2065 Class II HLA alleles registered on the IMGT/HLA database [32].  It is believed 
that such polymorphism has developed within the population to ensure that there will be at 
least some individuals whose HLA molecules are able to present suitable pathogen derived 
peptides to the appropriate antigen specific T cells to survive the disease and maintain 
continuation of the species [31].  However it is this polymorphism which creates some of the 
major difficulties presented in organ transplantation. 
1.5 Development and Education of Lymphocytes 
Lymphocytes are cells central to the adaptive immune system, and can be broadly split into T 
cells and B cells.  They both develop from undifferentiated precursors from the bone marrow 
and follow ordered and controlled stages of development marked by various gene 
rearrangement and proliferation phases.  They require specific signals from specialised 
microenvironments, namely the bone marrow for B cells and the thymus for T cells.  In these 
microenvironments they encounter specialised cells which provide signals and growth factors 
to encourage or cease development. 
1.5.1 T cells. 
Mature T cells express a complex known as the T cell receptor (TCR) on their surface.  It is this 
which recognises and interacts with a specific antigen in the context of an MHC molecule.  
Each T cell in circulation has a subtly different version of the TCR allowing interactions with 
different antigens, giving them a different specificity.  This great diversity allows the immune 
system to recognise many different potential pathogens. 
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The TCR is made up of a collection of polypeptides, the central pair of which are most 
commonly the α and β chain, and more rarely the γ and δ chains, combined with accessory 
chains to form a heterodimer with one antigen binding site, represented in Figure 3 below.   
Figure 3 - Diagram of the T cell receptor complex [33]. 
 
It is variation in the α and β chains, which provide the differing antigen specificity.  These 
chains consist of a variable amino terminal (V) and constant membrane proximal carboxy 
terminal (C). 
All T cell precursors start with the same collection of gene segments, which, during maturation 
in the thymus, randomly rearrange and combine to build a complete gene to encode the 
variable regions of each chain, represented in Figure 4 below.  The gene segments for the β 
chain are from three groups – V, D and J, and one segment from each group is taken to make 
up a complete and unique VDJ gene to encode the variable region of the β chain, which is then 
combined with one of two constant (C) β chain genes to produce a complete β chain gene.  
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The multiple gene segments available allow for hundreds of different VDJ β chain 
combinations. 
The α chain variable region genes contain just V and J gene segments and one α chain constant 
gene, however the variation it is possible to generate is immense. 
Figure 4 – The Sequence of Gene rearrangement in the T cell Receptor [33]. 
 
The rearrangement of TCR germline DNA sequences and the pairing of the α and β TCR 
products create a theoretical repertoire diversity of approximately 10
15
 different T cells in 
humans [34].  
Within the variable domains of these chains there are three hypervariable regions, known as 
the complementarity determining regions (CDR) 1 – 3, the main diversity being concentrated in 
CDR3, which is at the centre of the antigen binding site and interacts with the peptide being 
presented in the groove of the corresponding MHC molecule.  The CDR1 and 2 regions are less 
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variable and make contact with the two α helices forming the peptide binding groove on the 
MHC molecule. 
In order to prevent reactivity to self, or autoimmunity, the development and ‘education’ of T 
cells must ensure that they are able to recognise the bodies many different tissues as self and 
not attack unless instructed to do so, for example in malignancy, but still maintain the ability to 
recognise and eliminate foreign pathogens [35]. 
In order to prevent potentially deleterious self-reactive T cells being released into the 
periphery, those which have created T cell receptors that recognise self peptides with high 
affinity, must be recognised and removed.  There are two selection processes in the thymus, 
positive and negative.  Positive selection selects for TCR gene rearrangements which can 
recognise self MHC:self peptide complexes, and therefore are capable of functioning in self 
restricted responses.  If the TCR has no affinity for self MHC then they will receive signals to die 
by apoptosis.  However T cells that respond with high affinity to complexes of self peptide and 
self MHC class I or II molecules are also eliminated in a process called negative selection.  
Approximately 98% of the T cells that develop will die in the thymus by apoptosis through 
positive and negative selection [34]. 
During their development in the thymus the T cells will also receive signals to differentiate into 
different effector cells, namely the CD4+ T helper cells and the CD8+ Cytotoxic T cells, which 
will recognise peptide presented in MHC class II or class I molecules respectively.  The 
CD4/CD8 molecules along with a CD3 complex form the complete functional TCR complex 
required to be ligated for signal transduction and subsequent cellular activation. 
1.5.2 B Cells 
B cells also develop from precursors produced in the bone marrow, which is where their initial 
maturation continues.  These precursors require marrow stromal cells to develop, which retain 
the cells in the bone marrow and provide developmental signals.  
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B cells express an antigen receptor analogous to the TCR, known as the B cell receptor complex 
(BCR).  It is composed of a surface immunoglobulin (sIg) as the antigen receptor, coupled with 
a signal transduction complex.  The sIg molecule is composed of four chains, 2 heavy and 2 
light, each with variable and constant regions, which form 2 identical antigen binding sites, 
shown in Figure 5 below. 
Figure 5 - Diagram of the Structure of an Immunoglobulin molecule [36]. 
 
Like the TCR, the BCR is highly variable and generated through successive gene 
rearrangements.  The heavy chains again develop from groups of gene segments, V, D and J, 
which combine to form a functional variable region gene, which is combined with a constant 
region gene to allow production of a complete heavy chain.  The light chain variable regions 
are encoded by gene segments from two groups, v and J, which are also rearranged and 
combine with a constant light chain gene.  Once a complete and functional sIg molecule is 
expressed self-reactive clones are again removed by positive and negative selection before the 
cells are released into the periphery to undergo further maturation.  Naïve B cells, those that 




One of the main roles of a B cell in the acquired immune response is to produce antibody to a 
given pathogen in order to fight an infection, humoral immunity particularly protects against 
extracellular pathogens [37].  The antibody is a secreted form of the sIg presented in the BCR.  
Depending on the activation signals received, and subsequent gene rearrangements that 
occur, the secreted antibody can have one of a number of structures and functions.  They may 
bind to the pathogen, preventing it from entering the target cell, these are known as 
neutralising antibodies.  They may bind to the pathogen and facilitate its uptake and 
destruction by phagocytic cells, known as opsonisation.  The antibody may bind to the 
pathogen and activate the classical complement cascade, leading to the destruction of the 
target cell.  The complement cascade is a step wise series of proteolytic cleavage reactions 
whereby inactive complement components in the circulation are cleaved and become active, 
which then go on to cleave the next factor in the cascade.  For the classical complement 
pathway, triggered by antibody, there are nine active components, C1 – C9, with the final C5-
C9 forming the membrane attack complex, which is inserted into the membrane of the target 
cell causing it to lyse.  The cleavage of each component leads to the production of various 
fragments, some of which play other roles in the immune response.  For example, C5a has 
inflammatory and chemotactic properties, recruiting further phagocytes to the site of 
activation.  C3b can bind to the target and act as an opsonin, promoting the uptake and 











Figure 6 – Diagram presenting The complement cascade [18]. 
 
Initially the antibody produced in a humoral response will be of the IgM class, which has a 
pentameric structure, with 5 IgM molecules joined by 5 J chains.  This is the first antibody type 
seen in an antibody response and, whilst it’s a potent activator of the complement cascade, it 
is often of low affinity for the target antigen. 
The most abundant antibody class found in the serum is IgG.  Unlike IgM, IgG is a monomer, 
binding as a single IgG molecule.  Within the IgG class there are 4 subclasses, IgG1 – 4, defined 
by the functional (Fc) portion of the heavy chain and with varying effector functions.  IgG1 and 
3 are potent activators of complement, whereas IgG2 and 4 have limited to no ability to do 
this.  IgG can bind to, and activate other immune cells, such as the monocytes, neutrophils and 
NK cells via the heavy chain γ receptors FcγRI, II and III. 
IgA is the main Ig molecule secreted on mucosal surfaces, for example in the gut.  It can be 
found as a monomer when in circulation, but requires dimeric formation to be secreted.  As 
with IgM, an IgA dimer is formed by the joining of two monomers with a single J-chain.  
Binding of the J-chain to the polymeric immunoglobulin receptor (pIgR) expressed on epithelial 
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cells allows the antibody to be transported to the luminal surface of the epithelium.  The 
antibody is then released by cleavage of the pIgR, although part of the receptor remains bound 
to the IgA dimer to become the ‘secretory component’, with the final molecule comprising the 
complete secretory IgA [18]  Again IgA can fix complement and interact with immune cells such 
as the neutrophils. 
IgE is the main antibody class used to fight parasitic infections and seen in allergy, where is 
binds to and activates mast cells. 
A fifth class of antibody is IgD.  IgD is coexpressed with IgM on the surface of all naïve, and 
most mature, B cells.  Its expression ceases once the B cell has been activated and very little, if 
any, is secreted at any time.  The function of IgD is as yet unclear [18]. 
1.6.1 Production of Antibody 
Antibodies are a major effector in the adaptive immune response.  When a B cell encounters 
and binds to its cognate antigen via the BCR in the secondary lymphoid tissue, lymph node or 
spleen, the entire Ag/BCR complex is internalised and the antigen broken down, processed, 
into multiple short peptides.  These peptides are then loaded into the MCH class II molecules 
and presented on the B cell surface.  If the B cell then encounters an activated CD4+ T helper 
(Th) cell which is expressing a TCR cognate to the peptide:MHC on its surface, the T cell will 
provide signals for the B cell to become activated, in a process represented in figure 7 below.  
Some of these B cells will develop into short lived plasma cells, secreting low affinity IgM 
antibody.  Others undergo rapid division and, when interacting with the follicular dendritic 
cells and Th cells, begin to form a germinal centre.  During this rapid phase of division the cells 
begin the process of somatic hypermutation and affinity maturation, during which further 
gene alterations ensue, generally involving subtly changing the variable regions by point 
mutations, deletions or insertions of single nucleotides, and thus also changing the specificity 
of the antibody.  Often these changes will lead to an antibody of lower, or no, affinity for the 
target antigen, and these cells will receive apoptosis signals.  However if the new antibody 
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product is of higher affinity the cells will receive survival signals from the follicular dendritic 
cells presenting the antigen.  These surviving cells also receive signals from the appropriate Th 
cells to differentiate and undergo isotype switching, whereby the functional heavy chain gene 
is changed from IgM class to either IgG, IgA or IgE, dependant on the signals received and the 
type of pathogen encountered.  These surviving B cells then follow one of a number of possible 
routes.  They may re-enter the process of proliferation, mutation and selection or develop into 
an antibody secreting plasma cell or a memory B cell [38]. 
Figure 7 - Diagram demonstrating the requirement for T cell help in the activation of 
B cells and generation of an antibody response [18]. 
 
The plasma cells migrate to specialised survival niches in the bone marrow where they 
continue to produce circulating antibody.  These plasma cells are terminally differentiated, 
unable to divide and secrete antibody continuously even in the absence of antigen.  
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Controversy exists as to the life span of these cells.  The fact that antibody can persist and be 
detected in the plasma long after an infection has been resolved, and in the case of vaccination 
for example, for the life time of the individual, indicates that long term production of antibody 
by plasma cells in somehow facilitated.  There are currently three competing concepts.  The 
first is that the plasma cells may be short lived, generated from memory B cells in a process 
driven by persistent antigen.  The second is there is continuous generation of long lived plasma 
cells with a defined half-life, again derived from memory B cells in the circulation.  The third is 
that the plasma cells generated have unconditional survival due to the environment provided 
in the bone marrow niches and are independent of the memory B cell pool [38].  The number 
of survival niches is finite which limits the number of long lived plasma cells [39].  Plasma cells 
are rare and make up only 0.5% of all bone marrow cells and 0.05% of the peripheral blood 
cells [38]. 
The memory B cells re-enter circulation where they can provide a rapid response if re-
challenged with the same antigen.  These memory B cells are not terminally differentiated and 
do not continuously secrete antibody.  If these cells re-encounter their cognate antigen they 
can become rapidly reactivated, some of which will then become plasma cells secreting 
antibody and others of which will form another germinal centre and restart the affinity 
maturation process. 
The response seen when first encountering an antigen is known as the primary response, and 
tends to peak at 5 – 10 days following exposure, however when re challenged with the same 
pathogen, even years later, a secondary, or second set, response will ensue via the memory 
cells , allowing a rapid response peaking at 3 – 5 days. 
Once an antibody response has been stimulated and plasma cells generated it is often possible 
to continue to be able to detect a specific antibody for the lifetime of the individual.  However 
this is not always the case, particularly when the antigenic stimulus has been removed and 
years have passed.  In these cases whilst no antibody can be detected in circulation there will 
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still be a pool of memory cells, B and T, primed to respond if the individual is re-challenged 
with the same antigen.  Subsequent challenges with the same antigen can result in an 
anamnestic response, where antibody production increases very rapidly to eliminate the 
antigen.  Memory B cells can become activated within hours of re-exposure to an antigen and 
differentiate into plasma blasts and then plasma cells secreting antibody, it is not yet clear if 
this activation requires some or any T cell help in the same way as it is required in the initial 
response [38]. 
1.7 Generation of an acquired immune response. 
Generation of a response requires the interaction of multiple cell types under the correct 
conditions and results in various effector mechanisms to fight infection. 
The first step in generating a response is the uptake of the invading pathogen e.g. bacteria or 
viral particle, by specialised antigen presenting cells (APC), macrophage, dendritic cell or B cell, 
which transport it to the lymph node via the lymphatic system.  During transport the antigen is 
processed and broken down into shorted peptides which are then presented in an MHC class II 
molecule on the surface of the cell, in addition to this the cell also starts to express high levels 
of costimulatory and adhesion molecules.  Once in the lymph node the APC moves into the T 
cell rich areas where it becomes surrounded by CD4+ Th cells.  If a Th cell has a TCR 
complementary to the peptide:MHC CII complex being presented by the APC and receives 
adequate costimulatory signals, such as those received via ligation of CD28/CD80/86 and 
CD40/CD40L, it becomes activated, represented in figure 8 below.  The T cells then begin a 
process of maturation, differentiation and proliferation driven by various signals and cytokines.  
Activated Th cells may then encounter their cognate B cell in the lymphoid tissue providing 
signals to start an antibody response.  T cell help via an activated Th cell is also required for 
activation of CD8+ cytotoxic T cells.  If a T cell encounters its cognate antigen in the absence of 
costimulation it will be rendered anergic and unable to respond.  Activation of a naïve T cell 
will result in the formation of both effector and memory populations. 
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Figure 8 - The three signal pathway to T cell activation [40]. 
 
1.8 Allorecognition and the alloresponse. 
As discussed earlier the main problem encountered in the early years of transplantation was 
that of general immediate rejection of the foreign organ by the recipient.  The first long term 
success was achieved by transplanting a kidney between genetically identical twins.  We now 
know that this was successful due to the fact that the recipient’s immune system did not 
recognise the new kidney as foreign as they shared the same genes [9]. 
It is vitally important within an organism that the immune system can recognise self in order to 
prevent attack against self tissues and autoimmune disease.  In order to maintain this integrity 
self-compatible tissues are recognised as such by the expression of the histocompatibility 
antigens [17]. Transplantation involves the introduction of non-self tissues to an individual 
which express the major and minor histocompatibility antigens encoded by the donor genes.  
If the graft comes from a genetically identical donor, e.g. an identical twin, it is called 
syngeneic, and will not elicit a significant immune response as it expresses the same antigens 
as self.  However, if the transplant is between individuals who are genetically disparate, 
allogeneic, then under normal circumstances in an immunocompetent individual without 
immunosuppression, an adaptive immune response to the foreign tissue will ensue, leading to 
the destruction and rejection of the transplanted tissues [41].  This reaction against non-self is 
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known as the alloresponse and the targets to which the response is raised are called the 
alloantigens (alloAg), recognised in the process of allorecognition.  In man there are many 
potential alloAg, however the ones which elicit the strongest immune response are the HLA 
Class I and II molecules, encoded by the MHC [17]. 
T cells play a pivotal role in allorecognition [41].  There are three pathways of allorecognition 
described – direct, indirect and semi-direct [41].  
In the direct pathway allospecific T cells are able to recognise the donor MHC molecules as 
foreign directly.  It is hypothesised that the allograft, when transplanted, brings with it 
passenger donor APCs [42] which traffic to the secondary lymphoid tissue of the recipient and 
initiate direct responses [41].  The donor APCs provide the costimulatory signals required to 
activate the T cells.  Lafferty et al. [43] were able to demonstrate that cultured thyroid tissue 
has a prolonged survival after transplantation due to the loss of passenger APCs. 
Unlike a normal response, where foreign antigen must be processed and the presented in the 
groove of a self HLA on a self APC before a T cell can be activated, the donor APCs are directly 
presenting intact foreign HLA molecules to the recipient T cells, represented in figure 9 below, 
which explains the immediate nature of the direct pathway activation [35].  It is believed that 
the direct pathway dominates the immediate post-transplant period reducing over time as the 












Figure 9 - Model of Direct Allorecognition [45]. 
 
Direct Allospecific T cells are found in uniquely high numbers in the circulation of most 
individuals, with an estimated 10% of the recipient T cells being able to react directly with 




 of T cells being able to 
react to any other given antigen [46].  In an immediate post-transplant draining lymph node 
analysis it was demonstrated that >90% of the allospecific T cells were of the direct pathway.  
The high number of cells capable of reacting to foreign HLA molecules directly accounts for the 
strength of reaction seen [44].  The reason for this high level of alloreactivity is due to the high 
level of inherent cross reactivity of the TCR [44]. 
Two models have been proposed to account for the high frequency of direct alloreactive T cells 
–The high determinant density and the multiple binary complex models. 
High determinant density suggests that alloreactive TCR can directly recognise amino acid 
differences on the allo HLA molecule regardless of the peptide it is presenting.  Therefore 
every HLA molecule on the surface of a foreign cell could act as a ligand for the allospecific T 
cells.  This leads to a high frequency of ligands for potential allospecific T cells, meaning that T 
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cells expressing TCR of lower affinity are able to respond due to a high density of targets 
expressed on the cell [44]. 
The multiple binary complex model suggests that it is the peptide bound in the groove of the 
alloHLA molecule that is of greatest importance.  Differences in the HLA molecules leads to a 
different set of peptides being presented compared to those presented by self, so each 
peptide-allo HLA complex is recognised by a different alloreactive T cell and only one mismatch 
can stimulate a large number of diverse T cells [44]. 
It is thought that both mechanisms probably contribute to direct allorecognition [44]. 
The second pathway of allorecognition follows a more conventional route of antigen uptake, 
processing and presentation in a self MHC class II restricted manner.  This is the indirect 
pathway.  In this pathway the alloAg, in the form of foreign HLA molecules shed from the graft, 
are processed as any exogenous antigen would be by host APCs and then the resulting 
peptides presented to the host T cells in the context of self HLA molecules, see figure 10 
below.  The indirect pathway takes longer to become apparent due to the time taken to 
process and present the peptide.  However, unlike in the direct pathway, where donor APCs 
and therefore the response, are thought to diminish with time, the alloAg will continue to be 
shed for the lifetime of the graft and therefore continually stimulate an immune response.  
The indirect response is dominated by the CD4+ Th cells [35].  There are fewer allospecific Th 
cells with indirect specificity compared to those with direct [41].  As the T cell help for B cells 
to become activated requires interaction of a B cell presenting peptide:self MHC Class II to an 
appropriate activated Th cell, alloAb can only be produced via the indirect pathway [47].  So 
the presence of class switched alloantibody (AlloAb) is indicative of help provided by indirect 






Figure 10 - Model of Indirect Allorecognition [45]. 
 
The third pathway of allorecognition described is that of semi-direct allorecognition.  It is 
suggested that intact surface donor MHC:peptide complexes are acquired by recipient APC via 
cell-to-cell contact or in an exosomal manner.  Recipient APC can then present intact donor 
HLA CI and II molecules to both CD4+ and CD8+ T cells in addition to the processed peptides in 
self HLA molecules.  This could lead to crosslinking of a CD4+ Th cell from the indirect pathway 
with a CD8+ cytotoxic T cell recognising the intact donor HLA CI molecule in a direct manner.  
However there is no direct evidence of an in vivo role for this pathway in allorecognition and 
rejection [44]. 
1.9 Alloantibody and its Production. 
In an immune response to a typical pathogen, production of antibody specific for that 
pathogen by activated B cells would be expected.  This is also the case in the allo immune 
response.  In much the same way as other antibody production, the B cells specific for the allo 
Ag are activated by helper T cells specific for the same antigen, in a T cell dependent process 
which begins when an individual is exposed to non-self HLA molecules [37].   
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The area of recognition by an immune cell on an antigen is called the epitope, and whilst a T 
cell and a B cell may recognise and react to the same antigen, the epitope that they recognise 
is thought to be different.  A T cell epitope is in the form of a linear peptide created from the 
intracellular processing of the pathogenic protein presented in the context of a Class I or Class 
II HLA molecule on the surface of the cell, for CD8+ and CD4+ T cells respectively.  The 
determinant recognised by the antibody is a conformational or structural epitope, which is 
found on the 3D structure of the antigen, often involving amino acids from different points on 
the linear protein which have been brought together by peptide folding to produce the 
epitope.  The epitope is generally a small area on the surface of a larger molecule. 
HLA molecules are large proteins which often possess many antigenic determinants, or 
epitopes, on their surface.  Some of these epitopes will be limited to a single HLA molecule, 
private epitopes, whereas others will be found on the surface of multiple HLA molecules, 
public epitopes [48].  If an antibody response is raised to a mismatched epitope on the surface 
of a foreign HLA molecule and the epitope is shared by a number of HLA molecules, antibody 
raised to this HLA molecule will also be found to react with all the other HLA molecules which 
express the same epitope.  These are known as cross reactive groups or CREGs [49], therefore 
a single HLA mismatch may lead to the production of antibody specific for multiple HLA 
antigens.  In order to generate HLA specific antibody the activated and responding B cell must 
receive signals from corresponding helper T cells which recognise and respond to peptide 
presented in the context of self MHC Class II.  In the context of the alloresponse the peptide is 
generated through internalisation and processing of the non-self HLA molecule and will 
therefore activate the CD4+ helper T cells via the indirect allorecognition pathway.  As such, 
the presence of HLA specific antibodies is indicative of a response via the indirect 
allorecognition pathway [44], however depending on the epitope to which the antibody was 
raised and the cross reactive nature of HLA specific antibodies, presence of an antibody to a 
particular HLA antigen does not necessarily indicate that the T cell help and therefore the T cell 
memory was raised to that particular HLA antigen. 
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1.10 Rejection of Solid Organs following Transplantation. 
In a typical immuncompetent healthy individual transplantation of a solid organ from a non-
genetically identical donor will result in rejection [46].  Only a few amino acid differences 
between the donor and recipient HLA molecules can be sufficient to cause rejection [46].  The 
speed and pathology of the rejection varies depending on the sensitisation status of the 
patient pre transplant and the effector mechanisms involved in the response.  The types of 
rejection can broadly be divided into humoral, brought about by antibody responses, and 
cellular, where predominantly T cells will bring about the damage and destruction to the graft.  
In many cases however a mixed picture of both cellular and humoral mechanisms will be 
observed.  They are also divided on the basis of the speed of the rejection response, with four 
main categories – Hyperacute, accelerated acute, acute and chronic. 
1.10.1 Antibody Mediated Rejection 
The presence of preformed antibody directed towards donor HLA molecules have long been 
known to be a definite contraindication to transplantation.  Kissmeyer-Nielsen et al.[50] in 
1966 reported hyperacute rejection of kidney allografts in association with pre-existing 
humoral antibodies against donor cells.  Patel and Terasaki [16] reported in 1969 that in a 
group of 30 patients transplanted in the presence of antibodies cytotoxic to donor 
lymphocytes, 24, or 80%, lost their kidneys to hyperacute rejection.  In addition to hyperacute 
rejection, HLA specific antibodies have also been associated with both acute and chronic 
rejection [51].   
Hyperacute rejection of a graft is rejection or loss which occurs within 24 hours of 
transplantation, although often it will be within minutes of reanastomosis of the organ [52].  It 
is virtually always irreversible and occurs when an organ is transplanted in the presence of high 
levels of donor specific antibody, specific for either the HLA mismatches presented by the 
donor or due to blood group incompatibilities between donor and recipient to which the 
recipient has antibody e.g. a blood group A kidney being transplanted into a blood group O 
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recipient.  At the time of reperfusion the kidney fails to “pink up” and becomes flaccid, mottled 
and anuric [46].  Antibody becomes deposited on the vascular endothelium where it activates 
the classical complement cascade, resulting in endothelial necrosis, platelet deposition and 
initiation of the coagulation cascade [53].  There is not usually a cellular element to this type of 
rejection, with biopsy often showing no mononuclear cell infiltrate [54].  Hyperacute rejection 
is now a very rare occurrence due to improvements in HLA specific antibody detection and pre 
transplant crossmatching [51] in addition to blood group matching.   
Acute antibody mediated rejection (AAMR) usually occurs within days to weeks post-
transplant [46], although may occur years post-transplant, often coinciding with a decrease in 
immunosuppression [53].  20-30% of all acute rejection episodes will include an element of 
antibody mediated damage [52].  AAMR can be divided into accelerated acute rejection, 
generally occurring within the first two to four days post-transplant, or acute rejection, 
characterised by a sudden onset of graft dysfunction within the first few weeks post-transplant 
[52].  Accelerated AAMR is predominantly due to ABO or HLA specific antibody produced 
rapidly post-transplant in an anamnestic response due to the presence of immune memory to 
the HLA mismatches presented by the graft, in a classic ‘second set’ response [46].  In these 
cases the antibody prior to transplant is of low level and may not be detected by the antibody 
screening methods used, or in the case of HLA antibody incompatible transplantation, the 
antibody has been removed to a level deemed safe to transplant.   Grafts rejected in this way 
appear similar to those rejected hyperacutely, being enlarged and soft with numerous foci of 
haemorrhage.  There may be evidence of both humoral and cellular elements, although the 
cellular component does not generally predominate.  
Acute AMR is characterised by a sudden loss of function, due to inflammation [46], with 
patients presenting with a sudden rise in serum creatinine, fluid retention and possible fever 
and graft tenderness [55].  Patients are often sensitised pre-transplant, although the risk of 
AAMR is also increased due to non-compliance with immunosuppressive medication in 
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previously unsensitised patients, where de novo antibody production can be responsible [55].  
Common histological features include fibrinoid necrosis, microthrombi, acute tubular injury, 
neutrophil and macrophage infiltration [53], in addition C4d deposition on the peritubular 
capillaries, indicating complement activation, can often be seen on immunofluorescence 
staining [56].  In patients where de novo antibody production is responsible, especially in 
patients who are non-compliant, the histopathology is reported to be different to that in acute 
AMR in sensitised recipients, with a greater mix of humoral and cellular mechanisms [57, 58]. 
This form of rejection can be reversed if treated early following initiation of the response. 
However, it remains undesirable as damage sustained by the graft during the rejection episode 
can affect the long term function of the graft, and the comorbidity that is associated with the 
increased immunosuppression required to treat the rejection episode [59]. 
Chronic AMR presents as slow, progressive loss of graft function over months to years [53].  In 
recent years evidence has been presented that donor specific antibody plays an important role 
in chronic rejection, with circulating HLA specific antibody to Class I and/or Class II mismatches 
being found in a large proportion of renal allograft recipients and associated with late graft 
loss [60, 61]. Both de novo donor specific and non-donor specific antibody are commonly 
detected in patients diagnosed with chronic AMR [52].  Einecke et al.[62] attributed 63% of 
late graft losses seen in their study of 27 patients to chronic AMR.  El-Zoghby et al.[63] found 
20% of the 153 renal transplants studied were lost to acute or chronic AMR.  In a study of 
patients transplanted with a positive crossmatch, Bentall et al. [64] found over 90% of the 
biopsies taken at 5 years showed histological evidence of chronic AMR. 
There has been a concerted effort over the past 30 years to standardise the diagnosis of renal 
allograft rejection on biopsy through the generation of the Banff classification system [65] 
which aims to provide histopathologists with a guided framework around which various forms 
of allograft pathology can be diagnosed. 
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Diagnostic criteria for chronic antibody mediated rejection include histological evidence of 
chronic injury with at least two of the following – arterial intimal fibrosis without elastosis, 
duplication of glomerular basement membrane, multilaminated peritubular capillary (PTC) 
basement membrane and interstitial fibrosis with tubular atrophy.  In addition there must be 
evidence for antibody action or deposition in the tissue, such as C4d in the PTC, plus detection 
of circulating donor specific antibody [53]. 
1.10.2 T cell Mediated Rejection. 
Even in the presence of immunosuppression T cell mediated rejection (TCMR) remains a 
significant problem and is the dominant phenotype seen in early rejection [66].  Acute TCMR is 
diagnosed in 5-10% of unsensitised patients within the first year of transplantation [55].  T cells 
may be activated via the direct, indirect or semi direct pathways when donor alloAg is 
presented via the donor or recipients own APCs. However the lesions produced by the 
activated T cells are the same, independent of the route of activation [66].  The lesions 
produced are also similar regardless of the mismatch provoking the response – Class I, II or 
non-HLA [66].   
The initial response in a previously unsensitised recipient will require donor antigen from the 
graft to be presented in secondary lymphoid tissue by antigen presenting cells, originating 
either from the donor, in direct allorecognition, or the recipient’s own APCs in indirect 
allorecognition.  Once activated in a lymph node the effector T cells return to the graft where 
they initiate rejection [46]. 
In a previously sensitised recipient circulating memory T cells previously primed by exposure to 
the same non-self HLA, or those which recognise the mismatched antigens due to 
crossreactivity with antigens encountered during a previous infection, heterologous immunity 
[67], are able to enter and respond to the graft immediately without the requirement for initial 
priming in the secondary lymphoid organs. 
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The effector T cells responding to the mismatched antigens in a primary response will be 
composed of naïve T cells which have been primed in the secondary lymphoid organs and 
some memory T cells which may have been previously primed by infection and possess 
crossreactive TCR [68]. Effector T cells can home to the graft via two routes, firstly through 
recognition of antigen on the endothelium and secondly through their general role of 
patrolling the tissues [66].  Both memory and effector CD4+ helper and CD8+ cytotoxic T cells 
enter the graft [66].  Recognition of their cognate antigen by CD8+ T cells will lead to activation 
of their cytolytic activity, including release of perforin and granzymes A and B, resulting in 
destruction of the target cells. In addition they release chemokines and cytokines which act to 
recruit more cells into the graft including further T cells and macrophages [46].  CD4+ effector 
T cells activate both the cytotoxic T cells and the B cells, to produce antibody.  They also 
release cytokines recruiting further cellular infiltration, along with inducing the upregulation of 
expression of HLA on the surface of the endothelial and epithelial cells of the graft, 
encouraging further antigen recognition by T cells. 
1.11 Immunosuppression 
The development of immunosuppressive drugs was a key feature in the ability to offer organ 
transplantation as a viable treatment option.  The first attempts at immunosuppression for 
organ transplantation involved total body irradiation in the late 1950s. However the side 
effects encountered with this radical treatment were generally fatal to the patient [10, 11, 69].  
Since this time much work has been focussed on the development of immunosuppressive 
agents to facilitate successful transplantation.  The majority of these agents focus mainly on 
the T cell arm of the immune response as, along with inhibiting T cell mediated rejection, 
inhibition of the T cells should in turn inhibit the development of alloantibody due the T cell 
requirement in this process, and the activation of other cellular effectors of rejection such as 
macrophages.  The actions of T cells can be inhibited in three main ways – depletion of the 
cells, restricting their ability to traffic and by blocking their response pathways.  The small 
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molecule drugs, such as azathioprine (AZA), ciclosporine, tacrolimus (TAC), mycophenolate 
mofetil (MMF) and Sirolimus all have mechanisms of action which interfere with cellular 
response pathways during activation.  The first immunosuppressive agent to gain widespread 
use in renal transplantation was AZA [70] which, on metabolism, releases 6-mercaptopurine 
which is further converted to a number of compounds which act to halt DNA synthesis, 
thereby preventing cell proliferation.  In addition 6-mercaptopurine is believed to convert co-
stimulatory signals via CD28 from activatory to apoptotic [71], leading to depletion of activated 
T cells.  Whilst AZA may still be included in current IS regimens, its widespread use was 
reduced with the discovery of the calcineurin inhibitors (CNI), cyclosporine and then 
tacrolimus.  Both these agents act by engaging with the immunophilins, cyclophilin and FK506 
binding protein 12 (FKBP12) respectively, which in turn inhibit calcineurin activity, required for 
the de-phosphorylation and translocation of nuclear factor of activated T cells (NF-AT) into the 
cell nucleus, where it enhances the transcription of the genes encoding pro-inflammatory 
cytokines such as IL-2 [9].  IL-2 is a key cytokine in the signals required to promote activation 
and proliferation of T cells.  The agents Sirolimus and everolimus also engage with the 
immunophilin FKBP12. However the complex that is created does not affect calcineurin, but 
instead inhibits the action of the mammalian target of rapamycin (mTOR).  The mTOR 
pathway, activated by cytokines such as IL-2, provides the 3rd signal in T cell activation, see 
figure 8 above, and its inhibition leads to a blockade on cell proliferation and cell-cycle 
progression.  MMF is another small molecule drug which, on metabolism, releases 
mycophenolic acid.  Mycophenolic acid inhibits the enzyme inosine monophosphate 
dehydrogenase, which is required for purine synthesis and therefore DNA replication, again 
required for cell proliferation following activation [40].  Immunosuppressive regimens which 
use a combination of MMF and CNI are now commonplace and have been shown to improve 
both graft and patient survival, and reduce the incidence of rejection episodes [72, 73].  
Therapeutic antibodies are another group of immunosuppressive agents and can lead to either 
cellular depletion or inhibition of action depending on their target.  Depleting antibodies are 
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those which activate pathways leading to the destruction of cellular targets and can be specific 
to T cells, B cells or both.  Anti-thymocyte globulin (ATG) and anti-lymphocyte globulin (ALG) 
are polyclonal antibodies raised in animals through inoculation with human derived 
thymocytes or lymphocytes, and then subsequent isolation of the cellular specific IgG fraction 
[40].  A typical course of ATG lasts 3 – 10 days and leads to a profound and long lasting 
lymphopenia [74] through complement mediated lysis and opsonisation and removal of target 
cells [75].  Alemtuzumab (Campath) is a humanised monoclonal antibody (mAb) raised against 
cell marker CD52 and leads to destruction of CD52+ lymphocytes via complement mediated 
lysis, causing long term depletion of these cells from circulation.  OKT-3 (muromonab-CD3) is a 
mouse derived monoclonal antibody specific for the T cell receptor complex associated marker 
CD3.  Infusion of OKT3 initially leads to rapid lysis of circulating T cells followed by a lack of 
expression of CD3 in the returning T cell compartment [76] leading to an inability of these cells 
to respond to stimulation.  Non-depleting antibodies include basiliximab which is a mAb 
specific for the IL-2 receptor α chain, CD25.  CD25 is expressed on activated T cells and 
increases responsiveness of the cell to IL-2. Blocking CD25 through mAb binding reduces the 
activatory effect of IL-2 on T cells.  Belatacept is a cytotoxic T lymphocyte-associated antigen–4 
(CTLA-4) Ig fusion protein.  CTLA-4 is a transiently expressed cell surface molecule seen after T 
cell activation.  Like CD28 it can bind to CD80 and CD86 expressed on APCs, but unlike CD28, 
engagement of CTLA-4 leads to a negative signal being transduced.  Binding of CTLA-4Ig fusion 
protein to CD80 and CD86 on the APC blocks interaction with CD28 on the T cell and prevents 
co-stimulation from occurring leading to anergy of the responding T cells [77]. 
Corticosteroids have long been a mainstay of immunosuppressive regimens and the two most 
commonly used in renal transplantation are prednisolone and prednisone, which is 
metabolised into active prednisolone [9].  The mechanisms of action are wide including acting 
as agonists for the glucocorticoid receptors  leading to interference with gene transcription 
and production of pro-inflammatory cytokines along with other anti-inflammatory and 
immunomodulatory effects [78]. 
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Whilst the majority of immunosuppressive agents target T cells, a number of agents are now 
being investigated for use in reduction of alloantibody production or modulation of the 
damaging effects of alloantibody on a graft. These include the use of intravenous 
immunoglobulin (IVIg), CD20 specific mAb Rituximab, proteasome inhibitor bortezomib and 
complement component C5a specific mAb eculizumab.  The use and mechanisms of action of 
all these agents are discussed in ‘transplanting the sensitised patient’ below. 
No single immunosuppressive agent is able to provide complete prevention of rejection at 
tolerated doses and therefore the majority of centres worldwide utilise combinations of agents 
to provide the best protection from rejection and minimise the potential side effects.  Some 
immunosuppressive are used as induction agents, given in the weeks, days or hours pre 
transplant, ATG, basiliximab and Rituximab are common examples of this, often in patients 
who are deemed to be at higher risk of early acute rejection episodes.  These agents may be 
required again for treatment of active rejection episodes.  
One major problem with all immunosuppressive agents are the associated side effects, which 
can be the general increase in infection and cancers, such as skin cancer and post-transplant 
lymphoproliferative disorder, found with most agents, to more agent specific effects, such as 
nephrotoxicity and an increase in diabetes and hypertension with CNI, and diarrhoea and 
anaemia with MMF.  In general a patient, once transplanted, will remain on 
immunosuppression for the lifetime of the graft, so the potential side effects of 
immunosuppression must be weighed up against the benefits achieved through 
transplantation.  This is particularly important in the context of higher risk antibody 
incompatible transplantation where stronger immunosuppressive agents and regimens may be 




1.12 HLA matching and outcome. 
Due to the immunogenicity of HLA molecules, and their central role in allograft rejection, HLA 
matching at a minimum of the HLA A, B and DR loci has long been considered a benefit to long 
term transplant outcomes, with many studies providing evidence of increasing numbers of 
mismatches at these loci being associated with decreasing graft survival [79-81].  HLA matching 
remains an important factor in allocation algorithms used in many countries for the national 
allocation of deceased donor organs [82].  However with the introduction of ever more potent 
immunosuppressive regimens in recent years the importance of HLA matching on the long 
term graft survival has been called into question.  Su et al. examined the effects of HLA 
mismatching on graft survival for transplants performed between 1995 and 1998 in the United 
States, and found that in the 1995 cohort 3-6 antigen mismatches were associated with a 
higher risk of graft failure, but the effect reduced each year until in the patients transplanted in 
1998 only a 6 antigen mismatch was significantly associated with a risk of graft failure [83], 
however these patients were only followed up for a median of 2.2 years so the effects on long 
term survival were not investigated.  Martins et al. analysed the longer term (8 – 20 year) 
outcomes from 1314 deceased donor renal transplants split into four eras based on 
immunosuppressive protocols in use at their centre from pre 1990 to post 2000.  They found 
that HLA matching was significantly associated with graft loss in the early eras from pre 1990 
to 1996 but that since the introduction of mycophenolate mofetil, anti thymocyte globulin, 
tacrolimus and sirolimus to their immunosuppressive repertoire HLA matching was no longer a 
significant factor in graft loss [84].  Of note, whilst the differences in graft survival may not be 
significant, in all published studies HLA matched organs continue to show the best overall graft 
survival compared to mismatched organs. 
The apparent reduction in the influence of HLA matching and the increasing numbers of 
patients on transplant waiting lists worldwide has led some national registries to reduce the 
importance of HLA matching on allocation, such that the United Network of Organ Sharing 
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(UNOS) only considers matching at HLA DR and the California Transplant Donor Network no 
longer includes HLA matching in its’ allocation algorithm [85]. 
In the UK however HLA matching at HLA A, B and DR is still factored into the matching 
algorithm with ‘000’ matches being favoured over other match grades and a stepwise 
importance of increasing mismatches.  Analysis of the factors effecting outcome of renal 
transplants performed in the UK from deceased donors between 1995 – 2001 by Johnson 
et al., on behalf of NHS Blood and Transplant (NHSBT), found that whilst HLA A matching bore 
no significant influence on graft outcome, matching at both HLA B and DR did still exert a 
significant influence on longer term graft survival, with a cumulative effect of increasing 
mismatches at these loci [86].  The survival curves for these loci presented by this group can be 
seen in figure 11 below.  Following this analysis the UK has retained its policy on favouring well 
matched grafts where possible at all three previously mentioned loci [87]. It should however 
be noted that the authors did observe improvements in outcomes in patients transplanted in 
the latter time period of the study regardless of other influencing factors, which was suggested 
could reflect changes in immunosuppressive regimens. 
Figure 11 - The effect of HLA matching on UK Renal Transplant 5 year graft survival 






Other non-immune factors have also been found to exert a significant influence on long term 
graft survival including recipient and donor age, donor cause of death, initial disease of the 
recipient, length of cold ischaemic time of the organ, the length of time the recipient was 
waiting for an organ, donor and recipient body weight ratio, and patient ethnicity [86, 88, 89]. 
One longer term impact of reducing HLA matching between donor and recipient is the increase 
in sensitisation of these patients.  In the US the third most common reason for being on the 
transplant waiting list is due to failure of a previous graft [85] and it has been found that 
greater numbers of mismatches presented by the first graft leads to a higher level of 
sensitisation to HLA in patients following failure of the graft and return to the waiting list [90]. 
By reducing the importance of HLA matching there is the risk that patients will become more 
sensitised following failure of the primary graft reducing their chances of a re-graft in future, a 
concern borne out in a study by Meier-Kiresche et al.[85].  In the UK paediatric patients are 
given priority for well-matched kidneys partly in an effort to reduce the risk of sensitisation, as 
their age at the time of first transplant means that they are likely to require more than one 
graft over their lifetime.  If matching is reduced and patients do in general become more 
sensitised it is likely that the demand for HLA antibody incompatible transplantation could rise 
in the future. 
1.13 HLA sensitisation. 
Patients who produce Abs specific to HLA are known as sensitised.  The production of HLA 
specific antibodies generally requires exposure to non-self HLA antigens.  There are three main 
routes of sensitisation – previous transplantation, pregnancy and blood transfusion.   
Transplantation, and subsequent rejection or loss of the organ, often produces the strongest 
response with the longest lived Ab production.  In pregnancy the foetus acts in many ways as a 
graft, harbouring HLA Ags of the father, to which a response may be made, particularly in 
women who have had multiple pregnancies and blood transfusions [91].  As a consequence 
women are more likely to be sensitised, which is evidenced by the fact that a 2006 audit of the 
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UK renal transplant waiting list found 33% of the female patients were sensitised in 
comparison to only 17% of the males [92].  Transfusion of blood products also leads to 
exposure to non-self HLA and, despite the current practice of leucodepletion, is a common 
route to sensitisation [93].  Approximately 50% of patients receiving multiple blood 
transfusions will develop some level of HLA sensitisation [94]. However, the antibodies and 
response following a transfusion are often more transient in nature.  In addition, HLA specific 
antibodies are found in 1% of the population through no obvious cause [95], although more 
recently Morales-Buenrostro et al. found up to 63% of a group of 424 healthy male blood 
donors produced detectable HLA specific antibody [96], possibly due to the antibodies 
detected actually being specific for pathogens, but binding to shared epitopes [97], or due to 
antibody binding to epitopes exposed through the kit manufacturing process but not naturally 
revealed [98].  The specificity and strength of HLA specific antibody produced by a patient can 
vary and diminish over time [99] and in sensitised patients the strength and breadth of the HLA 
specific antibody can change following further sensitising events and also in response to 
alternative pro-inflammatory events such as infection or trauma [100].  Therefore it is 
recommended that patients awaiting a renal transplant are regularly monitored [99]. 
1.14 Methods for Detection and Identification of HLA specific 
Antibody. 
A large proportion of the work carried out by the transplantation laboratory involves the 
detection and identification of HLA specific antibody both in patients awaiting renal 
transplantation and in monitoring those who have been transplanted. 
There are two main routes by which potential donor specific antibody may be identified.  The 
first is through screening patient serum samples to detect the presence of, and identify the 
specificity of, antibody specific for HLA.  The second is through crossmatching a patient against 
a potential donor to detect actual donor specific reactivity.  Broadly these assays can be 
defined as being cell-based or solid phase. 
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1.14.1 Cell Based Assays 
1.14.1.1 Complement Dependent Microlymphocytotoxicity (CDC). 
The CDC assay was first described in 1964 by Terasaki and McClelland [15].  The basic premise 
of the test is that cells expressing a variety of HLA antigens are incubated with patient sera.  
Antibody present in the sera specific for antigens on the surface of the cells will bind.  Rabbit 
derived complement is then added and any bound antibody that is of the correct class and/or 
subclass, of sufficient titre and binds with high enough affinity will activate the classical 
complement cascade leading to the generation of the final membrane attack complex (MAC) 
and perforation the cell membrane.  Cell death, indicating the presence of a complement fixing 
antibody specific for an antigen on the cell, can then be visualised by the use of vital dye 
staining.  Dye is able to enter cells whose membranes have been perforated by MAC 
generation, and is unable to enter cells which have not been damaged by complement fixation.  
Staining can be observed using a fluorescence microscope.  When using a stain composed of 
ethidium bromide, acridine orange and haemoglobin living cells appear green and lysed or 
perforated cells appear red.  Strong, or high titre, antibody may lead to death of all the cells 
present, whereas weaker antibody may lead to only some of the cells being observed to have 
died.  The proportion of living to dead cells can be estimated and a score attached.  
International scoring generally follows ‘0’ for no cell death, through 2, 4, 6 and 8, representing 










Figure 12 - Example of Cells Observed in a CDC Assay (in-house photography). 
 
This method can be used for both the detection and identification of HLA specific antibody, 
and for donor crossmatching.  For identifying HLA specific antibody a patients’ serum sample is 
tested against a panel of cells of known HLA type, and analysis of the reaction patterns can 
indicate which HLA antigens the antibody in the sample is specific for.  The cell panels can be 
generated locally through use of donor or volunteer cells, or be purchased as pre-plated frozen 
cell panels.  The cell panels need to be designed to ensure that as many common HLA antigens 
as possible are represented.  A significant problem with the design of cell panels can be caused 
by linkage disequilibrium, where combinations of HLA alleles in a haplotype are found at a 
higher frequency than would be expected based on the frequencies of each individual allele.  
So if two antigens, for example HLA A1 and B8, are often presented together it can complicate 
HLA antibody specificity analysis in designating which antigen the antibody is directed at.  
Therefore it is necessary to design the panel to ensure that these antigens are represented on 
some cells separately.  When cell panels are generated locally the composition of the panel 
can vary between batches meaning that, when monitoring a patient over the longer term, 
variations in panel reactive antibody (PRA) value can occur not through changes to the 
patients’ antibody status but due to changes in the panel composition.  The differences in 
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panel composition between laboratories also means that PRA values cannot be compared with 
great accuracy between centres [101]. 
The method described above is often referred to as the National Institutes of Health (NIH) 
direct CDC.  Since its introduction a number of variations have been described in an effort to 
increase the sensitivity of the method. One such variation is the indirect antihuman globulin 
(AHG) CDC described by Johnson et al. in 1972 [102].  Here, following incubation of cells and 
serum, rabbit anti-human IgG antibodies are added prior to complement addition to amplify 
the cytotoxic response. This is believed to allow antibodies of titre or classes which are unable 
to efficiently fix complement to also be detected.  Antibodies of the IgM class are able to 
efficiently fix complement and can cause positive reactions in the CDC assay. However they 
may not be HLA specific, and, even if they are, the significance of IgM HLA specific antibody in 
solid organ transplantation has not been clarified [103-105].  Pre-treatment of serum with 
Dithiothreitol (DTT), which reduces disulphide bonds, causes the breakdown of the IgM 
pentameric structure, required for IgM to fix complement, and reduces its interference with 
the CDC assay, meaning any positive reactions observed can be generally assumed to be due to 
IgG class antibodies.  Even with the variations on the technique available the CDC assay 
remains relatively insensitive, generally only detecting high titre complement fixing antibodies 
[106] and whilst this is important in avoiding hyperacute rejection [16] both low level 
complement fixing and non-complement fixing antibodies have been associated with higher 
incidence of acute rejection and worse outcomes post-transplant [107] neither of which can be 
detected using the conventional CDC assay.  In addition it requires a relatively large number of 
viable cells, analysis is subjective and the assay requires a high degree of manual dexterity.  
Often the cells used in a simple CDC assay are unseparated, meaning that, when derived from 
peripheral blood, the majority will be T lymphocytes, mainly expressing HLA Class I only; up to 
20% of the cells will be B cells expressing HLA Class I and II.  To accurately assess the presence 
of antibody to both classes it is necessary to physically separate the T and B cells into separate 
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populations to be used in separate assays adding further to the technical challenges of this 
assay. 
1.14.1.2 Flow Cytometric Screening and Crossmatching. 
Cell based flow cytometric assays for HLA specific antibody detection use target lymphocytes, 
donor derived for the crossmatch and cultured cell lines for screening, which are incubated 
with patient serum to allow any antibody present to bind to targets on the cells.  Bound 
antibody is then detected through the addition of a fluorescence labelled secondary antibody 
which is detected and quantified using a flow cytometer.  The class and subclass of antibody 
can be defined by the addition of different secondary antibodies, most commonly IgG specific 
but also IgM, IgA and IgG 1 – 4 subclasses can be identified [92, 108, 109]. Flow cytometric 
based techniques have greater sensitivity compared to CDC [110].  Screening of patient sera on 
a large scale using flow cytometry with cellular targets is generally limited to the detection, 
rather than identification, of HLA specific antibody.  Various cell lines are pooled in an effort to 
ensure that all the major HLA specificities are covered within the pool.  Cell targets can be 
derived from pools of chronic lymphocytic leukaemia patients [111], PBLs [112, 113] and 
Epstein Barr Virus transformed lymphoblastoid cell lines [114, 115].  Any samples testing 
positive can then be further analysed using either individual cell lines or other antibody 
identification techniques.  In 1983 Garovoy et al. first described the use of flow cytometry for 
crossmatching in transplantation [116].  Initially they used a single colour technique to detect 
IgG binding to lymphocytes and found that it was up to 50 times more sensitive than the 
standard CDC XM test.  Further work led to the introduction of the two colour [117], and then 
three colour [118], crossmatching methods where addition of various alternative fluorescence 
labelled antibodies to target antigens on different cell populations allows for the easy 
differentiation of cell types in one test sample, so T cells and B cells can be separated on 
analysis through addition of differently coloured CD3 and CD19 specific monoclonal antibodies 
respectively.  Analysis of the FXM is generally based on comparison of the patient/donor 
reactions to a negative control, where, in addition to reactions with recipient sera, the donor 
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cells are incubated with a validated negative control serum, generally acquired from a pool of 
unsensitised AB blood group males.  Reactivity of the patient serum above that seen with the 
negative control indicates that there is antibody present in the patient sera that is binding to 
the donor cells.  The level of reactivity above the negative control required to constitute a 
positive FXM result is defined locally by each laboratory.  A positive T cell crossmatch is 
indicative of the presence of donor HLA class I specific antibodies, as T cells, unless activated, 
generally express only HLA class I.  A positive B cell crossmatch can be indicative of either low 
level HLA class I specific antibody, as B cells express higher levels of HLA class I than T cells 
[119, 120], or donor HLA class II specific antibody.  A summary of the causes of positive FXM 
can be seen in table 1 below. 
Table 1 - Influence of HLA class specificity of Antibody on Crossmatch Result. 
Antibody T cell FXM result B cell FXM result 
No HLA specific antibody Negative Negative 
Class I and II HLA specific Ab Positive Positive 
High titre Class I HLA specific 
Ab 
Positive Positive 
Low titre Class I HLA specific 
Ab 
Negative Positive 
Class II HLA specific Ab Negative Positive 
Autoantibody ?Negative Positive 
 
 Whilst a positive CDC XM has been shown to predict hyperacute rejection post-transplant 
[16], the flow cytometric crossmatch (FXM), being more sensitive and detecting antibodies of 
both lower titre and non-complement fixing types, has been shown to detect weaker donor 
specific antibody and identify patients who are at increased risk of antibody mediated 
rejection which would have otherwise been missed using CDC XM alone [121].  The T cell FXM 
in particular has been shown to have a greater value in predicting future antibody mediated 
rejection in comparison to the CDC XM [122-125].  The B cell crossmatch remains more 
controversial however with studies both supporting [126-129] and failing to support [130-133] 
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a correlation between a positive B cell FXM and poor graft outcome.  There is still much 
controversy surrounding positive cut off levels for the FXM, particularly for B cell crossmatches 
where higher background binding can be observed [134, 135]. Each centre must validate how 
much reactivity above negative control is significant and could be classed as being potentially 
detrimental to the outcome of the transplant when performed under the clinical conditions in 
their unit.  Whilst the basic FXM method is similar between centres standardisation of the 
technique is difficult to achieve due to variations in the method, differences between reagents 
and cytometers used and differences in the calculations used to generate the reaction value.  
These variations again highlight the requirement for centres to assess and set their own cut-
offs based on the clinical situation in their unit. Despite the difficulty in setting cut off levels for 
the FXM, the greater sensitivity of the FXM in detection of donor specific antibody compared 
to CDC XM means that in many centres it has largely replaced the use of the CDC XM in recent 
years.   
1.14.1.3 Autoantibodies. 
All cell based assays have the disadvantage of detecting antibodies to non-HLA targets, so 
called autoantibodies, along with alloantibody.  Autoantibodies are not HLA specific and will 
bind to targets on both donor and self-derived cells, and have been shown to have no effect on 
transplant outcome [136, 137].  The influence of these antibodies can be determined by 
performing auto-crossmatches whereby a patients’ own cells are incubated with their own 
serum samples in the same assay set up as a conventional crossmatch.  Any reactivity observed 
can be subtracted from the donor crossmatch to provide a more indicative crossmatch result.  
However this is easier to apply to FXM where definitive numerical values are achieved, and 
must always be carried out in conjunction with in depth antibody specificity analysis, 
particularly in highly sensitised patients, to ensure that all or most of the reactivity observed 
can be accounted for by non-HLA specific antibody.  Early studies investigating the cause of B 
cell positive FXM have reported up to 94% of B cell positive FXM could be due to non-HLA 
specific autoantibodies based on detection of potential DSA using screening techniques [138].  
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However, with the development of more sensitive screening and antibody identification 
methods this figure was reduced to 50% in more recent reports [139].  By including positive B 
cell FXM due to autoantibodies in analysis of the influence of a positive B cell FXM in renal 
transplant outcome then it is unlikely that an association would be found, highlighting the 
importance of investigation into the causes of a positive FXM result and if necessary testing for 
autoantibodies in conjunction to HLA specific antibodies by running an auto FXM test in 
parallel with the donor FXM.   
1.14.2 Solid Phase Assays. 
The alternative to cell based methodologies are the so called ‘solid-phase assays’ (SPA).  SPAs 
were first introduced in the 1990s and rapidly gained favour due to their increased sensitivity 
and specificity when compared to the cell based methods [140].  SPA are generally commercial 
kits which utilise intact HLA molecules that have been either solubilized and purified from cell 
membranes or recombinant HLA antigens from transfected cell lines [141] and then 
immobilised onto a solid matrix, most commonly a microtitre plate or polystyrene 
microparticles.  The benefit of using purified HLA molecules, when compared to whole cells, is 
that generally only HLA specific antibody is detected, with far less interference from non-HLA- 
and auto- antibodies.  The SPAs also allow for easy differentiation of HLA class I and II 
antibodies through separating these into either different testing wells or bead populations.  
With all the SPAs available there are three levels of testing – 
1. Detection – provides a yes/no answer to the presence of HLA specific antibody. 
2. Panel Reactivity – allows medium resolution of antibody specificity. 
3. Single Antigen – allows high resolution of antibody specificity. 
Detection methods use pools of HLA glycoproteins, generally separated into class I and II, and 
cover at least the majority of the HLA antigens found commonly in the population.  They 
provide a rapid and more cost effective method of high throughput screening, allowing the 
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identification of positive samples requiring more detailed analysis using higher resolution kits.  
Panel reactive, or phenotype panel, kits again separate HLA class I and II, and limit the HLA 
antigens present in each test well, or on each bead population, to that found on one donor 
cell.  So, for class I the maximum number of different antigens present would be 2 each of HLA 
A, B and Cw, and for class II it would be limited to a maximum of 2 each of the HLA DRB1, 3, 4 
or 5, DQ and, depending on the kit, DP.  Analysis of reactivity patterns allows identification of 
antibody specificity, although in highly reactive sera some specificities may be masked by the 
presence of others, particularly in the case of antibodies to Cw, DQ and DP [141].  It is thought 
that the phenotype panel kits may best reflect the in vivo situation as the panel may include 
phenotypes to which the patient has more than one donor specific antibody, allowing the 
assessment of the combined reactivity of these antibodies [109].  The most sensitive of the 
tests available are the single antigen panels, where each test well or bead population is coated 
in a single HLA specificity allowing for high resolution antibody analysis.  The single antigen 
methods are particularly useful in analysis of highly reactive sera giving the most accurate 
information available as to the exact HLA antigens to which a patient produces antibody [142]. 
In general the SPA routinely detect IgG class antibodies only, however they can be adapted to 
detect IgM [143, 144], IgG1-4 [145, 146], IgA [147] and more recently to directly assess 
complement fixation through the detection of the deposition of complement cascade 
components C4d [148] or C1q [149]. 
All SPAs provide an analyser derived numerical read out allowing analysis of the results to be 
more objective than CDC and also they are believed to be semi-quantitative giving an 
indication as to the titre of the antibody present [92, 150]. 
1.14.2.1 Enzyme-Linked Immunosorbant Assay (ELISA). 
The first commercially available SPA for HLA antibody detection and identification was in the 
form of an ELISA kit called PRA-STAT, launched in 1994 by SangStat.  The initial aim of the PRA-
STAT kit was to provide a method for HLA antibody identification that was more robust than 
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the CDC test, without the requirement for viable cells, validated complement , subjective 
analysis, detection of non-HLA specific antibodies and autoantibodies, and which gave a 
standard panel against which all patients could be tested [151].  Whilst the PRA-STAT kit is no 
longer available, other commercial ELISA kits are still routinely used in many laboratories, and 
have been found to be more sensitive than CDC in detecting HLA specific antibody [152].  For 
ELISA based methods the HLA antigens are immobilised in the well of a microtitre plate and 
patient serum is added.  Any antibody specific for the antigens in the well will bind during 
incubation and, following a wash step, a secondary antibody, specific for human IgG, is added, 
which will in turn bind to any patient antibody present in the well.  This secondary antibody is 
conjugated to a reporter molecule, such as alkaline phosphatase, which on addition of a 
substrate, such as p-nitrophenyl phosphate, will result in a colour change in the well.  This 
colour change is then measured using spectroscopy to assess the optical density and, in 
general, the greater the colour change the higher the level of antibody in the well. 
Disadvantages of ELISA based methods include the requirement for large serum volumes, 
relatively long incubation times and low throughput capacity in comparison to other SPAs 
available. 
1.14.2.2 Flow Cytometry 
Flow cytometric based SPAs are similar to more traditional cell based flow screening, but 
instead of cellular targets the HLA antigens are immobilised onto microparticles.  For detection 
tests these are separated into two pools of class I and class II coated beads.  On incubation 
with patient sera any HLA specific antibody will bind to the beads and is then detected using a 
FITC-conjugated secondary human IgG specific antibody.  The level of fluorescence is then 
assessed using a flow cytometer and the fluorescence signal achieved with the patient sample 
is compared to that achieved with a negative control serum, with the level of fluorescence 
above the negative control being indicative of the level of antibody binding.  Low titre 
antibodies, perhaps to only single specificities, may however be missed as the level of 
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fluorescence seen may not reach the positive threshold.  In these circumstances the 
architecture of the peak must be examined by an experienced technician to detect small 
changes to the curve shape, or the presence of small secondary peaks, which may indicate the 
presence of a low titre antibody. 
Antibody identification methods utilise pools of beads with different fluorescence properties 
due to variations in red fluorescence staining.  Each bead is coated with either a single 
phenotype or single HLA antigen and can be in pools of 8 – 12 different bead populations.  On 
analysis the different bead populations in the pool are separated due to the variations in red 
fluorescence staining and bound antibody is identified through the green fluorescent staining 
of the FITC conjugated secondary antibody.  Read out is based on median channel shift and 
comparison to a negative control [153].  The antibody identification panels available for flow 
cytometric analysis are limited in size by the ability to resolve different bead populations, 
meaning that, particularly in the single antigen setting, a panel size of 28 antigens requires 4 
bead pools and therefore 4 sample preparations.  Whilst this can be representative of a 
population many antigens are not included and therefore antibody specificities may go 
undetected. 
1.14.2.3 Luminex 
Luminex based methods are the most recently introduced SPA for HLA specific antibody 
testing.  Similar to the flow based methods, the Luminex assays use pools of microparticles 
coated in purified or recombinant HLA molecules.  The microparticles are specifically designed 
to be analysed using a Luminex flow analyser, and up to 100 different microparticles can be 
distinguished in one test based on the ratio of red to infra-red internal dye in each bead.  
Equipped with two lasers, the Luminex analyser simultaneously uses a red laser to identify the 
microparticle and a green laser to measure the R-phycoerythrin (PE)-conjugated secondary 
antibody bound to the analyte coating the bead, in the case of HLA antibody definition this will 
be a patient derived HLA specific antibody bound to HLA antigen coating the bead.  Analysis of 
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the combination of these two signals allows either the presence of antibody, in detection tests, 
or the specificity of antibody, in identification tests, to be defined.  The amount of PE 
conjugated antibody bound to a bead is given as a mean fluorescence intensity (MFI) value and 
can give an indication as to the titre of antibody present in the patient serum [150].  There are 
currently two manufacturers that produce Luminex kits for HLA specific antibody detection 
and identification, One Lambda and Gen-Probe, and whilst both aim to provide the same 
information, there are differences in manufacturing processes, assay method, reaction 
calculations and panel composition. 
Luminex based methods have been found to be the most sensitive of all the SPA currently 
available [154], however the clinical relevance of antibody detected by Luminex only, or by 
solid phase but not CDC, is a matter of great controversy.  A number of studies have been 
reported where the clinical effect of SPA only detected antibodies on transplant outcome have 
been investigated.  The general trend for the majority of reports is a detrimental effect of 
these antibodies, either by a reported reduction in graft survival or through an increase in 
observed rejection episodes [155-158].  However this is not always the case with further 
reports finding no association between SPA only antibodies and outcome, particularly in the 
case of Luminex single antigen only detected antibodies [159, 160].  With regard to low level 
donor specific antibody in renal transplantation consensus does now appear to be in favour of 
relevance, at least in the long term outcomes [161-163]. Roelen et al. [164] in a recent review 
concluded that low level DSA are not a contraindication to transplant, but are a risk factor for 
acute rejection.  
1.15 Accommodation  
One possible explanation for a lack of detrimental effect being seen with all donor HLA specific 
antibodies could be the development of accommodation.  Accommodation was first described 
in patients receiving ABO blood group incompatible transplants, where despite the initial 
reduction in ABO antibody titres following antibody removal and transplantation, the antibody 
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returned to circulation yet antibody mediated damage to the organs was not observed [165].  
The antibody does appear to be able to bind to the graft and fix complement, a finding borne 
out by the fact that many biopsies from these patients with functioning grafts show positive 
staining for C4d but no other histology indicating AMR [166].  Accommodation is defined as 
the acquired resistance of the transplanted organ to antibody mediated injury and is believed 
to involve Ab induced endothelial cell expression of pro-survival and cryoprotective proteins, 
along with regulation of the terminal complement components [167].  Jindra et al. [168] found 
that crosslinking HLA class I molecules on the surface of endothelial cells with low dose 
antibody induced cell survival through stimulation of the mTOR-2 pathway which led to an 
upregulation in the expression of anti-apoptotic protein Bcl-2.  Salama et.al. [169] reported 
that expression of another pro-survival protein, Bcl-xL, was also upregulated in the endothelial 
cells of patients who had circulating DSA but no demonstrable AMR on biopsy, following HLA 
antibody incompatible renal transplantation.  In a mouse xenograft model, in addition to Bcl-2 
and Bcl-xL, expression of other pro-survival genes such as A20 and cryoprotective proteins 
hemoxygenase and nitric oxide have been reportedly upregulated in the endothelial cells of 
accommodated cardiac xenografts but not in rejected hearts [170].  Ding et al. [171] using 
another mouse xenograft model found that accommodation could be induced by regular 
injection of low doses of donor specific antibody, and that this effect was likely to be due to 
the increase in expression of complement regulatory protein, decay accelerating factor (DAF), 
which has been found to inhibit hyperacute rejection.  This evidence suggests that particularly 
in patients who undergo antibody removal transplantation, the phenomenon of 
accommodation could at least in part explain why not all DSA are detrimental in the outcome 
data achieved. 
1.16 Transplantation of Sensitised Patients. 
Patients who produce any amount of HLA specific antibody are said to be sensitised.  In the UK 
a patient who produces HLA specific antibody reactive to >85% of a cell panel representative 
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of the general population are defined as being ‘Highly Sensitised’ by Organ Donation and 
Transplant (ODT).  Traditionally this level was defined by the patients’ treatment centre 
laboratory, using locally derived or kit based cell panels, to generate a panel reactive antibody 
(PRA) value, which represented the percentage of positive reactions against the panel.  Whilst 
this gave some indication as to the breadth of reactivity of a patient against a population of 
donors the value achieved was highly dependent on the composition of the testing panel.  In 
recent years ODT have published a computer based algorithm whereby the specificities of the 
antibody produced by a patient can be input, and a virtual % calculated reaction frequency 
(cRF) can be generated, by comparing the HLA types of the past 10000 blood group compatible 
donors and calculating the number of these donors with which a positive crossmatch may be 
expected based on the antibody specificity.  The values achieved range from 0% in 
unsensitised patients to 100% for the most highly sensitised patients, and give an indication to 
both the clinicians and patients as to their chances of receiving an organ offer through the 
national allocation system. 
The first option open to sensitised and highly sensitised patients is to wait for an offer of an 
organ from a compatible deceased donor through the national allocation system.  However 
this group of patients generally have much longer waiting times compared to unsensitised 
patients.  A recent report from the American Organ Procurement and Transplant Network 
(OPTN)  suggested that the numbers of offers decreased with increasing sensitisation, such 
that patients with cRF of 80-84 % had an offer rate of only 40% that of unsensitised patients, 
and this decreased dramatically to 1% in those patients classified as having 100% cRF [172].  Vo 
et al. reported that in the US only 6.5% of the highly sensitised patients of the national waiting 
list are transplanted annually compared to an overall transplantation rate in all groups of 20% 
[173].  A UK analysis of the waiting times for patients registered between 1998-2005 showed 
that unsensitised patients had a median waiting time of 788 days, patients with a cRF of 61-
84% waited 1696 days and the highly sensitised patients, cRF >85% waited 2232 days [92]. 
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An audit of UK kidney waiting list data by ODT indicates that in 2006 23% of patients awaiting a 
first transplant and 52% of patients awaiting a second, or subsequent graft, were sensitised 
[92].  An audit of the patients awaiting transplant at our centre in January 2013 found 56% of 
the waiting list were sensitised and 54% of these were classified as highly sensitised due to 
having a cRF of >85%.  With the advent of new technology allowing for more sensitive and 
sophisticated detection and identification of HLA specific antibodies it is likely that the number 
of patients on the waiting list classified as sensitised will continue to increase, this has been 
demonstrated on analysis of the numbers of patients awaiting transplant on the UNOS 
database who are highly sensitised increasing by 25% in the year 2002-2003 corresponding 
with the widespread introduction of Luminex based solid phase antibody detection systems 
across the US [174]. 
Phelan et al. have reported that in the Republic of Ireland waiting times for patients with a PRA 
of greater than 50% can be more than double that of patients who produce no HLA specific 
antibody, with a combination of being blood group O and sensitised having the longest waiting 
times [175]. 
Longer waiting times are associated with an increase in morbidity and mortality, with 
approximately 2-4% of patients on the renal transplant waiting list dying annually without 
receiving a graft [176].  In addition a longer waiting time, and therefore longer time on dialysis, 
is also associated with poorer long term outcomes post-transplant, in terms of both graft and 
patient survival [177]. 
Transplantation of an organ from a living donor offers good outcomes and can often be 
preferable to a deceased donor transplant.  However in our centre approximately 25% of the 
patients assessed for transplantation from a potential living donor will have antibody to this 
donor preventing a straight forward, low risk, direct transplant. 
Another option open to these patients who have a willing but incompatible donor is to enter 
into the national paired scheme.  Here a patient, and any associated potential living donors, 
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are registered in a pool with ODT, and four times a year an allocation ‘matching run’ is 
performed to identify compatible combinations of pairs, whereby the donor of one pair will 
donate to the recipient of another pair and vice versa.  This scheme is useful to patient and 
donor combinations who are ABO blood group incompatible and/or HLA antibody 
incompatible, although highly sensitised patients are still less likely to achieve a match than 
those that are unsensitised [178, 179].  The numbers of potential transplants from one run are 
increased by the inclusion of both two-way and three-way swaps, four-way swaps are also 
possible, however de Klerk et al. in a recent analysis of the Dutch waiting list, found that the 
numbers of possible transplants from a single run were not significantly increased by allowing 
both four-way or unlimited chains [180].  At our centre, since 2007 a total of 73 patients have 
been included in the paired matching run and over the past six years 18 of these have received 
a transplant through the scheme.  Having a high level of sensitisation reduces the possibility of 
being matched and of those who have not been transplanted through the scheme at our 
centre the majority are highly sensitised, highlighting the difficulties faced in transplanting 
these patients. 
In recent years a third option has become more routinely available to these patients, antibody 
removal.  Antibody removal, or de-sensitisation, is a term that covers a variety of therapies 
aimed at reducing or removing the donor specific antibody produced by a patient to allow 
successful transplantation from either a given living donor or through the deceased donor 
scheme.  Strategies have been developed to allow transplantation across both HLA and ABO 
blood group antibody incompatibilities [181]. However in this thesis I shall be concentrating on 
those applied to HLA specific antibody removal only. 
One of the earliest reports of successful renal transplantation following HLA specific antibody 
removal in the more recent era came from Taube et al. in 1984 [182].  They reported 
transplantation in a group of 5 patients all of whom were sensitised through previous failed 
transplants and were in urgent need of a subsequent graft.  The antibody removal method 
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adopted in this group of patients followed the regimen designed for removal of glomerular 
basement membrane specific antibodies in Goodpasture’s syndrome and consisted of thrice 
weekly plasma exchange (PEX) continued until the HLA specific antibody titres, assessed using 
CDC, fell below 1 in 10.  In total the patients received 6 – 10 sessions of PEX.  All 5 patients had 
a significant reduction in PRA and were transplanted with a deceased donor organ, having a 
positive CDC crossmatch pre-treatment, which was reduced to negative immediately prior to 
the transplant.  All 5 patients suffered multiple rejection episodes, and one patient died 6 
weeks post-transplant due to septicaemia.  Following this Palmer et al. in 1989 reported a 
series of 10 highly sensitised patients who underwent HLA specific antibody removal using 
extracorporeal immunoadsorption (IA), of which 7 went on to receive a transplant [183].  This 
method required the patient to be treated with plasma exchange. The plasma volume 
removed was then passed down a staphylococcal protein A column to remove the IgG 
antibody, prior to being returned to the patient.  Patients received 3-18 treatment sessions, 
with PRA assessment following each session.  All patients showed a reduction in PRA and of 
those transplanted both the CDC and flow cytometric crossmatches (when available) were 
reduced to negative pre transplant.  Overall there were only 6 reported episodes of rejection 
in the seven patients, one of the seven transplanted grafts failed to function and one had 
failed by one year. However in 1996 the same group published a follow-up report stating that 
from this series all the grafts that were functioning at one year, remained so by 5 years [184].  
Whilst these two series involved multiple antibody removal sessions for a significant length of 
time prior to transplantation, in 1996 Higgins et al. reported the use of IA immediately prior to 
transplantation in a series of 13 patients [185].  All 13 patients were sensitised with PRA 
ranging from 63-100% and had been waiting for a deceased donor transplant for at least 2 
years.  In this series antibody removal was not initiated until a deceased donor organ had been 
identified, the patient then underwent one or two sessions of IA, totalling up to 22 hours of IA 
pre transplant.  All 13 patients had the flow cytometric crossmatch reduced to negative.  6 
grafts failed within the first 6 months and 7 functioned, with a median graft survival at 26 
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months of 53.8%.  Of note the cold ischaemic time (CIT) for the donor organs ranged from 28-
62 hours, a period of time that would no longer be deemed acceptable, and may be in part 
responsible for the poor initial outcomes.  Following these early reports there have been a 
number of published single and multi-centre studies relating to HLA specific antibody removal 
prior to renal transplantation with a variety of success [186-191].  To date the majority of the 
protocols designed for desensitisation involve some combination of PEX or IA, intravenous 
immunoglobulin and/or Rituximab. 
Plasma exchange and immunoadsorption are two methods of physical antibody removal.  
When treated with PEX a patient’s blood is removed via a cannula and subject to 
centrifugation or double membrane filtration to separate the plasma from the cellular 
components [192, 193].  The cellular fraction is then returned in addition to plasma 
replacement, either albumin or fresh frozen plasma from a donor.  It is not specific for 
antibody and removes all plasma proteins including clotting and complement components.  
Exchange of a single blood volume will remove up to 63% of the plasma proteins, including 
antibodies [194].  IA is more specific for antibody and involves separating the plasma from the 
cellular components and then passing this down a sepharose-bound staphylococcal protein A 
or protein G column to which IgG type antibodies will bind with high affinity, prior to 
reintroduction of the filtered blood to the patient [195].  A diagram representing these two 
methods can be seen in figure 13 below.   IA has the advantage over PEX of being antibody 
specific and does not require the replacement of large plasma volumes.  Additionally it does 
not affect coagulation [196].  Three to six courses of IA can lead to a reduction in IgG of up to 
90% [195].  However, IA is significantly more expensive than PEX and in addition, those 
columns utilising protein A do not remove antibodies of the IgG3 subclass as efficiently as 
IgG1,2 + 4 [197] and since IgG3 subclass antibodies are able to fix complement very efficiently 
[198] this may be of relevance in antibody removal prior to transplantation.  Antibody removal 
through PEX or IA alone does not have a long term effect, with a rebound in antibody levels 
following an antibody removal session being seen within 3 hours due to diffusion of antibody 
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in the extravascular areas back into circulation [199, 200].  This can in part be compensated for 
by carrying out multiple sessions in a relatively short period of time.  Antibody removal does 
not stop antibody production and removal of large levels of antibody may in fact activate 
homeostatic feedback mechanisms, causing an increase in the production levels of antibody by 
plasma cells [201].  In an attempt to prevent resynthesis and rebound of antibody most 
protocols for desensitisation using PEX or IA involve the addition of immunosuppressant drugs 
(mycophenolate mofetil (MMF) and tacrolimus (tac)), intravenous immunoglobulin (IVIg) 
and/or anti-CD20 monoclonal antibody, Rituximab, or splenectomy [192]. 
Figure 13 - Diagram representing the mechanical process of antibody removal by PEX 
(a) and IA (b) [202].  
 
IVIg is the term given to a number of commercially available preparations primarily composed 
of IgG monomers isolated from the blood of up to 1000 donors, often using ethanol 
precipitation, and then pooled [193].  IVIg has been used as an antibody replacement therapy 
in a number of immunodeficiency conditions such as hypogammaglobulinemia and severe 
combined immunodeficiency [203] and since 1981 it has been recognised as a treatment 
option for autoimmune diseases such as chronic idiopathic thrombocytopenic purpura [204].    
There have been many theories proposed as to the mechanism of action of IVIg in combating 
antibody production, or its effects, and it is likely that many actions are involved [205].  IVIg is 
believed to effect the actions of the complement cascade by binding C3b and C4b and 
preventing them binding to the cell membrane so inhibiting the generation of the terminal 
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membrane attack complex of the complement cascade [206].  It has also been proposed that 
IVIg neutralises circulating antibodies through anti-idiotypic actions [203], although this has 
been questioned by subsequent studies [206].  IVIg is also believed to have effects on the 
cellular components of the immune system through binding to targets such as the Fcγ 
receptors on neutrophils, macrophages, NK cells and mast cells leading to non-specific effects 
such as inhibition of cytokine production and adhesion molecule activity [195].  It has also 
been shown to bind to the inhibitory receptor FcγIIB, inhibit expression of CD19 on activated B 
cells, induce apoptosis of B cells and inhibit alloreactive T cells [207, 208]. The use of IVIg in 
autoimmune diseases highlighted the apparent immunosuppressive effects of IVIg and in 1994 
Tyan et al. reported the use of IVIg to suppress production of HLA specific antibody in highly 
sensitised renal and cardiac transplant candidates to allow transplantation with an HLA 
antibody incompatible organ [209].  Since this time the use of IVIg both in desensitisation 
regimens and to treat antibody mediated rejection episodes has been widely reported.  In 
terms of its use in desensitisation two main protocols have emerged, the use of high dose IVIg, 
usually 2.0g/kg, alone, or low dose IVIg, from 100mg/kg, in conjunction with PEX or IA [195].  
The group at John Hopkins University in Baltimore first described the use of PEX with low dose 
IVIg for antibody removal, both for desensitisation prior to renal transplantation and as a 
rescue therapy for transplanted patients with acute humoral rejection, reported by 
Montgomery et al. in 2000 [210].  They reported a series of 7 patients treated with PEX, IVIg at 
100mg/kg, tac and MMF, 3 of which were post-transplant and suffering acute humoral 
rejection and 4 pre transplant who had positive CDC (n=1) or flow cytometric (n=3) 
crossmatches against their potential living donor.  The patients received 2 – 10 sessions of PEX 
and were transplanted once the crossmatch became negative.  All 4 patients had one or more 
episodes of antibody mediated rejection but they reported a 100% graft survival at 1 year. 
Jordan et al in 2003 reported a series of 45 highly sensitised patients treated with high dose 
IVIg, at 2g/kg, to reduce anti-donor activity [211].  28 of these patients had potential living 
donors with whom they had a positive crossmatch.  In these patients IVIg was added to the 
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CDC XM and if a reduction in reactivity was seen the patients were given a single dose of IVIg, a 
further XM, and, if negative, rapidly transplanted.  A similar strategy was employed with the 
patients awaiting a deceased donor.  42 patients were transplanted, all with a negative CDC 
XM but 7 remained flow XM positive.  Antibody mediated rejection was seen in 31% of the 
patients, leading to graft loss in 7%. However patient and graft survival at 2 years was 98% and 
89% respectively.  Over the past decade many groups have reported similar series of patients 
who have been treated with a variety of desensitisation regimens which include PEX and IVIg 
but additionally adapted to include other agents such as rituximab and anti thymocyte globulin 
(ATG).  Rituximab is a humanised chimeric monoclonal antibody directed against CD20 
expressed on developing and mature B cells from late-pro B stage to memory B cells, but not 
on plasma cells.  Infusion of Rituximab causes a rapid and prolonged depletion of circulating B 
cells and is currently licensed for treatment of non-Hodgkin’s lymphoma [212] and post-
transplant lymphoproliferative disease [195].  It is also under investigation for use in various 
autoimmune diseases as it is believed to reduce antibody production in certain situations, 
however since CD20 is not expressed on the main IgG producing plasma cell it is unlikely to 
cause immediate or potentially even long term effects on alloantibody production.  It has been 
proposed that eliminating the early B cells would ensure that no new alloantibody producing 
plasma cells could be generated, and in addition there would be no B cells available to present 
antigen to alloreactive T cells so preventing the generation of new alloantibody producing 
clones [212].  Vieira et al. [213] in 2004 reported a series of 9 patients who all had a PRA of 
>50% and had been treated with a single dose of Rituximab.  7 of the 9 nine patients showed a 
potential reduction in PRA within 6 months of dose, although this was not confirmed using 
antibody specificity analysis in all cases, and one patient went on to be transplanted having 
converted to a negative XM following treatment.  Ramos et al. investigated the splenic B cell 
populations in spleen samples taken from 25 patients who had been subject to various 
desensitisation regimens [214].  They noted that the addition of rituximab to the therapy did 
reduce the numbers of naïve B cells present in the spleen, but had no effect on the numbers of 
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memory B cells and plasma cells.  Of the regimens involved the only one where a reduction in 
the numbers of memory B cells was seen involved the addition of anti-thymocyte globulin 
(ATG) to the treatment plan, however this again did not cause a reduction in the plasma cell 
population.  ATG is a polyclonal antibody preparation generated by inoculation of animals, 
often rabbits, goats or horses, with human lymphocyte or thymocyte preparations.  The 
resulting purified IgG fraction contains antibody specific to many cell surface antigens found on 
T and B cells, NK cells and macrophages.  Its administration leads to rapid and prolonged 
lymphopenia.  It is used both as an induction agent prior to transplantation and also as a 
method of treating acute rejection episodes.  Stegall et al. carried out a comparison of the 
efficacy of three different desensitisation regimens [188].  Group 1 received high dose IVIg 
alone (n=13), group 2 received PEX, low dose IVIg and Rituximab (n=32) and group 3 received 
PEX, low dose IVIg, Rituximab and ATG (n=16).  In group 1 only 38% achieved a negative XM 
compared to 84% and 88% in groups 2 and 3.  Of those transplanted, 80% of group 1 and only 
37% and 29% if groups 2 and 3 had one or more antibody mediated rejection (AMR) episodes.  
They concluded that the regimen used for group 3 was the most effective, however the rate of 
AMR post-transplant was still significant.  Marfo et al. carried out an analysis encompassing 
the results from 21 published reports of renal transplantation following desensitisation 
between 2000 and 2010 [195].  There were a total of 725 patients included who were 
transplanted following desensitisation to remove donor specific antibody using various 
protocols.  Overall the patient survival rate was 95% and the graft survival 86% with a median 
follow up time of 2 years.  However, what was striking was the rate of acute T cell mediated 
rejection being 36% and acute antibody mediated rejection at 28%, which they reported to be 
significantly higher than the typical rate of <10% seen in unsensitised patients. 
A new immunosuppressive agent, bortezomib, has recently been reported to be effective in 
treatment of acute antibody mediated rejection of renal allografts which was refractory to 
other forms of treatment [215].  Bortezomib is a proteasome inhibitor which can cause 
depletion of antibody producing plasma cells.  Inhibition of the proteasome causes an 
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accumulation of unfolded proteins leading to cell cycle arrest and apoptosis. Plasma cells are 
particularly susceptible to apoptosis through proteasome inhibition due to their high protein 
production.  In addition to its effects on plasma cells, proteasome inhibition can also prevent 
antigen presentation to the immune system by stopping protein degradation and therefore 
the production of peptides required for incorporation into the groove of HLA molecules and 
their subsequent presentation on the cell surface [215].  Whilst the effect of bortezomib on 
PRA levels of highly sensitised patients awaiting transplant has so far been reported to be 
minimal [216], at least in the absence of other immunosuppression, with a demonstrable 
ability to reduce alloantibody production in rejecting patients, it is likely that bortezomib may 
become incorporated into antibody removal protocols pre transplant. 
Currently pre transplant HLA specific antibody testing is most useful in predicting AMR, which 
constitutes 5-30% of all rejection episodes [217].  However 70 – 95% of rejection episodes 
seen following solid organ transplantation are cellular in nature, and little can be done to 
accurately predict these [217].  In a recent study, Poggio et al., found no correlation between 
pre transplant PRA values and incidence of acute cellular rejection post-transplant [218]. 
Historically labs have used HLA antibody information as a marker for immune memory. 
However since antibodies to HLA can cross react widely between specificities due to shared 
epitopes, the original sensitising antigen is not always obvious.  Since T cell help is required for 
the production of HLA specific antibody, there will be T cell memory for the initial sensitising 
antigen or antigens, but not necessarily for all the HLA antigens to which antibody has been 
produced.  It would therefore be helpful to be able to identify if any of the HLA antigens 
presented by a potential donor are able to invoke a memory T cell response and therefore 
acute rejection. 
1.17 T cell Memory and Transplantation 
The human immune system is constantly being challenged by environmental antigens which 
results in the generation of multiple memory T cells.  These T cells are primed to respond 
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rapidly upon re-exposure to the initial stimulus.  Memory T cells possess a number of 
properties that allow for a rapid response compared to naïve T cells.  Naïve T cells are limited 
in their migration from circulation to mainly the secondary lymphoid tissues [219].  Once 
stimulated, a naïve T cell, within the confines of a secondary lymphoid organ, will differentiate 
into either an effector T cell or a memory T cell, dependent on the signals it receives [220, 
221].  These effector and memory T cells can then leave the secondary lymphoid organ and 
enter circulation, from which they can migrate into peripheral tissues.  Memory T cells are able 
to migrate through both lymphoid and non-lymphoid tissues [222, 223].  In addition to a wider 
ability to migrate, memory T cells have fewer requirements for activation, being able to 
interact with their cognate antigen in the periphery potentially without the need for co-
stimulation from APCs [224] and having far lower activation thresholds, allowing for responses 
to lower doses of antigen [225].  Expression of cytokines and their receptors, chemokines and 
adhesion molecules are all altered on becoming a memory T cell, which is thought to allow for 
more rapid migration to sites of infection and inflammation compared to naïve T cells [226].  
Following an infection a population of memory T cells generated to the stimulus are 
maintained in circulation until re-exposure [226].  This maintenance is most likely to be due to 
a low level of homeostatic proliferation of the memory T cells rather than being long lived cells 
[226]. 
Immune memory to non-self HLA antigens can be generated through exposure to non self HLA 
via previous transplants, blood transfusions and, in women, pregnancy.  Additionally, 
alloreactive memory T cells have been found in apparently unsensitised individuals [226].  
There are two suggested routes of generation of alloreactive memory T cells without exposure 
to non-self HLA – cross reactivity with infectious agents, or heterologous immunity, [227, 228] 
and homeostatic proliferation [229].  A number of published studies have demonstrated the 
ability of virally induced memory CD4+ and CD8+ T cells to cross-react with alloantigen in both 
mice and humans [230-233].  One example, from Burrows et al. [232] demonstrated that HLA 
B8 restricted CD8+ T cells generated in response to an EBV infection were able to crossreact 
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with various allo-HLA molecules including HLA B44.  The ability of these memory T cells 
generated through heterologous immunity to mount a rejection response has been 
demonstrated by Pantenburg et al. who reported that there was no difference between the 
rejection of skin allografts in mice when the memory T cells had been generated in response to 
Leishmania and were crossreactive, compared to those generated through previous allo 
exposure [234].  Homeostatic proliferation is another potential method to generate 
alloreactive memory T cells in the absence of exposure to non-self HLA.  Here it is believed that 
naïve T cells are capable of proliferating and differentiating into memory like T cells, which 
have acquired properties associated with the memory phenotype, such as the ability to 
infiltrate tissues [235].  This proliferation is initiated by the individual becoming lymphopenic 
such as during an infection or following lymphoablative treatment for disease or transplant 
rejection [236].  The memory T cells generated by homeostatic proliferation appear to be less 
efficient in their response compared to those generated through exposure to infection or non-
self HLA as Chalasani et al. demonstrated that memory T cells generated this way were less 
able to reject cardiac allografts compared to memory T cells generated by allo antigen 
exposure [235].  It is likely that memory T cells generated by alloantigen recognition via both 
the direct and indirect pathways will exist. 
1.18 Methods to Identify Alloreactive Memory T cells. 
Identification of allospecific T cells is more technically challenging than detecting HLA specific 
antibody.  Binding of antibody to its target antigen is a relatively simple process which can be 
detected in the various methods described earlier.  The binding and consequent activation of a 
T cell is a more complex process and as such more difficult to assay.   
1.18.1 Mixed Lymphocyte Reaction (MLR) 
Historically the mixed lymphocyte reaction, or MLR, has been used in an attempt to identify 
recipient T cell reactivity to a potential donor.  The MLR measures recipient T cell proliferation 
after culture with donor cells in vitro using 3H-thymidine incorporation.  It primarily measures 
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CD4 T cell reactivity via the direct pathway in cases of HLA class II mismatch [237].  It requires 
approximately 5 days to complete and the use of radioactivity, which would be best avoided 
[217].  The results achieved are also highly variable and no conclusive data have been 
published to indicate that the results correlate with transplant outcome [237, 238].  
Additionally this method only detects the proliferation capacity of the recipient cells. However 
many effector cells can only proliferate poorly on stimulation despite having very powerful 
effector functions such as the ability to secrete cytokines [239, 240] and therefore such 
reactivity may be missed.  Over 20 years ago variations on the MLR were introduced to assess 
T cell alloreactivity by analysing the ability of T cells to kill allogeneic target cells in the 
cytotoxic T lymphocyte assay (CTL) [239].  The CTL assay assesses CD8 T cell mediated killing of 
donor target cells via the direct pathway [237].  Additional variations include testing in limiting 
dilution in order to determine the frequency of the alloantigen reactive T cells. Here serial 
dilutions of responder and stimulator cells are mixed in culture and reactivity assessed by 
measuring proliferation, cytokine secretion or cytotoxicity [241].  Again the information gained 
from these assays is not always indicative of the post-transplant outcome, in addition the 
assays are labour intensive and the results not often reproducible [238, 239, 241].   
1.18.2 Flow Cytometric Detection Methods. 
A novel variation on the MLR is to use flow cytometric detection of the intracellular stain 
carboxyfluorescein succinimidyl ester (CFSE) which binds to intracellular proteins.  The 
fluorescence detected is halved with each cell division and can therefore give an indication of 
the extent of proliferation.  Flow cytometric based methods have the advantage of being 
highly sensitive, allowing phenotypic analysis of different cell populations, for example splitting 
CD4+ and CD8+ T cells, and the ability to analyse other markers simultaneously [242].  These 




Another flow cytometric based method for assessing T cell reactivity uses intracellular cytokine 
detection.  Waldrop et al. [243] reported a method whereby T cells are co-cultured with 
antigen presenting cells, which themselves had previously been incubated with specific viral 
peptides.  A secretion inhibitor is added, ensuring that any cytokines produced in response to 
this stimulation accumulate within the cells and can then be detected using fluorescent anti-
cytokine antibodies by flow cytometry. This assay is relatively quick, requiring only a few hours 
of incubation, but it is expensive and works only when there are high frequencies of 
responding cells (>1:10000) [239].  Suchin et al. adapted this assay to assess T cell alloreactivity 
post-transplant in mice [244]. 
A more direct method to assess which specific antigens a T cell can bind to is to use 
fluorescence labelled multimeric complexes of peptide plus either a class I or class II MHC 
molecule, called tetramers.  Binding of a T cell to one of these tetramers indicates that the cell 
possesses a TCR complementary to the peptide/MHC complex being presented.  Creation of 
these tetramer complexes is technically challenging, so only a limited number of peptide/MHC 
complexes are available.  In addition it has been found that binding of the T cell to a complex 
does not necessarily correspond with a functional effect, limiting the use of this method in 
analysis of the potential consequence of a transplant. [239] 
1.18.3 Enzyme-Linked Immunospot (ELISPOT) Assay. 
In recent years another promising method has been reported utilising the enzyme-linked 
immunospot assay (ELISPOT).  This was first described in 1990 as a method of detecting 
cytokine secretion from single lymphocytes following stimulation [241].  A number of groups 
have since used this method to probe for alloreactivity in T cells.  Briefly, ELISPOT plates with 
synthetic membrane bases are coated with cytokine specific capture antibodies.  Responder 
PBLs are added along with donor stimulator cells and incubated for 24-48 hours.  Activated T 
cells produce cytokines which are captured directly onto the well membrane.  Following 
washing steps the cytokine production is visualised using biotinylated enzyme linked detection 
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antibodies.  Spots develop on the membranes at the sites of the cytokine secreting cells and 
are then counted using a computer-assisted ELISPOT image analyser [239, 245]. The 
advantages of this method are that it provides functional information following a short culture 
period and it will detect low frequencies of responder cells. However it is expensive and only 
one cytokine can be measured in each well [239].  Heeger et al. reported that IFNγ production 
detected by ELISPOT within the first 24 hours of culture correlated with the presence of 
activated  memory T cells and that detection of these in increasing numbers correlated with 
the risk of post-transplant rejection episodes [245].  Interestingly they also found that the 
strength of alloreactivity appeared to be independent of the level of antigen mismatching 
[245].  Hricik et al. used the same method to assess IFNγ production by PBLs in response to 
donor and 3
rd
 party cells in serial samples taken post-transplant [246].  They reported a 
correlation between IFNγ production in samples taken in the early post-transplant period and 
subsequent renal function, independent of other factors associated with reduced graft 
function, namely the quality of the donor organ, effects of immunosuppressive drugs, 
recurrent disease and hypertension and presensitisation.  They did however suggest that the 
level of IFNγ production may be a surrogate marker for general immune reactivity, as they also 
found a correlation between IFNγ production in response to 3
rd
 party  cells and poor graft 
outcome [246].  Danielle van den Boogaardt et al.[247] again used the ELISPOT technique to 
measure the production of IFNγ and IL-10 by PBLs stimulated by donor cells post-transplant in 
8 patients with early biopsy proven acute rejection and 8 with stable renal function.  They 
found the patients with rejection had significantly higher numbers of IFNγ producing cells 
compared to the stable renal patients, and conversely a higher number of IL-10 producing cells 
in the stable patients compared to the rejectors.  Suggesting that IFNγ, a classical Th1 cytokine 
[248], indicates immune reactivity, whereas IL-10, thought by some to be a Th2 cytokine [249], 
may indicate a more ‘tolerant’ environment.  This highlights the potential benefits of testing 
for more than one cytokine.  A number of groups, including Poggio et al. [218], have adapted 
the ELISPOT method to create a test to define pretransplant T cell alloreactivity analogous to 
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the panel reactive antibody (PRA) analysis used to assess humoral sensitisation.  Here they 
stimulate patient PBLs with a panel of donor cells covering the major HLA antigens found in 
the population and assess reactivity based on numbers of IFNγ producing cells to generate a so 
called panel reactive T cell (PRT) value.  They found a correlation between PRT value and post-
transplant incidence of acute rejection, however they found no correlation between the PRA 
and PRT values, suggesting that PRA may not be indicative of cellular immunity.  A similar 
study published by Andree et al. confirmed both of these observations [250].  Both groups also 
found a correlation between the PRT level and length of time on dialysis prior to transplant 
[251], indicating that long term dialysis patients may have a generally heightened immune 
status prior to transplantation.  Of note, two retrospective studies found the predictive value 
of measuring IFNγ producing cells pre transplant was negated by the use of ATG induction 
therapy, which suggests that ATG may be able to inhibit memory T cell responses [252, 253]. 
All of the above reported ELISPOT assays are thought to be testing only the direct 
allorecognition pathway, the dominant pathway in the early alloimmune response.  Since 
memory T cells may have been primed via either the direct or indirect pathway, and the 
production of alloantibody requires T cell help via the indirect pathway, assessment of indirect 
memory T cells prior to transplant would be useful.  The ELISPOT assay has also been adapted 
to do this by Najafian et al. [254] and Poggio et al. [255].  Here they measured T cell reactivity 
to cytoplasmic membrane protein preparations from donor cells, which had been processed 
and presented by recipient antigen presenting cells.  Both groups reported higher numbers of 
IFNγ producing T cells in patients with poor graft function indicating chronic rejection, 
compared to those with stable function. 
1.19 T cell Cytokines and Rejection. 
When naïve T cells are first activated they are commonly thought to only produce IL-2 for at 
least the first 24 hours and require 3 – 6 days before complete differentiation into effector 
cells, which are then capable of secreting other cytokines such as IFNγ, IL-4, IL-5, IL-10.  
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However, it has been reported that prior to production of IL-2, naïve T cells initially produce 
TNFα before differentiation and development of other effector functions [256].  Unlike naïve 
cells, memory T cells are able to produce all these cytokines within hours upon reactivation.  
This difference in cytokine production allows the differentiation between naïve and memory T 
cell responses in culture [245].  The cytokines produced also give an indication as to the cell 
type responding.  There are three widely recognised CD4+ T cell subgroups – Th1, Th2 and 
Th17 – each with distinct functions and cytokine production profiles [257].  Commitment of a 
naïve T cell to one of these three lineages is dependent on the cell interaction with the APC, 
the cytokines to which they are exposed, the costimulatory molecules involved and the type of 
antigen [258]. Th1 cells produce IL-2, IL-3, IFNγ and TNFα and act against intracellular 
pathogens.  Th2 produce IL-4, IL-5, IL-6, IL-9 and IL-13 and are involved in humoral and cell 
mediated immunity [259].  Th-17 cells produce IL-17, IL-21 and IL-22 and are thought to be 
mainly primed to fight bacterial, fungal and protozoal infections [258].  All three of these cell 
types have been implicated in rejection of renal allografts [257, 259, 260].  Historically it has 
been believed that alloreactive Th1 cells induce rejection and alloreactive Th2 cells induce 
tolerance, and therefore the classical Th1 cytokines are associated with rejection and Th2 
cytokines with tolerance. However evidence is mounting that both Th1 and Th2 cells are 
capable of inducing allograft rejection [261]. 
There is much data in the literature to implicate Th1 cells with allograft rejection [262].  Upon 
activation Th1 cells produce IL-2, which promotes proliferation of alloreactive cytotoxic T cells.  
They activate other cell types to manifest their effector functions, such as delayed type 
hypersensitivity response by macrophages.  They are also able to directly damage the allograft 
through Fas/Fas ligand mediated cellular cytotoxicity [260]. 
IFNγ, along with IL-2 and TNFα, are classically seen as Th1 cytokines.  However it is also 
produced by NK cells, Tregs and CD8+ T cells [263, 264], so the presence of IFNγ cannot be 
directly linked to Th1 activity [257].  As outlined in the ELISPOT review above, several studies 
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have associated the production of IFNγ with acute and chronic rejection.  However this is not 
always the case.  Sadeghi et al. found that levels of IFNγ in the serum of renal allograft 
recipients at 24 months post-transplant was significantly higher in patients who had not 
experienced rejection episodes compared to those with chronic rejection and healthy controls 
[265].  Using animal subjects, Wang et al. found that IFNγ knockout mice rejected xenografts 
faster than the wild type mice [266].  This leaves the role of IFNγ as slightly confused with 
potential effects in both rejection and induction of tolerance. 
Although classically Th2 cells, and the cytokines they produce, have often been associated with 
tolerance or acceptance of a graft [261], the ability of Th2 cells to induce allograft rejection has 
been demonstrated by a number of studies which have shown that adoptively transferred Th2 
cell lines are able to induce rejection in animal models [260].  IL-5, produced by Th2 cells, 
recruits and activates eosinophils in transplanted tissue [267].  There have been a number of 
studies indicating that both IL-5 and eosinophils may be present during rejection episodes 
[268].  IL-4 is a prototypic cytokine produced by Th2 cells and promotes B cell proliferation, Ig 
class switching and survival of T cells [269, 270], in addition it can induce macrophage 
activation, promote Th1 responses [259] and induce increased expression of adhesion 
molecules on endothelial cells [267].  It is also produced by NK cells, mast cells, eosinophils and 
basophils [259].  In clinical transplantation studies IL-4 has been associated with chronic renal 
allograft rejection.  Uboldi de Capei et al. reported that in renal transplant recipients, 
development of chronic allograft rejection was associated with a high IL-4 producing genotype 
[271].  Whereas D’Elios et al. reported that CD4+T cell clones isolated from human kidney 
allografts during acute rejection produce high levels of IFNγ upon restimulation in vitro, but do 
not produce IL-4 or IL-5, indicating that IL-4 produced by T cells may not be involved in acute 
rejection episodes [272]. 
Th17 cells are thought mainly to be involved in directing other effector cells to act in infections 
caused by extracellular pathogens [257, 273].  Th17 cells, as a separate lineage from Th1 and 
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Th2 cells, were first described by two groups in 2005 [274, 275].  They are defined by their 
ability to produce IL-17, although it can also be produced by other T cell subsets, including 
CD8+ T cells, and have been identified to play major roles in the pathogenesis of inflammation 
and various autoimmune diseases, where IFNγ and Th1 cells had been previously thought to 
dominate [260, 273].  The cytokine, IL-17, had been described 10 years earlier by Yao et al. 
[276] and investigations into its involvement in transplant rejection had been started long 
before the exact producing cell had been identified.  Van Cooten et al. [277] reported that 
renal allograft biopsies taken during active rejection episodes from 6 patients could all be 
stained positive for the presence of IL-17 compared to none of the biopsies taken pre 
transplant or from a stable control group of patients.  Loong et al. [278] reported the presence 
of both IL-17mRNA in renal biopsies and IL-17 protein in the urine of patients with borderline 
rejection when compared to healthy controls.  A number of other studies have linked the 
presence of IL-17 and IL-21, another classical Th17 cytokine, to both acute and chronic 
rejection [260, 279].  Additionally 2 groups working with murine cardiac allograft models have 
described the finding that IL-17 producing cells are able to mediate rejection in mice unable to 
mount Th1 responses [280, 281].  IL-17 is thought to mediate inflammation through 
recruitment and activation of neutrophils [257, 282], so the involvement of IL-17, and the Th17 
cells, in allograft rejection is likely to be through the recruitment of neutrophils into the graft 
[283].  After transplantation of an organ neutrophils are one of the first effector cells to 
infiltrate the allograft and act as effector cells in rejection [260]. 
The various cytokines produced by these three T cell subsets, as well as having effector 
functions in graft rejection also act to regulate the responses by the other subsets.  So, for 
example IFNγ and IL-4 inhibit Th17 cells [257] and the Th2 cytokines, in particular IL-4 and IL-
10, are able to inhibit Th1 responses [260].  Each cell type and cytokine has at various stages in 
research been linked to both acute and chronic rejection, as well as a number of reports of 
links with tolerant profiles [260]. 
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1.20 Impact of Immune Memory on Transplantation. 
Immunological memory to non-self HLA antigens presents a number of challenges in solid 
organ transplantation.  Terasaki et al. reported in a study of graft survival rates from living 
donor transplants that the 3 year survival of husband to wife transplants was 87% if there had 
been no pregnancies, however this dropped to 76% if there had been previous pregnancies in 
the couple [284].  This suggests that previous exposure, and potentially generation of immune 
memory, can impact on long term survival of the graft.  Historically graft survival rates in 
patients receiving their second or subsequent cadaveric donor renal allografts have been lower 
than those receiving primary grafts [285-287].  However with the advent of better HLA 
matching, more sensitive crossmatching and HLA specific antibody screening methods the long 
term graft survival rates are now similar between first and second transplants [288].  In a 
single centre study Coupel et al. reported that, overall, recipients of second transplants had a 
graft survival rate similar to that of the primary graft recipients at 10 years.  However all 
patients included in this study received cadaveric grafts, which compared to living donors, 
allowed for greater matching and avoidance of HLA specificities to which the patients had 
antibody, with 64% of the re-graft group receiving organs with ≤2 HLA mismatches, out of a 
possible 6 recorded, compared to only 24% of the primary graft group [289].  A review of the 
outcome data from UNOS 1997-2002 indicates that patients receiving a second or subsequent 
graft from a living donor have poorer outcomes compared to primary allograft recipients 
unless the donor and recipient are well HLA matched [290].  This would suggest that regardless 
of the donor source outcomes of second and subsequent renal allografts have poorer long 
term outcomes when HLA mismatching is greater.  Many patients awaiting a second renal 
allograft are sensitised due to either rejection of the first graft, or due to withdrawal of 
immunosuppression following non-immune failure of the first graft, which gives the immune 
system full ability to mount a cellular and humoral response against the residing non-
functioning graft.  Patients who return to the transplant waiting list for a second graft will, if 
offered, receive a transplant which is generally well matched and lacking those mismatches to 
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which antibody has been produced, however the wait could be long and an offer may never be 
made.  These patients may well have a potential living donor available.  However living donors 
tend to be less well matched and may well harbour HLA antigens to which the potential 
recipient is sensitised.  It is these pairs to whom antibody removal may be offered as an 
alternative to waiting for transplantation through the deceased donor scheme or paired 
exchange scheme. 
One problem facing laboratories supporting transplantation is that is not always possible to 
know exactly which non-self HLA a patient has been previously exposed to.  Patients receiving 
multiple blood transfusions could have been exposed to countless non-self or mismatched HLA 
antigens, and responded to some, or all, of these, however the HLA types of these donor blood 
units would not commonly be known.  Additionally, in patients who have been sensitised by 
pregnancies in earlier life, it is not always possible to gain the HLA types of previous partners, 
and/or children, and therefore the exact HLA antigens to which the patient has been exposed 
are not available.  This is also true for patients receiving transplants many years previously, as 
HLA typing techniques were not as advanced and minimal information may be available.  In 
practice highly sensitised patients will often not have one single sensitising event and may in 
fact have received previous transplants, had multiple blood transfusions and pregnancies, 
making identification of all the non-self HLA antigens to which they have been exposed 
virtually impossible and therefore predicting which HLA antigens will invoke a strong memory 
response equally impossible.  In addition, as discussed earlier, not all memory T cells are 
generated through exposure to non-self HLA, so knowledge of previous HLA exposure may still 
not accurately predict the presence of donor specific memory T cells in a recipient. 
It is widely reported [157, 291-294] that not all HLA specific antibodies are deleterious to a 
transplanted organ.  Even looking back to the seminal work by Terasaki and Patel, only 80% of 
the patients with a positive CDC XM suffered hyperacute rejection.  Whilst this is a high 
number, why didn’t the other 20% of the transplants suffer the same fate?  As has been 
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proven with time the CDC XM test used in this first report is not very sensitive and detects only 
high titre complement fixing antibodies, generally believed to be detrimental to graft outcome, 
yet only 80% of these transplants failed immediately.  The present day Luminex single antigen 
methods give the highest and most sensitive resolution of donor specific antibody available, 
yet there is still no clear conclusion as to which DSA will be detrimental and which will not.  
With an increasing number of patients requesting assessment for antibody removal and 
incompatible transplantation it is becoming ever more important to be able to identify which 
antibodies are the most detrimental and provide an accurate risk assessment, both to the 
clinicians and the patients, as to the likelihood of both successful antibody removal to facilitate 
transplantation and of the potential outcome post-transplant.  Undoubtedly the titre of HLA 
specific antibody, particularly at the time of transplant, will play a part.  However as the 
conflicting reports in the literature suggest both low and high titre antibodies have been 
implicated, or not, in rejection of grafts.  Additionally with the introduction of the Luminex 
based solid phase assays what constitutes high titre is not yet clearly defined.  The 
characteristics of the antibody in terms of its ability to fix complement may also play a part. 
However, with the introduction of routine C4d staining on biopsy it is clear that not all 
episodes of AMR appear to involve complement fixation [295].  Smith et al. on reporting an 
adaptation of the Luminex single antigen bead assay to detect complement fixing antibodies 
found that in cardiac recipients the 1 year graft survival of patients with complement fixing 
DSA was 29% compared to 90% for those with no DSA, however for those patients with non-
complement fixing DSA it was 54%, still significantly lower than those without any DSA [148].  
Wahrmann et al. using the same method carried out a similar analysis in renal recipients and 
found no difference in graft survival between those with complement fixing and non-
complement fixing DSA, both had significantly increased rates of rejection in comparison to 
those patients without any DSA [296].  We suggest that it may not just be the presence of the 
antibody but the fact that the HLA antigen is ‘known’ to both the humoral and cellular arms of 
the immune response and can lead to activation of primed memory T cells.  The antibody 
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produced will only be specific for a small epitope on the HLA molecule and, as discussed 
earlier, these epitopes may be shared by multiple HLA antigens, meaning that sensitisation 
through exposure to one or two foreign HLA antigens can lead to the generation of antibody to 
multiple HLA molecules.  However, are all these antibodies equal?  We will investigate if in fact 
only patients challenged with the same mismatched HLA antigen to which the antibody was 
raised are at higher risk of failure following an antibody incompatible transplant due to the 
presence of B and T cell immune memory, compared to those in whom the antibody is reacting 
due to epitopes shared with previously mismatched antigens, and therefore lacking at least 
the T cell memory. 
Traditionally when assessing patients for renal transplantation we aim to choose the most 
compatible donor available.  This is achieved through HLA typing and matching, and avoiding 
all mismatches to which a patient has antibody, through extensive antibody screening and 
crossmatching, and, we suggest, incidentally avoiding HLA specificities to which T cell memory 
may have been generated.  However in the context of antibody removal transplantation, the 
fact that there is donor specific antibody present pre transplant automatically increases the 
risk that the graft will be rejected.  From the HLA antibody removal studies published to date it 
is clear that whilst HLA antibody incompatible transplantation provides a viable treatment 
option for some highly sensitised patients, the rates of success vary considerably and there is 
no distinct rationale as to which transplants are likely to be successful and which are not. 
We believe it is very important to ensure that the immune risk between the potential donor 
and recipient pair is extensively assessed in order to minimise the risk and provide a realistic 
prediction as to the success of the potential transplant to the patients, allowing an informed 
choice prior to proceeding to transplant.  In some cases there may be more than one 
incompatible potential donor, extensive immune risk assessment of each would provide a 
better basis for choosing the donor with whom the best outcome may be achieved.  A number 
of non-immune factors could be taken into account including age, sex and health of the donor.  
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However from an immunological point of view the ‘immune history’ of the patient is a good 
place to start.  This should include HLA specific antibody analysis and detection of memory T 
cell reactivity, along with knowledge of previous exposure to non-self HLA.  What the memory 
T cell assays discussed earlier have established is that donor reactive memory T cells, often as 
defined by rapid IFNγ production on stimulation, are detrimental to the long term outcome of 
renal transplants.  However researchers have often focussed the results on the ability to 
predict patients in whom reduced immunosuppressive protocols may be permissible and 
potentially the prediction of tolerance.  In this study the patients we are focussing on are those 
known to be highly sensitised and reactive to their donor based on HLA specific antibody 
detection.  Often these patients have multiple potential donors to whom they are sensitised 
and we would like to be able to probe for memory T cell reactivity to these specific donors in 
order to make an informed choice as to which donor would present the least immunological 
barriers to transplant and potentially provide the best outcome.  The very nature of HLA 
antibody incompatible transplantation means that all these patients will require significant 
immunosuppression and we need to be able to choose the ‘best’ donor from a ‘bad bunch’. 
The ELISPOT method described previously produces interesting results, however it only allows 
for the detection of one cytokine per well, it requires specialised equipment not found in every 
transplantation laboratory and it is expensive.  In this project we set out to develop a method 
to probe for T cell memory to specific donor HLA antigens using techniques and equipment 
familiar to the transplantation laboratory.  In addition we wanted to test for multiple cytokines 
produced upon stimulation in order to assess the profile of the reacting cells.  The results from 
both the T cell and antibody assays could then be combined to provide a detailed risk 
assessment of the potential transplant. 
Using these assays and observing the outcomes of HLA antibody incompatible renal 
transplants in relation to the results generated we aim to investigate the effect of immune 




1.21 - Aims and Objectives 
The aims of this project are to: 
1. Develop a laboratory testing repertoire to effectively assess the potential for 
antibody removal in sensitised patients. 
2. To assess the outcomes of these transplants for the effect of immune memory to 
HLA antigens presented by the donor. 
3. To develop an assay to effectively detect the presence of donor specific memory T 
cells in a recipient pre-transplant. 
4. To assess the relationship between presence of HLA specific antibody and donor 
specific T cell memory. 
5. Generate a rationale using these results to provide a detailed risk assessment pre 
transplant as to the likelihood of success, and highlighting which patients will be at 
highest risk of post-transplant rejection episodes and graft failure.  
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2 Materials and Methods 
Complete methods used for the individual tests are described in full in Chapter 3 for antibodies 
and Chapter 4 for T cells. 
All work was carried out using clinical samples taken for routine testing.  Where tests were 
performed over and above that required routinely only cells or serum surplus to requirements 
were used, therefore no samples were taken specifically for this project.  Ethical approval for 
this project was obtained from the Outer South East London Research Ethics Committee under 
project number 07/H0805/42.  Where cells from deceased donors where used all donor 
families had consented to the use of samples in research. 
The majority of the laboratory work for the antibody assays and all the laboratory work for the 
T cell assays was performed by myself.  In the latter stages of the project, where the antibody 
assessment methods were introduced into the routine work, the staff in the serology section 
of the laboratory, under my supervision, performed the practical aspects whilst I performed 
the data analysis. 
2.1 Patient Data Collection. 
In order to assess the effect of immune memory and the presence of HLA specific antibody on 
renal transplant outcomes, data from a large group of patients needed to be collected.  The 
main emphasis of the analysis is centred on the patients in whom there is demonstrable donor 
specific antibody, based on single antigen bead analysis and/or flow crossmatching and the 
requirement for antibody removal.  However in order to analyse these in the context of 
outcomes seen in all groups of patients at our centre, data for control groups was also 
collected. 
The HLA antibody incompatible transplants included in this analysis were performed at Guys 
Hospital between May 2005 and October 2012.  Due to the wide geographical area and 
number of referring renal units that are served by our laboratory to ensure sufficient data 
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could be collected the various control groups collected were limited to patients who received 
both their transplant and subsequent follow up at the Guys Hospital based renal unit only.  
Data for all transplants performed between January 2005 and December 2010 were collected.  
During this time a number of ABO blood group incompatible and combined HLA antibody and 
ABO blood group incompatible transplants were performed, to ensure that records of adverse 
events and the outcome data were not skewed by the presence of ABO incompatible 
transplants all these were excluded from the analysis. 
For the investigations into the effect of immune memory in relation to antibody the patients 
were categorised into 6 groups based on their sensitisation status and the presence of repeat 
HLA mismatches presented by the transplanted organ.  Repeat mismatches were defined as 
HLA antigens to which the patient had previously been exposed either via a previous 
transplant or pregnancy.  Clearly some patients in the sensitised group who had neither 
recorded transplants or pregnancy may have been sensitised via blood transfusion, however 
routine HLA typing of blood units is not performed and could not be accounted for, these 
patients were therefore allocated to the no repeat mismatch group.  Additionally it was only 
possible to include patients as having pregnancy repeat mismatches when a pregnancy was 
recorded, there may well be female patients in the no repeat mismatch group who have had 
unrecorded pregnancies.  A breakdown of the six groups and the numbers of patients involved 












Table 2 - Description of Patient Groups Studied. 
Group Number Status Number of Patients 
Group 1 HLA antibody negative, 
repeat mismatch negative 
169 
Group2 HLA antibody negative, 




 Party HLA specific 





 Party HLA specific 
antibody positive, repeat 
mismatch positive 
11 
Group 5 Donor HLA specific antibody 
positive, repeat mismatch 
negative 
31 
Group 6 Donor HLA specific antibody 




Various data were collected for each of these patients.  Clinical data were obtained from the 
hospital provided Electronic Patient Record (EPR) system. HLA related data were obtaind from 
our local database system, initially ORD and subsequently Manzen.  Data collected included 
transplant date, donor and recipient HLA type, gender and age, type of donor (living or 
deceased), relationship of donor and recipient in the case of living donors, recipient 
sensitisation status, details of previous sensitising events - including previous transplants and 
pregnancies with the HLA mismatches involved, induction therapy used, dates and outcomes 
of any ‘for cause’ biopsies performed, date and cause of graft loss if it occurred, and graft and 
patient survival up to 5 years post-transplant.  Additionally in the HLA antibody incompatible 
groups the crossmatch relative median fluorescence (RMF) and LABScreen single antigen bead 
median fluorescence intensity (MFI) values pre-treatment, for those requiring antibody 
removal, and pre transplant for all these patients were collected.   
For the investigations into immune memory and T cells similar data were collected, where 
patients were identified as being sensitised through their HLA antibody status, the HLA types 
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of the recipient and donor were recorded and the presence of any potential repeat HLA 
mismatches identified through comparison with the HLA types of previous donors, partners or 
children.  For the patients assessed using the T cell assay developed, who were subsequently 
transplanted, the occurrence of T cell mediated rejection episodes were also recorded in 
addition to the induction therapy received. 
The biopsy results for both Chapter 3 for antibody investigations and Chapter 4 for T cell 
investigations were taken from analysis and diagnosis by our local histopathologists.  When 
relevant the cause and time of graft loss was also confirmed.  The presence of rejection on 
biopsy was diagnosed by the histopathologists using the most recent Banff criteria, available at 
the time of the biopsy, and for the purposes of this analysis I have included all biopsies 
regarded as ‘suspicious of’ either antibody or T cell mediated rejection as representing a 
biopsy proven rejection episode in addition to those where the diagnosis was absolute.  All 
rejection episodes were broadly divided into those with antibody mediated rejection, those 
with T cell mediated rejection and those where both antibody and T cell mediated mechanisms 
were observed.  The date of each biopsy proven rejection episode (BPRE) was recorded and 
the time between transplant and the 1
st
 BPRE was calculated.  The initial biopsy results were 
provided for clinical reasons and were therefore read unblinded.  However the biopsies from 
patients who received HLA antibody incompatible transplants were subsequently re-analysed 
by a different histopathologist in a blinded fashion to confirm diagnosis. 
HLA typing of both donors and recipients was undertaken by the DNA section of our laboratory 
using LIFECODES SSO HLA typing kits produced by Gen-Probe for the Luminex.  These kits 
provide low to medium resolution HLA typing. 
2.2 Statistical Analysis. 
All statistical analysis carried out for this project was performed using the GraphPad Prism 6 
statistical software package. 
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The data used for all comparative tests was analysed for Gaussian distribution using the 
D’Agostino-Pearson normality test. Due to the small and diverse populations the majority were 
not found to be of Gaussian distribution and were therefore subject to non-parametric 
analysis.  The caution attached to these test types are that they are of lower power and are 
likely to infer less significance than the reality, particularly in small sample sizes.  Where 
appropriate, two-tailed analysis was used with a 95% confidence setting. 
Comparisons of antibody readout values between two groups of patients were analysed using 
the non-parametric Mann-Whitney U test, which analyses the significance between median 
values of two groups.  Where more than two groups were analysed together the non-
parametric one way ANOVA test, Kruskal-Wallis, was employed.  The p values generated 
through these calculations were recorded. 
The relationship between predicted and actual values, along with the relationship between 
values achieved with two methodologies, were assessed using linear regression analysis and 
the R
2
 value recorded.  R
2
 is a value between 0 and 1, the closer the value is to 1 the greater 
the relationship.  If R
2
 is 0.0 there is no relationship between the two variables. 
Survival analysis was performed using Kaplan-Meier survival curves where patients were 
censored at the end of their follow up period, if less than five years, or if an adverse event, 
such as death or graft loss, occurred that was not related to immunological loss of the renal 
allograft.  The survival curves were compared using the Mantel-Cox logrank method where 
two curves were compared or the logrank for trend when three of more curves were 
compared.  The logrank test and logrank for trend test both produce p values, which were 
recorded. 
For analysis of cytokine production in the T cell assay described in Chapter 4 the data were 
arranged in 2x2 contingency tables and subject to Fisher’s exact 2 tailed analysis, where the 
null hypothesis was that there is no difference between the two outcomes in the two groups 
that would not be expected to be seen in random population sampling.  This method is ideal 
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for small sample sizes, as tested in this study. P values were generated, where a small P value 
indicates that the correlation observed would rarely happen through random population 
sampling, that the null hypothesis is incorrect and that there is a difference in results between 
groups that is large enough to be significant.  A large P value, up to 1.0, indicates that there is 
no significant difference between the two outcomes in the two groups other than that which 
would be expected through random population sampling. 
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3 Antibodies in HLA Antibody Incompatible Renal 
Transplantation and their Relationship to Immune Memory. 
3.1 Introduction and Aims 
In 2005 the clinicians at our centre became interested in antibody removal as a route to 
transplant highly sensitised patients, initially those who were in urgent need of a transplant 
due to a failure of access for dialysis, but subsequently those who were highly sensitised and 
were unlikely to be offered a transplant via any other route.  Central to the success of any 
antibody removal programme is the ability to monitor donor specific antibody levels to assess 
the success of the desensitisation treatment and to provide advice on when the antibody is of 
a suitable level to perform the transplant.  In addition to this it was felt that it was essential to 
develop the ability to predict which patients would benefit from antibody removal and what 
the likelihood of a successful post-transplant outcome would be.  Therefore the aims for this 
part of the project were -  
• Introduction and validation of new Luminex technology for antibody monitoring in 
highly sensitised patients. 
• Development of methods to assess patient and donor pairs for potential antibody 
removal. 
• Assessment of post-transplant outcomes following antibody incompatible 
transplantation in relation to antibody titre and the effect of immunological memory. 







As outlined in the introduction there are various methods available to detect and identify HLA 
specific antibodies.  At this unit we use flow cytometry for donor crossmatching and bead 
based solid phase assays for HLA antibody detection and identification.  As outlined in the 
introduction these methods are sensitive, timely and provide objective results on which clinical 
decisions can be based.  Three main methods have been employed when gathering data for 
this project – 
• FlowPRA single antigen bead screening 
• LABScreen single antigen bead screening 
• 3-Colour Flow Cytometric crossmatching 
Initially I shall describe each method and then refer back to these when outlining the exact 
testing carried out. 
3.2.1 FlowPRA Single Antigen Antibody Identification Method. 
Prior to starting this project FlowPRA single antigen beads were the local antibody 
identification method of choice.  FlowPRA Single Antigen beads are produced by OneLambda 
(Canoga Park, CA) and allow for rapid flow cytometric detection of HLA specific antibodies.  
The bead mix consists of a number of different bead groups with varying fluorescent 
properties which can be separated on the FL2 channel based on their channel shifts.  4 vials, 
each containing 8 bead groups, are provided to cover the panel, with each having 7 different 
HLA specific beads plus a control bead group, giving a total of 28 different HLA antibody 
specificities to be detected.  Following incubation with patient sera, binding of any HLA specific 
antibody is detected through the addition of a FITC-conjugated anti-human IgG antibody, 
which is then detected through shifts on the FL1 channel.  FL1 shifts for each bead group are 
then compared to the equivalent bead group tested with the negative control sera.  The 
median channel value (Mdx) for the negative control is subtracted from that achieved with the 
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test sera to give a final Mdx value, and in general the greater this value is the greater the titre 
of antibody present in the serum.  The method used in this laboratory is a locally validated 
variation on the manufacturers’ guidelines, allowing the use of fewer beads and increasing the 
number of tests achieved from one kit.  The results gained using this variation have been 
validated by comparison with results achieved using the kit manufacturers’ instructions, with 
previously well characterised positive and negative patient sera.  The method is the same for 
both Class I and Class II single antigen beads. Briefly –  
A 96 well ‘v’ bottomed titre plate is labelled numerically for each serum sample plus a negative 
and positive control, with each sample being allocated 4 wells, one for each bead mix. 
Each vial of beads is mixed well and 2μl is added to the bottom to the appropriate well. 
10μl of patient sera is then added to each of the four designated test wells and mixed well by 
repeat pipetting.  
The plate is then sealed, wrapped in aluminium foil and incubated at room temperature for 30 
minutes on an orbital mixer set at 200rpm. 
Following incubation the beads are washed by adding 150μl of kit provided wash buffer, 
diluted 1:10 with distilled water to provide a working concentration.  The plate is sealed and 
centrifuged at 3450g for 3 minutes.  The waste is then gently decanted and, remaining 
inverted, blotted on absorbent paper. 
The wash step is repeated a further 2 times to give a total of 3 washes. 
A working dilution of FITC-conjugated anti-human IgG is produced by diluting the conjugate 
1:100 with wash buffer.  50μl is then added to each well. 
The plate is re-sealed and wrapped in aluminium foil before a further 30 minute incubation at 
room temperature on an orbital mixer set at 200rpm. 
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After incubation the plate is centrifuged at 3450g for 3 minutes and the diluted conjugate 
decanted as previously described. 
The beads are then washed twice with 150μl of wash buffer as previously described. 
Following the decanting of the final wash buffer the plate is transferred to a fume cabinet and 
200μl of 1% Formaldehyde is added to all wells and mixed well. 
The plate is then sampled using a Beckman Coulter FC500 flow cytometer. 
Median Channel Fluorescence (Mdx) values for each bead group are automatically exported to 
an Excel file for data analysis. 
The sample Mdx minus the negative control Mdx values are calculated along with visual 
comparison of the bead plots.  Observation of any shift in the control bead group can give an 
indication as to non-specific antibody binding to the beads. 
Figure 14 - Example of dot plots gained from flow cytometric analysis of FlowPRA 





3.2.2 LABScreen Single Antigen Screening Method. 
The start of this project coincided with the introduction of Luminex based antibody analysis 
methods to our local testing repertoire.  LABScreen single antigen beads are again produced by 
 
Negative Control – All 
bead groups are within 
the first log decade. 
Here bead group 4 can 
be seen to have 
significantly shifted into 
the 3
rd
 log decade, 
indicating the presence 
of antibody binding. 
Here bead groups 2, 4, 
5 and 6 can be seen to 
have shifted 
significantly in 




OneLambda (Canoga Park, CA) and are designed to be analysed using a Luminex fluoroanalyser 
as described in the introduction.  All samples included in this analysis were tested using our in-
house validated variation on the manufacturers recommended method.  The method used is 
the same for both the Class I and Class II specific beads. 
Briefly –  
Wells on a 96-well filter plate are vertically labelled for the number of samples to be tested, 
including wells for both a negative and positive control. 
Any unassigned wells must be covered using plastic plate sealers (alpha laboratories). 
In the test wells the filter is dampened by addition of 250μl of sterile water and incubated at 
room temperature for 5 minutes.  After this time water is completely removed using a vacuum 
manifold system. 
The vial of test beads is then well mixed and 3μl are added to each test well. 
12μl of patient or control serum is then added to the bead suspension and mixed by repeat 
pipetting. 
The plate is then covered and wrapped in aluminium foil before being placed on an orbital 
plate mixer set at 500rpm to incubate for 30 minutes at room temperature. 
Following this incubation the beads are washed by the addition of 250μl of kit provided wash 
buffer that has previously been diluted to a concentration of 1:20 with distilled water.  The 
wash buffer is removed using the vacuum manifold.  This wash procedure is repeated a further 
two times to give a total of 3 washes. 
After the final removal of wash buffer 100μl of manufacturer provided PE conjugated anti 
human IgG is added, having been previously diluted 1:100 with wash buffer. 
The plate is then re-covered and wrapped again in aluminium foil prior to a further 30 minute 
incubation on the orbital plate mixer set at 500rpm at room temperature. 
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After the incubation the beads are again washed.  Initially 150μl of wash buffer is added to 
each well and the wells drained using the vacuum manifold.  A further two washes each using 
250μl of wash buffer are then performed. 
Following the final wash the beads are re-suspended in 80μl of phosphate buffered saline 
before being read using a Luminex analyser. 
As discussed in the introduction the Luminex analyser collects a range of data from the bead 
sets in use, the most commonly referenced of which is the median fluorescence intensity 
(MFI).  The Luminex output from each run is published as a .csv file which can then be 
imported for analysis using an appropriate software package.  For the initial group of patients 
analysed this was performed using HLA Visual which was later replaced with HLA Fusion, both 
produced by OneLambda for analysis of all their Luminex kits.  Both software packages can use 
the same formulas to calculate results. Therefore the results achieved with both programmes 
are comparable.  Both programmes are fully interactive for the user, and whilst they have pre-
programmed values and specificity suggestions they both allow manual setting of cut-off 
ranges and assignment of specificities.  The reactivity of each test bead is ‘corrected’ for non-
specific binding using the value gained with the internal negative control bead, specific for 
each test well, and also for background binding or fluorescence of each bead by accounting for 
binding seen with the negative control serum run with each batch of tests.  This calculation is 
carried out by the analysis software which then produces bar graphs ranking the beads in 
order of the highest to lowest MFI values.  Initially the kit manufacturer recommended that 
beads with an MFI value of greater than 1000 be considered as positive.  Analysis should 
however consider results previously achieved, the pattern of antibody binding in terms of 
conforming to known crossreactive or shared epitopes, the presence of apparent ‘self’ 
reactivity and the HLA antigens involved in known sensitising events before specificities are 
assigned.  The profile of the bar charts can also be useful in assigning cut-off levels for a 
patient, where obvious demarcation between groups of beads lends itself to act as a cut-off 
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point.  At our centre we look to place the cut-off between 1-2000 MFI but depending on the 
profile presented and the patient history this can be increased or decreased. 






  The HLA specificity represented by the bead is listed on the X axis and 





on the Y axis 
All the DR4 coated beads 
are weakly positive, 
indicating the presence 
of a weak DR4 specific 
antibody. 
All the A23 and A24 coated 
beads are positive, indicating 
the presence of antibody 
specific for HLA A23 and A24. 
Class I Single Antigen Screening Class II Single Antigen Screening 
Figure 15 - Example of results produced by HLA Visual and HLA Fusion software when analysing LABScreen single antigen Beads. 
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3.2.3 3-Colour Flow Crossmatching. 
At Guys Hospital the flow crossmatch (FXM) has been our front line crossmatching method for 
20 years and as such we have robust cut off criteria based on long term clinical outcomes. 
3.2.3.1 Isolation of Peripheral Blood Lymphocytes. 
Lymphocytes are isolated using density centrifugation on a ficoll gradient from 20mls EDTA 
anticoagulated fresh donor peripheral blood samples.  Briefly,  
Peripheral blood was diluted at a ratio of 1:1 using phosphate buffered saline (PBS) (Sigma-
Aldrich), layered onto equal volumes of density centrifugation medium lymphoprep (Axis-
Shield), and centrifuged at 1690g for 15 minutes, see figure 16 below. 
The isolated lymphocyte layer was removed by pipette and the cells washed twice using PBS, 
centrifuging at 700g for 3 minutes to recover the cells each time. 
Figure 16 - Diagram depicting lymphocyte isolation using Lymphoprep (Axis-Shield) 
 
 
The cells were then washed for a third time using locally produced Flow Diluent comprised of 
PBS, 0.1% Foetal Bovine Albumin and 0.1%Sodium Azide. 








3.2.3.2 Flow Crossmatch Method. 
All samples are tested in duplicate, using a 3-colour flow crossmatch method. 
5ml Falcon tubes, two per serum sample to be tested, including a negative and positive 
control, are labelled appropriately. 
The negative control is commercially prepared human serum provided by the National 
Institute of Biological Standards and Controls (NIBSC) for flow cytometric crossmatching, using 
serum prepared from donations provided by blood group AB unsensitised males. 
The positive control is an in-house serum preparation from a pool of at least eight highly 
sensitised renal patients and is rigorously tested to ensure all the major specificities are 
included and that positivity can be expected with all donor cells encountered. 
To the bottom of each tube 20μl of serum is added, using a fresh pipette tip for each sample 
and ensuring the serum is well mixed prior to pipetting. 
30μl of PBLs are then added to the side of each tube and the tubes briefly centrifuged to 400g 
to bring the cells to the bottom of the tube. 
The cells and serum are then mixed well using a vortex and incubated at room temperature 
(20-25
o
C) for 30 minutes. 
Following incubation 2mls of Flow Diluent is introduced into each tube and the tubes 
centrifuged at 400g for 3 minutes to recover the cells.  The wash buffer is then vigorously 
decanted and the cells washed a further two times in the same manner. 
After the third wash and removal of the wash buffer 4μl of FITC conjugated polyclonal rabbit 
anti-human IgG F(ab’)2 antibody (Dako) is added to the bottom of each tube, using a fresh 
pipette tip for each addition.  Following  this 8μl of a 1:1 ‘megamix’ of PE conjugated 
monoclonal mouse anti-human CD3 antibody and PE-Cy5 conjugated monoclonal mouse anti-
human CD19 antibody (both Dako) is also added to the bottom of each tube, again ensuring a 
fresh pipette tip is used for each addition. 
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The tubes are then mixed well using a vortex and then incubated at 4
o
C for 30 minutes. 
Following incubation the cells are given a final wash using 4ml Flow Diluent and centrifuging at 
400g for 3 minutes.  The wash buffer is decanted and the cells are resuspended in 500μl of 
Flow Diluent ready for analysis using a Beckton Dickinson FACSCalibur flow cytometer.  




On flow cytometric analysis the lymphocytes are initially identified based on size through 
forward scatter and side scatter, all further analysis is based on the cells in this region (R1). The 
cell type can be identified as either a CD3 expressing T cell (R3) or CD19 expressing B cell (R2) 
through fluorescence emitted from either PE for the CD3 or PE-Cy5 for the B cell.  For FXM 
using PBL, where B cells are in lower proportion, cell counting continues until a minimum of 
1500 B cell events in R2 have been collected.  Any recipient derived IgG type antibody in the 
serum specific for an HLA molecule expressed by the donor will have bound to the donor PBL, 
and this will be detectable by the fluorescence produced by the FITC conjugated to the anti-
human IgG polyclonal Ab when passed through a laser.  An example of the readout achieved 
with a negative and positive control can be seen in figure 18 below.  The fluorescence emitted 
by the FITC is collected on a log scale and the median channel (MDX) at which the fluorescence 
is detected is collected as the readout for that sample, the higher this channel the more FITC 
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conjugated anti-human IgG is bound to the cell and therefore the greater the amount of 
recipient derived donor specific antibody is bound to the cell. 
Figure 18 - Example Readout for Negative and Positive Controls seen with 3-Colour 
FXM technique. 
 
The Mdx for both the T cells and B cells for each tube is collected and the duplicates compared 
to ensure they are within the limits of reproducibility, to be within 80% comparability, and the 
average of the two values is taken.   
The relative median fluorescence (RMF) for each cell type, for each serum sample tested, is 
then calculated by dividing the Mdx from the sample with the Mdx achieved with the 
appropriate cell type in the negative control.   
Relative Median Fluorescence (RMF) =   MDX WITH PATIENT SAMPLE 
     MDX WITH NEGATIVE CONTROL 
Lymphocytes are isolated based 
on size through forward scatter 
and side scatter 
T cells and B cells are 
separated by detection 
of CD3-PE or CD19-PE-
Cy5 
CD3 and CD19 Negative and 
Positive controls – Ab 
binding quantified by 
detection of FITC labelled 
human IgG specific 
monoclonal Ab binding.  
More FITC = More Ab bound 




In our centre for crossmatches against living donors any RMF ≥2.3 is deemed positive and 
potentially a contraindication to transplantation.  To ensure test validity the positive control 
must achieve an RMF of ≥4.0. 
3.3 Development of the Titre Crossmatch 
The initial patients in whom antibody removal was attempted at our centre were all 
approached in a manner similar to that reported by many centres.  Patients, identified as a 
candidate for Ab removal by the clinical team, often due to clinical urgency, underwent 
antibody removal indefinitely until a negative crossmatch was achieved, with either their 
designated living donor or a deceased donor when no living donor was available.  This 
approach led to very long and costly treatment periods and in a number of cases was not 
rewarded with a transplant, which was disappointing for both the patient and the clinical 
team.  The general regimen adopted included PEX, low dose IVIg and in some cases rituximab. 
Whilst PEX is generally well tolerated side effects can occur including reaction to the 
replacement albumin or fresh frozen plasma, hypotension, thrombosis, cardiac arrhythmias 
and myocardial infarctions [297], some of which were experienced by our initial patient group 
and became more common with increasing sessions of PEX.  The first change made was to 
replace traditional PEX with double filtration plasmapheresis (DFPP).  DFPP is similar to PEX in 
that the plasma is initially separated from the blood cells. However instead of then being 
discarded and the volume replaced, the plasma is filtered for a second time, through a smaller 
filter size which allows the passage of plasma components with smaller molecular weights, 
<70000 molecular weight, but traps and removes those with larger molecular weights, such as 
antibodies [298, 299]. The filtered plasma, minus the immunoglobulins, can then be returned 
with the blood cells to the patient.  DFPP was initially developed as an alternative to PEX for 
the specific removal of immunoglobulins without the requirement for replacement of large 




Figure 19 - Diagram Representing the Mechanical Process of DFPP [202] 
 
The second area for change was highlighted following discussion with our renal unit, where it 
was decided that a more stratified approach was required whereby patients with living donors 
were assessed for the feasibility for antibody removal during a work-up period prior to 
commencing the treatment.  Central to assessment process was the ability to predict which 
patients would benefit from antibody removal and, if so, how much treatment would be 
needed prior to transplant.  From our experiences with the initial patients it was apparent that 
not all antibodies appeared to be equal in terms of ease of removal, a finding that has been 
confirmed by other groups  [301].  So it was decided that the method by which the most 
information regarding the likely success of antibody removal would be achieved would be to 
perform a single 3L volume antibody removal procedure and then assess the level of antibody 
that had been removed and from this predict if sufficient antibody could be removed and if so 
the number of sessions that would be required pre transplant in order to achieve a negative 
crossmatch. 
At Guys Hospital we feel that the flow crossmatch gives the most accurate reflection of donor 
and recipient antibody compatibility of all the antibody analysis tests available.  This is both in 
terms of detecting antibody that will bind to the actual HLA molecules presented by the donor 




be accurately assessed by SPA since in vivo these levels can vary both over time, between 
individuals and in response to common drug treatments such as statins [302].  Whilst HLA 
expression levels on PBLs may not be a true reflection of expression in the kidney it is likely to 
be more comparable than antigen representation on the SPA formats, particularly the single 
antigen assays, where beads are coated in very high concentrations of single HLA specificities. 
In order to assess the possibility of achieving successful antibody removal to facilitate an 
antibody incompatible transplant we aimed to develop and assess the use of a titre FXM using 
recipient serum samples taken immediately prior to, and after, a single 3L DFPP and assaying 
against the potential living donor.  We hoped to gain an indication as to whether the reactivity 
was reduced, and, if so, predict the number of DFPP sessions required to achieve a negative 
crossmatch prior to transplant.  Discussion with the clinicians involved centred around what 
would be an acceptable crossmatch result required before a transplant could proceed.  It was 
decided that, for at least the early part of the programme, a negative crossmatch, so an RMF 
of <2.3 for both T and B cells, would be required, this was later expanded to an RMF of <4.0, 
the local cut off for deceased donor FXM, in patients with harder to remove antibodies.  
Therefore the aim of the titre crossmatch assessment would be to predict the potential 
number of DFPP sessions required to achieve this. 
3.3.1 Titre FXM Method. 
The Titre FXM method follows the same technique used for the standard 3-colour FXM at 
Guys.  The variation is in the serum samples used. 
The pre and post serum samples are titred using serial dilutions of the patient serum in 
negative control serum (NIBSC).  Samples were titred to 1:32 pre PEX/DFPP and 1:16 post 
PEX/DFPP with the rationale that antibody levels with significant reactivity beyond these levels 
could not be reduced to negative with a realistic number of DFPP sessions pre transplant.  
In addition to a donor based crossmatch an auto FXM was also performed using the samples at 
neat only to ensure any reactivity observed was donor specific and not non-specific reactivity. 
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3.3.1.1 Serial Dilution of Serum Samples. 
Nine 250μl eppendorff tubes were labelled pre – 1:2, 1:4, 1:8, 1:16 and 1:32, Post – 1:2, 1:4, 
1:8 and 1:16.  The initial serum storage tube for each sample was taken as the neat.  To each of 
the eppendorff tubes 100μl of negative control serum (NIBSC) was added.  100μl of the 
appropriate patient serum was then added to the first, 1:2, tube and mixed well.  From this a 
further 100μl was taken and added to the 1:4 tube and mixed well.  This process was 









From this point each dilution was treated as an individual serum sample and the titre FXM set 
up following the standard 3-colour FXM protocol above, with a total of 26 assay tubes, two for 
each serum sample plus two for the negative control and two for the positive control.  The 
results were collected and the RMF values calculated for each serum dilution.  The reduction in 
antibody strength, based on a reduction in the RMF value at neat and/or in the dilution at 
which a negative result was achieved, was assessed and the potential number of DFPP sessions 
required to achieve a negative flow crossmatch pre transplant calculated.  Where either the T 
or B cell crossmatch was stronger, as demonstrated by positivity to a higher titre against one 
of the cell populations, the number of DFPP sessions predicted was based on the strongest 
100μl 100μl 100μl 100μl 100μl 
Neat 1:2 1:4 1:8 1:16 1:32 
Figure 20 - Diagram representing serial dilution of serum samples. 
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crossmatch result. When the RMF value at 1:16 dilution of the post removal sample was not 
negative, i.e. the RMF was greater than 2.3 for this sample, it was reported that it would not 
be possible to remove the antibody to a level that would allow for a negative crossmatch pre-
transplant.  Where a reduction was seen and the crossmatch became negative at titres of 1:16 
or below on the post removal sample the predicted number of antibody removal sessions was 
calculated based on a similar reduction of titre being expected with each antibody removal 
session.  As had been observed with our original antibody removal patients, and previously 
discussed in the introduction, there is often a ‘bounce back’ in antibody levels seen, starting a 
few hours after the end of the antibody removal session.  This is believed to be due to 
synthesis of new antibody and movement of antibody in the extravascular spaces into the 
circulation.  To account for this an additional antibody removal session was added to the total 
number required pre transplant. For example, a reduction from 1:16 to 1:8 would indicate a 
requirement for 4 DFPP sessions pre-transplant, based on each session reducing the strength 
by one titre, with an additional session to cover possible antibody ‘bounce back’, giving a total 
predicted number of pre transplant antibody removal sessions of 5.  A reduction of 1:8 to 1:2 
would indicate a requirement of two sessions to achieve a negative crossmatch and then an 
addition treatment to cover potential bounce back, giving a total of 3 sessions.  If however the 
titre decreased but the RMF values at neat remained unchanged then the number of antibody 
removal treatments recommended would follow the calculation above, with the additional 




3.4.1 Introduction and Validation of Luminex Technology for Monitoring 
Donor Specific Antibody in Highly Sensitised Renal Transplant 
Recipients. 
3.4.1.1 Scene setting background work prior to project 
At the time of commencement of this project the Renal Unit at Guys Hospital had transplanted 
3 highly sensitised patients following antibody removal.  As part of the process our laboratory 
had been monitoring the levels of donor specific antibodies using our routine method of 
choice at the time, FlowPRA single antigen detection beads, in conjunction with numerous 
donor flow crossmatches both pre and post-transplant.  However with our commitment to 
embracing new technology and service improvement the decision to introduce Luminex 
technology was taken.  As part of the enormous validation process required, the assessment of 
the use of LABScreen single antigen beads to monitor HLA DSA in antibody removal patients 
was required. 
Samples were selected from these three patients, who had previously been screened using the 
current FlowPRA single antigen method and both T and B cell flow crossmatches.  Previous 
monitoring of these patients using the FlowPRA bead method in combination with flow 
crossmatches had highlighted the fact that changes in fluorescence detected on FlowPRA 
beads generally followed those of the flow crossmatch, giving similar indications as to the 
increasing and decreasing trends of the donor specific antibody levels.  This therefore allowed 
post-transplant monitoring of DSA to be carried out using FlowPRA beads, rather than 
repeated crossmatches, and using the values achieved to correlate back to pre transplant 
crossmatches and predict if the antibody had reached levels at which a positive crossmatch 
would be expected were it to be performed.  A representative example of such monitoring can 
be seen in figure 21 below which shows both T and B cell flow crossmatch RMF and 
corresponding FlowPRA single antigen bead fluorescence values from a patient undergoing 
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removal of an antibody specific for the mismatch HLA B60.  Since the antibody involved is to a 
Class I mismatch both the T and B cell crossmatch results are relevant.  The trendlines for all 
three data sets can be seen to follow similar patterns of increasing and decreasing values. 
Figure 21 - Serial samples from a patient undergoing antibody removal measured 
using FlowPRA single antigen beads (MDX) and T and B cell flow crossmatch (RMF). 
 
During the validation of the LABScreen single antigen beads these samples were analysed 
using the new method and the results compared to those achieved previously to assess the 
ability of the new single antigen beads to be used in the same manner.  A representative 
example of the results achieved can be seen in figure 22 below, where serial samples from the 
same patient featured in figure 21 above who was undergoing HLA specific antibody removal, 
focused on removal of HLA B60 specificity, were tested using both FlowPRA and LABScreen 


























Figure 22 - Comparison of FlowPRA (Flow bead) MdX values and LABScreen 
(Luminex) MFI values gained from testing of serial samples for the presence of HLA 
B60 specific Antibody. 
 
As can be seen in figure 22 above the results achieved with both kits showed very similar 
changes in fluorescence between each sample, as indicated by changing Mdx or MFI values.  
This indicated that LABScreen single antigen beads could be used in the same manner as the 
FlowPRA beads to monitor changes in donor specific antibody levels. 
This was further confirmed by comparing the trend in LABScreen MFI values with that seen for 
the flow crossmatch RMF values.  An example of this can be seen in figure 23 below, which, 
using samples from the same patient described in figures 21 and 22, plots the T and B cell RMF 
values achieved on crossmatching on the same chart as the MFI values for HLA B60 from the 
LABScreen single antigen beads, the antibody of interest, and allows comparison of the 















































Figure 23 - Trends in donor specific antibody levels as monitored by LABScreen 
(Luminex) single antigen beads and T and B cell flow crossmatching (RMF). 
 
 
The examples above were from a patient undergoing antibody removal for a single donor 
specific antibody directed at HLA B60.  To confirm that LABScreen single antigen MFI values 
could be equally useful in monitoring a number of donor specific antibodies in one patient 
similar analysis was carried out using serial samples from a patient with potential donor 
specific antibody to HLA A31, B56, DR4 and DR53.  The trend comparison of the individual MFI 
















































Figure 24 - Comparison of MFI values for multiple donor specific antibodies (A1, B56, 
DR4 and DR53) with RMF values from T and B cell flow crossmatches from testing 
serial samples from one patient. 
 
Whilst the trends are clearly comparable, visually the changes in the different specificities are 
complicated.  As the T and B cells express multiple HLA antigens on their surface, compared to 
just the single specificity as seen on the beads, I decided to investigate if the cumulative MFI 
value, achieved by addition of all the individual MFI values, would also correlate with the 
antibody level trends indicated by flow crossmatching.  Figure 25 below represents the same 
data seen in figure 24 above, but the individual MFI values for each donor specific antibody 
have been combined to give a total DSA MFI value, plotted against the RMF values achieved 
with the T and B cell flow crossmatches.  In this example it can be seen that to ensure the 
antibody is at a level that would be negative on flow crossmatch, RMF <2.3, the combined MFI 










































Figure 25 – Data presented in Figure 24 but simplified by calculating the cumulative 
MFI values for multiple donor specific antibodies (A1, B56, DR4 and DR53) compared 
to the RMF values achieved with flow crossmatching on T and B cells. 
 
These initial results indicated that the LABScreen screening methods yielded comparable 
results to those achieved with FlowPRA screening and that both could reflect the patterns and 
changes in fluorescence seen on crossmatching. 
3.4.2 Titre FXM Assessment. 
During this study titre crossmatches between 117 recipient and donor pairs have been 
performed using serum samples taken before and after a test antibody removal treatment.  In 
addition a further 34 titre crossmatches have been carried out using a single serially diluted 
serum sample from patients who did not receive a test antibody removal treatment.  As an 
ideal all the patients assessed using a test DFPP and titre FXM would first have had an initial 
FXM to ensure that the DSA present would be sufficient to give a positive result. However, due 
to time constraints, clinical urgency, and restricted donor availability this was not always 
possible.  In these cases crossmatch results were predicted to be positive, and the need for 
antibody removal assumed, based on the results achieved from the antibody screening 
methods employed, initially FlowPRA and then LABScreen Single Antigen bead testing.  In 






























and these are the patients in whom a negative crossmatch both pre and post was reported.  A 
comparison of the screening and crossmatch results will be performed in the next section. 
The results for all the titre crossmatches performed can be seen in table 3 below.  Each row 
represents a single crossmatch pair.  The donor HLA mismatches to which the recipient 
produces HLA specific antibody, as detected by LABScreen single antigen beads, are listed, split 
into HLA Class I and II specificities. The flow crossmatch results are divided into those achieved 
with the pre treatment sample (column marked pre PEX/DFPP) and those with the post 
treatment sample (column marked post PEX/DFPP).  The patients who did not receive a test 
antibody removal treatment and were crossmatched using a single pre DFPP/PEX sample are 
marked as ‘nt’ (not tested) in the post DFPP/PEX column.  Listed for each recipient and donor 
pair are the T and B cell flow crossmatch RMF values achieved with the neat serum sample, 
and for each of these the titre at which the last positive crossmatch value was achieved.  Those 
where the result was positive at neat only are marked as ‘neat’.  Those where the result was 
negative at neat are marked as ‘neg’.
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Table 3 - Final Titre and flow crossmatch T and B cell RMF results from 117 titre flow crossmatches between potential HLA antibody incompatible 
donor and recipient pairs, using serially diluted samples taken prior to and following a single antibody removal treatment using DFPP or PEX, and 
34 titre flow crossmatches using single serum samples from patients not treated with antibody removal. 
Crossmatch 
Pair 
Class I specificities Class II specifities 
Pre PEX/DFPP Post PEX/DFPP 














1 A3, Cw5 DR17, DQ2 neg 1.35 neg 2.26 neg 1.28 neg 2.12 
2 A3, Cw5 DR17, DQ2, DQ7 neg 1.41 neat 3.21 neg 1.16 neg 1.54 
3 A32, B61 DQ7 neg 2.25 1: 2 3.92 neg 1.74 neat 2.71 
4 A33, B58 DR15, 51 DQ6 neat 2.43 1: 8 8.61 neg 1.3 1:2 4.91 
5 A33, B58, Cw10 DR15, DR51, DQ6 neg 1.65 1: 2 5.11 neg 1.23 neat 2.68 
6 none DR13, DQ6 neg 1.05 1: 2 3.34 neg 0.94 neg 1.23 
7 B57 DR13, DQ6 neg 1.18 >1:32 11.98 nt nt nt nt 
8 none DR13, DQ6 neg 1.02 1: 8 5.91 nt nt nt nt 
9 A31 none neg 1.02 neg 1.25 neg 1.02 neg 1.59 
10 none DQ3, DQ6 neg 1.04 >1:32 8.43 nt nt nt nt 
11 none DQ3, DQ6 neg 1.12 >1:32 11.12 neg 1.09 >1:16 9.29 
12 A1, B35, Cw4 D11, DR52, DQ7 neg 1.41 >1:32 34.22 neg 1.06 >1:16 12.12 





Class I specificities Class II specifities 
Pre PEX/DFPP Post PEX/DFPP 














14 Cw15 DR11, DP0201 neg 1.46 1: 8 9.04 nt nt nt nt 
15 none DQ5 neg 0.96 neg 1.5 neg 1.03 neg 1.6 
16 A3 none neat 2.52 neg 2.13 neg 2 neg 2 
17 B35 none neg 1.13 neg 1.22 neg 0.97 neg 0.93 
18 A1, A3, B8, B44 
DR13, DR17, DR52, 
DQ2 neat 2.97 1:8 8.68 neat 2.81 1: 4 6.84 
19 A1  DQ2 DR53 neg 1.15 >1:32 9.33 neg 1 >1:16 8 
20 A66 none neg 2.29 1:2 3.18 neg 1.48 neg 1.69 
21 A2, A3, B57 DR4, 53 DQ5 1:8 21.89 1:32 27.21 1:4 8.5 1: 8 14.62 
22 A2, A3, B57 DR4, DR53, DQ5 1:2 6.19 1:8 7.14 neat 2.57 1: 2 3.46 
23 B7 DP0401 neg 1.15 neg 2.21 nt nt nt nt 
24 A1, B52 
DR13, 15 DR51,52 
DQ6 neg 1.16 >1:32 6.77 neg 1.15 >1:16 6.27 
25 A29, B44 Bw4 Cw5 DR7 ?DQ2 >1:32 34.42 >1:32 50.88 >1:16 21.69 >1:16 35.2 
26 B7 DR15, DR51 neg 1.01 >1:32 4.05 neg 1.06 1: 8 6.38 
27 A1 DQ2 neg 1.51 1:16 3.84 neg 1.35 1: 8 4.77 





Class I specificities Class II specifities 
Pre PEX/DFPP Post PEX/DFPP 














29 A2 DR11, DQ7 neg 2.21 >1:64 13.39 nt nt nt nt 
30 A2, B18 none >1:32 45.73 >1:32 23.13 nt nt nt nt 
31 A2, B44, Cw5 DR4, DQ7 >1:32 53.06 >1:32 35.31 nt nt nt nt 
32 A23, B44, B64 DR7 DQ2 neg 1.41 neat 3.28 nt nt nt nt 
33 A3, A29, B44 DQ5 neg 1.68 >1:32 21.47 neg 1.26 >1:16 16.84 
34 B18 none neg 2.02 neg 2.03 neg 1.09 neat 10.3 
35 A3, B7, B57, Cw7 DR15, DR51, DQ9 1:16 9.86 >1:32 12.61 1:2 6.26 >1:16 13.92 
36 B58 none neg 1.22 neg 1.37 neg 1.11 neg 1.33 
37 B57, Cw6 DR7, DP13, DP18 neg 1.11 neg 1.63 neg 0.96 neg 1.25 
38 A11 DR103, 4, 53 DQ5 neg 2.22 >1:32 23.51 neg 1.34 >1:32 17.08 
39 B44 none neg 0.96 neg 1.06 nt nt nt nt 
40 B35, Cw4 DQ2 DR53 neg 2.17 >1:32 8.39 neg 1.6 >1:16 8.02 
41 A2 none >1:32 24.78 >1:32 17.96 1:8 11.84 1: 8 8.09 
42 A2 none >1:32 26.9 >1:32 22.67 >1:16 16.4 >1:16 11.45 
43 A32, B60,  DR53, DQ7, DQ8 1:32 23.22 >1:64 32.64 1:8 8.25 1:32 17.91 





Class I specificities Class II specifities 
Pre PEX/DFPP Post PEX/DFPP 














45 B8, B45 DR17, DR52, DQ2 neg 1.69 1:16 18.05 neg 1.38 1: 8 12.8 
46 B45 DR17, DR52, DQ2 >1:32 8.09 1:16 9.25 nt nt nt nt 
47 A26, B8, B60, Cw7, Cw10 none 1:8 6.85 1:16 9.03 1:2 4.26 1:4 6.56 
48 A2, B7, B8, Cw7 none 1:16 5.63 1: 2 2.26 1:4 4.17 neg 1.79 
49 B18, Cw7 none 1:2 3.23 neg 2.04 neat 2.69 neg 1.98 
50 A24, B44, Cw7 DR4, DR53 1:8 17.47 1: 8 8.94 nt nt nt nt 
51 A23, A26, B44, Cw4 DR15, DR51 1:8 21.12 1:16 20.35 nt nt nt nt 
52 A23, A26, B44, Cw4 DR15, DR51, DP5 1:16 24.31 1:16 14.41 1:8 14.43 1:8 10.5 
53 A1, Cw7 DR15, DP51, DP10 neat 3.58 neat 6.44 neat 2.35 1:2 4.5 
54 A1, B8 none neg 2.26 neat 3.5 neg 1.42 neg 1.48 
55 A29, B57 none 1:8 6.6 1: 8 6.26 1:2 2.96 1:2 3.1 
56 A3 none neat 3.01 1: 2 2.49 neg 1.61 neg 1.68 
57 A36, A74, B44, B72, Cw2 DR11, DR15, DQ6 >1:32 21.21 >1:32 20 nt nt nt nt 
58 A1, A2, Cw4, Cw7 DR1, DR15, DR51 >1:32 25.73 >1:16 12.56 >1:16 15.72 1:8 6.92 
59 A3, A32, B63, Cw7 DR15, DR51 neg 1.68 neat 2.72 neat 2.72 neg 1.5 





Class I specificities Class II specifities 
Pre PEX/DFPP Post PEX/DFPP 














61 B44, Cw5 none neg 1.39 neg 1.27 neg 1.16 neg 0.87 
62 none DQ7 neg 1.03 >1:32 8.74 neg 0.94 >1:16 7.85 
63 B8 DQ2, DQ7, DQA5 neg 1.59 >1:32 15.61 neg 1.3 >1:16 13.7 
64 B8 DQ2, DQ7, DQA5 neg 2.23 >1:32 6.73 neg 1.79 >1:16 6.19 
65 B8  none neg 1.6 neat 3.16 neg 1.1 neg 1.52 
66 none DQ7 neg 1.3 1:16 3.8 neg 1.22 1:4 3.25 
67 none DQ6, DP20 neg 1.18 1:2 3.49 nt nt nt nt 
68 Cw7 DR11, DQ7 neg 1.27 1:2 3.31 neg 0.99 neat 2.31 
69 A1 none 1:8 5.76 1:8 5.31 1:4 5.08 1:4 4.18 
70 B44, Cw5 DR52 neat 3.25 1:2 4.17 neg 1.75 neg 2.13 
71 A2, B13, Cw6 DR7, DQ2 neg 1.9 1:4 3.61 neg 1.17 neg 2.25 
72 none DR17, DR52   neg 0.97 neg 0.88 neg 0.89 neg 0.66 
73 A2, A24, B57, B62 none neat 3.39 1:8 6.31 neat 3.36 1:4 5.78 
74 A3, A29, B45, Cw6 DQ2 DR53 1:2 4.05 1:2 4.33 nt nt nt nt 
75 A3, A29, B45, Cw6 none 1:2 3.92 1:4 4.7 neg 2.15 neat 2.75 





Class I specificities Class II specifities 
Pre PEX/DFPP Post PEX/DFPP 














77 B7 DQ6 1:2 4.02 >1:64 16.37 nt nt nt nt 
78 Cw2,9 DQ5 >1:16 11.98 >1:16 19.07 >1:16 8.54 >1:16 17.81 
79 A68 DR7, DQ2 1:2 6.26 1:4 8.56 neat 2.34 1:2 3.67 
80 A1, A3, B60, Cw10 none 1:2 3.55 1:4 6.85 neg 2.24 1:2 3.88 
81 A1 none neg 2.17 1:2 5.08 neg 1.85 1:2 4.15 
82 A3, A30, Cw9 none neat 2.92 1:2 5.35 neg 2.11 1:2 3.35 
83 none DR11, DR13, DQ6 neg 1.43 >1:32 35.34 neg 1.43 >1:16 41.67 
84 A2, B55 none neg 1 neg 0.94 neg 1.04 neg 0.76 
85 A2, B27 DR4 1:8 5.95 neat 4.94 1:2 3.35 neat 3.2 
86 
A24, B44, B51, Cw2, 
Cw16 none 1:4 3.93 1:8 4.04 neat 3.27 1:2 4.07 
87 B7, B44, Cw5 none 1:8 8.25 1:8 5.93 1:2 5.1 1:4 4.73 
88 none DR8, DQ4 neg 1.36 1:16 13.38 nt nt nt nt 
89 A2 none neg 1.13 neg 0.92 nt nt nt nt 
90 Cw10 none 1:4 5.34 1:2 2.82 neat 3 neg 1.81 





Class I specificities Class II specifities 
Pre PEX/DFPP Post PEX/DFPP 














92 none DQ5 neg 1.11 neg 2.15 neg 1.03 neg 1.52 
93 B13 DR11, DQ7 1:16 25.02 >1:32 22.02 1:4 8.54 1:8 8.96 
94 B57   none neg 1.42 neg 1.18 neg 1.29 neg 1.03 
95 A1, A33, B57 none >1:32 49.22 >1:16 52.59 >1:32 49.86 >1:16 44.51 
96 A2, B57, Cw7 none neg 1.71 neg 2.17 neg 1.07 neg 1.03 
97 A68 none 1:16 24.01 1:16 16.27 1:8 10.77 1:8 9.69 
98 A31, B56 DR4, DR53 neg 1.84 1:4 4.7 neg 1.28 1:2 2.68 
99 B35 none neat 2.31 neg 1.9 neg 1.41 neg 1.03 
100 A2, B57  DR14 neg 2.02 neat 2.55 neg 1.23 neg 1.07 
101 B44, Cw5 DP3 neat 2.42 1:2 4.2 neg 1.91 neat 3.78 
102 none DR17, DR52 neg 0.97 1:4 8.41 neg 0.93 1:4 8.43 
103 A1 DQ6, DQ8 neg 1.18 1:32 2.94 neg 1.08 1:16 2.83 
104 none DR13, DQ6 neg 1 >1:32 14.09 neg 1.03 >1:16 13.02 
105 B62, Cw9 DR13, DQ6 1:2 4.45 >1:32 7.83 neat 2.88 >1:16 6.35 
106 B13, Cw6 DR11 1:8 5.72 >1:32 18.01 1:4 3.74 >1:16 13.8 





Class I specificities Class II specifities 
Pre PEX/DFPP Post PEX/DFPP 














108 A1, A36, B18 ?DR51, DQ6 1:4 5.61 >1:32 9.33 1:2 3.65 >1:16 8.58 
109 A3, B72 DQ5 neat 2.9 1:4 4.35 neg 1.91 1:4 2.86 
110 A2, B62, Cw10 DR4, DQ7 1:8 11.56 >1:32 13.54 1:4 6.56 >1:16 9.94 
111 B44 DR15, DR51 1:4 9.34 1:16 20.03 1:2 4.9 18 10.44 
112 A1 DR17, DR52 neg 1.13 >1:32 9.37 neg 1.03 1:8 10.86 
113 A3, Cw7 DR4, DQ7, DQ8 1:2 4.39 1:2 5.11 neg 1.71 neg 2.02 
114 A2, Cw17 DR18, DR52 1:16 9.78 1:4 4.19 1:4 5.99 1:2 3.18 
115 A33, Cw14 none neg 1.54 neg 1.38 neg 1.24 neg 1.15 
116 B8 DR17, DR52 1:8 6.58 >1:8 10.31 1:2 2.67 1:4 4.17 
117 B57 DR7 1:2 5.37 1:4 6.31 nt nt nt nt 
118 B62, Cw9 DR13, DR52 1:4 6.39 1:8 10.4 neat 2.36 1:2 4.47 
119 A2 none >1:32 8.1 >1:32 8.55 1:8 5.26 >1:16 6.51 
120 A2 none 1:16 5.57 >1:32 9.81 nt nt nt nt 
121 B53 DP1, DP9 neg 1.2 1:8 4.92 nt nt nt nt 
122 A3, B60 DR8   1:4 8.64 >1:32 27.97 neat 3.62 >1:16 16.03 





Class I specificities Class II specifities 
Pre PEX/DFPP Post PEX/DFPP 














124 A1 none neg 1.07 1:2 3.43 nt nt nt nt 
125 none DQ2 neg 1.21 1:8 5.28 neg 1.1 1:4 4.17 
126 A2 DR4, DQ7 neg 1.28 1:32 13.89 nt nt nt nt 
127 none DR4, DQ7 neg 1.41 1:32 14.15 neg 1.08 1:8 9.06 
128 none DR15, DR51, DQ6 neg 1.2 1:16 14.14 neg 0.98 1:4 8.2 
129 B57, B58 none neat 2.34 1:4 5.73 nt nt nt nt 
130 B57 none neg 2.22 1:4 4.94 neg 1.77 1:4 3.98 
131 B44 none 1:2 4.66 1:4 6.58 neat 2.8 1:2 4.26 
132 A2, B44, Cw5 DR4, DR53 >1:32 30.99 >1:32 60.77 >1:16 19.82 >1:16 36.59 
133 Cw5 none 1:2 3.57 1:2 4.05 nt nt nt nt 
134 A1, A3, B7, B8 none 1:32 12.81 1:64 6.28 1:16 8.09 1:32 6.18 
135 A31, B44, B60, Cw5 DR1, DR8, DQ4, DQ5 >1:32 20.73 >1:32 29.95 >1:16 21.3 >1:16 29.96 
136 B7 DR15, DQ6 1:4 5.23 1:32 18.94 nt nt nt nt 
137 B7 DR15, DQ6 neat 3.23 1:16 16.5 neg 1.91 1:8 10.62 
138 A1, B8, Cw2 
DR16, DR17, DR51, 





Class I specificities Class II specifities 
Pre PEX/DFPP Post PEX/DFPP 














139 none DR13, DP3 neg 1.48 >1:32 18.02 neg 1.31 >1:16 15.75 
140 Cw6 none 1:8 4.05 1:8 3.7 nt nt nt nt 
141 Cw6 DR12, DR52 1:4 4.55 1:2 3.61 1:2 3.73 neat 2.82 
142 A23, A80, B57, Cw18 none >1:32 13.89 >1:32 5.23 >1:16 12.95 >1:16 4.33 
143 A3, B35, B51, Cw15 DR1 1:16 14.51 >1:32 21.95 1:4 8.79 >1:16 19.33 
144 A3 none 1:8 11.11 1:8 6.73 nt nt nt nt 
145 B35 none neg 1.27 neg 1.49 neg 1.12 neg 1.26 
146 B57 none neg 1.35 1:2 2.66 nt nt nt nt 
147 A24, B44 none  neg 1.26 neg 1.26 nt nt nt nt 
148 A26, A32, B35, B60, Cw10 DQ7 1:4 5.15 1:16 11.39 1:2 3.4 1:8 7.84 
149 A11 DQ6 1:2 4.06 1:32 11.88 neat 2.73 1:16 9.72 
150 none DR53   neg 0.96 >1:32 4.37 nt nt nt nt 




3.4.3 Analysis of the Predictive Value of the Titre Crossmatch 
assessment. 
Of the patients assessed using this method, 31 went on to be transplanted with an organ from 
the donor with which they were assessed.  Table 4 below summarises the titre crossmatch 
results using pre and post test PEX/DFPP samples.  Listed for each donor and recipient pair are: 
the pre and post test antibody removal T and B cell RMF values at neat, and titre to which 
positivity reached using these samples from the original test antibody removal titre flow 
crossmatch assessment, number of antibody removal sessions predicted to be required pre 
transplant using the original titre flow crossmatch assessment results ,as previously discussed, 
and the actual number of antibody removal sessions that were required prior to transplant to 
achieve a negative crossmatch.  The values in the final two columns are the numbers of 
antibody removal sessions, predicted or required respectively.  Where no antibody removal 
was either predicted or required ‘0’ is listed.  None of the patients, who following assessment 
using the test antibody removal and titre XM method, and being found suitable for an 
antibody removal transplant, have subsequently failed to receive a graft following antibody 
removal.  Three patients were treated with induction therapy of the anti-CD20 mAb Rituximab, 
which is known to generate false positive B cell flow crossmatches due to binding to CD20 
expressed on the B cell surface and, due to its chimeric nature, being detected as a bound 
antibody by the anti-human IgG FITC conjugate.  As, at our centre, Rituximab is given one 
month prior to transplant these patients could not be assessed by flow crossmatch prior to 
transplant and therefore their results will not be included in the following analysis.
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Table 4 - Summary of the antibody removal requirements in the transplanted group 
of patients, including the predicted number of antibody removal sessions based on 
the original test antibody removal and titre flow crossmatch assessment, and the 
actual number of antibody removal treatments given prior to transplant. 





































HLAi 5 2.32 1:2 3.08 1:8 1.47 Neat 1.66 Neat 1 1 
HLAi 6 2.5 1:2 5.44 1:8 1.45 Neat 2.32 1:2 2 
NT - 
Rituximab 
HLAi 7 3.47 1:2 3.3 1:4 2.5 Neat 2.48 Neat 2 1 
HLAi 8 6.39 1:4 10.4 1:8 2.36 neat 4.47 1:2 3 4 





1.37 neat 3.08 1:2 1.24 Neat 2.62 Neat 2 5 
HLAi 
11 
1.84 neat 4.7 1:4 1.28 neat 2.68 1:2 2 2 
HLAi 
12 
3.01 neat 2.49 1:2 1.61 Neat 1.68 Neat 1 1 
HLAi 
13 





1:8 6.37 1:4 8.51 1:4 4.6 1:2 4 4 
HLAi 
15 
9.78 1:16 4.19 1:4 5.99 1:4 3.18 1:2 4 5 
HLAi 
16 
1.27 neat 3.31 1:2 0.99 Neat 2.31 Neat 2 2 
HLAi 
17 





1.69 neat 18.1 1:16 1.38 Neat 12.8 1:8 6 6 
HLAi 
19 
2.26 neat 3.5 neat 1.42 Neat 1.48 Neat 1 1 
HLAi 
20 
5.35 1:2 12.5 1:8 2.61 Neat 5.5 1:2 4 4 
HLAi 
21 
6.19 1:2 7.14 1:8 2.57 Neat 3.46 1:2 3 3 
HLAi 
22 
2.52 neat 2.13 neat 2 Neat 2 Neat 1 0 
HLAi 
23 
1.01 neat 3.89 1:4 0.94 Neat 5.49 1:2 3 4 
HLAi 
24 
1.65 neat 5.11 1:2 1.23 Neat 2.68 Neat 2 2 
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1.71 neat 3.05 1:2 1.07 Neat 1.03 Neat 1 0 
HLAi 
27 
9.56 1:4 18.9 
>1:3
2 
3.79 Neat 10.2 1:8 6 8 
HLAi 
28 
1.11 neat 2.15 neat 1.03 Neat 1.52 Neat 0 1 
HLAi 
32 
1.39 neat 1.27 neat 1.16 Neat 0.87 Neat 0 0 
HLAi 
38 
1.18 neat 3.23 neat 1.03 Neat 1.4 Neat 1 2 
HLAi 
39 
9.34 1:4 20.0 1:16 4.9 1:4 10.4 1:8 5 5 
HLAi 
40 
1.85 neat 2.56 1:2 1.65 Neat 1.95 Neat 0 0 
HLAi 
41 
2.31 neat 1.9 neat 1.41 Neat 1.03 Neat 0 0 
HLAi 
42 
3.58 neat 6.44 neat 2.35 Neat 4.5 1:2 4 5 
HLAi 
43 
3.48 1:2 1.96 neat 2.38 Neat 1.67 Neat 2 0 
HLAi 
44 
3.23 1:2 2.04 neat 2.69 Neat 1.98 Neat 3 3 
 
Linear regression assessment of the association between the predicted number of antibody 
removal sessions and the actual number required prior to transplant to achieve a negative 
crossmatch gave an R
2
 value of 0.87 (p=<0.0001), indicating good correlation, shown in figure 
26 below.  In addition a two tailed paired t-test analysis found there was no significant 







Figure 26 - Linear regression analysis of the association between the predicted and 
actual number of antibody removal treatments required pre transplant. 
 
 
3.4.4 Influence of starting titre on number of antibody removal sessions 
needed pre transplant. 
To assess if the starting titre as assessed by FXM related to the number of antibody removal 
sessions required prior to transplant, the number of sessions of PEX was plotted against the 
starting titre for all positive T and B cell crossmatches.  The data is presented in figure 27 and 















Figure 27 - T cell FXM starting titre vs number of Antibody removal treatments 



































Figure 28 - B cell FXM starting titre vs number of antibody removal sessions required 
pre transplant. 
 
Mean 1.4 2.4 3.17 3 5.5 8 
Median 1 2 3 3.5 5.5 8 
 
Mean 1.6 1.9 6 4 5 
Median 1 2 6 4 5 
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For both the T and B cell starting titre there appears to be a general increase in number of 
antibody removal sessions required prior to transplant with increasing starting titre.  The T cell 
values may be affected by the influence of antibody removal for Class II specific antibody not 
reflected in the T cell titre value.  It can however be seen that there is a wide variation in the 
number of antibody removal treatments required in the lower titre antibodies, with for 
example a B cell FXM positive only at 1:2 requiring between 1 and 5 antibody removal sessions 
pre transplant. 
3.4.5 Effect of Antibody Specificity on the ability to successfully remove 
the antibody. 
Observation of the reduction in titre seen with a single antibody removal treatment over all 
the patients highlighted the fact that not all patients responded in the same way, with some 
showing a reduction of multiple titres and others showing no reduction in either titre or 
strength.  We assessed if the difference in response was due to specificity of the antibody, 
being directed at either HLA class I or class II or both.  The values are shown in table 5 below.  
Reduction in titre was classed as the difference in the number of dilutions where positivity was 
seen between the pre and post samples, for example a reduction from 1:8 to 1:2 is a reduction 
of 2 titre strengths and classed as ‘2’ .  ‘-‘ indicates negative at neat both pre and post, ‘0’ 
indicates no reduction in titre with a single DFPP, ‘1’ indicates a reduction of 1 dilution and ‘2’ 











Table 5- Summary of the reduction in titre on crossmatch and the donor HLA specific 




Class I Specific Antibody 
Class II specific 
Antibody 
Reduction in Titre 
T cells  B cells 
1 A3, Cw5 DR17, DQ2  - 1 
2 A3, Cw5 DR17, DQ2, DQ7  - 1 
3 A32, B61 DQ7  - 1 
4 A33, B58 DR15, 51 DQ6 1 2 
5 A33, B58, Cw10 DR15, DR51, DQ6  - 1 
6 none DR13, DQ6  - 1 
7 A31 none  -  - 
8 none DQ3, DQ6  - 0 
9 A1, B35, Cw4 D11, DR52, DQ7  - 0 
10 A30, Cw15 DR11, DP0201  - 2 
11 none DQ5  -  - 
12 A3 none 1  - 
13 B35 none  -  - 
14 A1, A3, B8, B44 DR13, DR17, DR52, DQ2 0 1 
15 A1  DQ2 DR53  - 0 
16 A66 none  - 1 
17 A2, A3, B57 DR4, 53 DQ5 1 2 
18 A2, A3, B57 DR4, DR53, DQ5 1 2 
19 A1, B52 DR13, 15 DR51,52 DQ6  - 0 
20 A29, B44 Bw4 Cw5 DR7 DQ2 0 0 
21 B7 DR15, DR51  - 2 
22 A1 DQ2  - 1 
23 A3, A29, B44 DQ5  - 0 
24 B18 none  -  - 
25 A3, B7, B57, Cw7 DR15, DR51, DQ9 3 0 
26 B58 none  -  - 
27 B57, Cw6 DR7, DP13, DP18  -  - 






Class I Specific Antibody 
Class II specific 
Antibody 
Reduction in Titre 
T cells  B cells 
29 B35, Cw4 DQ2 DR53  - 0 
30 A2 none 2 2 
31 A2 none 0 0 
32 A32, B60,  DR53, DQ7, DQ8 2 1 
33 B8, B45 DR17, DR52, DQ2  - 1 
34 A26, B8, B60, Cw7, Cw10 none 2 2 
35 A2, B7, B8, Cw7 none 2 1 
36 B18, Cw7 none 1 1 
37 A23, A26, B44, Cw4 DR15, DR51, DP5 1 1 
38 A1, Cw7 DR15, DP51, DP10 0 0 
39 A1, B8 none  - 1 
40 A29, B57 none 2 2 
41 A3 none 1 1 
42 A1, A2, Cw4, Cw7 DR1, DR15, DR51 1 1 
43 A3, A32, B63, Cw7 DR15, DR51  - 1 
44 A2, Cw12 DQ7  - 0 
45 B44, Cw5 none  -  - 
46 none DQ7  - 0 
47 B8 DQ2, DQ7, DQA5  - 0 
48 B8 DQ2, DQ7, DQA5  - 0 
49 B8  none  - 1 
50 none DQ7  - 2 
51 Cw7 DR11, DQ7  - 1 
52 A1 none 1 1 
53 B44, Cw5 DR52 1 1 
54 A2, B13, Cw6 DR7, DQ2  - 2 
55 none DR17, DR52    -  - 
56 A2, A24, B57, B62 none 0 1 
57 A3, A29, B45, Cw6 none 1 1 






Class I Specific Antibody 
Class II specific 
Antibody 
Reduction in Titre 
T cells  B cells 
59 Cw2,9 DQ5 0 0 
60 A68 DR7, DQ2 1 1 
61 A1, A3, B60, Cw10 none 1 1 
62 A1 none  - 0 
63 A3, A30, Cw9 none 1 0 
64 none DR11, DR13, DQ6  - 0 
65 A2, B55 none  -  - 
66 A2, B27 DR4 2 0 
67 
A24, B44, B51, Cw2, 
Cw16 none 2 2 
68 B7, B44, Cw5 none 2 1 
69 Cw10 none 2 1 
70 Cw15, Cw16 none 1  - 
71 none DQ5  -  - 
72 B13 DR11, DQ7 2 2 
73 B57   none  -  - 
74 A1, A33, B57 none 0 0 
75 A2, B57, Cw7 none  -  - 
76 A68 none 1 1 
77 A31, B56 DR4, DR53  - 1 
78 B35 none 1  - 
79 A2, B57  DR14  - 1 
80 B44, Cw5 DP3 1 1 
81 none DR17, DR52  - 0 
82 A1 DQ6, DQ8  - 1 
83 none DR13, DQ6  - 0 
84 B62, Cw9 DR13, DQ6 1 0 
85 B13, Cw6 DR11 1 0 
86 A2, B44   none  -  - 






Class I Specific Antibody 
Class II specific 
Antibody 
Reduction in Titre 
T cells  B cells 
88 A3, B72 DQ5 1 0 
89 A2, B62, Cw10 DR4, DQ7 1 0 
90 B44 DR15, DR51 1 1 
91 A1 DR17, DR52  - 2 
92 A3, Cw7 DR4, DQ7, DQ8 1 1 
93 A2, Cw17 DR18, DR52 2 1 
94 A33, Cw14 none  -  - 
95 B8 DR17, DR52 2 1 
96 B62, Cw9 DR13, DR52 2 2 
97 A2 none 2 0 
98 A3, B60 DR8   2 0 
99 none DR11  - 2 
100 none DQ2  - 1 
101 none DR4, DQ7  - 2 
102 none DR15, DR51, DQ6  - 2 
103 B57 none  - 0 
104 B44 none 1 1 
105 A2, B44, Cw5 DR4, DR53 0 0 
106 A1, A3, B7, B8 none 1 1 
107 A31, B44, B60, Cw5 DR1, DR8, DQ4, DQ5 0 0 
108 B7 DR15, DQ6 1 1 
109 A1, B8, Cw2 
DR16, DR17, DR51, 
DR52  - 0 
110 none DR13, DP3  - 0 
111 Cw6 DR12, DR52 1 1 
112 A23, A80, B57, Cw18 none 0 0 
113 A3, B35, B51, Cw15 DR1 2 0 
114 B35 none  -  - 
115 A26, A32, B35, B60, Cw10 DQ7 1 1 






Class I Specific Antibody 
Class II specific 
Antibody 
Reduction in Titre 
T cells  B cells 
117 A11, Cw5 DR11, DR52  - 1 
 
Analysis of the titre reduction seen on crossmatch in relation to the relevant antibody 
specificities found no significant difference between the groups – Class I only, Class II only and 
Class I and II in relation to T and B cell crossmatches respectively.  Kruskal-Wallis 1 way non-
parametric ANOVA analysis yielded a p value of 0.063, which whilst not significant does 
indicate a trend to there being a difference between the mean values.  Graphical 
representation of the data in figure 29 indicates that patients with class II antibody, detected 
on B cell crossmatches, appear to show the smallest overall reduction in titre with one 
antibody removal session, suggesting that HLA Class II specific antibodies may be more 
challenging to remove than HLA Class I specific antibodies.  However, the 95% confidence error 
bars presented on the graph do show the wide variability observed within each group and 
indicate that any trends observed should be approached with caution. 
Figure 29 - Reduction in titre by cell and antibody specificity following a single 




3.4.6 Comparison of FXM results with LABScreen Single antigen 
Screening Results. 
MFI values generated from LABScreen single antigen analysis are believed to be a semi-
quantitative value representing the strength of an antibody [150] .  Whilst FXM is our method 
of choice at Guys, it requires fresh donor derived PBLs to be collected for each FXM, which is 
not always easy to arrange due to the availability and location of the donor.  Therefore we 
wanted to assess if MFI values could be used in highly sensitised patients to accurately predict 
crossmatch results and act as a surrogate marker for the assessment of the requirement for, 
and likely success of, HLA specific antibody removal.   
By observing reaction patterns in our early antibody removal patients similar to those shown in 
figure 25 above, it was noted that the combined DSA MFI in different patient and donor pairs 
that equated to a predicted positive crossmatch showed great variation, indicating that it may 
not be possible to predict a positive crossmatch based on MFI values.  In addition 22 of the 
titre crossmatches predicted to be positive based on historical screening results were found to 
be negative on both the T and B cell crossmatch prior to any antibody removal.  To investigate 
the relationship between LABScreen single antigen bead MFI values and crossmatch results, 
samples from 58 patients who had received a test antibody removal treatment and had a titre 
flow crossmatch, along with samples from a further 10 patients who had been assessed by a 
single sample titre crossmatch, were tested at neat using LABScreen single antigen screening 
beads.  The MFI values for each donor specificity represented on the bead panel were 
collected.  Where more than one bead was present for a single specificity, such as for HLA A24 
and HLA DR4 seen in the example results provided in table 4, the average MFI of all the specific 
beads was recorded, unless the high resolution donor type was known and represented by a 
bead on the panel.  If more than one specificity was involved then the total sum of the MFI of 
all the beads was calculated, both separately for Class I and Class II plus a total of both Class I 
and II, as the total DSA MFI value had been found to mirror trends in crossmatch results over 
time in the patients who had previously undergone antibody removal.  This gave a total of 126 
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corresponding crossmatch and single antigen bead results.  The MFI and RMF values along 
with the specificities involved are summarised in table 6 below, where a sample was not tested 
either due to no HLA specific antibody to that class having been previously detected, or due to 
the patient providing only a pre DFPP sample, then ‘nt’ is marked in the appropriate column. 
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Table 6 – Table providing a summary of the T and B cell Titre Crossmatch RMF values and corresponding donor specific antibody MFI values in 
patient samples provided pre and post a test antibody removal treatment, with the relevant antibody specificities (Class I or II) listed. 
   Pre PEX/DFPP Post PEX/DFPP 
Crossmatch 
Pair 







Total                 
Class I 
MFI  









Total                 
Class I 
MFI  
Total             
Class II 
MFI 
1 A3, Cw5 DR17, DQ2 1.35 2.26 1996 3595 1.28 2.12 4946 3498 
2 A3, Cw5 DR17, DQ2, DQ7 1.41 3.21 1996 6252 1.16 1.54 4946 5774 
3 A32, B61 DQ7 2.25 3.92 7144 2657 1.74 2.71 13345 2270 
5 A33, B58, Cw10 DR15, DR51, DQ6 1.65 5.11 8446 12580 1.23 2.68 2819 20667 
6 none DR13, DQ6 1.05 3.34 nt 10052 0.94 1.23 nt 8697 
7 B57 DR13, DQ6 1.18 11.98 1706 16616 nt nt nt nt 
8 none DR13, DQ6 1.02 5.91 nt 16616 nt nt nt nt 
14 Cw15 DR11, DP0201 1.46 9.04 9353 20914 nt nt nt nt 
15 none DQ5 0.96 1.5 nt 8279 1.03 1.6 nt 9782 
16 A3 none 2.52 2.13 14056 nt 2 2 11553 nt 
18 A1, A3, B8, B44 
DR13, DR17, DR52, 
DQ2 2.97 8.68 19834 20752 2.81 6.84 21788 13502 
22 A2, A3, B57 DR4, DR53, DQ5 6.19 7.14 32734 22376 2.57 3.46 31374 15691 
23 B7 DP0401 1.15 2.21 2298 668 nt nt nt nt 
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   Pre PEX/DFPP Post PEX/DFPP 
Crossmatch 
Pair 







Total                 
Class I 
MFI  









Total                 
Class I 
MFI  
Total             
Class II 
MFI 
24 A1, B52 
DR13, 15 
DR51,52DQ6 1.16 6.77 6714 41168 1.15 6.27 3141 44074 
26 B7 DR15, DR51 1.01 4.05 nt 16412 1.06 6.38 nt 17318 
27 A1 DQ2 1.51 3.84 6829 12411 1.35 4.77 7434 13230 
28 Cw5 none 1.14 0.86 4852 nt nt nt nt nt 
34 B18 none 2.02 2.03 5061 nt 1.09 10.3 2520 nt 
35 A3, B7, B57, Cw7 DR15, DR51, DQ9 9.86 12.61 46588 46319 6.26 13.92 43187 30936 
36 B58 none 1.22 1.37 12369 nt 1.11 1.33 14421 nt 
44 B63 none 1.05 1.84 9587 nt nt nt nt nt 
46 B45 DR17, DR52, DQ2 8.09 9.25 1185 11759 nt nt 750 11672 
47 
A26, B8, B60, Cw7, 
Cw10 none 6.85 9.03 46770 nt 4.26 6.56 45195 nt 
48 A2, B7, B8, Cw7 none 5.63 2.26 34128 nt 4.17 1.79 39132 nt 
49 B18, Cw7 none 3.23 2.04 19017 nt 2.69 1.98 20788 nt 
52 A23, A26, B44, Cw4 DR15, DR51, DP5 24.31 14.41 30843 24781 14.43 10.5 34785 25966 
53 A1, Cw7 DR15, DP51, DP10 3.58 6.44 14013 22123 2.35 4.5 10851 23321 
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   Pre PEX/DFPP Post PEX/DFPP 
Crossmatch 
Pair 







Total                 
Class I 
MFI  









Total                 
Class I 
MFI  
Total             
Class II 
MFI 
55 A29, B57 none 6.6 6.26 15016 nt 2.96 3.1 nt nt 
58 A1, A2, Cw4, Cw7 DR1, DR15, DR51 25.73 12.56 32555 34697 15.72 6.92 34522 42298 
59 A3, A32, B63, Cw7 DR15, DR51 1.68 2.72 33562 24134 2.72 1.5 21206 25304 
60 A2, Cw12 DQ7 1.39 8.9 7395 3614 1.12 8.48 8908 8855 
61 B44, Cw5 none 1.39 1.27 20895 nt 1.16 0.87 14053 nt 
63 B8 DQ2, DQ7, DQA5 1.59 15.61 5193 7694 1.3 13.7 3457 13652 
64 B8 DQ2, DQ7, DQA5 2.23 6.73 9133 7622 1.79 6.19 7741 8799 
70 B44, Cw5 DR52 3.25 4.17 12592 4586 1.75 2.13 10094 2206 
71 A2, B13, Cw6 DR7, DQ2 1.9 3.61 14192 24718 1.17 2.25 4637 13642 
77 B7 DQ6 4.02 16.37 10629 7500 nt nt nt nt 
80 A1, A3, B60, Cw10 none 3.55 6.85 27723 nt 2.24 3.88 29618 nt 
81 A1 none 2.17 5.08 12378 nt 1.85 4.15 12812 nt 
82 A3, A30, Cw9 none 2.92 5.35 22801 nt 2.11 3.35 22168 nt 
83 none DR11, DR13, DQ6 1.43 35.34 nt 21205 1.43 41.67 nt 30300 
86 
A24, B44, B51, Cw2, 
Cw16 none 3.93 4.04 26013 nt 3.27 4.07 22183 nt 
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   Pre PEX/DFPP Post PEX/DFPP 
Crossmatch 
Pair 







Total                 
Class I 
MFI  









Total                 
Class I 
MFI  
Total             
Class II 
MFI 
87 B7, B44, Cw5 none 8.25 5.93 26114 nt 5.1 4.73 28857 nt 
91 Cw15, Cw16 none 3.48 1.96 17838 nt 2.38 1.67 17377 nt 
92 none DQ5 1.11 2.15 nt 11206 1.03 1.52 nt 9288 
93 B13 DR11, DQ7 25.02 22.02 2574 23062 8.54 8.96 9284 14014 
96 A2, B57, Cw7 none 1.71 2.17 22036 nt 1.07 1.03 13198 nt 
98 A31, B56 DR4, DR53 1.84 4.7 10026 12598 1.28 2.68 4234 6854 
99 B35 none 2.31 1.9 7003 nt 1.41 1.03 nt nt 
100 A2, B57  DR14 2.02 2.55 13640 1706 1.23 1.07 5017 nt 
101 B44, Cw5 DP3 2.42 4.2 10156 10751 1.91 3.78 6641 10490 
103 A1 DQ6, DQ8 1.18 2.94 2721 17943 1.08 2.83 2177 14915 
105 B62, Cw9 DR13, DQ6 4.45 7.83 8964 7165 2.88 6.35 8902 10230 
106 B13, Cw6 DR11 5.72 18.01 17777 3204 3.74 13.8 18520 3863 
110 A2, B62, Cw10 DR4, DQ7 11.56 13.54 11507 8977 6.56 9.94 24833 33381 
112 A1 DR17, DR52 1.13 9.37 1427 28010 1.03 10.86 900 28114 
116 B8 DR17, DR52 6.58 10.31 6800 6711 2.67 4.17 4700 3711 
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   Pre PEX/DFPP Post PEX/DFPP 
Crossmatch 
Pair 







Total                 
Class I 
MFI  









Total                 
Class I 
MFI  
Total             
Class II 
MFI 
117 B57 DR7 5.37 6.31 6685 3400 nt nt nt nt 
118 B62, Cw9 DR13, DR52 6.39 10.4 15042 5412 2.36 4.47 9930 3054 
125 none DQ2 1.21 5.28 nt 18356 1.1 4.17 nt 14130 
134 A1, A3, B7, B8 none 12.81 6.28 26100 nt 8.09 6.18 26520 nt 
135 A31, B44, B60, Cw5 DR1, DR8, DQ4, DQ5 20.73 29.95 24651 46745 21.3 29.96 45645 37184 
139 none DR13, DP3 1.48 18.02 nt 7145 1.31 15.75 nt 12602 
142 A23, A80, B57, Cw18 none 13.89 5.23 27547 nt 12.95 4.33 32191 nt 
143 A3, B35, B51, Cw15 DR1 14.51 21.95 16324 2617 8.79 19.33 32951 11850 
146 B57 none 1.35 2.66 1200 nt nt nt nt nt 
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A26, A32, B35, B60, 




The bead MFI values were compared to the crossmatch RMF values to assess if the cumulative 
donor specific bead MFI values could predict a crossmatch result in these highly sensitised 
patients.  Due to the differences in expression of HLA class I and class II molecules between T 
and B cells, the analysis split the results into three groups – the association between Class I 
MFI and T cell RMF, the association between Class II MFI and B cell RMF and the association 
between combined Class I and II MFI and B cell RMF.  Initial linear regression analysis of all 
three groups indicated that whilst there was some association between MFI and RMF it was 
not possible to confidently predict an RMF value for either T or B cells from the MFI values 
within the 95% confidence window.  The analysis is shown in figures 30, 31 and 32 respectively 
below.  In these figures the dots represent corresponding RMF and cumulative DSA MFI values 
from a single sample, the solid line is the line of regression and the two dotted lines represent 
the 95% confidence interval. 











Figure 31 – Linear regression analysis of total Class II DSA MFI against B cell RMF. 
R 
2
 = 0.12  
 
Figure 32 – Linear regression analysis of total DSA MFI against B cell RMF. 
R 
2
 = 0.14  
To assess if there was a difference in total DSA MFI values between those crossmatches that 
were positive at neat and those that were negative the three data sets were also analysed 
using the unpaired non-parametric Mann-Whitney test.  The results are shown in figures 33, 






Figure 33 - Total Class I DSA MFI against negative and positive T cell crossmatches at 
neat. 
p = <0.0001  
 



































Figure 35 - Total Class I and II DSA MFI against negative and positive B cell 
crossmatches at neat. 
p = <0.0001  
 
The p values achieved for all three groups indicate a significant difference between the median 
MFI value achieved for the crossmatches which were negative and those which were positive. 
However the range of MFI values in all groups show considerable overlap, particularly in the 
lower values, indicating again that total DSA MFI may not be accurately predictive of a FXM 
result.  The B cell crossmatches however do indicate that a total Class II DSA MFI of greater 
than 30000 and a total combined Class I and II DSA MFI of greater than 50000 are always 
associated with a positive B cell crossmatch. Up to these values however there seems to be 
equal likelihood of a positive or negative crossmatch.  The T cell crossmatches indicate that a 
total Class I DSA MFI of greater than 20000 is commonly associated with a positive crossmatch, 
but again at lower values there is no association.
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The titre crossmatch involves multiple dilutions and sample tubes in comparison to a routine 
crossmatch, making it more time consuming, costly and demands a higher volume of donor 
cells.  To assess if it was possible to predict the final titre achieved from the results gained 
against the neat sample only the results were separated into final titre and plotted against the 
RMF value at neat.  Kruskal-Wallis non-parametric ANOVA analysis was employed to assess if 
there was significant variation between any of the median values for the respective titre 
groups.   
Figure 36 - T cell RMF values at neat against final titre of crossmatch. 













Figure 37 – B cell RMF values at neat against final titre of crossmatch. 
p = <0.0001  
As can be seen in figure 36 and 37 above there is an obvious trend between the median RMF 
values achieved at neat and the final titre of the crossmatch, both for the T cell and the B cell, 
with increasing RMF values at neat being associated with a higher final titre.  It can also be 
seen however that the higher the titre the wider the range of starting RMF value, with overlap 
being seen between groups. 
To assess if the single antigen bead MFI values also followed a similar trend, potentially 
allowing prediction of a final titre prior to performing a crossmatch, the same analysis was 
carried out replacing the RMF values with the total DSA MFI values.  The results were split into 
two groups – the T cell titre against total class I DSA MFI and the B cell titre against combined 









Figure 38 - Total Class I DSA MFI against final titre of the T cell crossmatch. 
p = <0.0001  
 
Figure 39 – Total Class I and II DSA MFI against final titre of the B cell crossmatch. 
p = 0.0002  
As can be seen, whilst the ANOVA analysis indicates that there is a significant difference 
between at least one pair of the median MFI values of the groups, there is clearly no trend 
similar to that seen with the RMF values relating to increasing MFI values at neat 
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corresponding with increasing titre values.  Again indicating that the MFI values achieved with 
the single antigen beads may not be indicative of RMF values on crossmatch. 
3.4.7 Association with Post-transplant Outcome. 
Whilst it is apparent that antibody levels vary between patients based on the results achieved 
with both the flow crossmatches and with the single antigen beads the significance of these 
levels in relation to post-transplant outcome needed to be investigated.  By comparing pre 
transplant antibody results with post-transplant outcomes in our HLA antibody incompatible 
groups we hoped to be able to define a level, either pre-treatment or pre transplant, at which 
there was a higher risk of post-transplant complications and failure. 
Data was collected for all the HLA antibody incompatible transplants – where potential donor 
specific antibody had been detected using single antigen screening beads with or without a 
positive T or B cell flow crossmatch.  In those patients where antibody removal pre transplant 
was required due to a positive crossmatch, both the pre-treatment and pre transplant 
crossmatch RMF values and total DSA MFI values were collected.  In the patients who were 
single antigen bead positive only, not requiring antibody removal, the pre transplant values 
only were collected.  In addition in patients where the graft was lost during the time period 
studied the time in days to graft loss and the cause of graft loss – rejection or other, non-
immunological causes, such as death of the patient with a functioning graft – was also 
recorded.  The incidence of biopsy proven rejection episodes (BPRE) in the first year that 
included a diagnosis of antibody mediated rejection was also recorded.  It can be seen that a 
number of patients in the HLA antibody incompatible group who did not require antibody 
removal have been included despite having low levels of HLA specific antibody, in their 
immediate pre transplant sample. However in all patients historic levels of antibody were all 
greater than 2000 MFI, so on this basis have been included in the analysis.  The data is 
summarised in table 7 below. 
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It must be noted that with regard to immunosuppressive regimens this group of patients in 
particular are mixed.  Due to the evolving nature of HLA antibody incompatible transplantation 
patients have not all been treated the same.  As discussed earlier a few patients have received 
Rituximab as part of their induction therapy.  In addition, as will be discussed fully later, more 
recently transplanted patients have received Campath or ATG induction therapy.  All other 
patients have received Basiliximab induction.  Our standard triple therapy immunosuppression 
regimen, consisting of MMF, tacrolimus and prednisolone, has been followed in at least the 
immediate post-transplant period for all patients.  Due to the already small numbers involved, 
for the following analysis all the patients have been included regardless of the induction 
therapy received.  A separate analysis comparing outcomes in patients who did and did not 




Table 7 - Summary of the antibody specificities, MFI and RMF results pre-treatment and pre-transplant in the HLA antibody incompatible patients. 
  Pre Treatment Pre Transplant      







































1518 y - - No No 
HLAi 2 B62, Cw9, DR13, DR52 7.11 11.54 20454 1.25 1.76 3790 y 9 other No No 
HLAi 3 Bw4 (B49) 2.58 3.2 5860 1.57 
Rituximab 
- NT 
2735 y 614 other No Yes 
HLAi 4 A3, DP2, DP4 1.47 8.18 28182 0.97 2.79 12342 y - - Yes Yes 
HLAi 5 A31, B56, DR4, DR53 1.45 4.38 16895 1.07 2.02 6830 y - - No No 
HLAi 6 A2, B42, DR18 14.73 14.16 18319 2.12 2.9 12723 y 478 Rejection Yes Yes 
HLAi 7 Cw7, DR11, DQ7 1.08 3.45 14020 1.05 2.89 20305 y - - Yes Yes 





10190 y - - No No 
HLAi 9 
A31, B8, B45, Cw6, DR17, 
DR52 
13.89 9.54 38669 3.45 4.21 25008 y 48 Rejection Yes Yes 
HLAi A11, B55, C9, DR14, DR52 2 11.6 26779 1 0.85 6665 y - - Yes Yes 
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  Pre Treatment Pre Transplant      





































A2, A3, B57, DR53 DQ5 2.26 5.55 35223 1.47 3.93 30617 y - - Yes Yes 
HLAi 
12 
A3, B35, DR1, DQ5 1.76 2.49 11046 1.29 2.01 8431 y - - Yes Yes 
HLAi 
13 
DQ7 0.94 5.49 9999 1.09 6.07 15089 y - - No No 
HLAi 
14 
B58, DR15, DR51, DQ6 1.47 5.42 47453 1.14 2.86 19328 y 200 Rejection Yes Yes 
HLAi 
15 
A23, B8, B44 3.73 9.64 27103 2.13 3.96 11686 y - - Yes Yes 
HLAi 
16 
DR4, DQ7 nt nt - 1.01 0.75 1669 n - - No No 
HLAi 
17 
B44, C5, DR4 nt nt 32902 1.19 2.09 8600 n - - No No 
HLAi 
18 
Bw4 B63 nt nt - 1.2 1.45 3300 n - - Yes Yes 
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  Pre Treatment Pre Transplant      




































B44 nt nt - 1.24 1.22 780 n - - Yes Yes 
HLAi 
20 
DR11 nt nt - 1.19 1.6 600 n - - No No 
HLAi 
21 
B7 nt nt - 1.34 1.74 1200 n - - Yes Yes 
HLAi 
22 
B35 nt nt - 0.9 1.05 500 n 1324 other No No 
HLAi 
23 
B44 nt nt - 0.88 1.14 3800 n - - No No 
HLAi 
24 
B62, Cw9, DR13, DR52 2.5 5.31 7260 1.26 1.83 4500 y - - No No 
HLAi 
25 
DQ1 0.9 2.79 8577 0.92 1.47 3454 y 970 other No No 
HLAi 
26 
A24 2.8 3.79 8475 1.45 1.92 3656 y - - No Yes 
HLAi 
27 
DP0301 2.18 4.76 10320 1.36 2.98 6310 y 316 Rejection No Yes 
163 
 
  Pre Treatment Pre Transplant      




































Bw6 2.32 3.08 4028 1.09 1.46 692 y 208 other No Yes 
HLAi 
29 
B35 3.19 3.75 7500 1.05 
Rituximab 
- NT 
2860 y - - No No 
HLAi 
30 
A3 3 3.89 10098 1.29 2.37 5478 y - - No No 
HLAi 
31 
A3, A29, B45, Cw6 2.99 4.27 8484 1.53 1.9 6920 y - - Yes Yes 
HLAi 
32 
A3 11.14 6.18 6350 1.98 2.53 5181 y 237 Rejection Yes Yes 
HLAi 
33 
A1, B8 2.41 3.66 18442 1.17 1.12 6626 y - - No No 
HLAi 
34 
A2, B57, DQ9 1.71 3.05 15300 1.31 1.13 6959 y - - No No 
HLAi 
35 
DQ5 0.99 2.71 9763 nt nt 10905 y - - No No 
HLAi 
36 
Cw7 nt nt - 0.88 1.68 1498 n - - No No 
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  Pre Treatment Pre Transplant      




































DQA5 nt nt - 0.94 2.77 6529 n - - No No 
HLAi 
38 
Cw12, DR15 nt nt - 1.01 1.6 10700 n - - No No 
HLAi 
39 
A30 nt nt - 1.39 2.21 3448 n - - No No 
HLAi 
40 
A24 nt nt - 1.01 1.06 2830 n 231 Rejection No Yes 
HLAi 
41 
A11 nt nt - 2.19 1.37 6145 n 2049 Rejection Yes Yes 
HLAi 
42 
Cw10 nt nt - 1.14 2.76 3000 n - - No No 
HLAi 
43 
B75 nt nt - 1.08 1.64 1400 n - - No No 
HLAi 
44 
A2 nt nt - 0.97 0.71 1400 n - - No Yes 
HLAi 
45 
A30 nt nt - 0.93 1.02 800 n - - No Yes 
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  Pre Treatment Pre Transplant      




































A2 nt nt - 0.99 1.89 780 n - - No No 
HLAi 
47 
B35 nt nt - nt nt 8000 n - - No No 
HLAi 
48 
B14 nt nt - 1.01 2.05 2000 n - - No No 
HLAi 
49 
DR1 nt nt - 0.99 1.04 800 n - - No No 
HLAi 
50 
B8 nt nt - 0.97 1.26 4500 n - - No No 
HLAi 
51 
DQ7 nt nt - 1.07 1.04 917 n - - No No 
HLAi 
52 
Cw8, DQ9 nt nt - 1 1.76 5500 n - - No No 
HLAi 
53 
A32 nt nt - 0.91 0.86 2000 n - - No Yes 
HLAi 
54 
Cw7 nt nt - 0.94 0.99 1300 n - - No No 
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3.4.8 Association with Graft Survival. 
For the purposes of the following analysis outcome was defined as graft survival or failure, due 
to rejection, over the course of the study period, with a median follow up time of 1351 days 
(range - 249 – 3096).  Failures due to other non-immunological causes were censored from the 
analysis.  There were 5 such failures recorded in this patient group, 2 patients died with a 
functioning graft, 1 graft was lost due to renal vein thrombosis secondary to prolonged 
hypotension, 1 was lost due to recurrent disease and 1 was lost following patient death due to 
infection of the graft. 
The initial analysis of data centred round comparing the pre-treatment RMF, T or B cell, and 
total DSA MFI values with occurrences of graft loss in the patients who required antibody 
removal prior to transplant.  Secondly, the pre-transplant values were also analysed including 
all the HLA antibody incompatible transplants, regardless of the need for antibody removal.  As 
previously discussed T cells, unless activated, express only HLA Class I, whereas B cells express 
both HLA Class I and II.  This means in general terms that T cell positive FXM are due to Class I 
specific antibody whereas B cell positive FXM can be due to Class I and/or II specific antibody.  
To account for the different expression of HLA on the T and B cells the groups analysed were - 
T cell RMF pre-treatment in patients with HLA Class I or Class I and Class II specific antibody, B 
cell RMF pre-treatment in all patients, T cell RMF pre transplant in patients with HLA Class I or 
Class I and Class II specific antibody, B cell RMF pre-transplant in all patients, Total DSA MFI 
pre-treatment and Total DSA MFI pre-transplant.  Due the small patient numbers involved, 
particularly in the failure due to rejection group, the data for each group was analysed using 
the non-parametric t-test, Mann-Whitney U,  and the results can be seen in figures 40 – 45 
below.  The p values achieved are indicative of significant differences between groups. 
However, due to the small numbers involved, they must be treated with caution.  The dot plots 




Figure 40 - Graft survival or failure due to rejection vs Pre-treatment T cell RMF in 
patients with HLA class I or Class I and II specific antibody. 
p = 0.0424  
Figure 40 above indicates that there is a significant difference in pre-treatment T cell RMF 
values between the group who had functioning grafts throughout the study period and those 
whose grafts failed.  It would indicate that a starting T cell RMF of greater than 10 indicates a 
strong risk of graft failure due to rejection. 
Figure 41 – Graft survival or failure due to rejection vs pre-treatment B cell RMF in all 
HLA antibody incompatible transplant patients. 
p = 0.0550  
The B cell RMF values pre-treatment are not as clearly associated with graft survival or failure 
as the T cell values above, although there is a difference in the mean RMF values in each 
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group.  There is obvious crossover of values, however the group of patients whose grafts failed 
due to rejection all had an RMF of >5, compared to less than a third of those where the graft 
survived. 
Figure 42 – Graft survival or failure due to rejection vs pre-transplant T cell RMF in 
patient with HLA Class I or HLA Class I and Class II specific antibody. 
p = 0.0265  
Again the pre transplant T cell RMF values are significantly different between the two groups. 
However there is less of a clear difference than that seen with the pre-treatment values.  It can 
be seen however that the graft survival group all have negative T cell flow crossmatches pre 
transplant, with RMF values below 2.3, however in the failure group, 1 of the five has a 
positive T cell crossmatch, although less than the cut off of 4 used in the latter part of the 











Figure 43 - Graft survival or failure due to rejection vs pre-transplant B cell RMF in 
patients with HLA Class II or HLA Class I and Class II specific antibody 
p = 0.0291  
The difference in the B cell pre transplant RMF values is statistically significant. However the 
dot plot shows that the range of values seen in both groups is similar.  In the majority of cases 
where the graft was lost the RMF was greater than 2.3.  There is one clear outlier in the 
survival group with a B cell RMF of 6 pre-transplant.  This reactivity was explained by the 
infusion of IVIg prior to the FXM as the FXM had been negative prior to this infusion, therefore 













Figure 44 - Graft survival or failure due to rejection vs pre-treatment total DSA MFI in 
all patients receiving an HLA antibody incompatible graft that required antibody 
removal. 
p = 0.2845  
The pre-treatment MFI values are found to not be significantly different between the two 
groups.  In this case it may be possible to conclude that a combined DSA MFI of greater than 
38000 is associated with future graft failure to rejection, however with the small numbers and 
a graft failure also seen in patients with an MFI similar to, or below, the mean of the survival 
group this should be treated with caution. 
Figure 45 - Graft survival or failure due to rejection vs pre-transplant total DSA MFI in 
all patients receiving an HLA antibody incompatible graft. 
p = 0.0922  
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The pre transplant total DSA MFI values are also not significantly different between the two 
groups, and it is clear that the values achieved in both groups are within the same range and 
therefore it is not possible to associate a pre transplant DSA MFI value with future loss due to 
rejection. 
3.4.9 Association with Antibody Mediated Rejection in the First Year Post 
Transplant. 
A similar analysis was performed comparing T and B cell RMF and total DSA MFI values in both 
the pre-treatment and pre transplant samples with the incidence of patients diagnosed with 
one or more episodes of rejection involving antibody during the first year post-transplant. 
Figure 46 - Pre-treatment T cell RMF values compared to incidence of antibody 
mediated rejection in the first year post-transplant. 
p = 0.0777  
The T cell RMF values pre-treatment, shown in figure 46 above, whilst having a significant 
difference in the mean values between the two groups, show considerable crossover.  It may 
be once again possible to suggest that patients with an RMF of greater than 10 are likely to 
suffer an episode of AMR in the first year, although these were also the patients who lost their 
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grafts to rejection during the first year.  At values lower than that there is no clear difference 
between the groups. 
Figure 47 - Pre transplant T cell RMF values compared to incidence of antibody 






























The mean pre transplant T cell RMF values are again significantly different and here it is 
possible to see that again patients with a pre transplant T cell RMF of greater than 2, so 
nearing or above the positive threshold of 2.3, are likely to suffer an episode of AMR during 












Figure 48 - Pre-treatment B cell RMF values compared to incidence of antibody 
mediated rejection in the first year post-transplant. 
p = 0.0478  
Whilst the mean B cell pre-treatment RMF values are just significantly different, as figure 48 
above indicates the ranges of values in both groups are very similar and, based on this data,it 
is not possible to suggest a starting B cell RMF above which a patient is at risk of one or more 
episodes of AMR in the first year.  Increasing patient numbers may allow for more significant 














Figure 49 - Pre transplant B cell RMF values compared to incidence of antibody 
mediated rejection in the first year post-transplant. 
p = 0.0276  
Again, whilst statistically significant, the data in figure 49 above, clearly show that there is no 
obvious association between the pre transplant B cell RMF values and the incidence of AMR in 











Figure 50 - Pre-treatment total DSA MFI values compared to incidence of antibody 





























The ranges of pre-treatment DSA MFI values in both groups again show considerable overlap, 
although the mean values of the two groups are significantly different.  The data does suggest 
that a total DSA MFI value of greater than 25000 is likely to be associated with one or more 
episodes of AMR in the first year post-transplant.  However, values below that are equally 













Figure 51 - Pre transplant total DSA MFI values compared to incidence of antibody 
mediated rejection in the first year post-transplant. 
p = <0.0001  
The difference in the mean values of the total DSA MFI pre transplant are highly significantly 
different, but once again there is considerable overlap in the lower values.  The data indicates 
that a total DSA MFI value of greater than 10000 pre transplant is highly indicative of AMR 
post-transplant, but at values lower than that it is not possible to predict occurrence of AMR 
based on the MFI values. 
A similar analysis was carried out for overall incidence of BPRE in the first year – combining all 
the episodes of T cell and antibody mediated rejection, graphs not shown.  As can be seen 
from the information in table 7 eight patients suffered episodes of TCMR only in the first year.  
When including these additional patients the only values to yield a significant difference were 
the T cell RMF values pre-treatment, giving a p value of 0.0023.  The other groups had p values 
ranging from 0.2454 – 0.3147, which are not statistically significant.  Therefore there appears 




Overall 6 of the 54 HLA antibody incompatible grafts have been lost to rejection.  5 of these 
came from the group requiring antibody removal due to a positive crossmatch and all were 
due to either AMR or combined AMR and TCMR.  The group of patients who were DSA positive 
but crossmatch negative lost only 1 graft, this was due entirely to TCMR. 
3.4.10 Assessment of transplant outcome and the effect of immune 
memory. 
At the start of this study it was hypothesised that patients who had preformed donor specific 
antibody to an HLA antigen to which they had previously been exposed were likely to have 
both T and B cell immune memory to this antigen, and therefore show a more rapid and 
vigorous response when re-challenged with the same antigen compared to patients who were 
DSA positive, but not challenged with a repeat mismatch.  In order to assess the effect of pre 
formed donor specific antibody and the presence of repeat mismatches on the outcome of 
renal transplants data for both study and control groups was collected as described in the 
methods section.   
To assess the effect of pre formed donor specific antibody on renal transplant outcomes, 
patients were categorised as being HLA specific antibody negative, 3
rd
 Party antibody positive 
and donor specific antibody positive.   
To assess the effect of the presence of repeat mismatches presented by the donor organ, 
patients were categorised as being repeat mismatch negative or repeat mismatch positive. 
To assess the effect of the presence of repeat mismatches to which preformed donor specific 
antibody was also present or absent, indicating the presence of immune memory directly to 
some or all of the mismatches being presented, each of these groups were then subdivided 
into those who received a graft presenting a repeat HLA mismatch from either a previous graft 
or pregnancy and those who were not challenged with a repeat mismatch.   
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For purposes of the assessment of immune memory on outcomes for patients whose grafts 
failed during the study period, those who failed due to reasons other than rejection were 
censored, in addition to those who died with a functioning graft.  Loss due to rejection was 
defined by reference to the histological reports of biopsies taken between transplant and 
return to dialysis, or patient death. 
Overall 20 grafts were lost due to non-immunological causes.  13 patients died with a 
functioning graft, 4 grafts were lost to recurrent disease, 1 deceased donor organ failed to 
function and was removed, 1 was lost following major post biopsy bleed and 1 was lost due to 
renal vein thrombosis secondary to prolonged hypotension in the immediate post-transplant 
period. 
The demographics of the patient groups can be seen in table 8 below.  
For data analysis follow up to 5 years, or 1825 days, has been included.  
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Table 8 - Demographics of all six groups of patients included in the Chapter 3 antibody analysis. 
  





No HLA Specific 






 Party Antibody 






















Number of Recipients 169 5 48 11 31 23 
Median (range) Age at time of 
Transplant 
Donor 44 (3 - 75) 42 (24-55) 49.5 (12-67) 50 (23-66) 44 (20-65) 41 (20-68) 
Recipient 44 (17-77) 48 (39-62) 43 (18-73) 49 (26-64) 46 (25-72) 41 (20-68) 
Sex (M:F) 
Donor 82:87 2:3 29:19 10:1 15:16 16:7 
Recipient 116:53 2:3 23:25 5:6 14:17 10:13 
Donor Type - Deceased:living 76:93 3:2 27:21 3:8 9:22 1:22 
Median Cumulative Number of 
Mismatches (A,B,DR) 
3 2 2 3 3 3 
Median Number of Previous Transplants 0 1 0.5 1 0 1 
Median time of follow up 2040 (974-3075) 
1828 (1354-
2784) 
1634 (1060-2989) 1780 (1136-2294) 1383 (249-3096) 
1320 (319-
2200) 









No HLA Specific 






 Party Antibody 






















Mean DSA MFI Pre treatment - - - - 9549 21869 
Mean DSA MFI Pre Transplant - - - - 4067 9030 
Mean T cell RMF Pre treatment - - - - 3.01 4.00 
Mean T cell RMF pre Transplant - - - - 1.16 1.36 
Mean B cell RMF pre treatment - - - - 3.94 7.26 




Graft survival analysis was performed by generating Kaplan-Meier curves for each data set.  
The p values quoted are generated by the logrank test or the logrank test for trend. 
Initially the overall graft survival over five years was compared between all six groups of 
patients.  Since no single group fell below a survival of 85% the ‘y’ axis representing percentage 
of patients surviving had been edited to show only 70% and above to allow for easier 
observation of trends, as represented in figure 52 below.  This is the case for all the following 
Kaplan-Meier curves presented.  
 
Figure 52 - Overall graft survival comparison across all six groups of patients. 
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p = 0.0076 
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The overall graft survival analysis presented in figure 52 above indicates that patients who 
produce no HLA specific antibody have the best 5 year graft survival rates, with survival 
decreasing based on the presence of 3
rd
 party then donor specific antibody, with the group 
showing the lowest 5 year graft survival rates being those who produce donor specific 
antibody and are presented with a repeat mismatch.  A more in depth analysis of these 
differences follows. 
3.4.11 The effect of HLA specific antibody on renal transplant outcomes. 
Initially the effect of the presence or absence of donor HLA specific antibody on renal 
transplant outcome was compared.  The graft survival in these two groups can be seen in 
figure 53 below. 
Figure 53 - Renal graft survival based on the presence or absence of donor HLA 
specific antibody. 
 
Whilst there is a clear difference in outcome between the DSA negative and positive groups to 
assess if the presence of any HLA specific antibody is associated with an increase in graft loss 
due to rejection the absence of any HLA specific antibody, the presence of 3
rd
 party HLA 
specific antibody only or donor HLA specific antibody on renal transplant outcomes was 
compared.  The graft survival in these 3 groups can be seen in figure 54 below. 
p = 0.0178 
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Figure 54 - Renal graft survival based on the presence or absence of HLA specific 
antibody. 
 
The group of patients with preformed donor specific antibody clearly have lower graft survival 
compared to the other two groups, however the group producing 3
rd
 party HLA specific 
antibody also have lower graft survival than those who are HLA specific antibody negative.   
To assess the effect of the titre of DSA on outcomes, graft survival rates in the DSA positive 
group of patients who required antibody removal due to positive crossmatch were compared 
with the DSA positive patients who were crossmatch negative and did not receive antibody 











p = 0.0082 
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Figure 55 - Renal graft survival in DSA positive patients based on the requirement for 
antibody removal. 
 
The curve presented in figure 55 above clearly shows that titre of antibody may well be 
important in graft survival and confirms the earlier finding that antibody detected by 
crossmatching, rather than just on single antigen screening beads, may be more significant in 
longer term outcomes. 
The final analysis of the DSA positive patients was to assess if the HLA class to which the 
antibody was directed had an impact on graft survival rates in this group.  Patients were 
divided into those with HLA Class I only DSA, HLA Class II only DSA and those with both HLA 










p = 0.0754 
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Figure 56 - Renal graft survival in DSA positive patients based on the HLA Class to 
which the DSA was directed. 
 
Although not statistically significant, the survival curves in this analysis suggest that antibody 
to HLA Class I only are the least detrimental to outcome, with a potential cumulative effect 
where patients transplanted across both HLA Class I and Class II DSA have the lowest five year 
graft survival rates. 
3.4.12 The effect of the presence of repeat HLA mismatches on renal 
transplant outcomes. 
To investigate the effect of the presence of one or more repeat HLA mismatches on renal 
transplant outcomes the patients were initially divided into those presented with a repeat 
mismatch and those which were not, regardless of the presence of HLA specific antibody.  The 







p = 0.2435 
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Figure 57 - Renal graft survival comparison between patients presented with a 
repeat HLA mismatch and those which were not. 
 
Although not statistically significant, this analysis indicates that the presence of a repeat HLA 
mismatch may impact on the 5 year graft survival rates.  However it must be noted that half 
the small number of repeat mismatch positive patients also had DSA, which could be 
influencing the results. 
The patients presented with a repeat HLA mismatch had all previously been exposed to non-
self HLA through either a previous transplant or pregnancy.  To assess if the route of previous 
exposure had an impact on graft survival in patients with a repeat mismatch, regardless of HLA 
antibody status, the repeat mismatch positive group were divided into those exposed via 









p = 0.1160 
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Figure 58 - Renal graft survival comparison in patients presented with a repeat HLA 
mismatch based on previous exposure through either pregnancy or transplant. 
 
Again the small numbers involved hamper any meaningful statistical comparison, however the 
trend of the data suggests that previous HLA exposure via pregnancy may be more detrimental 
than via transplant to graft survival, although this is not statistically significant and would 
require greater patient numbers for confirmation. 
3.4.13 The effect of immune memory on renal transplant outcomes. 
The hypothesis when starting this investigation was that patients transplanted with a kidney 
which presented an HLA mismatch to which they had previously been exposed, and produced 
HLA specific antibody, demonstrating the presence of immune memory, would have lower 
overall graft survival compared to patients who were presented with an HLA mismatch to 
which they produced demonstrable antibody but to which they had not previously been 
directly exposed, the antibody believed to be a consequence of epitope crossreactivity.  To 
assess this the DSA positive patients were divided into those presented with repeat 
mismatches to which they had produced antibody and those who were not.  The survival curve 
generated can be seen in figure 59 below. 
 
 
p = 0.4375 
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Figure 59 - Renal graft survival comparison in patients presented with a repeat HLA 
mismatch to which they produce antibody and those that were not. 
 
This data would suggest that there is no difference in 5 year outcomes between those patients 
who produce DSA and are presented with a repeat mismatch and those who are not. 
To assess if the HLA Class of the repeat mismatch with DSA has an effect the DSA positive, 
repeat mismatch positive patients were further subdivided into those who were presented 
with just a Class I, those with just a Class II and those with both Class I and Class II repeat 









p = 0.6875 
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Figure 60 - Renal graft survival comparison in patients presented with a repeat HLA 
mismatch to which they produce antibody based on HLA Class. 
 
Again, despite the small numbers involved, there does appear to be a trend suggesting that 
those patients who are presented with both HLA class I and class II repeat mismatches, to 
which they also produce antibody, have lower graft survival rates.  This again does not reach 
statistical significance and would require a larger group of patients to study before the trend 
observed could be confirmed. 
To assess if the presence of HLA Class I and II repeat mismatches is detrimental in all grafts, 
regardless of antibody status, all patients who received a graft presenting both HLA class I and 
II repeat mismatches during the study period were divided into those with DSA and those 








p = 0.1527 
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Figure 61 - Renal graft survival comparison in patients presented with repeat HLA 
Class I and II mismatches with and without donor specific antibody. 
 
Again, despite the small numbers, a trend, whilst not statistically significant, does appear to be 
present where patients who have previously been exposed to a combined HLA Class I and II 
mismatch, to which they have formed an immune response culminating in IgG class antibody 
generation, have worse outcomes compared to those who have previously been exposed but 
do not appear to have formed an antibody response. 
3.4.14 The Effect of Immune Memory on Biopsy Proven Rejection 
Episodes. 
Whilst overall graft survival, or loss to rejection, is a good indicator of the effects of the various 
parameters on outcome, patients may well suffer one or more episodes of immunological 
rejection which do not, at least in the immediate study period, result in graft loss.  Data was 
collected for all the patients investigated in this study relating to the number and timing of 
biopsy proven rejection episodes (BPRE).  The most common renal graft biopsies performed at 
our centre are ‘for cause’ biopsies, where a change in renal function, as indicated by a rise in 
serum creatinine or reduction in estimated glomerular filtration rate, suggests the graft is not 
functioning as well as previously seen.  Biopsies are analysed by the histopathology 
department and reported on with reference to the current Banff criteria for diagnosis of 
p = 0.2118 
191 
 
causes of renal allograft dysfunction.  For the purposes of this analysis ‘for cause’ biopsies that 
indicated definite, or were ‘suspicious of’, T cell mediated rejection (TCMR) or antibody 
mediated rejection (AMR) were classed as a BPRE.  The date of the first BPRE for each patient, 
the total number of BPRE over the study period and the aetiology of the rejection, being 
TCMR, AMR or both, were all recorded.  The time in days to the first BPRE was calculated by 
subtraction of the transplant date from the biopsy date, to give the difference in days.  For the 
purpose of the initial investigation all BPRE, whether TCMR, AMR or both, were combined, 
separate analysis of the different types of rejection is detailed later.  The time to first BPRE was 
chosen as a distinct end point as immune memory responses are known to occur more rapidly 
in response to a stimulus to which the individual has previously been exposed, a second set 
response, when compared to a primary response in an individual naïve to a particular non-self 
antigen.  Therefore when investigating the influence of immune memory on transplant 
outcomes it was hypothesised that patients who received a graft bearing mismatches to which 
their immune system  had previously been exposed would generate a response and have 
earlier rejection episodes than those who were not presented with a mismatch of which they 
had memory.  The time to first BPRE was calculated for all patients who has a BPRE over the 
study period in five of the six groups of patients.  In the HLA specific antibody negative, repeat 
mismatch positive group of patients only one suffered a BPRE, at day 13 post-transplant. 
However, they could not be included in the analysis as a single value for a group cannot be 
subject to statistical analysis.  The mean time in days for each group was then compared using 
a non-parametric one way ANOVA, Kruskal-Wallis test. A summary of the results can be seen in 
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Figure 62 - Time to first biopsy proven rejection episode in all groups of patients. 
p = 0.0014  
The mean time to 1
st
 BPRE is different between the various patient groups.  Within each 
antibody status group the patients who are presented with a repeat mismatch all have a 
shorter time to 1
st
 BPRE compared to the repeat mismatch negative patients.  There were no 
obvious differences between the patients who made up the majority of each group and those 
that could be classed as outliers.  One potential reason for late rejection could be related to 
patient non-compliance with the immunosuppressive medication, or rejection following 
immunosuppression reduction or withdrawal, although this was not noted in the patient 
records.  To further assess the effect of a repeat mismatch, regardless of the presence of HLA 
specific antibody, the time to 1
st
 BPRE was compared between the patients presented with a 
repeat mismatch and those who were not.  The data was analysed using an un-paired t-test.  






Figure 63 - Comparison of time to 1st BPRE between patients with and without a 
repeat mismatch. 
p = 0.0467  
There is a clear difference between these two groups, not just in the mean time to 1
st
 BPRE, 
but also in the range of time points that this is seen, with patients presented with a repeat 
mismatch having a shorter time to first BPRE and all being earlier than the mean time in the no 
repeat mismatch group. 
A similar analysis was carried out to compare those patients who were DSA positive with those 












Figure 64 - Time to 1st BPRE in patients with and without DSA. 
p = 0.2316  
Whilst there is a difference in mean time to 1
st
 BPARE between groups, it is not statistically 
significant.  There are two clear outliers in the DSA positive group where there was a longer 
time to first BPRE than seen with the other rejecting patients.  These patients demonstrate no 
obvious differences from the other patients in terms of characteristics. Other than these 
patients the time to first BPRE is generally earlier than many of the DSA negative group. 
To assess if there is an effect of DSA titre on time to first BPARE a similar analysis was carried 
out limited to the DSA positive patients, regardless of repeat mismatch status, comparing time 
to 1
st
 BPARE in those who required antibody removal due to a positive flow crossmatch and 
those who were single antigen bead positive only and did not receive antibody removal pre 










Figure 65 - Time to 1st BPRE in DSA positive patients with and without the 











































This indicates that there is little difference in the mean time to 1
st
 BPRE between the patients 
with DSA at levels requiring antibody removal compared to those who did not require antibody 
removal pre-transplant.  
The final analysis was to investigate the effect of immune memory on time to 1
st
 BPRE by 
comparing the patients who were DSA positive with and without the presence of a repeat 
mismatch.  Analysis was carried out as previously described and the comparison graph can be 











Figure 66 - Time to 1st BPRE in DSA positive patients with and without a repeat 
mismatch. 
p = 0.0355  
 
This analysis indicates that patients who have been previously exposed to an HLA mismatch 
and generated an immune response, and therefore immune memory, as demonstrated by the 
production of IgG class HLA specific antibody, have shorter times to rejection episodes 
diagnosed on biopsy compared to those patients who produce DSA but not in direct response 
to the same mismatch. 
The data presented above regarding time to 1st BPRE has combined instances of both TCMR 
and AMR as total BPRE.  Data was however collected for the aetiology of the rejection episode 
recorded.  Table 10 below summarises the total number and percentage of patients in each 





























































43 20 47 36 39 56 
% of BPRE 
with T cell 
involvement 
100 100 100 100 83 54 




18 0 20 75 33 92 
 
The proportion of patients diagnosed with BPRE across all groups are similar, although the DSA 
positive with repeat mismatch group do clearly have a higher rate of 56% compared to a range 
of 20 - 47% across the other groups.The type of rejection diagnosed clearly varies with a T cell 
element being found in all BPRE in all groups except the DSA positive patients.  The % of BPRE 
with an antibody element also varies widely, ranging from 0 – 75% in the non-DSA groups up 
to 92% in the DSA positive repeat mismatch positive group.  Perhaps most striking is the 
difference between the two DSA positive groups where only 33% of the BPRE diagnosed had 
an antibody element in the repeat mismatch negative group compared to 92% in the repeat 
mismatch positive group.  Fishers 2 tailed analysis of the effect of DSA in the presence of a 
repeat mismatch compared to DSA with no repeat mismatch on occurance of BPRE with an 
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antibody element gave a significant difference with p=0.0026.  The data can be seen in table 
11 below. 
Table 11 – 2x2 comparison of repeat mismatch status in patients who produce pre 
transplant donor specific antibody and were subsequently diagnosed with antibody 
mediated rejection on biopsy. 
 No Ab mediated rejection Ab mediated rejection 
DSA positive, Repeat MM 
negative 
27 4 
DSA positive, Repeat MM 
positive 
11 12 
    
As discussed earlier a local audit of rejection rates in 2010 found higher than expected rates of 
T cell mediated rejection across all patients.  This led to a change in the immunosuppressive 
regimen used at the end of 2010.  Whilst this change will not have influenced the data 
collected for patients in the control groups some of the patients in the HLA antibody 
incompatible transplant group did benefit from the review.  One major change that was made 
was to give patients with donor specific antibody induction therapy of Campath or anti-
thymocyte globulin (ATG) prior to transplant.  By depleting recipient T cells from the 
circulation it was believed that rates of T cell mediated rejection would be reduced.  To assess 
if this change in immunosuppressive regimen has had an effect on the data presented above a 
smaller comparison in the DSA positive groups was performed comparing rates in patients who 











Table 12 - Summary of BPRE in DSA positive patients before and after the use of T 
cell depleting induction therapy. 
 
No pre transplant T cell 
Depletion 
Pre transplant T cell 
depletion 
Total number of Patients 39 15 
Number of patients with 
BPRE 
18 7 
% of patients with BPRE 46 47 
% of BPRE with T cell 
involvement 
78 43 




The percentage of patients with one or more BPRE in each group is the same. However, it does 
appear that the proportion of these which had T cell involvement has indeed decreased, 
although has certainly not been eliminated.  Of interest, the proportion of BPRE with antibody 
involvement is greater in the group treated with T cell depletion pre transplant compared to 
those without T cell depletion, although this is not statistically significant with p=0.35.  To 
investigate if this could be due to differences in the patients included in the two groups in 
terms of immunological complexity a breakdown of the type of transplant and antibody status 







Table 13 - Summary of patients with and without pre transplant T cell depletion. 
 
No pre transplant T cell 
Depletion 
Pre transplant T cell 
depletion 
Number of DSA positive, 
Repeat mismatch negative 
25 6 
Number of DSA positive, 
Repeat mismatch positive 
14 9 
Number of patients needing 
Ab removal. 
16 11 
Mean MFI pre treatment 14458 20729 
Mean MFI pre transplant 6549 10425 
Number of grafts lost to 
rejection 
4 (10%) 2 (13%) 
 
As can be seen from the data in Table 13 above, the group of patients receiving T cell depletion 
therapy pre transplant include a higher proportion of DSA positive repeat mismatch positive 
patients, a higher proportion of patients requiring antibody removal with higher average DSA 
MFI values both pre-treatment and pre transplant.  However the percentage of patients losing 
their grafts to rejection in each group is similar, perhaps indicating that pre transplant T cell 





Prior to starting this project our unit had successfully transplanted three patients following 
removal of donor HLA specific antibody, either alone or in addition to removal of ABO blood 
group antibody.  However, antibody removal had also been unsuccessfully attempted in a 
further three patients.  For all these patients, both the transplanted and the untransplanted, 
the treatment periods were long, often involving months of twice weekly antibody removal 
therapy in addition to their usual dialysis treatments.  These treatment sessions are time 
consuming for the patients and clinicians in addition to being costly to the healthcare system.  
There are also logistical problems associated with this approach, especially for a busy 
transplant unit without dedicated operating theatres, in that once the window of opportunity 
for transplant is reached the operation must happen rapidly.  This requires availability of the 
transplant team, the facilities and most importantly the donor, when a living donor is being 
used, or the offer of a deceased donor where no living donor is suitable.  Following the 
unsuccessful attempts at antibody removal, in addition to the logistical problems encountered 
with the successful transplants, it was decided that a more stratified approach was required to 
identify which patients would benefit from antibody removal therapy, how much antibody 
removal would be required prior to the transplant, so that a date could be booked, and if 
possible to provide an indication as to the risk of failure and adverse events post-transplant.  
As a unit we devised a strategy whereby patients would be treated with a single antibody 
removal session and samples taken prior to and immediately after would be assessed for 
changes in donor specific reactivity.  It was hoped that the information generated would allow 
assessment as to the likely success of antibody removal in achieving a transplant, in addition to 
an estimate as to the number of sessions required pre transplant to achieve a negative flow 
crossmatch.  This information would then be used to allow the transplant to be scheduled in 
an organised fashion with adequate notice for the donor.  At Guys Clinical Transplantation 
Laboratory we have over 20 years’ experience of the use of flow cytometric crossmatching in 
assessing the suitability of a patient and donor pair to proceed to transplant, it was therefore 
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logical to use this method in assessing the effectiveness of antibody removal in these patients.  
The FXM has the benefit over the CDC XM of being more sensitive and detecting antibodies of 
lower titre and non-complement fixing isotypes, both of which have been associated with 
poorer long term graft survival [303].  Analysis of both the strength of reactivity at neat in the 
pre and post samples, along with the reduction in the titre at which the crossmatch becomes 
negative, was used to predict how many antibody removal sessions would be required to 
achieve a negative flow crossmatch pre transplant.  During the course of this study 117 
recipient and donor pairs have been assessed using this method in addition to 34 pairs 
assessed without a test PEX or DFPP.  The results achieved showed great variation in reactivity 
levels and in the ability for antibody to be removed, with some pairs showing little or no 
reduction both on dilution and following antibody removal and others becoming negative 
following just one session.  It has previously been reported that some antibody specificities are 
more resistant to removal than others.  Zachary et al. [301] reported that in their experience 
Class II specific antibodies showed greater resistance to removal than those specific for Class I 
antigens.  To assess if this was also the case in our group of patients we analysed the 
difference in the number of titres reduced by a single antibody removal treatment in these 
patients, dividing them into those with just Class I, Class II or Class I and II DSA.  We found that 
the greatest reduction in titre was seen on the T cell FXM, detecting Class I antibodies only, in 
patients with Class I or Class I and II DSA.  The patients showing the least reduction in titre 
were those with Class II or Class I and II DSA detected using the B cell FXM.  Whilst our results 
did not reach statistical significance they did indicate a similar finding to that reported by 
Zachary et.al..  This would suggest that patients with Class II DSA will require higher treatment 
volumes prior to transplantation compared to those with just a Class I specific DSA. 
31 patients assessed using the titre crossmatch method went on to be transplanted from the 
donor with which they had been assessed.  There have been no instances of patients being 
assessed as suitable for antibody removal, using the titre XM method, who we have 
subsequently tried and failed to transplant.  However, we cannot comment on the number of 
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patients who we have ruled as being unsuitable to transplant with an organ from the 
prospective donor, but in whom the transplant could have proceeded successfully following 
antibody removal.  The predicted number of antibody removal treatments and actual number 
needed to achieve a negative crossmatch pre transplant in this group were compared.  The 
results indicated that this pre-treatment assessment did accurately predict the number of 
treatments required in most cases.  The starting titre, particularly with the B cell positive FXM, 
also showed a requirement for an increasing number of antibody removal sessions pre 
transplant with an increasing starting titre, however in the lower titres there was considerable 
variation in the requirement, with, for example, some patients positive only at neat requiring 
no antibody removal whereas others required up to 5 sessions.  In the patients where a 
different number were needed to that predicted, the majority appeared to require a greater 
number of removal sessions than first predicted, indicating an underestimate.  There are a 
number of possible reasons for this.  The first is that patients referred to us for potential HLA 
antibody incompatible transplantation are often assessed early in process to ensure we have 
accurate antibody information.  They are then entered into at least two matching runs of the 
paired exchange scheme, with the aim of receiving a compatible graft.  If they are not 
successful in the paired exchange matching runs they are then worked up for a direct antibody 
incompatible graft.  This means there can be at least 6 months between the initial assessment 
and the commencement of the final antibody removal treatments, during this time we often 
find, for as yet unexplained reasons, there is an apparent increase in the antibody levels.  This 
may be due to the longer time on dialysis, infections, vaccinations or blood transfusions during 
the waiting period.  Another possible explanation could be that many of our HLA antibody 
incompatible transplants are pairs that have been referred from other units, often in distant 
parts of the country, and whilst the patient attends our unit for the test antibody removal 
treatment, the donor often provides blood locally which is then transported to our laboratory 
for testing.  Indeed some of our donors have been from other countries including America, 
Africa and Thailand, meaning the donor blood is in transit for a considerable period of time 
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before being processed in our laboratory.  It is possible therefore that the cells used for the 
assessment crossmatch are not in the optimum condition for testing, with potentially lower 
expression levels of the target HLA antigens.  This would lead to lower reactivity on crossmatch 
and therefore a reduced estimate of the number of antibody removal sessions required.  For 
the final crossmatch prior to transplant the donor blood is taken and processed within hours, 
meaning the quality of the test cells and expression levels of HLA on their surface will be 
greater.  One solution to avoid the need for fresh cells for a crossmatch would be to assess the 
antibody levels using solid phase assays, such as the LABScreen single antigen beads.  The 
single antigen beads have the disadvantage of being very costly, indeed a single one off screen 
with these beads for HLA Class I and II is over twice as expensive as a titre FXM, but if the 
results were indicative of the potential crossmatch result and remove the need to courier 
donor blood then the cost could perhaps be justified.  The cost of carrying out serial dilution 
analysis using single antigen beads in the same way as the titre FXM would however be 
prohibitive. Therefore it is the values achieved at neat that would need to be indicative of a 
final crossmatch.  Background work at the beginning of the project using serial samples from 
our early HLA antibody incompatible transplants validated the use of LABScreen single antigen 
beads for post-transplant antibody monitoring in these patients, as the relative variations in 
fluorescence seen with these beads correlated well with that seen with the FlowPRA single 
antigen beads.  In addition the relative variations in MFI values also reflected the changes in 
RMF on FXM, meaning for a particular patient and donor pair an MFI value could be estimated 
to indicate if the level of DSA post-transplant had exceeded that which would give a positive 
FXM, alleviating the need for the post-transplant FXM used in the early patients.  It was also 
shown that in patients with multiple DSA the MFI values for each specificity could be combined 
to give a total DSA MFI value that also well reflected the changes in reactivity seen on FXM, a 
technique which has also been adopted by other units [304]. A number of patients who 
underwent test antibody removal and titre FXM were found to have a negative FXM with a 
sample taken pre-treatment, not requiring antibody removal.  These patients had all been 
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identified as being at risk of a positive XM due to the antibody specificities detected on 
screening, either by our laboratory or the laboratory serving the referring unit.  So another 
area of interest was to find if there is a DSA MFI level above which a positive FXM is expected 
in these highly sensitised patients.  To assess this, samples from 58 of the patients who had 
received a test DFPP and 10 patients who had not, which had all been tested against their 
prospective donor by titre FXM were also tested at neat only using LABScreen single antigen 
beads.  The total Class I DSA MFI or total Class I and II DSA MFI values were then compared to 
the RMF values at neat from the T and B cell FXM respectively.  In addition the MFI values 
achieved at neat were also compared to the titre at which the FXM became negative.  Both 
these analyses found no clear correlation between the single antigen bead MFIs and the FXM 
results.  There did not appear to be an MFI threshold above which a positive FXM would be 
expected for either the T or B cells.  There were instances of strongly positive FXM with very 
low MFI values and weakly positive or negative FXM with very high MFI values.  In addition the 
DSA MFI values at neat did not give any indication as to the titre to which the crossmatch 
would reach.  Therefore our data would suggest that, at least in the highly sensitised patients, 
it is not possible to confidently predict a crossmatch result based on single antigen bead MFI 
values.  By relying on these values alone there would be the risk of encountering an 
unexpectedly strongly positive crossmatch during final work up, along with the risk of 
subjecting a patient to unnecessary antibody removal in the face of a negative FXM or indeed 
excluding a patient from further work up for an antibody incompatible transplant.  In 2010 
Gloor et al. [304] reported a strong association between XM results and single antigen bead 
MFI levels.  Their analysis was stratified on crossmatch strength and type, negative XM had the 
lowest MFI values, FXM with a channel shift of less than 300 had the next highest MFI values, 
followed by those positive FXM with channel shifts greater than 300 and finally those where 
the CDC XM was positive had the strongest MFI values.  However the data presented by the 
group does show considerable overlap of MFI values in each group, with no obvious MFI level 
at which the XM result could be confidently predicted.  The authors did note that some 
207 
 
strongly positive XM had weak or negative DSA on screening.  In addition the study did not 
include any DSA to HLA-Cw, -DQA or –DPB as the HLA types at these loci were not known, 
which may well influence the results seen.  There are a number of possible explanations as to 
why the bead and XM results do not always equate.  For a number of years it has been known 
that, as with most antibody detection methods, the Luminex beads are susceptible to the 
prozone effect [305].  Prozone is the phenomenon whereby high titre antibodies are 
apparently either not detected or detected only at very low levels, leading to false negative 
results.  Testing of the sera at dilution often reveals the true nature of the strength of the 
antibody present.  There have been a number of theories suggested to explain this 
phenomenon, including steric hindrance, where in theory so much antibody is competing for 
the binding sites available that only relatively few manage to bind the target.  Dilution reduces 
the number of antibodies competing per antigen available, allowing more to bind and 
therefore be detected on assay [306].  This is likely to be a greater problem in high titre sera 
with the single antigen screening beads where the density of antigen present on the beads is 
far higher than would be seen in vivo.  More recently other suggestions have been published.  
The presence of HLA specific pentameric IgM antibodies in the sera have been suggested to 
block the binding sites available to the IgG antibodies [307], Kosmoliaptsis et al. reported that 
the prozone effect can be avoided through treatment of the sera with DTT, analogous to that 
used to eradicate the influence of IgM antibodies in the CDC tests [308].  Further to this work 
Schnaidt et al. [309] suggested that the effect of DTT on reducing prozone was not necessarily 
due to the removal of the IgM antibodies, but actually due to the additional effect DTT has on 
complement proteins in the serum.  Classical complement component C1, made of C1q, which 
interacts with the pathogen surface or the antibody bound to the target, and proteases C1r 
and C1s, is also sensitive to cleavage by DTT.  Schnaidt et al. hypothesised that the prozone 
phenomenon was due to the binding of C1 in the test serum to the antibody bound to the 
target antigens on the beads.  This then blocks the binding sites for the secondary detection 
antibody, commonly targeted at the Fc region, so giving a false negative result.  
208 
 
Ethylenediaminetetraacetic acid (EDTA) is a common anticoagulant used for blood collection.  
One property of EDTA is to chelate metal ions, including Ca
2+
, a property to which C1 is 
sensitive.  C1 is also sensitive to heat inactivation, where incubation of sera at 56
o
C for 30 
minutes, leads to inactivation of C1.  Schnaidt et al. went on to test sera treated with DTT, C1 
inhibitor C1INH or heat inactivated, and plasma taken from EDTA anticoagulated samples.  
They found that prozone seen with the untreated sera was virtually eliminated with all the 
treatment methods and that it was reinstated by the addition of an external source of C1.  This 
does indicate that blocking by C1 is a major factor in the prozone phenomenon.  With this 
knowledge it is therefore possible to suggest that samples where a low or negative MFI value 
was recorded, yet a strongly positive FXM result found, were actually suffering a prozone 
effect and treatment of the sera to remove C1 may reveal a different result.  With this 
information our laboratory recently performed its own evaluation of sera treatment for 
routine testing and all sera are now heat inactivated by incubation at 56
o
C as part of the 
sample processing on arrival in the laboratory.  Of note, in the evaluation performed the effect 
on crossmatching was also assessed and it appears that heat inactivation of the sera does not 
alter the FXM results, indicating that prozone is less commonly seen using this method.  
Another possible explanation for the low MFI – high FXM results could be the detection of 
non-specific, or non-HLA antibodies, on crossmatch.  It is unlikely that non-specific auto 
reactive antibodies can explain the difference seen in the majority of these cases, as all 
patients also had an auto FXM performed to rule out the presence of auto antibody.  However 
other, as yet undefined, targets could be responsible for the increased crossmatch results.   
The alternative difference seen between the bead MFI and the FXM RMF values, was that high 
DSA MFI values were found in some patients where the crossmatch was weakly positive or 
negative.  One cause could be the prozone effect on the FXM. However this would have been 
seen as an increase in reactivity on dilution, which was not observed.  Another more likely 
explanation is that the antibodies being detected using the single antigen bead method are not 
in fact specific for epitopes that are accessible on the native HLA molecule, but directed at 
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epitopes exposed during the manufacturing process used to create the beads.  These epitopes 
are most likely due to incorrect folding of the HLA protein and, for Class I molecules, a lack of 
association with the β2 microglobulin.  These alterations in conformation lead to the detection 
of apparent HLA specific antibodies by the beads, which are most likely clinically irrelevant [98, 
310, 311].  The detection of such antibodies has been given as a reason to explain the high 
number of individuals, up to 63% in one study [96], who are apparently sensitised despite 
receiving no alloimmunising events.  Another possible explanation for weak and negative FXM 
results in the presence of high titre antibody could be that the donor expression levels of HLA 
antigens are low either due to changes in the promoter regions of the HLA gene or due to the 
immunomodulatory influence of drugs such as statins.  Guidelines published by the European 
Federation of Immunogenetics, to which we comply, suggest that when genotyping an 
individual at high resolution the method used should allow the detection of genes more 
commonly associated with changes in the promoter region leading to reduced or no 
expression of the given antigen.  In cases where an obvious and unexpected discrepancy was 
found between bead MFI and FXM RMF the donors were typed by sequencing and  therefore 
this should not be a cause.  To absolutely confirm the HLA expression by a given donor the 
cells could be HLA typed using the more traditional cytotoxic typing method which provide the 
phenotype rather than genotype.  This was not performed as our laboratory does not include 
this test in our repertoire. However in the future it may be of relevance to investigate in some 
cases.  Statins are commonly prescribed drugs aimed at lowering blood cholesterol levels, 
which have also been found to have immunomodulatory effects, some of which are through 
the reduction of expression of HLA class I molecules on some cell types [302], and effect HLA 
class II expression on other cell types [312].  If potential donors have been prescribed these 
then it is possible that the FXM result could be falsely negative or weak due to lower target 
expression.  
It should be noted that all the antibody analysis included in this study has been performed 
using LABScreen single antigen beads. There are however other single antigen beads available 
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from a different manufacturer, Gen-probe.  These beads are also for use with the Luminex 
analyser and comprise a similar panel and methodology.  Due to the prohibitive cost the 
samples were not tested using both kits available. It is possible that testing with kits from the 
alternative manufacturer could help identify true HLA specific antibodies and provide different 
MFI values, which could be of better correlation with the FXM results.  Another kit related 
concern is that lot numbers of the kits used changed on a number of occasions during the 
study period.  There is the theoretical possibility that antigen density on the beads can vary 
significantly between lots [110, 313], meaning it is possible that the MFI values derived could 
be different between lots. However this should not be significantly common problem as in 
theory it would only affect samples in which maximum binding to all the antigens on the bead 
is achieved.  At our laboratory all new lot numbers undergo rigorous validation before being 
put into routine use, which includes testing multiple samples to check for consistency of 
results, in terms of specificity and MFI value, with previous lots, and testing with Class specific 
mAbs, which gives an indication of changes in Ag density.  Variations between lots in recent 
years have been found to be small. 
Patients testing positive by both FXM and beads, could still show less correlation than 
expected due to maximum binding, or saturation, being achieved on either the beads or the 
FXM [307].  Here all the targets available are bound meaning that the maximum possible MFI 
or RMF that can be achieved, has been.  Due to differences in the antigen expression levels 
between cells and the single antigen beads it is likely that this would not occur at the same 
level for both. 
Groups have had varying success in associating bead MFI values with both CDC and flow XM 
results [142, 150, 314, 315], with the greater certainty surrounding the prediction of those 
which will be negative based on negative screening results.  The crossmatch, either CDC or 
FXM, has long been seen as a requirement prior to transplant, with a negative crossmatch 
indicating low risk of early rejection.  Therefore it has been seen as important for screening 
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results to predict XM results.  However, in deciding how to assess patients who were eligible 
for antibody removal and the risk of post-transplant complications and graft loss, I decided to 
investigate if either the FXM RMF values or the single antigen bead MFI values were associated 
with post-transplant outcomes in our HLA antibody incompatible group.  There were 54 HLA 
antibody incompatible transplants included in the analysis based on the detection of DSA on 
the single antigen beads, of which 27 required pre transplant antibody removal due to the 
presence of a positive FXM on either the B cells alone or both the T and B cells.  Initially I 
analysed the association between the various antibody values, pre-treatment and pre 
transplant, and whether a graft had been lost due to rejection only during the study period.  
When drawing conclusions from these results it must be remembered that there is a wide 
variation in the follow up time in this group of patients, from 249 to over 3000 days.  Firstly the 
T and B cell RMF values and DSA MFI values were compared to survival in the group of patients 
requiring antibody removal pre transplant.  For the crossmatch results in this group the T cell 
RMF seemed to show the greater association with future graft loss, particularly in the pre-
treatment sample, where an RMF of >10 was found in all of the patients who lost their graft 
and none of the patients who did not.  Whilst there was a significant difference in the mean 
values of the two groups, the B cell RMF showed less association and whilst all the patients 
who lost their graft had an RMF of >5 an equal number of patients in the survival group also 
had similar starting B cell RMFs. The pre-treatment DSA MFI value also showed a difference 
between the two groups and here the majority of the failed transplants had a total DSA MFI of 
greater than 38000 where none of the surviving grafts were above this level.  The analysis of 
the pre-transplant values included all patients classified as HLA antibody incompatible.  The 
results with these samples were less conclusive with again the only possible association being 
found with the T cell RMF being >2.0.  The range of B cell RMF values and total DSA MFI values 
in both groups were similar, despite both having different mean values, meaning that these 
data would suggest it is not possible to predict future outcome using these values.  A number 
of the graft losses due to rejection recorded were in fact lost due to TCMR rather than AMR, 
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therefore an association between antibody values and loss may not be entirely expected.  
Whilst graft survival or failure is a conclusive outcome, other post-transplant complications can 
occur.  HLA antibody incompatible transplants are associated with higher rates of antibody 
mediated rejection episodes post-transplant compared to antibody compatible grafts [195] 
and whilst the majority of these rejection episodes can be resolved if treated promptly, the 
occurrence of, and damaged caused by, early AMR is associated with a reduction in long term 
graft survival [303, 316, 317].  The ability to predict which HLA antibody incompatible grafts 
are at most risk of AMR in the first year post-transplant would assist in both identifying 
patients who require even more vigilant follow up, and allow the laboratory to convey to 
clinicians and patients an indication of risk for AMR, and therefore risk of reduced long term 
survival.  The incidence of AMR in the first year post-transplant, as diagnosed on biopsy, was 
recorded for all the HLA antibody incompatible transplants.  The T and B cell RMF and total 
MFI values both pre-treatment, in the patients requiring Ab removal, and pre transplant in all 
the HLA antibody incompatible grafts were compared between the patients who did and did 
not suffer at least one episode of AMR in the first year post-transplant.  The T cell RMF and 
total DSA MFI values both pre-treatment and pre transplant did indicate a level above which 
AMR would be likely.  For the T cells patients with a pre-treatment RMF >10 or a pre transplant 
RMF >2 all suffered AMR, and were generally the same patients who went on to lose their 
graft. However below these values there were no differences between the groups.  For the 
total DSA MFI all patients with a pre-treatment value of >25000 or pre transplant value of 
>10000 were diagnosed with AMR in the first year, although at lower values there were no 
differences.  Neither the pre-treatment or pre transplant B cell RMF values were associated 
with an increased risk of AMR, despite the mean for each group being significantly different.  
The same analysis with total BPRE, regardless of the aetiology, found no association of 
incidence with antibody values.  This would indicate that the level of DSA detected has no 
association with T cell mediated rejection.  It must be noted however that a number of 
patients were transplanted after a change in immunosuppressive protocol in 2010 and 
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received T cell depletion induction therapy, which could possibly skew the results observed 
with regard to TCMR episodes. This will be investigated in more depth later in the discussion. 
From our data, despite the small patient numbers, it is possible to conclude that the T cell RMF 
value appears to be the most predictive of both future graft loss and occurrence of AMR in the 
1
st
 year.  Patients presenting with a T cell RMF of >10 prior to treatment and those with a total 
DSA MFI value of >38000 appear to be at the greatest risk of graft failure, although patients 
with lower values also failed.  Those with a pre-treatment T cell RMF of >10 or a total DSA MFI 
of >25000 appear to be at most risk of AMR within the first year, although, again, patients with 
lower values also suffered AMR.  It is of interest to note that of the 27 patients who were 
classified as DSA positive on bead analysis but were FXM negative, and did not receive 
antibody removal prior to transplant, only one patient lost their graft due to rejection and on 
all biopsies this was classified as only being of T cell in nature.  In the group who required 
antibody removal there were five graft losses due to rejection and all five where either solely 
AMR or combined AMR and TCMR.  This would suggest that, in this group at least, it is the 
detection of antibody on the FXM which is most relevant and, that the DSA detected on single 
antigen screening is only clinically relevant when associated with a positive FXM, regardless of 
the MFI value.  This directly contradicts a study published by Hirai et al. [318] who reported 
that in a retrospective analysis of their patients DSA MFI values of 800 – 2500 were highly 
associated with both acute and chronic rejection.  These patients all had negative CDC and T 
cell XM.  In a similar analysis Thielke et al. failed to find any association between pre transplant 
sensitisation as detected by FXM and the incidence of BPRE post-transplant in their group of 
antibody incompatible transplants [190].  Data published by Gloor et al. [304] also showed that 
whilst high baseline DSA levels did correlate with an increased risk of AMR, AMR was also 
frequently found in patients with low DSA titres.  They concluded that baseline DSA as 
measured by both XM and single antigen beads was not sufficient to predict subsequent AMR.  
They also reported a similar finding, that baseline T cell crossmatching results correlated with 
graft loss, where patients with strongly positive pre-treatment crossmatches were at greatly 
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increased risk of graft loss compared to patients with lower antibody levels.  Amico et al. [163] 
published a retrospective study where 334 consecutive renal transplants were investigated for 
the presence of DSA detected by single antigen bead screening at the time of transplant and its 
association with the development of AMR post-transplant.  The patients all had negative CDC 
XM but had not been assessed by FXM.  67 of the patients were found to have DSA on the day 
of transplant following single antigen screening and 55% of these went on to suffer an AMR 
episode within 200 days compared to just 6% of those that were DSA negative.  When 
comparing the patients with DSA who did and did not present AMR on biopsy they found no 
difference between the cumulative MFI values for each group.  In addition the patients who 
were diagnosed with AMR had a 20% lower five year graft survival rate compared to both the 
DSA negative and DSA positive but no AMR groups, which were both the same.  Unfortunately 
since no FXM were performed by this group it is not possible to assess if the FXM results would 
have shown greater association.  In general these published studies agree with the findings 
presented here in terms of the lack of association of the bead MFI values with outcome, and a 
lack of consensus between positive screening beads and a positive crossmatch.  This does call 
into question the MFI cut off values that should be employed when registering unacceptable 
antigens for potential renal transplant recipients with the national allocation systems.  There is 
clearly the risk that specificities may be registered that would not be associated with a positive 
crossmatch and others may not be registered that would. 
Since only a limited association was found between antibody strength prior to transplant and 
graft outcome, it is clear that this is not the only factor associated with the success or failure of 
an antibody incompatible graft.  The hypothesis being tested by analysing our outcome results 
is that immune memory may play a major role in graft survival or failure, and in the incidence 
of rejection post-transplant in the antibody incompatible group.  The presence of true IgG class 
alloantibody indicates that an immune response, through exposure to non-self HLA, and 
presentation of allopeptide by an allospecific B cell to a helper T cell via the indirect pathway 
of allorecognition in a germinal centre has occurred [47].  As previously discussed, HLA specific 
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antibodies recognise small epitopes on the accessible areas of HLA molecules.  An epitope may 
be specific for a single HLA antigen or be found on multiple HLA antigens, leading to a single 
antibody clone being reactive against numerous HLA antigens.  The helper T cell providing the 
activatory signals to the presenting B cell will however be specific for an entirely different 
epitope.  The indirect Th cell recognises linear epitopes on peptides, usually 13 – 17 amino 
acids in length, generated through the processing of the HLA molecule by the B cell and then 
presented in the context of a self HLA class II molecule.  In recent years there has been 
considerable interest in identifying the epitopes to which antibodies react [319], both in order 
to explain antibody reactivity patterns seen and also to identify HLA antigens which may 
present fewer immunogenic epitopes to an individual [320].  However the technical challenges 
involved has meant there has been less work investigating the epitopes to which indirect Th 
cells are reactive.  The studies published to date are limited and have drawn mixed 
conclusions, with some suggesting that, whilst there may be multiple peptides generated, 
there is usually a single immunodominant peptide responsible for generating the response 
[321] and others suggesting that there may be multiple immunogenic epitopes, including some 
generated from the more conserved regions of the HLA molecules [322] indicating an ability 
for wide crossreactivity similar to that seen with antibody.  Either way, it is possible that whilst 
exposure to a limited number of non-self HLA molecules may generate a wide ranging 
alloantibody response and apparent B cell memory, the T helper cell memory may be limited 
to just the original alloantigen.  My starting hypothesis was that when transplanting across HLA 
antibody barriers the presence of a repeat HLA mismatch with donor specific antibody 
presents a greater likelihood of activating a full memory immune response, and likely rejection 
episode, than the presence of an antibody which is just epitope crossreactive and to which 
there may not be full immune memory.  To examine this I collected outcome data from not 
just our HLA antibody incompatible transplant group, but also various control groups, based on 
HLA antibody status, namely those patients who did not produce any detectable HLA antibody 
pre transplant and those in whom HLA specific antibody was present, but donor specificities 
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had never been detected.  These groups were then further subdivided into those patients who 
received a graft during the study period that presented a repeat HLA mismatch to which they 
had previously been exposed, via a previous transplant or pregnancy, and those receiving a 
graft which did not present a repeat mismatch.  Analysis was based on graft losses due to 
rejection only up to five years post-transplant. Patients were censored if the graft failure was 
due to death of the patient, graft loss through causes other than rejection and at the end of 
their follow-up period if less than five years.  Initial analysis of the effect of antibody indicated, 
as expected, that the patients with pre formed donor specific antibody showed the lowest 
graft survival rates up to five years of 89% and HLA antibody negative at 96%.  When the 
analysis was further subdivided to include those patients with 3
rd
 party, non- DSA, as a 
separate group, they were found to have an intermediate survival rate of 92%.  The presence 
of 3
rd
 party antibodies pre transplant has previously been associated with lower graft survival 
rates than those patients in whom no HLA specific antibody has been detected [323], although 
in earlier studies this could often be potentially explained by incomplete antibody analysis, 
excluding loci such as HLA Cw, DQ or DP, all of which have been included in this analysis.  One 
potential explanation could be that these patients had previously produced DSA, the levels of 
which had been modulated over time to become undetectable, but which returned following 
transplant to cause rejection.  However, only two anamnestic antibody reposes were seen in 
this group of patients and neither resulted in graft loss.  Another possible explanation could be 
the presence of donor specific antibody to antigens other than HLA, such as the major 
histocompatibility complex class I chain-related molecule A (MICA) [324] which have been 
associated with rejection and graft loss, these were not tested for in this study.  The cause of 
graft loss in this group was found to be mainly due to T cell mediated rejection, with only one 
patient losing their graft to AMR.  Interestingly the patient who lost their graft to AMR was the 
only graft loss to rejection in the 3
rd
 party antibody positive with repeat mismatch group, and 
this was over two years post-transplant, so is probably due to non-compliance and de novo 
antibody production rather than a memory response.  The presence of 3
rd
 party antibody 
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indicates that an immune response to non-self HLA has occurred in the past and therefore 
raises the possibility that alloreactive memory T cells may be present, accounting for an 
increased immune reactivity to further mismatches.  Assessment of the effect of the strength 
of DSA, as determined by the requirement for antibody removal pre transplant, in the DSA 
positive group found that those requiring antibody removal had a significantly lower graft 
survival rate of 79% compared to 97% in the patients who did not require antibody removal.  
To assess if the class of HLA to which the antibody was directed was a factor, the DSA positive 
patients were split into those with just HLA Class I, just HLA Class II and those who had DSA to 
both HLA class I and II mismatches.  I found that those with just HLA Class I had the highest 
survival rates of 93% compared to 86% for the patients with Class II alone and 80% for those 
with both.  One explanation could be that those patients with both HLA class I and II specific 
antibody had antibody to more donor antigens than either group alone, and we were seeing a 
cumulative effect. However this was not the case with the mean number of mismatches to 
which there was antibody in the surviving group being 1.8 and 2.6 in the failed group, which 
whilst different is not significantly so (p=0.3244).  Bentall et al. [64] recently published similar 
findings, reporting that patients with DSA to HLA Class I only had superior 5 year graft survival 
rates of 85% compared to just 63% in those with Class II alone or both Class I and II.  They also 
concluded that single antigen bead MFI levels were not associated with graft survival rates in 
these patients.  However Amico et al. [163] found no association of DSA Class and outcome, 
however all patients in this study were XM negative so single antigen bead MFI values alone 
were used in DSA assessment.   We then investigated the effect of the presence of at least one 
repeat mismatch, regardless of antibody status, on outcome.  Here, those without a repeat 
mismatch had a 95% graft survival compared to 88% in the repeat mismatch group.  When the 
source of the original sensitising event was investigated it was found that those presented with 
pregnancy repeat mismatches had a lower graft survival of 82% compared to the transplant 
repeat mismatches of 88%.  Since a number of the patients transplanted in the pregnancy 
repeat mismatch group received an organ from either their partner, who may be fully 
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mismatched, or their child, who would present a haplotype mismatch, we investigated if this 
was associated with a greater number of repeat mismatches compared to the transplant 
repeat mismatch group.  This was the case with the mean number of pregnancy repeat 
mismatches being 3.9 compared to 1.9 in the transplant repeat mismatch group (p=0.0009).  
This could therefore be a cumulative effect, with a greater number of repeat mismatches being 
associated with worse outcome.   
To assess the effect of combined DSA and repeat mismatches graft survival in the DSA positive 
group was calculated based on the additional presence of a repeat mismatch.  Here the 
patients who were both DSA positive and were presented with repeat mismatches had a 
slightly worse outcome of 87% compared to 90% for the DSA positive repeat mismatch 
negative group.  Further, in the DSA positive repeat mismatch positive group all graft failures 
were in patients presented with both HLA class I and II repeat mismatches, from prior 
pregnancy, to which they had DSA.  Two of the three failures in the DSA positive repeat 
mismatch negative group were female, so previous pregnancy exposure cannot be ruled out, 
although it was not recorded.  In addition, whilst previous pregnancy and transplant exposure 
was assessed as a repeat mismatch, it is not possible to include or exclude repeat mismatches 
from previous blood transfusions, immune memory from which could not be accounted for.  
The presence of both class I and II repeat mismatches was however only found to be 
detrimental to graft survival when DSA was also present, with no failures being seen in 
patients without DSA, indicating repeat mismatches alone are not sufficient to lead to 
rejection. 
Whilst graft survival or loss is a solid end point, the variability in follow-up times for these 
patients could skew the data presented and re-analysis in a further five years could present 
greater, or smaller, differences between these groups.  The speed at which an immune 
response is seen is also an indication of the presence of immune memory.  Both primed 
memory T and memory B cells can be seen to respond within hours of re-exposure to an 
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antigen [38, 325].  I hypothesised that patients who were exposed to repeat mismatches and 
therefore potentially possessed immune memory would have shorter times to the first episode 
of biopsy proven rejection.  Since the follow up time for all patients was long enough to have 
allowed acute rejection episodes to occur, the time to first BPRE was compared between all six 
groups, based on antibody and repeat mismatch status, and showed that overall the patients 
presented with repeat mismatches had shorter mean times to first BPRE regardless of the 
presence of DSA.  Indeed further analysis based solely on the presence or absence of a repeat 
mismatch, regardless of DSA status, found that the time to first BPRE was significantly lower in 
the repeat mismatch positive group compared to the repeat mismatch negative patients 
(p=0.0467), indicating that the presence of DSA does not represent the full extent of immune 
memory or reactivity present.  In contrast the presence of DSA, regardless of repeat mismatch 
status, does not significantly affect the time to first BPRE (p=0.2316).  Additionally the strength 
of DSA, as defined by the need for antibody removal, was also not associated with a difference 
in time to first BPRE (p=0.6656), indicating that the strength of antibody is not associated with 
a more rapid immune response.  The combination of DSA and repeat mismatch was 
significantly associated with a shorter time to 1
st
 BPRE compared to DSA positive repeat 
mismatch negative (p=0.0355).  
I also investigated the effect of DSA and/or repeat mismatches on the overall proportion of 
patients to suffer one or more BPRE.  The values were similar across all groups except in those 
patients with DSA and a repeat mismatch, where 56% of patient had a BPRE, compared to a 
range of 20-43% in the other groups.  A breakdown of the aetiology of BPRE showed that 
TCMR was more common in all groups except the DSA positive, repeat mismatch positive 
group where only 54% of BPRE included a T cell component compared to 83% in the DSA 
positive repeat mismatch negative group.  AMR was significantly more common in the DSA 
positive repeat mismatch positive group with 92% of BPRE including an antibody component 
compared to 33% in the DSA positive repeat mismatch negative group.  The 3
rd
 party positive 
repeat mismatch positive group also had a higher proportion of patients with antibody 
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involvement, where 75% of BPRE included AMR compared to just 20% of the 3
rd
 party positive 
repeat mismatch negative.  
It must be noted that the patients in the DSA positive repeat mismatch negative group had 
lower overall antibody levels on all tests used and only 39% required antibody removal, 
whereas 65% of the DSA positive repeat mismatch positive group required antibody removal.  
It could be suggested that this is the reason behind the differences in survival and time to BPRE 
in these groups.  However the reduced survival rates in the third party antibody groups, 
particularly those with repeat mismatches, and the lower time to 1
st
 BPRE in the 3
rd
 party 
positive, repeat mismatch positive group, indicates that previous exposure, even in the 
absence of DSA generation, can result in immune memory generation and a more rapid 
response upon re-exposure potentially due to direct T cell memory responses.  Only two 
patients in the 3
rd
 party antibody positive group showed an anamnestic antibody response 
post-transplant, indicating the presence of low level undetected DSA pre-transplant, the 
remainder of patients with AMR produced de novo DSA sometime post-transplant. 
It may perhaps be expected that patients who are DSA positive and presented with a repeat 
mismatch have higher DSA levels than those not presented with a repeat mismatch.  Whilst 
often DSA to an antigen is assumed to be a single specificity, it is in fact most likely that 
multiple B and T cell clones are involved in generating antibody specific for a single non-self 
HLA antigen to which they are exposed. Therefore antibodies generated will be specific for 
more than one epitope presented by the antigen, whereas they may only bind to single 
epitopes on crossreactive antigens.  Multiple clones of antibody binding to beads or cells 
would lead to higher reactivity readings than seen with lower levels of binding of single 
antibody clones to crossreactive epitopes. 
One limitation of the data presented is the eclectic mix of induction therapy included.  It can 
be noted that the rate of TCMR seen in our control group of antibody negative patients is high 
at 43%, and an internal audit aimed at tackling this rate led to a change in immunosuppression 
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protocol in 2010.  Firstly cyclosporine A was replaced with tacrolimus in all patients, both those 
previously transplanted and for all further transplants.  Additionally whilst basiliximab was a 
commonly used induction agent, patients identified as higher risk due to the presence of DSA 
pre transplant were given either the anti-CD52 mAb, Campath, or, in those patients with 
contraindication to this, anti-thymocyte globulin (ATG).  Campath causes profound and long 
term depletion of T cells, in addition to variable depletion of B cells, NK cells, dendritic cells 
and monocytes [326] and its use as an induction agent pre transplant has been reported to be 
associated with lower rates of acute rejection compared to other forms of immunosuppression 
[327].  The use of T cell depleting induction agents in the final 15 DSA positive patients could 
well skew the data in terms of TCMR.  Comparison of BPRE between those patients 
transplanted before the introduction of Campath and those after showed that overall there 
were a similar proportion of patients diagnosed with BPRE (46% vs 47%) but that, 
unsurprisingly, the Campath treated group had almost half the incidence of TCMR (43% vs 
78%).  However there was significantly more AMR in the Campath treated group (86% vs 56%).  
One explanation for this could be that when observing the immune status of the patients, 
those transplanted with Campath included a greater proportion of patients with repeat 
mismatches and more patients requiring antibody removal, indicating a higher level of 
antibody pre transplant.  Various groups reporting on the use of Campath induction in renal 
transplantation have also encountered higher than expected AMR [326, 327] although this is 
not uniformly the case [328, 329].  Zachary et.al. [301] have reported that the use of T cell 
depleting agents during the removal of antibody prior to transplant results in an increase or 
recurrence of DSA in these patients.  They suggest that T cells may be required for the active 
down regulation of DSA production and that elimination of these cells removes this regulatory 
mechanism allowing unfettered antibody production.  Of note it has been reported that 
memory T cells are somewhat resistant to depletion by Campath. Therefore these could be 
responsible for the observed rates of rejection.  Overall the actual proportion of grafts lost in 
the study period is however similar between the two groups (10% vs 13%), indicating the use 
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of T cell depleting induction agents may improve graft survival rates. However this may also be 
reflective of the shorter follow up times available for the Campath treated group of patients.  
Despite the use of T cell depleting agents, 43% of the patients with Campath induction still had 
TCMR on biopsy.  Published observations of the T cell populations following Campath 
induction have revealed that >90% of the T cells are depleted, however those remaining are of 
the effector memory T cell phenotype [330], believed to be somewhat resistant to depletion.  
Profound depletion of T cells may then activate homeostatic proliferation of both the newly 
emerging naïve T cells into memory T cells and also expansion of the undepleted effector 
memory T cells [236, 331, 332].  Effector memory T cells initiate their effector function in the 
periphery so those remaining would still be capable of involvement in graft rejection episodes 
[330]. 
The profile of donor specific antibody production post-transplant could also have a significant 
effect on graft survival and incidence of rejection episodes [333]. However, whilst this would 
be an area of interest to pursue in these patients, the aim of this project was to develop a 
method of risk assessment pre transplant, based on antibody and sensitisation status, in order 
to categorise potential antibody incompatible patients on risk. 
3.6 Conclusions 
The data presented here suggests that antibody detected by single antigen beads alone should 
be treated with caution as it may not be a contraindication to transplant.  Assessment of the 
need for antibody removal, and the number of treatments required by performing a test 
antibody removal and titre crossmatch, provides an efficient and cost effective method of 
identifying those patients in whom antibody removal may be possible, and allows efficient 
transplant planning to be put in place.  HLA antibody incompatible patients presented with a 
repeat mismatch are at higher risk of both graft failure and rejection episodes indicating that 
immune memory does play a part in the post-transplant outcome.  Whilst the data may not 
change our future approach to HLA antibody incompatible transplantation, it will certainly 
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allow us to provide a risk assessment for each recipient and donor pair and guide the clinicians 




4 Memory T cells in HLA Antibody Incompatible 
Transplantation. 
4.1 Introduction and Aims 
As discussed in the introduction whilst there are a number of assays described to test for 
recipient T cell memory to donor HLA, none described to date is particularly accurate at 
defining donor specific T cell reactivity pre-transplant and they often focus on the production 
of a single cytokine as a marker of T cell activation.  However, since there is no clear cytokine 
to choose that is absolutely linked with rejection or tolerance I decided that it is important to 
select a range of cytokines produced across the three previously described Th cell subtypes 
that could be assessed to identify potential increased immune risk to the allograft and possibly 
give an indication as to the mediators of any potential future rejection episodes.  The 
activation of Th cells was particularly of interest as they are required for activation of both 
cytotoxic T cells and the B cells to produce antibody, of particular relevance in HLA antibody 
incompatible transplants.  For this reason I decided initially to test for the production of IFNγ, 
TNFα, IL-2, IL-5, IL-8 and IL-17 by responder cells.  In designing an assay to probe for memory T 
cells I also decided that for ease of integration into the routine testing repertoire of a clinical 
transplantation laboratory the methods and equipment used should be familiar to staff and 
commonly found. 
4.1.1 Aims for this study. 
The aim for our T cell assay was as follows – 
• To develop a method to assess the response of T cells found in the peripheral blood of 
highly sensitised transplant candidates to the HLA antigens expressed by a potential 
donor.   
• By assessing the cytokines produced at various time points we hoped to be able to 
identify the presence of memory T cells of all the subsets described above. 
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T cells may respond to proteins other than HLA expressed on the surface of cells derived from 
other individuals.  In order to just identify recipient cells which would respond to the 
mismatched HLA antigens I decided not to use whole donor or stimulator cells.  Initially I 
investigated the use of HLA coated beads designed for HLA antibody specific detection on the 
Luminex platform as the stimulator particles.  The patient cells were to be cultured with 
different HLA-luminex beads, culture medium sampled at various time points and tested for 
the presence of the cytokines listed above. 
Basic Techniques used for all the following tests. 
4.2.1 Peripheral Blood Mononuclear Cell (PBMC) Isolation. 
All work was carried out under sterile conditions. 
Peripheral blood was diluted at a ratio of 1:1 using phosphate buffered saline (PBS) (Sigma-
Aldrich), layered onto equal volumes of density centrifugation medium lymphoprep (Axis-
Shield), and centrifuged at 600g for 20 minutes. 
The isolated lymphocyte layer was removed by pipette and the cells washed twice using 10ml 
PBS, as described in the previous chapter. 
Culture medium was made, comprised of: 
500ml RPMI 1640 without L-glutamine (Gibco),  
5ml 100x L-Glutamine (Gibco), 
5ml 100 µg/ml Penicillin streptavidin (Gibco), 
5ml sodium pyruvate (Gibco),  
5ml 100x non-essential amino acids (Gibco), 
5ml 1M HEPES buffer (Gibco), 
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45ml sterile filtered human AB serum (Sigma –Aldrich),  
Cells were then re-suspended in the culture medium to give a concentration of 250000 cells 
per 200µl. 
Cell counting was performed using a haemocytometer and viability assessed using trypan blue 
staining. 
4.2.2 Cytokine Analysis. 
Detection of cytokines in the supernatant was performed using the Fluorokine® MAP 
multianalyte profiling kit from R&D Systems, for use with the Luminex ®100
TM
.  All the 
cytokines we wished to detect required only the use of base kit A.  This was chosen as it had 
the capability of detecting multiple cytokines simultaneously in a limited sample volume. 
4.2.2.1 Principle of the Assay. 
Luminex specific colour-coded microparticles are provided pre-coated with analyte specific 
antibodies.  Combinations of these beads can be created by the user to set up an panel specific 
to the analytes being tested.  The microparticles are mixed with the sample, or standard, and, 
the bead bound antibody binds to the analyte of interest if present.  Following washing of the 
beads a biotinylated antibody cocktail specific to the analyte(s) of interest is added to the test 
wells.  Following further incubation and wash steps, a streptavidin-phycoerythrin conjugate is 
added.  This will bind to the biotinylated detection antibodies.  Following another period of 
incubation and washing the microparticles are re-suspended in buffer and read using the 
Luminex analyser which, using two lasers, will determine which bead is being detected, and 
therefore which analyte, and how much phycoerythrin is bound and therefore how much 
analyte is present.  In order to quantify the amount of analyte being detected, pre-defined 
standards can be run to create a standard curve for each analyte from which the analyte 
concentration in the test sample can be calculated. 
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4.2.2.2 Cytokine Assay Method. 
All supernatant samples had been stored at -20
o
C, as suggested by the manufacturers, and 
thawed immediately prior to testing. 
All buffers and diluents were prepared as instructed in the kit guidelines.  Briefly - 
Wash Buffer Concentrate provided was diluted 20ml wash buffer concentrate with 480ml 
deionised water. 
Microparticle concentrates for each analyte were prepared in the mixing bottle provided 
within 30 minutes of use.  For a 96 well testing plate 50 µl of each microparticle concentrate 
was added to the bottle and this total volume was then diluted with 5ml of the microparticle 
diluent provided. 
The biotin antibody cocktail was prepared by adding 50 µl of each of the analyte relevant 
biotin antibody concentrates to the 5.25ml vial of Biotin Antibody Diluent provided.  This could 
then be stored at 2-8
o
C for 1 month. 
The streptavidin-PE detection conjugate was diluted by adding 55 µl to 5.5ml working wash 
buffer.  This was exposed to minimum light at all times and, once made, was stored in a foil 
wrapped tube.  Once prepared this could be stored at 2-8
o
C for 1 month. 
The kit standards, Standard cocktail 1 and Standard cocktail 2, were reconstituted by addition 
of 1ml of 1x Calibrator diluent RD5K provided.  They were then left for 15 minutes with 
intermittent gentle agitation.  7 dilutions were then made using 7 labelled polypropylene tubes 
where 300 µl of Calibrator diluent was added to tube 1 and 200 µl each to tubes 2 – 7.  100 µl 
of each reconstituted standard was then added to tube 1 and mixed well.  100 µl of the 
contents of tube one was then added to tube 2, which was again well mixed before further 
transfer of 100 µl from tube 2 to tube 3.  This was continued until all 7 dilutions had then been 
prepared.  The initial calibrator diluent provided the 8
th
 standard and served as a blank.  Kit Lot 
appropriate standard values for each analyte contained within the standard cocktails were 
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detailed with the concentration at neat provided as pg/ml.  All eight standards were tested on 
each cytokine analysis run. 
A template for the Luminex 100 analyser was created using the template wizard.  A pre-
defined bead region, as defined by the lot specific kit insert, was assigned for each analyte 
being tested.  A minimum count of 50 events per bead region was set with a flow rate of 
60µl/Min and a sample size of 50 µl.  The doublet discriminator gates were set to 7500 and 
15500.  
4.2.2.3 Test Procedure 
1. All reagents were prepared as described above. 
2. A 96 well filter plate was labelled and pre-wet by adding 100 µl of wash buffer, which 
was then removed using a vacuum manifold. 
3. 50 µl of the microparticle mix was added to each test well. 
4. 50 µl of standard or sample was added to the appropriate test well and mixed by 
repeat pipetting. 
5. The plate was covered and wrapped in foil to prevent exposure to light and then 
incubated for 3 hours at room temperature on a horizontal orbital microplate shaker 
set at 500 rpm. 
6. Following incubation the liquid was removed from the plate again using the vacuum 
manifold and the beads washed by addition of 100 µl of wash buffer which was again 
removed using the vacuum system.  This was repeated three times. 
7. 50 µl of diluted biotin antibody cocktail was then added to each test well and the plate 
re-covered and wrapped in foil to be incubated for 1 hour at room temperature on the 
orbital shaker. 
8. The wash procedure in step 6 was repeated. 
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9. 50 µl of diluted Steptavidin-PE was added to each well and the plate recovered and 
wrapped in foil and incubated at room temperature for 30 minutes on the orbital 
shaker. 
10. The wash procedure in step 6 was repeated. 
11. The microparticles were resuspended in 100 µl of was buffer and the plate mixed for 2 
minutes on the orbital shaker. 
12. The plate was then read within 90 minutes using the Luminex analyser. 
4.2.2.4 Data Analysis 
Data was collected by the Luminex as MFI units for each bead region.  To ensure that no 
cytokines were present in the culture medium used, this was tested following each culture 
assay performed.  In addition each assay included wells containing just test cells with no 
stimulator particles to ensure that the cells were not producing significant amounts of 
cytokines without specific stimulation.  The analyte specific MFI values for these negative 
control wells were subtracted from the positive control wells and each stimulator test well to 
give overall cytokine production values for each test well.  These resulting MFI values were 
then plotted using Microsoft Excel to provide a visual interpretation of the each cytokine 
produced in each test well at each time point. 
The raw MFI results gained for all the experiments outlined in this chapter can be found in 
Appendix 1 – 4. 
4.3 Initial Experiments 
The first two experiments were carried out to ascertain if we could set up a system in which 
cellular cytokine responses to HLA antigen presented on a solid phase could be detected. 
For these first tests the stimulator particles used were Luminex specific  LIFECODES Lifescreen 
Class I and Class II ID beads produced by Gen-Probe for HLA specific antibody analysis.  These 
kits utilise 5.6 micron microspheres designed to be analysed using the Luminex platform.  The 
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beads in these kits are designed to detect panel reactive HLA Class I or Class II specific IgG 
antibodies in serum.  The beads are coated with affinity purified Class I or Class II HLA 
glycoproteins isolated from different individuals.  The class I kit comprises of 50 and the class II 
of 30 test beads, each coated in one individuals HLA class I or class II antigens. The respective 



































Table 15 - Gen-Probe Class II PRA Kit Composition. 
 
The cells used were PBMCs extracted from peripheral blood of two healthy unsensitised 
volunteers, from this point named ‘Cell 1’ and ‘Cell 2’.   
In these experiments 250000 volunteer PBMCs were incubated in a ‘U’ bottomed 96-well plate 
with 3µl of class I, class II or class I+II beads at neat, 1:10 and 1:100 dilutions, with and without 
the addition of CD28 (molecular probes) for costimulatory signals, of which 2µl of neat or a 
1:100 dilution of stock 1µg/ml was added.  
Two negative control wells were included, one containing culture medium only and one 
containing just cells but no HLA-luminex beads.  
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A positive control well was included containing PBMCs plus human T cell activatory 
CD3+CD28+ dynabead stimulator beads (Gibco), to provide evidence that the cells were 
capable of responding in a detectable manner. 
Each combination was tested in triplicate. 
A summary of the well contents can be seen in table 16 below.  
Table 16 - Plate Layout for Experiment One. 
Well 
Number Contents 
 1 Negative Control - Medium Only 
 2 Negative control - Cells only 
 3 Positive control - CD3/28 0.2μl 
 4 Positive control - CD3/28 0.1μl 
 5 Positive control - CD3/28 0.05μl 












7 Class I Beads - 1:10 
8 Class I Beads - 1:100 










10 Class I Beads - 1:10 
11 Class I Beads - 1:100 












13 Class II Beads - 1:10 
14 Class II Beads - 1:100 










16 Class II Beads - 1:10 
17 Class II Beads - 1:100 
18 Cells + CD28 (neat) 
 19 Cells + CD28 (1:100) 
 20 Class I + II beads + CD28 neat 
 21 Class I + II beads + CD28 1:100 
  
Test plates were then incubated at 37
o
C for up to 72 hours with the first cell and 7 days with 
the second cell. 
During this time 50 µl of supernatant was sampled from each well at various time points.  For 
the first cell, Cell 1, this was at 16, 24, 48 and 72 hours.  This was then adapted to 24, 72 hours 
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and 7 days for the second cell, Cell 2.  After each sample was taken, 50 µl of fresh culture 
medium was replaced. 
The supernatant samples were frozen immediately and stored at -20
o
C prior to testing for the 
presence of cytokines.  
Analysis of the cytokines was carried out as previously described and the MFI values gained 
from the negative control, culture medium only well, were subtracted from those values 
gained with the test wells to give a calculated total MFI value for each cytokine in each well.  
The cytokines initially tested for were IFN-γ, TNF-α, IL-5, IL-8 and IL-17. 
4.3.1 Initial Results. 
As may have been expected, due to the fact that the PBMCs were from unsensitised healthy 
individuals, no significant cytokine production was observed in any test well at any time point 
other than the positive control, with the exception of the IL-8 cytokine, which was found to be 
produced in all test wells including the cells only negative control well, as shown in figure 67. 

























































































































































































‘Off-record’ discussion with other users of the R&D Fluorokine MAP test system indicated that 
positive detection of IL-8 in all test wells was a common occurrence and may be a due to non-
specific binding in the test system.  Another potential explanation could be that there was 
unspecific macrophage activation or oxidative stress of the cells, although it may be expected 
that other cytokines in the test system would also have been produced if this was the case.  
In view of these results it was decided that a similar experiment should be carried out using 
cells from a sensitised renal patient who had undergone previous organ transplantation, had 
produced detectable HLA specific antibodies and may well have T cell memory to specific HLA 
antigens. 
4.4 Experiment 2. 
Cells remaining after extraction for routine flow crossmatching tests from a sensitised renal 
patient were used for the next experiment in line with our ethical approval. 
Patient one was a female, long term renal patient.  Her HLA type was HLA A1,2 B8,44 Cw5,7 
DR4,7 DR53 DQ2,7.  She had received two previous renal transplants in 1979 and 1982, both of 
which included HLA class I mismatches, but had not been typed for HLA class II as it was not 
routine at the time of transplant. Serum screening revealed she had produced multiple HLA 
class I and II specific antibodies.  She was being assessed for a potential antibody removal 
transplant from a donor presenting mismatches to which she had antibody including DR11, 
and against whom she had a positive FXM.  As she had received previous transplants and 
produced HLA specific antibody I hoped that her T cells may respond to stimulation by HLA 
antigens. 
It was decided that in addition to using the Gen-probe Class I and II ID beads as detailed 
previously, beads coated in single specificities would also be used.  These single antigen beads, 
purchased from OneLambda (Canoga Park, CA), and can be purchased as vials of 96 mixed 
specificities or as vials containing a single group of beads coated in a single specificity.  Since 
the patient had antibody to HLA DR11 and possibly DR52, proven by flow crossmatch, single 
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antigen beads coated in HLA DR11 and DR52 were selected along with the self-specificity HLA 
DR7 to assess potential background reactivity against beads rather than the HLA molecules on 
their surface.  The plate was set up following the plate layout in table 17 below. 
Each well was tested in duplicate.  250000 patient cells were added to each well along with the 
bead volumes as detailed in table 17. 
Each reaction combination was tested with and without plate bound CD28, where 200µl of a 
1:100 dilution of CD28 was introduced to the appropriate test wells, incubated for 30 minutes 
to allow binding to the well surface and then washed three times using 250µl PBS per wash. 
50µl of supernatant was sampled from each well and stored at -20oC prior to cytokine 
analysis.  The time points sampled were 24 and 48 hours and day 7.  After each sample was 
taken, 50μl of fresh culture medium was replaced. 

















Table 17 - Plate layout for T cell experiment 2. 
Well number Contents 
1 Neg Medium Only, No CD28 
2 Neg Medium Only, with CD28 
3 Positive Control, no CD28 
4 Positive Control, with CD28 
5 Negative, cells only, no CD28 
6 Negative, Cells only, with CD28 
7 CI mixed beads 5 µl, no CD28 
8 CI mixed beads 5µl, with CD28 
9 CII mixed beads 5µl, no CD28 
10 CII mixed beads 5µl, with CD28 
11 CI+II mixed beads 5µl, no CD28 
12 CI+II mixed beads 5µl, with CD28 
13 DR11 2µl, no CD28 
14 DR11 2µl, with CD28 
15 DR52 2µl, no CD28 
16 DR52 2µl, with CD28 
17 DR7 2µl, no CD28 
18 DR7 2µl, with CD28 
19 DR11 10µl, no CD28 
20 DR11 10µl, with CD28 
21 DR52 10µl, no CD28 
22 DR52 10µl, with CD28 
23 DR7 10µl, no CD28 
24 DR7 10µl, with CD28 
25 DR11 + 52, no CD28 





4.4.1.1 Results from Experiment 2. 
MFI values for each cytokine tested at each time point in each test well were collected.  These 
were plotted as bar charts for each cytokine using excel.  These results are presented below in 













Figure 68 – Figure indicating detection of IFN-g production, as an MFI value, in each 
test well at each test time point in experiment 2.
 
Figure 69 - Figure indicating detection of TNF-a production, as an MFI value, in each 










































































































































































































































































































































































































































































Figure 70 - Figure indicating detection of IL-2 production, as an MFI value, in each 
test well at each test time point in experiment 2 
 
 
Figure 71 - Figure indicating detection of IL-5 production, as an MFI value, in each 








































































































































































































































































































































































































































































Figure 72 - Figure indicating detection of IL-8 production, as an MFI value, in each 
test well at each test time point in experiment 2. 
 
Figure 73 - Figure indicating detection of IL-17 production, as an MFI value, in each 




































































































































































































































































































































































































































































As can be seen from the graphs above, other than IL-8 as previously discussed, the only 
cytokine produced at detectable amounts was TNFα, the majority of which was found in wells 
containing the Class I mixed beads, although lower levels were also found in the wells 
containing class II mixed beads and a small amount in the wells containing the single antigen 
beads or peptide, at all time points.   
The presence of CD28 did not appear to influence the cytokine production. 
4.4.2 Experiment 2 - Discussion 
TNFα is a pro-inflammatory cytokine produced by T cells, macrophages and NK cells and its 
detection in the test wells containing the class I or II mixed beads, but not in the cell only 
negative control well, indicated that some cellular activation was occurring in response to the 
presence of HLA coated beads.  Lower levels were detected in the single antigen bead wells, 
including the well containing self HLA molecule DR7.  Production above the level seen in the 
cell only negative control well was not found in the test wells containing HLA derived peptides. 
Since the patient had received two previous grafts, both with known HLA class I mismatches, 
and produced antibody specific to those mismatches, it would be quite safe to assume that 
there should be some direct T cell memory to the Class I HLA antigens.  The production of 
TNFα in the Class I bead containing wells could reflect this.   
The HLA antigen coating the single antigen beads is derived from recombinant sources and is 
potentially not of the exact conformation found in vivo.  In addition, it is likely that the peptide 
being presented in the groove of each of the HLA molecules on the single antigen bead surface 
is the same.  Since in the normal immune response the TCR recognises and responds to both 
the HLA molecule and the peptide it presents, it is possible only a few or none of the T cells in 
the culture recognised the peptide being presented.  In vivo a cell would present many 
different cell or pathogen derived peptides in the same HLA molecule over its’ surface, 
allowing T cells of many different specificities to respond.  The peptide being presented is 
thought to be important in the TCR recognition process [42].  The class I and II mixed ID beads 
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are coated with HLA antigens purified from different donor cell sources and as such are 
thought to contain of wide variety of peptides in their presentation grooves.  It could be this 
difference in peptide variety which explains why the Class I and II mixed beads showed the 
greatest reaction.   
Both the class II mixed beads and the class II single antigen beads show lower levels of 
stimulation compared to the class I mixed beads.  The patient produces a number of HLA class 
II specific antibodies. However since the class II HLA types of her two previous donors are 
unknown, the exact class II specificities to which she has previously been exposed are not 
known, therefore it is possible that the T cell memory is limited to one or two specificities, 
whilst the antibody produced is to epitopes found on a number of HLA antigens and the DR11 
antibody is just a consequence of shared epitopes and cross reactivity. 
The mild reaction above baseline seen in the wells containing the DR7 coated beads could 
potentially be explained by either the fact that the DR7 on the bead surface is not in the 
‘natural’ conformation and is being recognised as ‘non-self’, or that the peptide being 
presented is in fact causing the response.  As discussed in the introduction there are two 
widely recognised, non-mutually exclusive, theories used to explain the high numbers of direct 
alloreactive T cells found in the peripheral blood of most individuals, and these centre around 
whether it is the HLA molecule, or the peptide which is being presented, that causes the 
stimulation.  The high determinant density theory suggests that it is the allogeneic HLA 
molecule itself that is directly recognised by the alloreactive T cell and the peptide bound to 
the HLA molecule is of secondary importance.  The multiple binary complex theory suggests 
that it is the peptide being presented by the non-self HLA molecules that is the primary point 
of recognition and the non-self HLA molecules themselves are of secondary importance.  It is 
possible that the DR7 HLA molecules on the single antigen Luminex beads are presenting a 
peptide to which some of the patient alloreactive T cells can respond and reactivity is seen 
following the multiple binary complex theory. 
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The strongest reaction was seen with the class I mixed beads. However using the mixed beads 
would not allow us to be able to identify which HLA antigens are causing the reaction and 
therefore whether the reaction would be donor specific.  The best way to assess specific donor 
reactivity would be to incubate the cells with donor derived HLA antigens, which would also 
contain donor derived peptides in the grooves of the HLA molecules, and therefore represent a 
better in vitro simulation of the potential stimulatory incompatibilities that would be 
encountered in vivo. 
Two kits aimed at testing for donor specific HLA antibodies are available, which allow the user 
to strip intact HLA molecules from the surface of donor cells and immobilise them on either a 
Luminex compatible bead or the surface of a micro-ELISA plate.  Previous work in our 
laboratory had validated that the donor HLA molecules bound to the micro-ELISA plate was of 
sufficiently natural conformation to detect HLA specific antibody present in patient serum.  I 
decided to investigate the use of these kits to repeat the previous T cell assays using donor 
derived HLA molecules. 
4.5 Experiment 3. 
These experiments utilised both the LIFECODES donor specific antibody detection kit for 
Luminex and the LIFECODES MicroAMS ELISA based kit, both produced by Gen-Probe.  Both 
kits use the same principle, Class I and Class II HLA glycoproteins are solubilized, via cell lysis, 
from donor lymphocytes, and captured using class-specific monoclonal antibodies which have 
been immobilized in the microwells of the micro AMS plate or on the surface of Luminex 
beads.  The lysate containing the glycoproteins can be stored at -80
o
C for up to two years, 
allowing for future and post-transplant testing. 
4.5.1 Lysate Preparation 
Both methods follow the same protocol for lysate preparation. 
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Lymphocytes are isolated from donor peripheral blood or spleen samples following the density 
gradient centrifugation cell separation method outlined earlier in the chapter. 
The packed cell volume of the final cell pellet produced must be estimated.  This can be done 
by adding an equal volume of water to an identical tube and measuring this volume of water. 




To every 10µl of packed cells, 100µl of diluted lysis buffer is added.  The lysis buffer is diluted 
by addition of 10 µl lysis buffer provided to 90 µl of sterile deionised water. 
Cells and diluted lysis buffer are mixed well and vortexed to encourage cell lysis. 
The lysate is then centrifuged at 1000-1500 rcf for 5 minutes to pellet the cell membranes and 
debris. 
The supernatant is transferred to a clean tube and can either be frozen at -80
o
C for up to two 
years or kept on ice and used immediately. 
4.5.2 Donor Specific Beads. 
The donor HLA specific beads were prepared following the kit instruction, briefly: 
The donor cell lysate was defrosted and centrifuged at 8000-12000 rcf for 4-5 minutes. 
The vial of test beads provided in the kit was centrifuged at 600-800 rcf for 30 seconds and 
then vortexed to thoroughly resuspend the beads. 
The number of test wells required for each donor lysate was calculated and enough beads and 
lysate were mixed in a small tube to cover all wells plus extra to allow for pipetting loss.  Each 
test well required 8µl lysate plus 5µl beads.  After thorough mixing the beads and lysate were 
incubated for 30 minutes at room temperature. 
In a deviation from the kit instructions the beads were then washed prior to incubation with 
the recipient cells to remove any residual lysate buffer.  This was achieved by addition of 50 µl 
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of sterile PBS, gentle vortex mixing, then centrifuging at 600-800 rcf for 30 seconds after which 
the supernatant was gently decanted.  The beads were washed a total of three times and 
finally resuspended in enough cell culture medium to allow the addition of 10 µl of bead 
suspension to each test well. 
4.5.3 ELISA plate preparation. 
The donor HLA specific microELISA plate was prepared following the manufacturer’s 
instructions, briefly: 
Enough Class I and II specific ELISA wells to prepare all the test wells needed were removed 
from the appropriate pouches, and fitted to the 96 well plate frame provided in the kit. 
The number of Class I and Class II test wells required was calculated and the lysate diluted as 
follows: 
For each Class I well, 2 µl of lysate was diluted in 14 µl of lysate and conjugate diluent (LCD) 
provided in the kit. 
For each Class II well, 4 µl of lysate was diluted in 12 µl of LCD. 
15 µl of the appropriately diluted lysate was added to each test well, the plate covered and 
then incubated at 37
o
C for 40 minutes. 
Following incubation the wells were washed 3 times, each time adding 140µl of PBS and then 
vigorously decanting the well contents and blotting with absorbent paper. 
These first three experiments using the donor specific kits were aimed at assessing the ability 
to detect donor specific T cell responses using these platforms and to compare the results 
achieved using the bead and ELISA plate methods to ascertain which, if either, would be the 
preferable format for further testing. 
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Three patients undergoing investigations for HLA antibody incompatible renal transplantation 
were identified and cells from both the patients and donors, excess to routine testing 
requirements, were used to perform the assays. 
Donor cell lysate was prepared as outlined above and, using these, both Luminex beads and 
microELISA plates were created. 
The assays using the microELISA format were performed in the ELISA wells provided in the kit, 
those performed using the beads as stimulators were carried out in a standard ‘U’ bottomed 
96 well plate. 
Testing included wells with and without the addition of soluble CD28 where 2µl of neat stock 
1µg/ml was added to each test well as appropriate. 250000 PBMCs were added to each test 
well as appropriate and the pates sealed and incubated at 37
o
C.  The testing combinations are 
outlined in table 18 below. 
Table 18 - Test combinations used in Experiment 3. 
Negative control – Medium only 
Negative control – Cells + medium 
Positive Control – Cells + CD3/28 stimulator beads 
Class I ELISA without CD28 
Class I ELISA with CD28 
Class II ELISA without CD28 
Class II ELISA with CD28 
Luminex Beads with CD28 
Luminex Beads without CD28 
 
50µl of culture supernatant was collected at 24, 72 and 120 hours from each well and tested 
for the presence of the cytokines IFNγ, TNFα, IL-2, IL-5, IL-8 and IL-17 using the method 
previously outlined. 
The MFI values gained with the negative control, cells only well were subtracted from the test 
wells to give an indication of cytokine production above baseline. 
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4.5.3.1 Pair One. 
The potential recipient was a female patient who had received two previous renal transplants.  
She was highly sensitised, producing multiple Class I and II HLA specific antibodies. The HLA 
types, previous mismatches and HLA specific antibodies involved are outlined in table 19 
below. 
Table 19 - Pair One HLA information. 
Patient 1 HLA type A2,68 B42,52 Bw4/6 Cw16,17 DR8,17 DR52 DQB4,7 
Donor 1 HLA type A1,36 B18 Bw6 Cw4,5 DR15,17 DR51,52 DQB2,6 
Previous Mismatches A1, B18.  Class II HLA type of previous donors not complete, may be 
repeat mismatches. 
Donor Specific Ab A1, A36, B18, DQ2 
Crossmatch Result T & B cell positive. 
4.5.3.2 Pair One Results. 
No production of IFNγ, IL-2, IL-5, IL-8 and IL-17 was seen above baseline, other than in the 
positive control, however production of TNFα was detected in both the Class I and II ELISA 
wells tested with additional CD28 at all time points.  TNFα was additionally detected at 72 
hours in the ‘beads without CD28’ well.  The results for TNFα can be seen in figure 74 below. 





































4.5.4 Pair Two. 
The potential recipient was a male renal patient who had received one previous transplant.  He 
was highly sensitised, producing multiple Class I and II HLA specific antibodies.  The HLA types, 
previous mismatches and HLA specific antibodies involved are outlined in table 20 below. 
Table 20 - Pair Two HLA information. 
Patient 2 HLA Type A3,26 B37,61 Bw4,6 Cw2,6 DR13 DR53 DQB6 
Donor 2 HLA Type A26,68 B37,71 Bw4,6 Cw6,7 DR11,13 DR52 DQB6,7 
Previous Mismatches Cw7 
Donor Specific Ab Cw7, DR11, DQ7 
Crossmatch Results B cell positive 
 
4.5.4.1 Pair Two Results. 
Due to a technical problem involving evaporation in some wells, only data for 24 and 72 hours 
are available for this pair. 
No production of IFNγ, IL-2, IL-5 and IL-8 was seen above baseline in any of the test wells at 
either time point, other than in the positive control.  IL-17 production was detected in the class 
II ELISA well with CD28 at 72 hours.  TNFα production was detected in all test wells and most 















Figure 75 - IL-17 Production in Pair Two 
 










































































4.5.5 Pair Three. 
The third patient was a male renal patient who had received two previous grafts.  He was 
highly sensitised producing multiple Class I and II HLA specific antibodies.  The HLA types, 
previous mismatches and HLA specific antibodies involved are outlined in table 21 below. 
Table 21 - Pair Three HLA Information. 
Patient 3 HLA Type A2,68 B53,65 Bw4,6 Cw4,5 DR1,13 DR52 DQ5,6 
Donor 3 HLA Type A3,68 B53,65 Bw4,6 Cw4,8 DR13 DR52 DQ6 
Previous Mismatches No repeat mismatches presented by donor 3. 
Donor Specific Antibodies A3 
Crossmatch Results T & B cell positive 
 
4.5.5.1 Pair Three Results. 
No production of any of the cytokines tested was detected in any of the test wells other than 
the positive controls. 
4.5.6 Experiment Three Discussion. 
This set of three experiments gave some interesting results.   
The mismatches between pair one included two Class I repeat mismatches from two previous 
transplants, to which HLA specific antibody had been produced.  One of her two previous 
donors had not been fully HLA class II typed so we were unable to assess the presence of 
repeat class II mismatches from this donor, however there were no repeat mismatches from 
the second donor at DR and DQ.  We expected to see a response to the donor Class I antigens 
and potentially a response to the Class II.  The main responding cytokine detected was TNFα 
which was found predominantly in the Class I and II ELISA test wells where soluble CD28 had 
been added, and additionally at 72 hours only in the beads only test well. 
The mismatches between pair two included a repeat Cw7 mismatch from a previous graft, to 
which HLA specific antibody had been produced.  There were no repeat HLA class II 
mismatches from the previous donor graft, although the patient has produced multiple HLA 
class II specific antibodies.  We expected to see a response to the donor Class I antigens, but 
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potentially not to the Class II.  The main responding cytokine detected was again TNFα in both 
the Class I and Class II ELISA test wells containing additional CD28, plus in the beads + CD28 
well at 72 hours only.  In addition some IL-17 was detected in the Class II ELISA well with CD28 
at 72 hours only.  Unfortunately due to evaporation of the culture medium no results are 
available for 120 hours for this pair. 
The mismatches between pair three did not include any repeats at any loci from his two 
previous donor grafts.  There was a single antibody specificity incompatibility involved to the 
mismatched HLA A3.  Detection of this antibody is believed to be due to epitope crossreactivity 
with the previously mismatched HLA A1 and A11 from the two previous grafts, as antibodies to 
all the specificities known to share the epitope in the cross reactive epitope group (CREG) can 
be detected by single antigen bead screening.  Since there were no Class I repeat mismatches 
and there were no Class II mismatches between the donor and recipient we did not expect to 
detect any reactivity with this pair.  This was the case, and other than the positive control, no 
cytokine production was detected in any test well above the negative control baseline. 
TNFα appears to have been the major cytokine detected using this assay so far.  TNFα is a pro-
inflammatory cytokine produced by a variety of cell types, including monocytes/macrophages, 
lymphocytes, endothelial cells and fibroblasts.  It elicits many effects during the immune 
response including immune cell activation and trafficking, cell survival and differentiation [334, 
335].  Excessive production and dysregulation in the TNF signal pathways have been linked to a 
number of autoimmune diseases including rheumatoid arthritis, multiple sclerosis and Crohn’s 
disease.  Due to the nature of the cells separated from the peripheral blood of the patients for 
use in this assay, TNFα production detected here can be limited to T cells, Th1, Th2, Th17 and 
CTLs have all been found to produce TNFα on stimulation, monocytes and NK cells.  Monocytes 
are phagocytic mononuclear cells which make up 10-15% of the circulating white blood cells.  
They are bone marrow derived and following a brief period of circulation (24 – 72 hours) enter 
the tissues where they undergo further differentiation into either macrophages or dendritic 
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cells, dependent on the signals received and the local tissue environment [336-338].  They are 
central to both the innate and adaptive immune systems, microbial products such as 
lipopolysaccharide can directly activate monocytes to produce pro-inflammatory cytokines 
such as TNFα and IL-1β, and anti-inflammatory cytokines such as IL-10.  
Monocytes/macrophages may also be stimulated by Th1 cells in an antigen dependent fashion, 
whereby the antigen specific T cell recognises processed peptide presented in an HLA class II 
molecule on the surface of the macrophage.  In addition to the TCR ligation, CD40L on the T 
cell binds to CD40 on the macrophage surface, providing a co-stimulatory signal for the T cell 
and the macrophage.  This CD40L-CD40 interaction plus production of IFNγ by the Th cell, 
activates the macrophage to produce cytokines including TNFα and also activates the T cell.  In 
addition activated CD8+ CTLs can also activate macrophages to produce TNFα. 
The TNFα production seen in our assay could potentially be explained as being due to non-
allospecific reactivity of monocytes.  However this does not explain the differences seen in 
TNFα production between the cell only negative control wells and the stimulator wells, where 
the only difference is the presence of donor derived HLA molecules, suggesting some form of 
allospecific recognition. Also, the addition of CD28, for costimulation, appears to lead to an 
increased level of cytokine production compared to the wells where no CD28 is added, again 
this would indicate a more specific response is occurring.  Finally, the responses seen were 
generally as expected, whereby the patient cells exposed to repeat mismatched HLA antigens 
responded and the patient who had not previously been exposed to the HLA antigens present 
did not respond.  These factors all suggest that some form of T cell recognition and consequent 
activation is occurring.  Another possible explanation could be that we are not detecting 
memory responses but naïve responses.  Naïve T cells have a unique ability to produce TNFα 
rapidly after activation and prior to acquiring effector functions [256].  Recent work has 
suggested that both naïve CD4+ and CD8+ T cells found in the periphery are able to rapidly 
produce TNFα following TCR ligation and interaction with an APC, many hours before cell 
division or production of other classical cytokines such as IL-2 or IFNγ [339, 340].  It is possible 
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that direct recognition of the donor derived HLA molecules in addition to CD28 binding could 
lead to activation of allospecific naïve T cells in the culture.  
The detection of TNFα in our assay could be of interest when comparing it to the post-
transplant outcome, as TNFα has been linked to rejection of renal transplants in multiple ways.  
A number of groups have studied the effect of polymorphisms in a number of cytokine genes 
and their relationship to cytokine production and transplant outcome.  TNFα is one such 
cytokine, where polymorphism in the encoding gene has a functional effect on the production 
of TNFα.  A single nucleotide polymorphism (SNP) in the promoter region of the gene at 
position -308 is associated with a 6-7 fold increase in production of TNFα in vitro [341-343].  A 
number of studies have looked at the effect of either donor or recipient TNFα high production 
genotype and post-transplant outcome.  The general consensus is that high TNFα production is 
associated with an increased risk for acute rejection, late rejection and vascular rejection, 
although this risk decreases with good matching at HLA DR [344, 345].  TNFα production by 
monocytes has also been associated with the development of transplant glomerulopthy in 
renal allograft recipients, with high levels of TNFα secretion from  the transplant recipient 
cultured PBMCs correlating with the development of transplant glomerulopathy but not with 
HLA specific antibody production or C4d staining on biopsy [346].  Culture experiments 
identified the main TNFα producing cells as monocytes [346].  Further work on monocytes in 
renal transplantation have identified CD14+CD16+ monocytes as being associated with 
subclinical atherosclerosis in renal graft recipients [347].  CD14+CD16+ monocytes are 
considered to be highly proinflammatory due to their ability to produce high levels of 
proinflammatory cytokines such as TNFα [348].  In addition higher numbers of circulating 
CD14+CD16+ monocytes have been identified in the blood of patients suffering from end stage 
renal failure when compared to healthy controls [349] indicating a higher immune activation 
status.  High levels of TNFα in the serum and urine of renal allograft patients have also been 
found during episodes of acute rejection [350, 351]. 
256 
 
The fact that only TNFα was found to be produced at detectable levels is slightly confusing as 
other cytokines might have also been expected.  It was decided for the next experiments to 
change the array of cytokines being detected to IFNγ, TNFα, IL-2, IL-4, IL-5, IL-10 and IL-17, to 
reflect the potential cell types being activated. 
The results from experiment three indicated that as a concept the assay showed some 
promise, with reactivity, or lack thereof, being detected when expected in previously 
sensitised patients.  Comparison of the results achieved using the beads vs the ELISA based 
format indicated that the ELISA format gave the best results, especially when an external 
source of CD28 was added.  It was decided that all further work would be based on the ELISA 
format with the addition of CD28.  The benefit of the ELISA method was that it allowed for 
separation of the Class I and Class II HLA antigens, giving a greater amount of information 
about the sensitisation status of a patient.  A reduction in the number of test wells also meant 
that we could add an additional random 3
rd
 party donor stimulator cell into the assay for each 











4.6 Experiment 4 
Over a number of months a further 34 donor and recipient pairs were identified with cells 
excess to routine testing requirements.  For each pair recipient cells were separated and 
frozen in in-house sterile freezing mix composed of RPMI 1640 with Glutamine (Gibco), Heat 
inactivated Foetal Bovine Serum (Gibco) and Dimethyl Sulphoxide (Sigma) in a 45:45:20 ratio, 
and stored at -80
o
C, lysate was generated from the donor cells and stored at -20
o
C until used.  
Each experiment was set up in batches of 6 pairs, to fill one plate.  The test wells were as 
described in table 22 below. 
Table 22 - Experiment 4 plate set up. 
Negative Control – Cells only 
Positive Control – Cells plus CD3/28 stimulator beads 
Patient cells vs donor lysate 
Patient cells vs donor lysate 
Patient cells vs 3
rd
 party lysate 
 
• The ELISA wells were prepared as described previously. 
• 250000 recipient cells were added to each well.   
• 2µl of 1ng/ml CD28 was added to each well. 
• Plates were incubated at 37oC. 
• Supernatant was sampled at 18, 72 and 120 hours and stored at -20oC for testing later.   
• Cytokine production was analysed as previously described. 
Full details of patient and donor/3
rd
 party types and sensitisation can be found in appendix 4. 
4.6.1.1 Experiment 4 Results. 
Overall the results from tests with 30 patient cells were included in analysis, all were tested 
both against HLA molecules isolated from their potential donors and with those isolated from 
random 3
rd
 party cells.  Results from 4 Patient/Donor pairs were excluded due to lack of cells 
or poor cell viability.  In total this gave results from 60 patient/donor test pairs to analyse.  
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Patients were divided into two groups, sensitised and unsensitised, based on HLA antibody 
production and/or previous transplants and recorded pregnancies. 
One cytokine, IL-4, was not detected in any assay in either the donor specific test wells or in 
the positive controls.  The standards provided with the test kit did produce detectable results 
on the Luminex test, indicating that the kit was able to detect IL-4.  Possible explanations for 
this could be that there was either no IL-4 produced by any test cell at any point under any 
stimulation, or that there was some form of inhibition occurring during the Luminex assay 
detecting IL-4.  Therefore the IL-4 results are not included in analysis. 
A full summary of all the data generated can be found in appendix 4. 
4.6.1.2 Unsensitised Patients. 
There were 6 patients recorded as being unsensitised.  Of these 2 were female patients and 4 
male.  All 6 had been screened on multiple occasions and produced no detectable HLA specific 
antibody.  In addition all 6 had no recorded sensitising events, however previous unrecorded 
transfusions, and pregnancies in the female patients, could not be excluded.  An overview of 
the results achieved in these patients can be seen in table 23 below.  The patient and donor 
pair number assigned at the start of testing is listed under ‘No.’ and the gender of the patient 
is listed as ‘F’ for female and ‘M’ for male.  If a response was observed the HLA class (CI or CII) 
to which the response was seen is indicated either to the donor or to the 3
rd
 party stimulator, 
under the column labelled ‘Response’.  If no response was seen this is indicated by ‘none’.  
Where a response was recorded the time point at which it was first observed is recorded in the 
column ‘time to first response’, again divided into responses to the donor or 3
rd
 party 
stimulator.  The cytokines detected in the response are listed in the ‘cytokines produced’ 
column.  The HLA mismatches presented by either the donor or the 3
rd
 party stimulators are 
listed in the column ‘mismatches present’.
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Table 23 - Overview of results observed in unsensitised patients. 
  
Response 
Time to 1st 
Response 

















Donor 3rd Party 
1 F 














None None  -  -  -  - B35, Cw4 
A68, B60, 
Cw10 

























DR1, DQ5 DR1, DQ5 
4 M 











































Following my hypothesis that early responses would be seen in the patients who were 
sensitised and also presented with repeat mismatches it was expected that none of these 6 
patients would show a response.  However, this was the case in only 2 of the patients, with the 
other 4 showing detectable cytokine production of various profiles.  It is noticeable that the 
cytokines produced, and the timing of their production, is comparable in both the donor 
specific and 3
rd
 party wells for each patient. 
Looking at each patient individually, patient 1 shows an early IFNγ response to both class I and 
II of the donor but TNFα and IL-5 in response to the class I of the 3
rd
 party only.  This indicates 
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that there may be a certain specificity to the response and that it is specific to the different 
mismatches presented by each donor cell.  This patient is a 51 year old female, therefore 
previous unrecorded pregnancy or blood transfusion cannot be excluded.  The patient went on 
to be transplanted from the test donor with an ABO incompatible kidney, requiring Rituximab 
induction, which is still functioning 3 years post-transplant and has had no recorded rejection 
episodes, observed both through functional testing and biopsy. 
Patient 2 showed no response to either the donor or third party, as expected.  This patient has 
been transplanted with a kidney from the test donor, which is still functioning 3 years post-
transplant with no recorded rejection episodes. 
Patient 3 showed a similar response to both the donor and 3
rd
 party class I and II, with the 
greatest range of cytokines and similarity in profiles being seen with the two class II tests.  
Interestingly both the donor and 3
rd
 party cells shared the same Class II mismatches of DR1 and 
DQ5, which could again indicate some level of specificity in the reaction.  This patient is a 39 yr 
old male and has had no recorded sensitising events, although previous unrecorded blood 
transfusions cannot be excluded.  He was transplanted with a kidney from this donor which is 
still functioning 3 years post-transplant with no recoded rejection episodes. 
Patient 4 showed similar responses to both the class I and II donor and 3
rd
 party.  In this case 
both the donor and 3
rd
 party were HLA identical so similar responses would be expected.  This 
is a 49 year old male who has no recorded sensitising events, although, once again, 
unrecorded blood transfusions cannot be excluded.  The patient went on to receive a kidney 
from this donor which is still functioning 3 years post-transplant with no recorded rejection 
episodes. 
Patient 5 is a 23 year old female.  Her cells showed no response when stimulated with the class 
I HLA molecules, however IFNγ production was detected in response to both the donor and 3
rd
 
party Class II HLA molecules.  In this case however no HLA mismatches are shared by the donor 
and 3
rd
 party.  She went on to receive an ABO incompatible transplant from this donor, 
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requiring rituximab induction, which is functioning well at 3 years post-transplant with no 
episodes of biopsy proven rejection. 
Patient 6 showed no response to either the donor or third party, as expected.  This patient has 
been transplanted with a kidney from the test donor, which is still functioning 3 years post-
transplant with no recorded rejection episodes. 
4.6.2 Sensitised Patients. 
There were 24 patients tested who were classified as sensitised, either due to previously 
recorded transplants or pregnancies, or due to the fact that they produced HLA specific 
antibody detected in multiple samples on screening.  19 of these were female and 5 male.  10 
patients were sensitised through pregnancy, 12 through a previous, failed, renal transplant and 
2 had unidentified sensitising events, presumed to be blood transfusion.  Overall, when both 
donor specific and 3
rd
 party responses were included there were 48 T cell response 
combinations to be analysed.  Of these a response was seen in 39/48 cases, 3/39 to Class I 
only, 7/39 to Class II only, 29/39 to both Class I and Class II.  9/48 showed no response.  A 
summary of patient details and responses can be seen in table 24 below.
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Time to 1st 












Party Donor 3rd Party Donor 3rd Party 
7 F 
CI CI CI CI CI  - 24 hrs 24 hrs TNFα, IL-10 TNFα, IL-10 
A24,31 B7,62 
Cw9 A3, B60, Cw10 






CI  - CI  - CI  - Day 3 24 hrs IL-5, IL-17  - 
A66, B41, 
Cw17 
A24, 31, B7,62 
Cw9 






CI CI CI CI CI CI 24 hrs Day 5 IFNγ, IL-2 IL-5 A3,32 B7 Cw7  A3 B57 Cw4 
CII CII CII CII CII CII 24 hrs 24 hrs TNFα, IL-10 TNFα, IL-5, IL-10 
DR4, 53 
DQ7,8 
DR4, 7 53 
DQ8,9 
10 F 
CI CI  - CI CI CI 24 hrs Day 5 IFNγ IL-5, IL-17 Cw2,7  
A1,32 B35,55 
Cw4 
CII  - CII  - CII CII 24 hrs  - 
IFNγ, IL-2, IL-5, 
IL-17  - DR4,15 51,53 DR11,14 DQ5,7 
11 F 
CI CI CI  - CI CI 24 hrs 24 hrs IL-10 IL-10 A2 B37 Cw6 A26 B37 Cw6 




 -  -  - CI  - CI  -  -  -  -  - A2,11 B44, Cw5 













CII CII CII  -  -  - 24 hrs 24 hrs TNFα TNFα, IL-2 DR17, DQ2 DR1,13 
14 F 















Time to 1st 












Party Donor 3rd Party Donor 3rd Party 
DQ2 
15 F 
CI CI CI  - CI CI 24 hrs 24 hrs 
TNFα, IL-2, IL-





CII CII  -  -  - CII Day 3 Day 3 IL-17 IL-2, IL-5, IL-17 DR9,13 DQ5 DR17 
16 F 
 -  -  -  -  -  -  -  -  -  - A1,3 B7 Cw7 
A1,24 B8,44 
Cw5,7 
 -  -  -  -  -  -  -  -  -  - DR8 DQ4 DR13,17 DQ2 
17 F 





 -  - CII CII  -  -  -  -  -  - DR13, DQ6 DR9,13 53 DQ6 
18 F 
CI CI CI  - CI CI 24 hrs 24 hrs 
TNFα, IL-5,IL-
10, IL-17 TNFα, IL-5 
A2, B60, 
Cw10 
A2, B41, B44, 
Cw5,17 
CII CII  -  -  -  - Day 3 Day 3 IL-5  IL-5  - DR4, 13 DR53 
19 F 
CI  - CI  -  - CI 24 hrs  - TNFα  - B27,44 Cw2,5 
A23,80 B52,57 
Cw16,18 
CII CII CII  - CII CII 24 hrs 24 hrs TNFα, IL-2  IFNγ, TNFα DQ7 DR7 
20 F 
CI CI CI  - CI  - Day 5 Day 3 IFNγ, IL-17 IFNγ, IL-5, IL-10 B57, Cw6 A11 B55 Cw9 
CI CII  -  -  -  - Day 3 Day 3 IFNγ IFNγ, TNFα, IL-5  - DR10, 14 DQ5 
21 F 
CI CI  -  -  - CI 24 hrs 24 hrs 
IFNγ, TNFα,IL-2, 
IL-10, IL-17 TNFα, IL-10  - A2, B18 
CII CII  -  -  -  - 24 hrs 24 hrs TNFα, IL-10 TNFα, IL-10  - DR7, DR53 
22 M 
CI CI CI  - CI CI 24 hrs 24 hrs IFNγ, TNFα,IL-2 IFNγ, TNFα,IL-2 
A23,80 B57 
Cw16,18 A3 B7,57 Cw6,7 
CII CII  -  -  -  - 24 hrs 24 hrs IFNγ, TNFα IFNγ, TNFα  -  - 
23 M 
 -  -  - CI CI CI  -  -  -  - A1,3 B35 Cw4 A2 B44 Cw2,5  
CII CII  -  -  -  - 24 hrs 24 hrs IL-10 
IFNγ, TNFα, IL-2, IL-
5, IL-10, IL-17 
DR4 DR53 










Time to 1st 












Party Donor 3rd Party Donor 3rd Party 
24 M 
CI CI CI CI CI CI 24 hrs 24 hrs IL-10 TNFα, IL-10 A2 B62 Cw9 A2 B18,62 Cw9 




 -  -  - CI  - CI  -  -  -  - B18 Cw7 
A1,32 B8,44 
Cw5,7 






CI CI  -  - CI CI 24 hrs 24 hrs TNFα TNFα, IL-10 A1 B35 Cw4 A1 B7 Cw4,12 






 -  - CI  - CI CI  -  -  -  - A2 B44 Cw5  A23,66 B49 






CI CI CI  -  -  - 24 hrs 24 hrs 
TNFα, IL-10, IL-
17 TNFα, IL-10 A1,26 B37 
A3 B35,62 
Cw4,9 
CII CII CII CII  -  - 24 hrs 24 hrs TNFα, IL-10 TNFα, IL-10 DR13 DR1,13 DQ2 
29 F 
CI CI CI CI CI CI 24 hrs 24 hrs TNFα TNFα A11 B55 Cw9 
A33 B53,71 
Cw10 




 -  - CI CI CI CI  -  -  -  - A11 B44 Cw5 A31 B8,45 Cw6 







The group in whom I expected to see the greatest responses were those where there was 
demonstrable donor specific antibody and this antibody was directed at a mismatch to which 
the recipient had previously been exposed, classified as a repeat mismatch (Ab+RptMM+).  The 
group in whom we expected to see the fewest responses were those where there was no 
donor specific antibody and no previous exposure to the mismatches presented by the 
potential donor or 3
rd
 party (Ab-RptMM-).  A response was defined as production of any 
cytokine, or combination of cytokines, at any of the time points tested. 
Analysis of correlation was performed using Fisher’s exact 2 tailed test and the p value 
recorded. 
Table 25 - 2x2 table - Class I DSA positive Repeat Mismatch Positive vs DSA negative 
Repeat mismatch negative. 
Class I Response No Response 
Ab+RptMM+ 16 6 
Ab-RptMM- 9 12 
 
Analysis of the Class I information gives a p value of 0.0666, indicating that the association 
between the antibody and repeat mismatch status with the response outcome is approaching 
statistical significance. 
Table 26 - 2x2 table - Class II DSA positive Repeat Mismatch Positive vs DSA negative 
Repeat mismatch negative. 
Class II Response No Response 
Ab+RptMM+ 8 4 
Ab-RptMM- 22 10 
 
Similar analysis of the Class II information gives a p value of 1.000 indicating there is no 
association between the antibody and repeat mismatch status with the response outcome. 
Additionally combination of the Class I and II results indicates no statistically significant 
association of the antibody and repeat mismatch status with an observed response (p=0.3623). 
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Cytokine specific analysis, comparing production of each individual cytokine against antibody 
and repeat mismatch status, also failed to produce any statistically significant results 
(p=0.3548 – p=1.00), with the exception of IL-10, where production of IL-10 in the Class I group 
was associated with a lack of antibody production and repeat mismatches (p=0.0414). 
There was also no significant difference in the timing of cytokine production between the two 
groups with 19/24, or 80%, of the Ab+RptMM+ group producing a cytokine response within 24 
hours, compared to 25/31, or 81%, of the Ab-RptMM- group. 
Comparison of general sensitisation status and response again yielded no significant results, 
with sensitisation being associated with any response giving a p value of 1.000, a Class I 
response giving a p value of 0.508, a Class II response p=0.293. 
Production of donor specific antibody, regardless of the presence of a repeat mismatch, was 
also not associated with generation, or absence, of a cytokine response, p=0.8476. 
Presence of a repeat mismatch, regardless of the production of a donor specific antibody, was 
again not associated with generation or absence of a cytokine response, p=0.4273. 
Association between gender of the patient and cytokine production was also analysed and 
there was found to be no statistical significance (p=1.000). 
In conclusion the original hypothesis behind the development of the test, that greater 
numbers of T cell responses would be observed in patients presented with repeat HLA 
mismatches, particularly where donor specific antibody is present, compared to patients who 
were unsensitised or who were not presented with repeat mismatches, was not confirmed. 
4.6.3 Transplanted Patients. 
Previously published results from the groups investigating the IFNγ ELISPOT method, described 
in the introduction, indicated an association of T cell responsiveness, as measured by IFNγ 
production, and rejection episodes post-transplant [241].  Of the 30 patients tested in this 
group of experiments, 14 went on to be transplanted with an organ from the donor used as a 
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stimulator in the donor specific test wells.  A summary of these patients can be seen in table 
27 below.  This table includes the relevant cytokine data taken from tables 23 and 24 
presented previously, and presents the specific responses seen following stimulation of patient 
cells by HLA isolated from samples provided by the subsequent donor.  In this table the 
donor/recipient pair is indicated in the ‘No.’ column and corresponds with the identification 
number assigned during the initial experiments represented previously in tables 23 and 24.  
The ‘type of transplant’ column indicates if the patients received an antibody compatible graft, 
an ABO blood group incompatible graft, an HLA antibody incompatible graft or a combined 
ABO and HLA antibody incompatible graft.  The ‘mismatch’ column shows the mismatches 
presented by the donor cells.  The ‘induction therapy’ column indicates the induction therapy 
administered to the recipient prior to transplant – none, IVIg alone, Campath, Rituximab or 
combined rituximab and campath.  The ‘T cell mediated rejection on biopsy’ indicates with 
‘yes’ or ‘no’ if T cell mediated rejection was diagnosed on post transplant biopsys at any point 
duing the first 2 years post transplant.  The ‘class I’ and ‘class II’ response columns list the 
cytokines detected at any sampling time point in response to donor class I or class II specific 
stimulation during the culture experiments described previously.
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None No None None 
3 Compatible 
A1 B35 Cw4 
DR1 DQ5 








None No TNFα, IL-10 TNFα, IL-10 
5 ABOi 
A3 B52 Cw1 
DR1 DQ5 
Rituximab No None IFNγ 
6 Compatible 
A1 A24 B44 
Cw5 DR13 
None No None None 
11 HLA/ABOi A2, B37, Cw6 Campath No TNFα, IL-10 TNFα, IL-10 
13 HLAi 








A1,3 B7 Cw7 
DR8 DQ4 














Campath No None IL-10 
28 ABOi 







A11 B55 Cw9 
DR14 DR52 
Campath No TNFα TNFα 
30 HLAi 





No None None 
 
The transplanted group is made up of a mixture of patients who received a compatible graft, a 
graft which was ABO blood group incompatible, a graft which was HLA antibody incompatible 
or one which presented both ABO and HLA antibody incompatibilities.  The variation in 
transplant type also led to a variation in induction therapy used, which included some 
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occasions of Campath for lymphocyte depletion, Rituximab for B cell depletion and no cell 
depleting induction therapy.  The post-transplant outcomes in terms of the occurrence of T cell 
mediated rejection episodes in patients treated with Campath need to be treated with caution 
as T cell depletion would inhibit the ability for a T cell mediated response to be mounted.  In 
our centre the patients who do not receive Campath or Rituximab are treated with anti-CD25 
mAb Basiliximab for induction.  All patients then receive triple therapy of mycophenolate 
mofetil (MMF), Tacrolimus (Tac) and steroids in the immediate post-transplant period. 
All patients have been followed up of a minimum of 2 years.  All recorded episodes of biopsy 
proven T cell mediated rejection were from ‘for cause’ biopsies taken at times of clinically 
implied suspected rejection.  As previously outlined biopsy analysis was performed by 
histopathologists and reported in the context of the internationally agreed Banff criteria [352].   
3 of the 14 transplanted patients suffered from one or more episodes of biopsy proven T cell 
mediated rejection.  1/3 received an HLA antibody incompatible transplant, 1/3 received an 
ABO blood group incompatible transplant and one received an antibody compatible transplant, 
which also presented no HLA mismatches.  None of these patients received Campath 
induction.  All three patients showed T cell responsiveness to their donor as indicated by 
cytokine production during the assay. 
11 of the 14 transplanted patients suffered no episodes of T cell mediated rejection.  4/11 
produced no cytokines during the assay, 6/11 produced a very limited response, often with 
only one cytokine being detected to either class I or class II, 1/11 showed a wider ranging 
response to the donor HLA class II molecules.  Three of these 11 patients did receive Campath 
induction therapy, therefore observation of TCMR would be less likely in the short term post-
transplant period.  The cytokine production profiles of these patients were limited, showing 
production of TNFα and/or IL-10. 
The three patients in whom TCMR was diagnosed all showed a wide range of cytokine 
production on stimulation in the Class I test wells.  The major difference in cytokine production 
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between the rejector and non-rejector group is that all those who had an episode of TCMR 
produced the cytokine IL-17 on stimulation.  Of the transplanted group, only 1 patient 
produced IL-17 who did not go on to have a biopsy proven episode of rejection.  Comparison 
of the timings of the IL-17 production showed that 3/3 patients who suffered TCMR produced 
IL-17 in response to the Class I molecules at days 3 – 5. IL-17 production in the patient who did 
not suffer TCMR was in the class II stimulator well and detected in the first 24 hours only.  In 
addition, as discussed earlier, the cytokine production profiles with the donor specific wells 
and the 3
rd
 party test wells are generally similar, possibly suggesting that this is an indication as 
to general responsiveness rather than anything donor specific.  Comparison of the profiles 
seen in these 4 patients against their potential donor and the 3
rd
 party showed that in the 3 
rejectors the profiles were indeed similar with the exception of IL-17 production, which was 
only seen in the donor specific well, however in the patient who didn’t reject, IL-17 was seen in 
both the donor and 3
rd
 party wells.  Of note, one patient in the TCMR group received an 
apparent HLA identical transplant, yet still suffered an episode of TCMR and still responded on 
stimulation in vitro.  Since the only apparent addition to the test wells was donor derived HLA 
molecules, differences, potentially in the peptide being presented may be responsible for 
stimulating the patient cells. 
The mean time to 1
st
 episode of biopsy proven TCMR in this group was 11.3 days, with a range 
of 6 – 15 days.  Patient 28 had a donor organ nephrectomy at day 7 due to uncontrolled T cell 
mediated rejection.  Patient 13 and Patient 21 have retained there grafts which remain 
functional at 3.5 and 2.8 years post-transplant respectively. 
Analysis of the IL-17 data using Fisher’s exact test gives a p value of 0.0027 indicating strong 
statistical significance, the data used for analysis is presented in table 28 below.  Whilst the 
numbers involved are too small to draw genuinely significant conclusions these results would 
indicate that IL-17 production on stimulation in vitro could be indicative of future TCMR 
episodes and warrants further investigation.  
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Table 28 - 2x2 table presenting analysis of IL-17 production at day 3 of culture 
following stimulation with potential donor cells and subsequent diagnosis of T cell 
mediated rejction on post transplant biopsy. 
 IL-17 at day 3 of culture No IL-17 at day 3 of culture 
T cell mediated rejection 3 0 
No T cell mediated rejection 0 11 
 
IFNγ production did not appear to be associated with future rejection episodes, with only one 
of the TCMR group producing IFNγ on stimulation compared to 3 in the non-TCMR group. 
Only 2/14 transplanted patients showed a detectable IL-2 response, interestingly both these 
two patients were again in the TCMR group.  None of the non-TCMR showed an IL-2 response.  
Production of IL-2 was again detected later on in the assay period, at days 3-5. 
None of the transplanted patients showed an IL-5 response. 
The production of TNFα or IL-10 also does not appear to be linked with future episodes of 
TCMR, p=0.1923 and p=0.5227 respectively.  All of the TCMR group produced both TNFα and 
IL-10 on stimulation, however 4/11 of the non-TCMR also produced TNFα and/or IL-10.  
Further investigation, with a larger sample size, may be able to give a better indication as to 







The rationale behind the development of this test system was to assess if memory T cells could 
be stimulated in vivo to produce detectable cytokines in response to donor derived HLA 
molecules.  It was hoped that this system could help to identify patients who had memory T 
cell responses to their potential donors, particularly in the HLA antibody incompatible group, 
in order to help identify the most suitable donor, when multiple donors were available, and 
those patients who were at high risk of developing T cell mediated rejection.  Sindhi et.al. 
recently reported that 70-95% of rejection episodes in renal allografts include a cellular 
component [217], however most solid organ transplantation laboratories do not routinely 
assess a patients’ cellular reactivity to a potential donor, relying on HLA specific antibody 
status to act as a marker for overall immune reactivity against a given donor and thus avoiding 
hyperacute and acute antibody mediated rejection.  In part this is due to the ease and 
reliability of HLA specific antibody testing methods compared to those assays currently 
available for assessment of T cell reactivity. 
Prior to testing it was assumed that patients in my study who were sensitised to their potential 
donor, in terms of HLA specific antibody production, and had had previous sensitising events 
involving one or more of the HLA antigens presented by the potential donor, would be more 
likely to produce a rapid detectable cytokine response on stimulation due to the presence of 
donor specific memory T cells.  Whereas unsensitised patients, or those whose previous 
sensitising events had not included any of the HLA antigens presented by the potential donor, 
would have milder responses, potentially later in the testing period, if any response at all.  This 
made the assumption that patients would only possess memory T cells to HLA antigens to 
which they had previously been exposed.  However, analysis of the data generated found no 
correlation between detected cytokine responses and previous exposure to HLA.  Indeed wide 
ranging cytokine production was detected in 4/6 of the unsensitised patient group.  
Comparison of patients in whom we had previously detected potential donor specific antibody 
and who had previously been exposed to one or more of the HLA mismatches presented by 
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the donor (Ab+Rptmm+) with patients who produced no potential donor specific antibody and 
had not been previously exposed to any of the HLA mismatches showed no statistical 
difference in cytokine production (p=0.362).  However when divided into class I and class II 
results the association of a class I repeat mismatch with antibody and cytokine production was 
nearing significance (p=0.0666), indicating that there was potential correlation between an 
observed response and previous sensitisation.  Presence of a repeat mismatch alone, 
regardless of antibody status, and presence of donor specific antibody alone, regardless of 
repeat mismatch status, were also not significantly associated with cytokine production, 
p=0.4273 and p=0.8476 respectively.  Additionally production of no single cytokine could be 
associated with previous HLA sensitisation.  This overall result should perhaps not have been 
unexpected as they generally agree with previous observations made by groups developing the 
IFNγ ELISPOT method discussed in the introduction.  Heeger et.al. and Nickel et.al. have both 
reported that donor specific T cell reactivity as demonstrated by IFNγ production in the 
ELISPOT system, was independent of a patients previous sensitisation events, HLA specific 
antibody production, age and donor HLA mismatches [245, 353].  Andree et.al. and Poggio 
et.al. also demonstrated that T cell reactivity against a panel of stimulator cells, which provides 
a ‘Panel reactive T cell’ (PRT) score is also independent of a patients sensitisation status [250, 
354].  However these two groups did report a correlation between PRT and HLA mismatches, 
previous transplants and being female, which was not found in this current study.  One of the 
strongest correlations reported was between IFNγ production and length of time on 
dialysis[251].  Due to difficulty in obtaining complete historical dialysis records for all our 
patients we were unable to assess this in our group of patients.  The detection of IFNγ 
responses, or indeed other cytokines, following stimulation by antigens to which a patient has 
not previously been exposed is not unexpected as it has been estimated that 10% of mature 
naïve T cells in circulation exhibit cross-reactivity against HLA molecules to which they have 
not previously been exposed [240, 355, 356]. 
274 
 
It is perhaps not surprising that sensitisation as measured by HLA antibody production is not 
associated with T cell reactivity, as both the original IFNγ ELISPOT and our T cell assay are 
observing early cytokine production and therefore are likely to be detecting direct and possibly 
indirect alloresponses rather than just the indirect T cell responses required for allo antibody 
production.  Najafian et.al. and Poggio et.al. have both reported an alternative IFNγ ELISPOT 
assay which detects indirect T cell reactivity via stimulation with donor HLA derived peptides 
[254, 255], however whilst both associate post-transplant T cell reactivity with poor renal 
function and chronic allograft nephropathy, neither reported an observed relationship with 
HLA specific antibody production. 
The cytokines tested for in this assay included IFNγ, TNFα, IL-2, IL-4, IL-5, IL-10 and IL-17, 
although due to lack of detection in any test, including all the positive controls, meant that IL-4 
could not be included in the analysis.  Two of the most commonly detected cytokines were 
TNFα and IL-10, often together but also individually.  As discussed previously the presence of 
TNFα could be due to activation of naïve T cells or memory Th1 cells in response to TCR 
ligation, or due to non allospecific activation of monocytes.  In the initial results from 
experiment 3 it appeared that maximal TNFα production was being detected in the wells 
presenting HLA mismatches to which the recipient was previously sensitised and therefore 
suggested that it may be being produced in an allospecific response by T cells.  However 
continuation of the assay with a further 30 pairs showed that TNFα production was a little 
more non-specific, appearing even in the test wells of unsensitised patients.  No correlation 
between TNFα production and either presence of repeat mismatches or HLA antibody 
sensitisation could be found.  
Comparison of the responses seen with donors and the respective third parties shows that the 
profile of cytokines produced in response to stimulation is very similar.  This is in agreement 
with reports from Hricik et.al. [246] that numbers of IFNγ producing T cells were similar in 
response to both donor and 3
rd
 party, indeed in their study it was the number of IFNγ 
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producing cells in response to the 3
rd
 party stimulators, not the donor stimulators, that showed 
statistical significance with acute rejection post-transplant.  It is possible therefore that 
detection of cytokine responses after allo stimulation is more a reflection on immune reactivity 
status that donor specific reactivity.  Whilst, as previously discussed, a number of studies have 
correlated the number of IFNγ producing cells with both acute rejection episodes post-
transplant and renal function, as measured by creatinine or glomerular filtration rates, at 3 and 
6 months, none to this authors knowledge has provided a definition of ‘acute rejection 
episode’ or described the nature of the rejection, defining it as cellular or antibody mediated 
or both.  In the report by Hricik et.al. [246] 29% of the transplanted patients included were 
sensitised, producing HLA specific antibody, although it is not reported if these antibodies 
were donor specific, nor were the crossmatch results reported, therefore it is possible that 
AMR could be the cause of the reported acute rejection episodes.  A number of the other 
studies included patients in whom antibody removal was required to facilitate transplantation, 
however the nature of acute rejection episodes reported post-transplant was not 
documented.  So whilst numbers of IFNγ producing T cells in response to stimulation may be 
indicative of future acute rejection episodes there is not enough reported data to indicate that 
these patients would benefit from immunosuppressive therapy aimed at the T cell or humoral 
components of the immune response. 
Whilst the results from all 30 pairs were indicative of the ability to detect cytokine responses 
on stimulation, it is the results from the 14 pairs who went on to be transplanted that yield the 
most direct information regarding cytokine production and clinical outcome.  Cytokine analysis 
in our group of 14 patients who went on to be transplanted with an organ from the donor 
providing the stimulator cells in the assay showed some interesting results.  3 of these patients 
went on to suffer TCMR episodes, whilst 11 showed no TCMR episodes, however 2/11 did 
suffer antibody mediated rejection (AMR) episodes, probably related to the fact they were HLA 
antibody incompatible transplants.  Overall the TCMR group produced a wider range of 
cytokines compared to the non-TCMR group.  4/11 non-TCMR group produced no cytokines on 
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stimulation, of the remaining seven, 6 produced very limited cytokine responses with TNFα 
and IL-10 being the most commonly detected cytokines, with only 1 producing a wider 
response.  Of note, only 1/3 TCMR group produced IFNγ on stimulation compared to 2/11 non-
TCMR patients, neither of which received Campath or other lymphoablative induction therapy, 
which would have questioned the validity of this observation.  Comparison of the 
characteristics of the 14 patients who were tested and subsequently transplanted shows a very 
immunologically diverse group.  The three patients with TCMR were very varied, all were 
sensitised as defined by the detection of HLA specific antibody on serum screening, one 
received an HLA identical cadaveric graft, one being apparently unsensitised to the donor and 
receiving an ABO incompatible graft and one sensitised patient who received an HLA 
incompatible graft following antibody removal with a donor to whose mismatches they had 
previously been exposed.  In the 11 non-TCMR group, 3 patients were sensitised and received 
HLA incompatible grafts, following antibody removal, from donors to whose HLA mismatches 
they had previously been exposed, one also required HLA antibody removal but the 
mismatches presented by the donor were not repeats from previous sensitising events and 
seven were unsensitised patients receiving HLA and ABO antibody compatible grafts.  
Therefore it could be concluded that previous HLA mismatches and HLA antibody production 
are not indicators of future TCMR episodes alone. 
Whilst TNFα was universally detected in the TCMR group, it was also detected in 4/11 non-
TCMR group, so could not be significantly correlated to post-transplant outcome in relation to 
TCMR episodes.  The finding of TNFα and IL-10 being produced in the same test wells is 
somewhat confusing as TNFα is a classical pro-inflammatory cytokine and IL-10 an anti-
inflammatory cytokine, the production of which is reported to inhibit TNFα production [357].  
Both are produced by activated monocytes but also by different T cell populations, with TNFα 
being associated with Th1 responses and IL-10 with Th2.  The cytokine profiles observed don’t 
appear to fit with any typical Th1 or Th2 pattern, where the detection of IFNγ might be 
expected to be accompanied by IL-2 and TNFα, signifying a Th1 type response, whereas IL-4, IL-
277 
 
5 and IL-10 might signify a Th2 response.  This highlights the complexity of the responses 
generated and the fact that multiple cell types might be involved.  It is virtually impossible to 
dissect out which cells types are being activated using cytokine analysis alone, more detailed 
flow cytometric analysis of the cultured cells could possibly elucidate the different cell types 
involved and may be of interest in future work. 
IL-10 has previously been associated with graft acceptance and stable function.  Higher 
numbers of CD4+ IL-10 producing cells have been associated with stable graft function in lung 
transplantation [358], renal transplantation [247] and in the absence of graft versus host 
disease in bone marrow transplant recipients [359].  It has been suggested that a higher ratio 
of IL-10 producing cells to those producing IFNγ as measured on ELISPOT in response to donor 
specific stimulation, is an indicator of stable graft function and low IL-10 producing cell 
numbers associated with acute rejection [247].  Individuals can be divided into high and low 
producers of certain cytokines, including IL-10, by analysis of single nucleotide polymorphisms 
(SNPs) in the promoter regions of the cytokine genes.  There is a SNP at -1082 in the IL-10 
gene, with the -1082G being associated with higher IL-10 production and -1082A with lower 
production [271].  It has been reported that patients with the higher producing genotype are 
protected from chronic rejection in comparison with the lower producing group [271].  
However other studies have demonstrated that high levels of IL-10 in the urine and plasma of 
transplant recipients is associated with development of renal allograft rejection [360].  In 
addition analysis of intrarenal mRNA expression of the gene encoding IL-10 found a correlation 
between high levels of mRNA and development of acute rejection [361].  Several cell types 
produce IL-10 including activated monocytes, regulatory T cells and Th2 cells [362, 363].  IL-10 
is the main cytokine produced by both Th2 and regulatory T type 1 (Tr1).  In addition activated 
Tr1 cells will produce transforming growth factor – beta (TGF-β) and activated Th2 cells would 
produce IL-4 and IL-5 [363, 364].  In our assay IL-10 production was only accompanied by IL-5 
in 5 of the 39 IL-10 positive tests, so these could be due to Th2 responses.  Unfortunately TGF-
β was not included in our cytokine testing panel so we cannot draw conclusions as to the origin 
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of the IL-10 with regard to Tr1 cells, but can assume that not all the incidences of IL-10 are due 
to Th2 production.  IL-10 production within the transplanted group did not appear to correlate 
with TCMR, with 2/3 TCRM group and 4/11 non-TCRM group producing IL-10 on stimulation. 
None of the transplanted patients produced an IL-5 response in conjunction with IL-10, so it is 
unlikely to indicate Th2 activation. 
Our finding that IFNγ production did not appear to be associated with TCMR episodes post-
transplant is in agreement with other reported findings that IFNγ production is not a positive 
indicator of rejection in all cohorts.  Two retrospective studies  using the IFNγ ELISPOT failed to 
find an association with acute rejection episodes, however this is thought to have been due to 
the treatment of patients with ATG pre transplant, which would inhibit a T cell response [252, 
253]. Analysis of cytokines in the serum of patients post-transplant by Sadeghi et.al. [265] 
found serum levels of IFNγ were significantly elevated at 24 months post renal transplant in 
patients without any apparent rejection episodes compared with both healthy controls and 
chronically rejecting patients.  Ghafari et.al. [365] also found that serum levels of IFNγ did not 
correlate with episodes of acute rejection within the first month when measured pre 
transplant and at 7 and 14 days post-transplant. 
Of all the cytokines analysed in the transplanted patients in this study the striking difference 
between the two groups was the production of IL-17, where all 3 TCMR patients produced IL-
17 on stimulation compared to only 1 of the non-TCMR group.  The correlation of the 
detection of IL-17 with an episode of biopsy proven TCMR was statistically significant, with a p 
value of 0.0027.  The numbers on which this analysis is based are small, however the strength 
of this finding cannot be dismissed on this basis.  Whilst, as expected, the responses to both 
the donor and 3
rd
 party stimulators were similar for the majority of the cytokines detected in 
these patients, IL-17 was only produced in the donor specific wells and not the third party.  In 
addition the profile of production was the same for all three patients, where IL-17 did not 
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become detectable until day 3 and then remained so until day 5.  In two of the three patients 
this was also accompanied by IL-2 production.   
Of note, results found in the original development experiment 3 also detected a patient who 
produced IL-17 at day three, this time in response to class II stimulation.  This data has not 
been included in the analysis for the transplanted patients due to the differences in set up and 
cytokines analysed.  However this patient was also transplanted with a kidney from the donor 
used as a stimulator and he too went on to suffer an episode of TCMR in the early post-
transplant period.  Of the other two patients tested in that set of experiments, who did not 
produce IL-17 at any time point, one went on to also receive a transplant from their respective 
stimulator donor and whilst they suffered multiple episodes of AMR, no TCMR could be 
detected on biopsy.  If the results from these two patients are also included in the analysis the 
p value, from Fisher’s exact test, becomes even smaller at p= 0.0021. 
As discussed in the introduction IL-17 is a relatively newly identified cytokine and its main 
producing cell, Th17, even more recently defined.  Initially it was reported that T cell 
production of IL-17 was limited to just CD4+ helper T cells, however mounting evidence has 
been published to suggest that CD8+ cytotoxic T cells are equally capable of producing IL-17 on 
stimulation [366].  In addition, Shin et.al. reported that only T cells of the memory CD45RO+ 
phenotype are capable of producing IL-17 as they found no expression of IL-17 mRNA by naïve 
CD45RA+ cells on stimulation [366].  When separated CD4+CD45RO+ and CD8+CD45RO+ T cell 
populations were cultured and stimulated by ionomycin/PMA the memory CD4+ T cells were 
able to respond without further signals, however the memory CD8+ T cells appeared to require 
further costimulatory signals, possibly from CD4+ T cells, APCs or NK cells, although the exact 
nature of these signals could not be specified [366].  In addition to memory T cells, NK cells, γδ 
T cells and neutrophils have also been associated with IL-17 production.  
Initial work investigating the conditions required for induction of a naïve T helper precursor 
cell to commit to becoming a Th17 cell was carried out using mouse derived cells.  It has been 
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commonly reported that the naïve CD4+ T cells require exposure to TGF-β, IL-21 and dendritic 
cell-derived IL-6 in order to differentiate into an IL-17 secreting Th17 cell [367-369].  Some 
groups later confirmed these requirements in human naïve T cells, showing that TGF-β, IL-23 
and/or IL-21 can lead to differentiation into IL-17 producing cells [370-372].  However more 
recently published work reported by Evans et.al. [373] suggests that human naïve CD4+ T cells 
require different conditions before commitment to the Th17 line.  They reported that 
stimulation of naïve T cells in the presence of TGF-β and IL-6 does not cause differentiation of 
these cells to Th17, and the presence of TGF-β may in fact inhibit their generation.  They 
instead demonstrated that generation of these cells requires stimulation through the T cell 
receptor as well as interaction with Toll-like receptor activated monocytes.  They also report 
that methods used to generate Th17 cells from naïve T cells failed to stimulate the production 
of substantial numbers, <2%, and that the greatest numbers of Th17 cells, up to 28% of the 
population, were generated following stimulation of memory T cells via their TCR and 
interaction with activated monocytes.  Since prior to stimulation <0.5% of the population were 
IL-17+ it is suggested that the Th17 cells came not from expansion of an existing population 
but from directed differentiation into IL-17 producing Th17 cells from memory T cells.  Of note 
the culture period used where peak responses were seen following interaction with monocytes 
and stimulation of the TCR by anti-CD3 mAb was 3 days. 
All three of the patients who suffered TCMR produced IL-17 in response to donor HLA class I 
stimulation which was first detected at day 3 of the assay.  From this one possible scenario 
could be drawn.  As discussed previously TNF-α production was also noted, this can be 
produced in abundance by activated monocytes and it’s detection early in this assay could 
indicate that the recipient monocytes present in the culture are being activated by some 
aspect of the donor lysate being introduced into the well, they may well be taking up and 
processing the donor HLA class I molecules and presenting them in the context of self HLA 
class II on their surface.  Memory T cells present in the culture which possess a TCR 
complementary to donor HLA derived peptide in self HLA class II molecules on the surface of 
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the monocyte, may become activated and ushered down the route of Th17 differentiation by 
both ligation of their TCR and further interaction with activated monocytes.  The data reported 
by Evans et.al. [373] would suggest that this could indeed lead to IL-17 production being 
detectable at day 3.  This would also suggest the presence of donor specific memory T cells 
capable of an indirect response in the patient.  The mean time to biopsy proven TCMR episode 
in this group of three patients is 11.3 days, with a range of 6 – 15 days, it is likely that as all 
these were ‘for-cause’ biopsies that the initiation of the rejection episode was earlier than 
these timings would suggest, indicating that all three suffered early acute rejection potentially 
due to activation of memory T cells. 
Another possible explanation is that the IL-17 is being produced by activated memory CD8+ 
cytotoxic T cells, potentially recognising the donor HLA Class I molecules present in the test 
well directly, and receiving co-stimulatory signals either directly from interaction with other 
cells in the culture or from cytokines being produced by other cells present.  If this were the 
case however it may be expected that a response would be seen prior to day 3. 
Only 1 patient, patient 21, who had TCMR on biopsy produced detectable IFNγ in addition to 
IL-17 and other cytokines.  This is of interest as Harrington et.al. have reported that IFNγ, when 
added to in vitro culture, inhibits the generation of Th17 cells [274] and therefore it might be 
expected that both may not be found in the same culture.  This again highlights the complexity 
of defining the exact cell types involved in this assay. 
One patient in the transplanted group who did not suffer an episode of TCMR also produced 
low but detectable levels of IL-17 on stimulation.  The timescale of this response was however 
completely different from that seen in the TCMR group, with the IL-17 response being 
detected at 24 hours only and not being detectable at later time points.  It is possible that this 
detection was due to non-specific cytokine production, an artefact of the cytokine Luminex 
assay or that the patient did indeed suffer a sub-clinical episode of TCMR for which a biopsy 
was not taken. 
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Since the identification of the cytokine IL-17 a number of groups have investigated its’ role in 
rejection of solid organ transplants.  Strehlau et.al. investigated the intragraft expression of a 
number of immune activation genes in 60 renal allograft biopsies, among the cytokines 
investigated IL-17 was shown to be expressed solely in samples taken from rejecting organs, 
but it was not a reliable indicator of all rejection episodes as it was not found to be expressed 
in all rejecting samples [374].  However it is not clear from the report if diagnoses of rejection 
on all the biopsies were T cell mediated.  Following this study, Van Kooten et.al. demonstrated 
that the cytokine IL-17 could be detected by immunofluorescent staining in all of the renal 
biopsies studied compared to none of the biopsies taken from healthy control or pre 
transplantation [277], in addition they demonstrated that the expression of IL-17 protein was 
significantly increased in the infiltrating cells in acute TCMR.  More recently Loverre et.al. [375] 
demonstrated that in 50 renal allograft biopsies, the presence of IL-17 secreting cells was 
significantly found in those where acute TCMR had been diagnosed compared to those where 
antibody mediated rejection, BK nephropathy and calcineurin inhibitor nephrotoxicity had 
been diagnosed.  Additionally, identification of the cell source of IL-17 indicated that 80% of 
the IL-17 producing cells present in the biopsy sample were CD4+ Th17.  This confirms 
numerous previous reports of the involvement of IL-17 producing CD4+ Th17 cells in the 
pathogenesis of acute TCMR in renal transplants [376-378].  Th17 cells have also been 
implicated to have a pathogenic role in lung [379, 380], liver [381], small bowel [382] and heart 
[281] allograft rejection.  The majority of studies implicating IL-17 and Th17 cells in allograft 
rejection have concentrated on the detection of IL-17 protein or mRNA on biopsy.  It would be 
of interest on expansion of this assay to a wider test group to assess IL-17 production on 
allograft biopsy in comparison to production in the pre-transplant assay. 
IL-17 is an overarching term used to describe a family of structurally homologous cytokines IL-
17A – IL-17F [383].  Human Th17 cells have been shown to produce two isoforms of IL-17, IL-
17A and IL-17F [260].  In a number of studies using animal models it is IL-17A, not IL-17F, that 
has been found to be implicated in transplant rejection [260] and inflammation [384].  The 
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cytokine detection kit used in this assay has been confirmed to detect IL-17A only, with 
negligible cross-reactivity with other isoforms of IL-17 (personal communication with R&D 
systems). 
One patient in the transplanted TCMR group received an HLA identical kidney.  She had 
received one previous renal transplant and was sensitised, producing a wide range of HLA 
specific antibodies but due to the lack of HLA mismatches, based on 2 digit HLA typing at all 
loci, between her and the donor it was assumed that we would not see a T cell response on 
assay, and that TCMR post-transplant was unlikely.  However production of a number of 
cytokines was observed after donor stimulation, including IL-17 at day 3, and TCMR was 
reported on biopsy post-transplant.  There are two possible explanations for this, the first is 
that there were differences in the minor histocompatibility antigens being presented by the 
donor, or that at a higher resolution there were differences in the HLA antigens between 
donor and recipient.  Minor histocompatibility antigens (mHA) are peptides derived from cell 
proteins encoded by polymorphic genes, the presentation of which is restricted to specific HLA 
molecules [385].  The Collaborative Transplant Study reported that the 10 year graft survival 
rate for renal transplants between HLA identical siblings stands at 82.5%, and whilst some 
losses will be due to non-immune factors, some are believed to be due to immunologically 
driven loss, with Terasaki reporting that up to 56% of the losses could be due to immune 
mediated causes [386, 387].  It has been suggested that responses to the mHA may be the 
cause of at least some of these graft losses [388, 389].  Mismatches in the mHA between donor 
and recipient in combination with the correct HLA antigen required for presentation of the 
mHA could trigger T cell responses [390].  There are now a total of 10 Y-chromosome encoded 
and 14 autosomal encoded recognised mHA [391].  Of note, 3 of the HLA antigens involved in 
our pair include HLA A1, B8 and B44, all of which are able to present various mHA.  Two of the 
potential mHA are A1/HY and B8/HY which could be discounted as the donor and recipient 
were both female and therefore Y chromosome encoded mHA are not relevant.  There are 5 
HLA B44 restricted mHA, all of which have tissue distribution limited to hematopoietic cells 
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and B cells, so whilst they may be relevant to the T cell culture assay as the donor HLA 
molecules are derived from some of these cells, it is unlikely that they would be relevant in a 
solid organ transplant.  This leaves one potential mHA, HA-3, which is restricted to 
presentation by HLA A1 and has broad tissue distribution.  Typing for mHA has not been 
performed in this study so differences between donor and recipient cannot be confirmed, but 
it remains a possible target for T cell activity.   
Another theory behind the observed reactivity could be due to mismatches at a higher 
resolution.  The most obvious target when observing the HLA types involved would be HLA 
B44.  HLA B*44:02 and *44:03 are the two most commonly represented of the B44 group of 
antigens in the population.  They differ by only one amino acid at position 156, with B*44:02 
having an aspargine and B*4403 having a leucine at this position.  This difference is located on 
the α2 helix, and whilst it doesn’t much alter the repertoire of peptides that can be presented 
by the B44 molecules, it does render them targets for CD8+ T cells which are able to 
discriminate between the two types [392].  However higher resolution typing at HLA B44 
revealed both donor and recipient to be HLA B*44:02.  Complete high resolution typing for the 
pair was not performed, so it cannot be discounted that there were other unrevealed 
mismatches at the 4 digit level that could be responsible for the reactivity observed. 
The discovery that in our population IL-17 production in response to donor stimulation pre-
transplant correlated well with episodes of TCMR post-transplant indicates that this assay 
could be used as a tool to aid decisions regarding pre transplant induction therapy.  In 2010 
our renal unit introduced a three tier risk based immunosuppressive protocol.  Patients were 
deemed to be at higher risk of rejection when they were being transplanted in the presence of 
donor specific antibodies detected on Luminex single antigen bead screening, regardless of the 
crossmatch result, with those presented with repeat mismatches as being at greatest risk.  
These patients are now given Campath as part of their induction routine.  Introduction of this T 
cell assay could help identify which patients are at need of Campath induction therapy and 
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which would potentially gain no benefit from this treatment.  Whilst this could initially be for 
the patients involved in HLA antibody incompatible transplants, as the data showed, 2/3 
patients with TCMR did not fall into this category, therefore expansion of the test to a wider 
group of patients may also prove clinically useful.  Unfortunately due to the culture time 
required before an IL-17 response could be detected it would not be suitable for pre transplant 
assessment for deceased donor organs where rapid implantation is required.  Additionally, 
since the IL-17 production in these cases was donor specific a panel reactive T cell test, akin to 
that reported by Heeger et.al. for IFNγ, would also potentially not be of benefit. 
If further work did indeed confirm that IL-17 detection in this assay correlated with TCMR 
episodes in a larger study it could be possible to transfer this knowledge to a different 
platform, such as ELISPOT.  However if the theory that activated monocytes are required to 
initiate Th17 responses is true then it would be necessary to include monocytes in the ELISPOT 
assay, which has been reported to be avoided by some groups by removal of adherent cells 
prior to final ELISPOT testing [389]. 
Overall the results indicate that the presence of memory T cells as detected by IL-17 
production on stimulation correlates with the development of TCMR post-transplant.  
However the results achieved across all patients do not appear to correlate with previous HLA 
exposure or the presence of DSA.  This would suggest that the prediction of either direct or 
indirect T cell memory based on either repeat mismatching or the presence of DSA is 





5 Final Conclusions and Future Aims. 
The hypothesis put forward at the start of this study was a simple one, suggesting that the 
outcomes of renal transplants across HLA antibody incompatibilities would be negatively 
influenced by immune memory.  Patients presented with repeat mismatches to which they 
had made antibody being more likely to demonstrate both cellular and humoral memory 
responses, indicated by earlier and more vigorous rejection episodes, than patients in whom 
donor specific antibody could be detected but who were not presented with a repeat 
mismatch.  It was assumed that the presence of donor specific antibody prior to transplant 
indicates previous activation of both the cellular and humoral immunity via the indirect 
pathway, and that by re-challenging a recipient with the same mismatched antigen both these 
arms of the adaptive immune response would be rapidly re-activated, leading to early 
rejection.  The presence of DSA without a repeat mismatch was assumed to be due to antibody 
epitope cross reactivity from previous sensitising events that would not necessarily indicate 
the presence of T cell memory.  This however did not account for the presence of direct 
alloreactive memory T cells, which would not be expected to be involved in the alloantibody 
response, but that could still initiate early rejection.  When analysing the time to 1st BPRE the 
mean time in all patients presented with a repeat mismatch was considerably shorter 
regardless of the antibody status, in part this could be accounted for by the presence of direct 
memory T cells not indicative of antibody presence.  There may also be a cumulative effect of 
both the number of repeat mismatches and the number of specificities to which DSA is 
generated.  When graft survival in the DSA positive repeat mismatch positive group were 
compared dividing them into class I only, class II only and both class I and II, the single classes 
showed 100% graft survival over the study period and it was those patients presented with 
both class I and II that showed poor 5 year graft survival rates.  This could be an effect of both 
more mismatches and antibody clones, in addition to the likelihood of direct CD4+ Th cell 
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memory to the class II mismatched antigens activating both the humoral arm and the direct 
cytotoxic T cells specific for the class I mismatches. 
I had hoped that by combining results from the antibody tests and the T cell assay it would be 
possible to link both arms of the immune response, however using the assay methods 
described in this thesis it is clear that there is only a very limited relationship between 
antibody production and T cell memory.  Whilst I theorise that the T cell assay developed could 
be detecting a memory response from the indirect Th17 cells, direct alloresponses could also 
be occurring accounting for some of the other cytokine production.  In a wider group of 
patients it may be possible to link the production of other cytokines with both direct and 
indirect T cell activation. 
The production of IL-17 on stimulation in vitro appears to correlate closely with TCMR post-
transplant, if this cytokine is being produced by Th17 cells then it is unlikely that it would 
correlate with humoral immunity.  Th2 type T cells are most closely associated with a humoral 
immune response and none of the cytokines tested for, that were typical of a Th2 response, 
appeared to correlate with humoral immunity in terms of recipient antibody production.  IL-4 
production by Th2 cells is closely linked to B cell proliferation and Ig class switching, it is 
therefore unfortunate that the IL-4 detection in our assay system appeared to fail, either due 
to kit failure or potentially due to a lack of Th2 cytokine producing cells in the isolated PBMCs.  
Since IFNγ is also not a classical Th2 cytokine it is possible that other reported assays of T cell 
memory, which also found no association with humoral immunity are being skewed by the 
cytokine profiles being selected.  The cytokines produced by the different T cell subsets are 
believed to influence each other’s action, it may only be truly possible to observe and link T 
cell memory with antibody status by isolating and assaying Th2 cells alone without the 
interference of other cytokine producing T cell groups. 
288 
 
Part of the rationale behind the initial hypothesis was that both T cell and antibody mediated 
rejection would be influential on outcomes of HLA antibody incompatible transplants.  
However as the breakdown of aetiology of BPRE in the different patient groups showed, in the 
antibody positive (DSA or non-DSA) repeat mismatch positive groups the proportion of 
antibody mediated BPRE was high, and in the DSA positive group exceeded the TCMR quite 
considerably.  One possible explanation could be that the Th2 memory T cells required for 
naïve B cell activation, along with the upregulation and honing of the antibody response, are 
not in fact in the graft but isolated in the secondary lymphoid organs interacting with both 
naïve and memory B cells in newly formed germinal centres and therefore not appearing on 
biopsy as a classical T cell mediated rejection episode, but still being highly influential in the 
antibody response and rejection episode. 
The presence of donor specific Th2 cells have been linked to chronic rejection and since the 
current thinking is that the majority of chronic graft damage is due to the action of DSA this 
could be due to the link between Th2 and DSA production. 
In terms of T cell memory it has been noted that CD4+memory T cells can have a Th2 bias 
following re-stimulation so increasing antibody responses [226], which could be highly 
influential on antibody production post-transplant.  D’Elios et.al. used cytokine staining on 
renal allograft biopsies from patients with acute and borderline rejection to characterise the 
subsets of Th cells and noted that the majority of graft infiltrating Th cells are Th1, with Th2 
cells being extremely rare [272]. 
With regards to the presence of DSA and repeat mismatches, overall it is difficult to separate 
the effect of antibody strength and the presence of repeat mismatches on either overall graft 
survival or BPRE post-transplant.  The DSA positive repeat mismatch positive group had 
significantly higher DSA levels in terms of strength on testing and the need for antibody 
removal pre transplant.  When observing the effect of the strength of antibody in terms of 
289 
 
FXM RMF or MFI on beads on graft failure due to rejection or occurrence of AMR, only the T 
cell RMF values pre-treatment and pre transplant showed some correlation, although not in all 
cases.  Both B cell RMF and bead MFI levels showed only very limited association, certainly not 
enough to rule a transplant as being at too high risk of failure to be attempted.  This suggests 
that the strength of antibody prior to transplant may not be a useful sole prognostic indicator 
for post-transplant outcomes.  However, when graft survival was analysed on the basis of the 
requirement for antibody removal pre transplant it was found that those requiring antibody 
removal did have decreased graft survival in comparison to those who did not, indicating that 
having any strength of positive FXM pre-treatment was an automatic risk factor in terms of 
failure.  However, the group of DSA positive patients requiring antibody removal included a far 
higher proportion of patients who were also presented with a repeat mismatch.  When all 
groups were combined based on the presence of a repeat mismatch, those that were 
presented with a repeat mismatch had worse overall survivals, however once again the 
proportion of patients with additional DSA was greater in the repeat mismatch group.  
Therefore potentially a combination of repeat mismatch with DSA provides the worst outcome 
and should be treated as those at the greatest risk of graft failure due to rejection, with 
additional caution given to those where there is a combination of both HLA Class I and II 
mismatches.  In terms of the speed of a rejection event following transplant all patients 
presented with a repeat mismatch had the fastest time to 1st BPRE, regardless of the antibody 
status, with the exception of one patient in the antibody negative repeat mismatch positive 
group, the fastest time to BPRE was seen in the DSA positive repeat mismatch positive group.  
Neither the presence of DSA nor the requirement for antibody removal influenced the time to 
first BPRE, so it can therefore be concluded that the main factor, under assessment, 
influencing the speed of a rejection episode is the presence of a repeat mismatch, possibly 
indicating the involvement of memory T cells from the direct allorecognition pathway. 
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It is clear from both the antibody related and the T cell assay results that immune memory to 
HLA antigens is not as simple as the original hypothesis suggests and that potentially the T cell 
memory response and the antibody response do not appear to be as closely linked as we first 
hypothesised, with responses in the T cell assay system not correlating with the production of 
HLA specific antibody or the presence of repeat mismatches.  Additionally, whilst the donor 
specific antibody positive with repeat mismatch group had the worst post-transplant 
outcomes, this could not categorically be separated from the amount of antibody present pre-
transplant.  Since the requirement for T cell help for memory B cell responses on stimulation is 
an unknown quantity and may in fact not be required  [38], in addition to the fact that the 
antibody secreting plasma cells are long lived and continuously producing antibody at some 
level this is perhaps not a surprising conclusion. 
Longer term follow up of these patients may provide some more conclusive results as to the 
effect of repeat mismatches on graft survival.   
The time to rejection is shorter in those patients showing sensitisation to HLA through 
antibody production and being presented with a repeat mismatch, indicating that at some 
level immune memory in either arm of the adaptive response can be predicted through the 
presence of repeat mismatches. 
I have developed a process and accompanying repertoire of tests to be employed to assess the 
ability to remove donor specific antibody to allow antibody incompatible transplantation to 
proceed, some of which detected can provide a limited ability to predict post-transplant 
outcome and identify patients at risk of early rejection episodes and graft failure. 
I have also developed an assay which appears, in the small numbers presented, to detect the 
presence of donor specific memory T cells pre-transplant capable of eliciting TCMR post-
transplant with 100% accuracy, interestingly in patients who may not necessarily have been 
thought to possess them.  Further development of this assay and assessment in larger patient 
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cohorts, potentially in all living donor renal transplants, will be an important continuation of 
this project. 
Investigation into the isolation of Th2 cells and a separate assay system to detect Th2 memory 
cells capable of driving the antibody response may allow closer linking of T cell and humoral 
memory.  With expansion of the starting hypothesis to suggest that the presence of Th2 
memory T cells, potentially primed by repeat mismatches, may be more indicative of poorer 
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7 Appendix 1. 
The following tables present the raw MFI values achieved with the beads for each test 
cytokine, in each testing combination at each time point sampled for the two cells from 
healthy volunteers tested in the initial experiment 1, described in T cell Chapter 4. 
Experiment 1 – Volunteer Test Cell 1 – Raw Cytokine MFI Results. 








Neg Control 7.5 5 1 9317 3637.5 
CD3/28 0.2 129 153 29 7336.5 5004.5 
CD3/28 0.1 12 14 3 7793 4033 
CD3/28 .05 13.5 26.5 4 8350.5 3194 
CI neat 7 8 1 7726.5 8454 
CI 1:10 6 5 1 7291 2956 
CI 1:100 7 6 1 7846 3323 
CI neat + CD28 6 6 1 6395 4076 
CI 1:10 + CD28 6 7 1 7162 4004 
CI 1:100 + CD28 7 6 1 6736 5032 
CII neat 6.5 9 5 7740 9965 
CII 1:10 6 6 1 6557 2981.5 
CII 1:100 5.5 5 1 7334 2504 
CII neat + CD28 7.5 7 1 6626 6628.5 
CII 1:10 + CD28 7 6 0 6852.5 3538 
CII 1:100 + CD28 5 5 1 8090 3120 
CD28 neat 8 6 1 8603 5822.5 
CD28 1:2 6 5 1 8421.5 3193.5 
CD28+ CI + CII 10 8 1 7639 10754.5 








Neg Control 9 6 1 8414 3160.5 
CD3/28 0.2 528 184.5 73 7902 5575 
CD3/28 0.1 19 27.5 4 7933.5 4279 
CD3/28 .05 29 33.5 9 8960 3233 
CI neat 10 7 1 8205 9428 
CI 1:10 6 5.5 1 7200 3384.5 
CI 1:100 7 5 1 7790 3299 
CI neat + CD28 6.5 6 1 6096 4306 
CI 1:10 + CD28 8 7 1 7745 4516 
CI 1:100 + CD28 7.5 6 1 6724 6096 
CII neat 8 7 4 7720 9784 
CII 1:10 7 5 1 8442 3000 
CII 1:100 6 6 1 9972.5 2834.5 
CII neat + CD28 8 7 1 6347 6557.5 
CII 1:10 + CD28 7 5.5 1 6732.5 3757 
CII 1:100 + CD28 6 5 1 6611 3355 
CD28 neat 6.5 5 1 7492 5587 
CD28 1:2 6 6 1 6618 4527.5 
CD28+ CI + CII 11.5 8 1 6011 10691 
CD28 1:100 + CI+CII 14 8 1 6496 10879 
h o u Neg Control 7 6 1 8690 2633.5 
315 
 
 Test Day Sample IFN-g IL-17 IL-5 IL-8 TNF-a 
CD3/28 0.2 6183 495 1133 6352.5 5788 
CD3/28 0.1 363.5 216.5 39 7450 3281.5 
CD3/28 .05 166.5 164.5 72 7558 2619 
CI neat 8 19 1 4064 6992 
CI 1:10 6.5 5 1 6420.5 2764.5 
CI 1:100 6 5 0 7914 2994 
CI neat + CD28 6 7.5 1 6263.5 3323 
CI 1:10 + CD28 6 6 1 8702.5 3797 
CI 1:100 + CD28 6 6 1 6401 5007 
CII neat 6 7 4 7049.5 7206.5 
CII 1:10 5 5 1 7033 2387 
CII 1:100 6 6 1 8646 2243.5 
CII neat + CD28 6 6 1 5059 5384 
CII 1:10 + CD28 5.5 5 0 6897 3142 
CII 1:100 + CD28 6 5 1 7645 2901 
CD28 neat 5 4 0 927 735 
CD28 1:2 5 5 0.5 1256.5 814.5 
CD28+ CI + CII 6 6 0 806.5 1581 








Neg Control 6 6 1 8597 2197 
CD3/28 0.2 8798 921.5 1729.5 6906 4600 
CD3/28 0.1 442 299 46 8088 2179 
CD3/28 .05 165 301.5 110 7796 2297 
CI neat 6 37 1 2280.5 1789 
CI 1:10 6 7 1 7843 1854 
CI 1:100 6 5 1 2230.5 2046.5 
CI neat + CD28 6 8 1 7692 2742 
CI 1:10 + CD28 5 5 1 8009 2820 
CI 1:100 + CD28 7 6 0 4522 3768 
CII neat 8 14 4 7001 6267 
CII 1:10 6.5 6 1 7293 2275.5 
CII 1:100 9 9 1 8271 1855 
CII neat + CD28 7 14 1 8182.5 4985 
CII 1:10 + CD28 5 4.5 1 379.5 607 
CII 1:100 + CD28 6 5 1 7716 1809 
CD28 neat 6.5 11 1 7629.5 3977 
CD28 1:2 5 4 0 1219.5 551.5 
CD28+ CI + CII 7 6 0 827 1155 
CD28 1:100 + CI+CII 7.5 5 1 1479 1781 
316 
 
Experiment 1 – Volunteer Test Cell 2 – Raw Cytokine MFI Results. 






no CD28 Neg 7 7 2 22 7 
no CD28 Neg 6 6 1 18 7 
Pos 1 6 9 1 15937 1147.5 
Pos 2 6 11 3 14771 337 
no CD28 CI 6 7 1 15327 482.5 
No CD28 CI 5 13 1 14623 903 
No CD28 CII 6 6 1 14300.5 137 
No CD28 CII 6 8 1 15297.5 755 
No CD28 CI+II 6 8 1 15219 148.5 
No CD28 CI+II 6 7 1 16746 798.5 
Sol CD28 Neg 6 7 1.5 16 7 
Sol CD28 Neg 6 7 1 20.5 8 
Sol CD28 CI 6 7 1 13869 540.5 
Sol CD28 CI 9 11 1 14975 5573.5 
Sol CD28 CII 6 10 0 15608.5 221.5 
Sol CD28 CII 6 8 1 15719 278 
Sol CD28 CI+II 6 7 1 15282 514 
Sol CD28 CI+II 6 11 3.5 14765 274 
PB CD28 Neg 7 7 1 17 8 
PB CD28 Neg 6 7 1 18.5 7 
PB CD28 CI 7 18 1 13941 4655 
PB CD28 CI 7 8 1 14429 2357 
PB CD28 CII 7 11 6 15610 4740 
PB CD28 CII 5 8.5 4 14040 3066 
PB CD28 CI+II 7 7 2 15141 4429.5 






no CD28 Neg 7 7 1 23 8.5 
no CD28 Neg 6 7 1 25 8 
Pos 1 821 1451.5 14370 15367.5 3703.5 
Pos 2 930.5 903.5 8395 16756.5 3189 
no CD28 CI 5 7 1 14475.5 430 
No CD28 CI 5 12 1 15385 749.5 
No CD28 CII 6 9 1 16146 880.5 
No CD28 CII 6 7 1 15972 621.5 
No CD28 CI+II 6 7 1 15630.5 568.5 
No CD28 CI+II 6 9.5 4 14183 264.5 
Sol CD28 Neg 6 7 1 20 8 
Sol CD28 Neg 6 6 1 16 9 
Sol CD28 CI 5.5 7 1 13198 459.5 
Sol CD28 CI 7 22 1 14001 4761 
Sol CD28 CII 7 17 1 15163 1665 
Sol CD28 CII 6 7 1 15481 233.5 
Sol CD28 CI+II 7 7 1 17208 323 
Sol CD28 CI+II 5 8 2 13217 1302 
PB CD28 Neg 6 7 1 20.5 8 
PB CD28 Neg 6 7 1 21 7 
PB CD28 CI 7 16 1 14857.5 3158 
PB CD28 CI 6 11 2 5647 2449.5 
PB CD28 CII 8 14 8 14572 4266.5 
PB CD28 CII 8 14 7.5 14183 3688 
317 
 
Test Day Sample IFN-g IL-17 IL-5 IL-8 TNF-a 
PB CD28 CI+II 6 8 1 15100 1720.5 






no CD28 Neg 6 6 0 12 8 
no CD28 Neg 6 7 1 11 7 
Pos 1 571 1045 10611.5 16688 2803 
Pos 2 612.5 1229 6735 16231 2528 
no CD28 CI 6 11 1 15724.5 655 
No CD28 CI 6 7 1 15349 239.5 
No CD28 CII 6 8 1 16055.5 410 
No CD28 CII 6 10 1 14768.5 498 
No CD28 CI+II 6 11 3 16899 460 
No CD28 CI+II 6 9 2 15423 239 
Sol CD28 Neg 5 6 1 18 7.5 
Sol CD28 Neg 7 7 1 18 8 
Sol CD28 CI 7 14 2 14496 2537.5 
Sol CD28 CI 5 10 1 14860 1058.5 
Sol CD28 CII 6 8 1 15159.5 212.5 
Sol CD28 CII 7 26 1 13727.5 1273 
Sol CD28 CI+II 5.5 7 2 9563 995.5 
Sol CD28 CI+II 6 6.5 1 11.5 8.5 
PB CD28 Neg 7 7 0 9 7 
PB CD28 Neg 6 6 1 11.5 8 
PB CD28 CI 6 34 1.5 14476.5 3173.5 
PB CD28 CI 7 10 1 13971 1729 
PB CD28 CII 7 16.5 13 15179.5 3121.5 
PB CD28 CII 6 19 8 15172 2920.5 
PB CD28 CI+II 6 8 2 16042 1424 





8 Appendix 2  
The following tables present the raw MFI values achieved with the beads for each test 
cytokine, in each testing combination at each time point sampled for the two cells from 
patients tested in the experiment 2, described in T cell Chapter 4. 
Experiment 2 – Test Patients Cells 1 – Raw Cytokine MFI Data. 
Test 








Neg Medium Only, No CD28 6.5 5.0 5.0 1.0 23.0 8.8 
Neg Medium Only, with CD28 6.0 5.5 5.5 1.0 10.5 9.5 






















Negative, cells only, no CD28 6.0 5.0 4.5 1.0 9802.5 125.0 
Negative, Cells only, with 
CD28 6.5 5.5 4.8 0.5 
10253.
0 141.5 










CII mixed beads 5ul, no CD28 6.8 5.0 5.0 1.0 
11048.
5 728.8 
CII mixed beads 5ul, with 
CD28 5.8 5.0 4.0 1.0 9936.5 611.3 
CI+II mixed beads 5ul, no 
CD28 6.0 6.3 5.5 1.0 9866.8 
3368.
3 
CI+II mixed beads 5ul, with 





DR11 2ul, no CD28 7.0 4.8 6.0 0.8 
11325.
3 257.5 
DR11 2ul, with CD28 6.0 5.0 4.5 1.0 
10743.
0 233.8 
DR52 2ul, no CD28 6.0 5.5 5.0 1.0 
10969.
8 286.0 
DR52 2ul, with CD28 6.0 4.5 4.8 0.5 
11130.
8 371.5 
DR7 2ul, no CD28 5.3 4.5 5.0 1.0 
10657.
0 343.8 
DR7 2ul, with CD28 6.0 4.0 5.5 1.0 
10624.
5 218.3 
DR11 10ul, no CD28 6.0 5.0 5.0 1.0 
10119.
0 128.5 
DR11 10ul, with CD28 6.0 5.0 5.0 1.0 
11267.
0 212.5 
DR52 10ul, no CD28 6.0 5.5 5.0 1.0 
11058.
3 427.5 
DR52 10ul, with CD28 6.5 5.0 4.8 1.0 9811.0 466.8 
DR7 10ul, no CD28 6.3 4.5 4.5 1.0 
10763.
5 431.3 
DR7 10ul, with CD28 6.5 4.5 4.5 1.0 
10367.
0 554.0 




Day Sample IFN-g IL-17 IL-2 IL-5 IL-8 TNF-a 
0 
DR11 + 52, with CD28 6.0 4.0 7.0 1.0 9826.5 361.5 
DR7 peptide, no CD28 6.0 5.0 5.0 1.0 9513.0 121.0 
DR7 peptide, with CD28 6.0 5.0 5.0 1.0 9833.5 189.0 
DR17 peptide, no CD28 6.0 5.0 5.0 0.0 
10062.
0 199.0 








Neg Medium Only, No CD28 6.5 4.3 4.5 1.0 10.0 10.0 
Neg Medium Only, with CD28 6.0 5.0 4.5 1.0 10.0 10.0 


























Negative, cells only, no CD28 6.5 4.8 4.8 1.0 
10053.
5 97.8 
Negative, Cells only, with 
CD28 6.5 4.5 5.5 1.0 
10100.
5 98.8 










CII mixed beads 5ul, no CD28 6.0 4.5 5.0 1.0 
10648.
0 442.0 
CII mixed beads 5ul, with 
CD28 6.5 5.5 4.5 1.0 9879.0 402.3 
CI+II mixed beads 5ul, no 





CI+II mixed beads 5ul, with 





DR11 2ul, no CD28 6.0 4.0 5.5 0.5 
11044.
0 156.8 
DR11 2ul, with CD28 6.5 5.3 4.5 1.0 
10817.
8 251.0 
DR52 2ul, no CD28 5.5 4.0 5.0 1.0 
10477.
0 181.3 
DR52 2ul, with CD28 6.5 5.0 5.0 0.5 
10688.
5 278.8 
DR7 2ul, no CD28 6.0 5.5 5.3 1.0 
10141.
3 300.8 
DR7 2ul, with CD28 5.5 5.0 4.0 0.5 
10474.
5 182.8 
DR11 10ul, no CD28 5.0 4.0 1.0 1.0 1836.5 25.5 
DR11 10ul, with CD28 6.0 5.0 4.0 1.0 9803.0 159.5 
DR52 10ul, no CD28 6.0 4.0 5.0 1.0 
10007.
5 297.5 
DR52 10ul, with CD28 6.0 5.5 5.0 1.0 9699.5 342.5 
DR7 10ul, no CD28 5.5 6.0 5.5 1.0 
10500.
0 266.3 
DR7 10ul, with CD28 5.8 4.5 5.0 0.8 9945.3 320.0 
DR11 + 52, no CD28 5.5 9.5 6.0 1.0 
10339.
0 372.0 
DR11 + 52, with CD28 5.0 5.0 7.0 1.0 
10491.
0 270.5 
DR7 peptide, no CD28 6.0 5.0 4.0 1.0 
10201.
5 86.0 






Day Sample IFN-g IL-17 IL-2 IL-5 IL-8 TNF-a 
DR17 peptide, no CD28 6.0 4.0 5.0 1.0 9907.0 160.0 







Neg Medium Only, No CD28 5.0 4.5 4.0 0.5 11.5 8.8 
Neg Medium Only, with CD28 5.0 4.5 4.5 1.0 69.0 9.3 




















Negative, cells only, no CD28 5.5 4.5 5.0 1.0 9593.3 67.5 
Negative, Cells only, with 
CD28 5.5 4.5 4.5 1.0 
10320.
3 66.0 
CI mixed beads 5 ul, no CD28 6.3 7.0 5.0 1.0 9457.5 
1521.
5 
CI mixed beads 5ul, with CD28 6.0 6.5 5.5 1.0 9837.0 
1353.
5 
CII mixed beads 5ul, no CD28 6.5 5.0 4.5 1.0 
10424.
5 290.3 
CII mixed beads 5ul, with 
CD28 6.0 5.0 4.5 1.0 9933.3 279.5 
CI+II mixed beads 5ul, no 





CI+II mixed beads 5ul, with 
CD28 5.5 6.0 5.0 1.0 9735.8 
1041.
5 
DR11 2ul, no CD28 5.3 4.0 5.0 1.0 
10412.
8 113.0 
DR11 2ul, with CD28 5.5 4.5 5.0 1.0 
10646.
0 128.8 
DR52 2ul, no CD28 5.0 4.0 4.5 1.0 
10895.
0 122.8 
DR52 2ul, with CD28 6.0 4.0 5.0 1.0 
10165.
8 153.0 
DR7 2ul, no CD28 6.0 4.5 4.5 1.0 
10009.
0 174.5 
DR7 2ul, with CD28 5.3 4.0 2.5 0.5 5945.5 82.3 
DR11 10ul, no CD28 5.0 4.0 5.0 1.0 
10559.
5 74.5 
DR11 10ul, with CD28 5.0 4.0 5.0 1.0 
10209.
5 103.0 
DR52 10ul, no CD28 5.8 4.0 5.3 1.0 
10335.
3 195.3 
DR52 10ul, with CD28 6.0 4.8 5.5 1.0 
10131.
8 199.8 
DR7 10ul, no CD28 5.8 6.0 5.0 1.0 
10636.
5 231.5 
DR7 10ul, with CD28 5.5 4.5 4.0 1.0 
10151.
3 219.5 
DR11 + 52, no CD28 5.5 8.0 4.5 0.5 
10513.
0 221.0 
DR11 + 52, with CD28 6.0 4.0 5.0 1.0 
10554.
5 164.5 
DR7 peptide, no CD28 6.0 4.0 4.0 1.0 
10415.
0 72.0 
DR7 peptide, with CD28 6.0 4.0 5.0 1.0 9836.0 78.0 
DR17 peptide, no CD28 6.0 4.0 6.0 1.0 
10214.
0 117.5 






9 Appendix 3 – Experiment 3 
The following tables list the raw MFI values achieved for each test cytokine bead group, at 
each time point and in each test combination, for the three patient/stimulator pairs tested in T 
cell experiment 3 outlined in Chapter 4. 
Test Pair 1 – Raw Cytokine MFI Results 
Class I 







 Neg Control - Medium Only 7 3 3 1 11 8.5 
Neg Control - Cells Only 166.5 200 161 14 11400 2438.5 
Positive Control 6149 276 5060 525 10190 11816.5 
CI  7 6.5 48 1 12627 256.5 







 Neg Control - Medium Only 7 4 2 0 783 8 
Neg Control - Cells Only 146 120.5 11 14 9572 2323 
Positive Control 8529 410 206 2049 6841 10370 
CI  7 20 28 1 12070 258.5 








 Neg Control - Medium Only 7 3 4 1 20 8 
Neg Control - Cells Only 102.5 44 4 12 10847 1309.5 
Positive Control 9434 315.5 24.5 2467 7808 8556.5 
CI  6 9 11 1 12095 84 
CI + CD28 7 4.5 10 1 11029 109.5 
Class II 







 Neg Control - Medium Only 6 3 4 1 12 8 
Neg Control - Cells Only 7 8 10 1 12495 1019.5 
Positive Control 2697 245 7402 1042 11882 11725 
CII  8 4 17 1 11932 149.5 







 Neg Control - Medium Only 6 3 4 1 18 9 
Neg Control - Cells Only 6 13 15 1 12995 1147 
Positive Control 3977 344.5 23.5 5674.5 6795 12664.5 
CII  7 6 17 1 13507.5 204 








 Neg Control - Medium Only 6 3 4 1 8 7.5 
Neg Control - Cells Only 6 3 4 1 11 8 
Positive Control 9 3 9 2 138 9.5 
CII  8 5 9 1 12184 70 
CII + CD28 6 5 8 1 12674 64 
        
Beads 








 Neg Control - Medium Only 6 3 3 1 12 8 
Neg Control - Cells Only 7 6 13 1 12108 119 
Positive Control 2269 199 6656.5 373.5 10984.5 6489 
322 
 
Beads 6 4 4 1 957 9 







 Neg Control - Medium Only 6 3 3 1 29 8 
Neg Control - Cells Only 6.5 8 27 2 3532 501 
Positive Control 3687.5 427.5 3883 1978.5 7514.5 12744.5 
Beads 6 1 1 1 2 5 
Beads + CD28 6 2 1 0 1 7 








 Neg Control - Medium Only x x x x x x 
Neg Control - Cells Only x x x x x x 
Positive Control x x x x x x 
Beads x x x x x x 
Beads + CD28 x x x x x x 
 
Test Pair 2 – Raw Cytokine MFI Results. 
Class I 







 Neg Control - Medium Only 7 4 3 1 11 8 
Neg Control - Cells Only 8 88.5 27 2 11568 743 
Positive Control 5118 969 3759 2285 10935 11631 
CI  8 25 12 1 11490 2096 







 Neg Control - Medium Only 6 4 3 1 13 7.5 
Neg Control - Cells Only 9 420 22 3 11617.5 568 
Positive Control 8796.5 1444.5 316 5519.5 8536.5 11302 
CI  6 170.5 89 1 11195 1179 








 Neg Control - Medium Only x x x x x x 
Neg Control - Cells Only x x x x x x 
Positive Control x x x x x x 
CI  x x x x x x 
CI + CD28 x x x x x x 
Class II 







 Neg Control - Medium Only 6.5 3 4 1 12 8 
Neg Control - Cells Only 7 19 18 1 11024 4195.5 
Positive Control 3885 1474.5 3666 2529 10260 13339 
CII  7.5 18 14 1 12122.5 2564.5 







 Neg Control - Medium Only 6 170.5 89 1 11195 1179 
Neg Control - Cells Only 6 3 4 1 11 8 
Positive Control 5008 1270 11 4707 8257.5 10653.5 
CII  6 195 53 1 10256 1773 








 Neg Control - Medium Only x x x x x x 
Neg Control - Cells Only x x x x x x 
Positive Control x x x x x x 
CII  x x x x x x 


















Neg Control - Medium Only 6 4 3 1 13 8 
Neg Control - Cells Only 7 5 9 1 10792 208.5 
IFN-g IL-17 IL-2 IL-5 IL-8 TNF-a 
Positive Control 1180 1213.5 9300 2452 10881 9692 
Beads 6.5 5 12 2 11363 189.5 







 Neg Control - Medium Only 6 4 4 1 27 7 
Neg Control - Cells Only 4 3 4 1 334 65 
Positive Control 2918 2361 46 6698 4532.5 6854 
Beads 3 5 21 1 1836 786 








 Neg Control - Medium Only x x x x x x 
Neg Control - Cells Only x x x x x x 
Positive Control x x x x x x 
Beads x x x x x x 




Test Pair 3 – Raw Cytokine MFI Results. 
 
Class I 







 Neg Control - Medium Only 6 3 4 1 10 8 
Neg Control - Cells Only 8 28 17 1 12167 1986.5 
Positive Control 343.5 174 1614 59.5 11124 5953 
CI  7 4 5 1 12987 1674 







 Neg Control - Medium Only 6 4 4 1 11 8 
Neg Control - Cells Only 7 78 12 1 11399 1085 
Positive Control 2307 488 269.5 997 9634 5639 
CI  6 4 6 1 11917 821 








 Neg Control - Medium Only 6 3 4 1 10 8 
Neg Control - Cells Only 7 93 27.5 1 12854 797.5 
Positive Control 2564.5 420 48 1133 10125 4184 
CI  6 3 5 1 12237.5 630 





















 Neg Control - Medium Only 6 3 3 1 11 8 
Neg Control - Cells Only 8 7 7 1 11756 1973.5 
Positive Control 126 111 1591.5 68.5 11841 6524 
CII  6 5 4 1 12472 829.5 







 Neg Control - Medium Only 6.5 3 4 1 11 8 
Neg Control - Cells Only 7 42 23 1 11949.5 1506 
Positive Control 607 167 11.5 806 9625.5 4875.5 
CII  7 4 22 1 12705.5 442 
CII + CD28 6 15 7 2 11062 2398 
 Neg Control - Medium Only 6 3 3 1 9 8 
120 Hours 
 
Neg Control - Cells Only 6 23.5 36 1 12351 1189 
Positive Control 553 99 7 631 9927 3160 
CII  6 4 16 1 12706 328.5 
CII + CD28 6 13 8 3 11654 1800 
Beads 
 







Neg Control - Medium Only 6 3.5 4 1 14 8 
24 Hours 
72 Hours 
Neg Control - Cells Only 5.5 3 4 1 11257 431 
Positive Control 10 41 809.5 13 12594 1359 
Beads 7 3 3 1 12288 333.5 
Beads + CD28 7 7 11 1 12322.5 822 
Neg Control - Medium Only 6 4 4 1 20 8 
72 Hours 
120 Hours 
Neg Control - Cells Only 8 5 9 1 11751.5 1252.5 
Positive Control 70.5 401 97 360 11234.5 6433.5 
Beads 6 5 5 1 11030 5394 
Beads + CD28 5 4 6 2 582 763.5 
Neg Control - Medium Only x x x x x x 
120 Hours 
Neg Control - Cells Only x x x x x x 
Positive Control x x x x x x 
Beads x x x x x x 
Beads + CD28 x x x x x x 




10 Appendix 4 – Experiment 4 Information 
Patient Sensitisation and Donor/3
rd
 Party Mismatch information – the table below summarises the patient sensitisation information and the HLA mismatches 
presented by the donor or 3
rd
 party stimulator cells.  ‘Patient’ represents the patient number assigned during testing.  ‘Gender’ indicates the sex of the patient’ 
‘Sensitised’ indicates the patient has received a previous transplant and/or produces demonstrable HLA specific antibody detected using LABScreen mixed bead 
testing.  ‘Donor MM’ and ‘3
rd
 Party MM’ lists the HLA class I and II mismatches presented by the donor or 3
rd
 party stimulator cells.  ‘HLA Ab’ lists any HLA specific 
antibody identified on serum screening which is specific for one or more mismatches presented by either the donor or 3
rd
 party stimulator. 
Patient Gender Sensitised Donor MM HLA Ab  3rd party MM HLA Ab  
1 F No 
A2,68 B60 Cw10 DR11 
DR53 DQ7 No A2, B61, Cw2, DR4, DQ8 no 
2 M No 
B35 Cw4 DR15 DR51 
DQ5 No 
A68, B60, Cw10, DR7, 
DR11, DQ7 no 
3 M No A1 B35 Cw4 DR1 DQ5 No 
A33, B44, B65, Cw5, 
Cw8, DR1, DQ5 no 
4 M No 
A1,24 B44 Cw5 DR13 
DQ6 No 
A1, A24, B8, B44, Cw5, 
Cw7, DR13, DQ6 no 
5 F No A3 B52 Cw1 DR1 DQ5 No 
A2, B35, Cw4, DR15, 
DR51, DQ6 no 
6 M No A1 A24 B44 Cw5 DR13 No 
A3, A32, B7, B35, Cw4, 
DR4, DR53, DQ7, DQ8 no 
7 F Yes 
A24, 31 B7, 62 Cw9 
DR12,15 DR51, DQ6 Yes - Ab = A31  
A3, B60, Cw10, DR15, 
DR51, DQ6 no 
326 
 
Patient Gender Sensitised Donor MM HLA Ab  3rd party MM HLA Ab  
8 F Yes 
A66, B41, Cw17, DR13, 
DR52, DQ7 Yes - Ab = A66  
A24, A31, B7, B62, Cw9, 
DR12, DR52, DQ7 no 
9 F Yes 
A3, A32 B7 Cw7 DR4 
DR53 DQ7,8 
Yes - Ab = A3, cw7, 
DR4, DQ7,8 
A3, B57, Cw4, DR4, DR7, 
DR53, DQ8, DQ9 
Yes - Ab = A3, DR4, 
DR7, DR53, DQ8, DQ9 
10 F Yes Cw2,7 DR4,15 DR51,53 
Yes - Ab = Cw2,7 
DR4,15 DR51,53 
A1, A32, B35, B55, Cw4, 
DR11, DR14, DQ5, DQ7 
Yes - Ab = A21, A32, 
Cw4, DR11, DQ5 
11 F Yes A2, B37, Cw6 Yes - Ab = A2, B37 
A26, B37, Cw6, DR13, 
DR15, DR51, DQ6 Yes - B37 
12 M Yes DQ7 Yes - Ab = DQ7 
A2, A11, B44, Bw4, Cw5, 
DR4, DR11, DR53, DQ7, 
DQ8 
Yes - Ab = A2, B44, DQ7, 
DQ8 
13 F Yes 
A3, 29 B45 Cw6 DR17 
DQ2 
Yes - Ab  = A3, A29, 
B45 
A3, B57, B65, Cw6, Cw8, 
DR1, DR13 Yes - Ab = A3, B57, B65 
14 F Yes 
A33, 68 B71 Cw10 DR10, 
13 DR52 DQ2 Yes - Ab = Cw10 
A1, A3, B35, B39, Cw7, 
DR1, DR11, DR52 Yes - Ab = Cw7 
15 F Yes 
A2 B49,51 Cw16 DR9,13 
DQ5 
Yes - Ab = A2, B49, 
B51 
A3, A29, B8, B45, Cw6, 
DR17 Yes - Ab = A3, DR17 
16 F Yes A1,3 B7 Cw7 DR8 DQ4 No 
A1, A24, B8, B44, Bw4, 
Cw5, Cw7, DR13, DR17, 
DQ2 no 
17 F Yes 
A1,3 B57,65 Cw6,8 DR13 
DQ6 Yes - Ab = A1, A3, B57 
A2, A33, B49, B51, Cw7, 
Cw16, DR9, DR13, 
DR53, DQ2 no 
18 F Yes A2 B60 Cw10 Yes - Ab = A2 
A2, B41, B44, Bw4, Cw5, 
Cw17, DR4, DR13, DR53 Yes - Ab = A2, B41, B44 
19 F Yes B27,44 Bw4 Cw2,5 DQ7 Yes - Ab = DQ2 
A23, A80, B52, B57, 
Bw4, Cw16, Cw18, DR7 Yes - Ab = A80, DR7 
20 F Yes B57 Cw6 Yes - Ab = B57 
A11, B55, Cw9, DR10, 
DR14, DQ5 no 
21 F Yes No mm No A2, B18, DR7, DR53 Yes - Ab = A2 
22 M Yes A23,80 B57 Cw16,18 
Yes - Ab = A23, A80, 
B57, Cw18 A3, B7, B57, Cw6, Cw7 Yes - Ab = B57, Cw6 
23 M Yes 
A1,3 B35 Bw6 Cw4 DR4 
DR53 DQ8 Yes - Ab = B35 
A2, B44, Cw2, Cw5, DR4, 
DR53, DQ8 Yes - Ab = A2, Cw5 
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Patient Gender Sensitised Donor MM HLA Ab  3rd party MM HLA Ab  
24 M Yes A2 B62 Cw9 DR13 DR52 Yes - Ab = A2 
A2, B18, B62, Cw9, DR4, 
DR11, DR52, DR53, 
DQ7, DQ8 Yes - Ab = A2 
25 F Yes 
B18 Cw7 DR11 DR52 
DQ7 Yes - Ab = DR11 
A1, A32, B8, B44, Cw5, 
Cw7, DR12, DR17, 
DR52, DQ2, DQ7 
Yes - Ab = B8, DR17, 
DQ2 
26 M Yes 
A1 B35 Cw4 DR11 DR52 
DQ7 
Yes - Ab = A1, B35, 
Cw4, DR11, DR52, 
DQ7 
A1, B7, Cw4, Cw12, 
DR14, DR15, DR51, 
DR52, DQ6 
Yes - Ab = A1, Cw4, 
Cw12, DR14, DR15, 
DR51 
27 F Yes A2 B44 Cw5 DR4 DR53 
Yes - Ab = B44, Cw5, 
DR4, DR53 
A23, A66, B49, DR15, 
DR51, DQ6 Yes - Ab = A23, A66, B49 
28 F Yes A1 A26 B37 DR13 No 
A3, B35, B62, Cw4, Cw9, 
DR1, DR13, DQ2 no 
29 F Yes 
A11 B55 Cw9 DR14 
DR52 
Yes - Ab = A11, B55, 
Cw9, DR14, DR52 
A33, B53, B71, Cw10, 
DR13, DR52, DQ2 
Yes - Ab = A33, B53, 
B71, Cw10, DR13, DR52 
30 F Yes 
A11 B44 Cw5 DR11 
DR52 DQ7 
Yes - Ab = A11, B44, 
Cw5, DR11, DR52 
A31, B8, B45, Cw6, 
DR17, DR52, DQ2, DQ7 






The following pages list, on an individual patient basis, the raw median fluorescence intensity (MFI) values achieved for each cytokine bead group, in each test 
well, at each time point for experiment 4 described in section 4.6.  The cytokine detected is listed in the first column, and the results are divided into day 1, 3 and 5 
sampling time points and further divided into those achieved in the negative control control well, the positive control well and test wells 1, 2 and 3 at each time 
point.  Where test wells 1 and 2 are replicates derived from donor stimulators and test 3 is the response seen to the third party stimulator.  There are two tables 
per patient, the first presenting the raw results in the class I stimulator wells and the second from the class II stimulator wells. 
Patient 1 – Cytokine Raw MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 179 8753 431 546 312 97 10989 246.5 306 175 79 8159 267.5 305 284 
TNFα 5612.5 10263.5 5298 5469 6288 3967 7166 3391.5 3724 4211 2785 5035 2251 2484 2879 
IL-2 31.5 18798 32 13 7 35 251 150 29 76.5 121 40 127.5 127 452 
IL-5 4 389.5 4 4 3 3 1150.5 6 3.5 2 6 761 5 49 400 
IL-17 53 2616.5 53 26 16 128 6310.5 111.5 84 74.5 288.5 3987 476 325 359 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 365.5 10031 478 402.5 380.5 230 12287 242 203 148 440.5 9428 85.5 65 46 
TNFα 8053 13078.5 5530.5 6096.5 7101 5262.5 10227 3529 4094 4328 3287.5 5913 1933 2221 2696 
IL-2 10 24283 13 8 11 172.5 201 47 62 33 87 30 126 107.5 143.5 
IL-5 7 922.5 4 5 5 7 3753.5 4 5 5 8 2158.5 8 4 4 





Patient 2 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 171.5 7469 456.5 280.5 304.5 97.5 8487.5 214 213 150 31.5 4658 67 56.5 40 
TNFα 8738 8090 1934.5 2988 2966 6006 7499.5 1260.5 2252 1788.5 3520 5253 801 1187 1011.5 
IL-2 14 6953 25.5 26 21 171.5 90.5 40 72 61 310 43 46 100.5 67 
IL-5 1 232 1 1 1 3 533 1 1.5 1 2 295 1 1 1 
IL-17 18 459 19 10.5 14 67 1714 28 90 40 82 612.5 21 48 72.5 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 394.5 7991 400.5 394.5 406.5 192 10329.5 261.5 155 308 52 7026.5 60.5 43 87 
TNFα 7224 6944 2554 3297 2299 5191.5 5262 1507 2144 1392 3677 3173.5 912.5 1175 796 
IL-2 24 11428 43 14 24 39.5 378.5 60 62 24 92.5 16 91 69 35 
IL-5 2 349 1 1 1 2 1158 1 1 1 1 718 1 1 1 





Patient 3 – Raw Cytokine MFI Results. 
Class I 
               
 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 65.5 501 35 94 96 34 435 29 78 57 18 153.5 12 26.5 27 
TNFα 3185 5142 3215.5 3249 6537 2103 3556.5 2065.5 2279 3950 1298 1765 1219 1250.5 2190.5 
IL-2 15 283 7 20 9 14 41 8 16 7 12 15.5 5.5 13 7 
IL-4 10 11 10 12 11 7 7 7 8 7 7 7.5 8 6 9 
IL-5 1 4 1 1 2 1 4 1 1 1 1 3 1 1 2 
IL-10 2307.5 3317.5 3310.5 2841 5430 29 67.5 44 45.5 90 32.5 102.5 91 49 93.5 
IL-17 85 213.5 18 61 21 84 162.5 16 63 22 62 88 18 33 12 
                Class II 
               
 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 10 217 186.5 96.5 84 8 230.5 107.5 51 39 13 98 36 21 19 
TNFα 1956 2975 4635.5 3670 2727.5 1989.5 2367.5 2805 2447 1880 1185.5 1414.5 1638 1166 1180 
IL-2 4 221 15 14 24 7 26.5 12 14 38 23 21 22 8 31 
IL-4 11 11 11 11 11.5 7 8 8 6.5 9 7 8 7.5 7.5 8 
IL-5 1 3 1 1 1 1 2 2 1 1 1 2 1.5 1 1 
IL-10 2102.5 3122.5 3800 2888.5 2469 99 90 49.5 37 30 50 75 46 28.5 36 





Patient 4 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 147 5755 62.5 63 58 504 9953 52.5 47 132.5 154.5 7292.5 18 24 101.5 
TNFα 2006 7015 2337 2288.5 2123 964.5 10305.5 992 1140 1211.5 487 6399 469 1011 1050 
IL-2 1073.5 22032.5 5.5 6 9 251 15288 7 9 55 46.5 336 3 13 52 
IL-4 4 335.5 3 4 3 3 109 3.5 4 2 2.5 7 2 2 3 
IL-5 43 3901 1.5 2 2 59 8662 2 2 2 34 5877 2 1 4 
IL-10 1734 7197 1984 1716 1514.5 506 1747 538.5 634 572 114 51 110 124 88.5 
IL-17 133 2457 6 5 6 443 15039 16 9 50 296 14312 8 26 48 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 92 4541 109 56.5 95 126 8111.5 1056 77 382 127 6589 691.5 36.5 502 
TNFα 1889.5 7119 2536 2502 2497 939.5 9451.5 1366 1398 1410 756 6120.5 1267 992 1197 
IL-2 265 20705 689 7.5 13.5 82 20975 404 14 52 50 899 91 16 27 
IL-4 4 389 3 3 4 3 246.5 4 3 3 3 12 2 3 3 
IL-5 12 3569 18 1 2 10 6491 107 1.5 5 8 4778 92 1 5.5 
IL-10 1450 6907 1843.5 1653 1458 356 1308.5 574.5 660 622.5 98 52.5 103 114.5 91.5 





Patient 5 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 2600.5 10597 2384.5 2351 1652.5 1331 10905.5 1487 1321 944 444.5 8783 467 516 255.5 
TNFα 6481.5 10559 4052 2508 3828 4298.5 7296.5 2914 1791 2648.5 2405 4429.5 1217 1340.5 1595 
IL-2 32.5 1635 13 18 19 14.5 53 11 16 11 19 27 14 13.5 70 
IL-5 3 191 3 1 2 3 170 3 1 1.5 1 84.5 2 2 1 
IL-17 689 2113.5 554 583.5 545.5 288 1061 230 263.5 271 141 473 136 160.5 145 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 774.5 8422.5 3344 1508.5 1996 385.5 8153.5 1676 727 1050 94.5 5151 830.5 237.5 314 
TNFα 4880 7609 4107 2195.5 2397.5 3289 4899 2248 1425.5 1586.5 2040.5 3221 1745 861.5 808.5 
IL-2 17 4140.5 15 14 13 17 62.5 12 12 15 44.5 34 13 15 28.5 
IL-5 2 226 1 1 1 2 215.5 1 1 1 2 112 1 1 1 





Patient 6 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 87 4896 22 15 16 352 8785 14 13 14 95 9024 9 8 8 
TNFα 1231 7312 1691 1607 1672.5 539 7625 643 729 630 221 7081.5 247.5 241 222 
IL-2 113 21675 28 3 3 59 19082 17 4 2 18.5 2402 10 2 2 
IL-4 3 68 3 4 3 3 86 3 2 3 3 6 3 3 2 
IL-5 21 1167 29 25 46 23 2912 15 18 28 14 5127 9 9 15 
IL-10 623 4427.5 710 526 634 216 2044 148 191 214 64 172.5 43 47.5 63 
IL-17 36 1509 3 3 4 305 5113 3 2 3 170 7198 2.5 2 3 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 553 3093 275 23 39 1121 10831.5 394 12 417 416 10057 132 8 117 
TNFα 1715.5 5265 1882 2165.5 2319 879 10090.5 680 654 1083 354 6490 256.5 230 420 
IL-2 4111.5 18744 3365 10 10 2158 21424.5 1474.5 12 61 1148 4452 687.5 7 15 
IL-4 4 53 5 3 3.5 3 369.5 3 3 3 3 29 3 3 3 
IL-5 76 989 112 34.5 48.5 120 6685 66 16 75 127 5394 43 10 44 
IL-10 841 3842 1015 732.5 844.5 144.5 6059.5 154 82 285 34 272.5 34 17 66 




Patient 7 – Cytokine Raw MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 54 7040 125 73 137 163.5 7180.5 87.5 47 89 52 4348.5 25 17 29 
TNFα 2818 6789 4175 4321 4509 1891 4274.5 2398.5 2536 2419.5 1149 2155 1162 1222 1184.5 
IL-2 212 8873.5 133.5 76 161 129 816 76.5 57 74 41 46 21 31.5 24.5 
IL-4 11 12 11 12 11 10 8 11 11 10 7 8 7 8 8 
IL-5 1 58.5 1 1 2 2 52.5 1 1.5 1 1 31.5 0.5 2 1 
IL-10 2011 3798 3563 3874.5 3547.5 527.5 640.5 834 918 611 13 16 14 14 12.5 
IL-17 58.5 1075 20 22 10 140.5 936 30 20 14 193 536 31 25 30.5 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 108.5 10705 127 111 121 207 8869 102 105 x 65 4753 27 39 42 
TNFα 4145.5 8377.5 4086 3839 4304 2839.5 5487 2181 2289.5 x 1618.5 2015 1244 1197 1355 
IL-2 123 5726.5 121.5 219.5 187.5 163 226 187 113 x 71 15 75 63 51.5 
IL-4 10 13 11 11 10 11 8 8 8 x 8 5.5 7 7 7 
IL-5 1 37 1 1 2 1.5 28.5 4 1.5 x 1 12 1 3 1 
IL-10 2547.5 4449 3742 2616 2712.5 898.5 938 663.5 693.5 x 24 12 21 16 15 





Patient 8 – Cytokine Raw MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 49 5977.5 95 103 49.5 45 6865 74 81.5 88 34 4759 98 211.5 100 
TNFα 2132 3132 1566.5 2181 1378 1199 2589 922 1283 625.5 650 1644 523 757 338.5 
IL-2 25 1927 13.5 10 16.5 19 222 27 32.5 54 126.5 21 42 41 48.5 
IL-4 12 11 12.5 11 11 8 8 9 5 9 7 7 7 7 7 
IL-5 1 34 1 2 1 1 37 1 1 1 1 29 21 3 1 
IL-10 2383 2251 1017 1619 758.5 941 823.5 252.5 527 132 47.5 20 22 28 22 
IL-17 62 559 26 22 12 71.5 1142 68.5 51.5 57 200.5 611.5 320 247 126 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 17 7633 64 75 64 23 7794 46 77 111 13.5 5503 35 56 89 
TNFα 1114 3875.5 1383 1472 1416 640 2854.5 471.5 721 674.5 436.5 1951 413 371 420.5 
IL-2 14.5 1853 11 22 22 134 103 54.5 27 81 75 15 37 52.5 37.5 
IL-4 11 10 10 10 10 8 9 8 8 8 7 7 5 6 6.5 
IL-5 1 71 1 1 2 4 79.5 3 1 3 9 59.5 4 1 9 
IL-10 472 1633 720 802.5 676 100 509 115 180 116.5 8 14 13 14 7 






Patient 9 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 2098 9767 6000 380.5 156 4298 9748 7015 213 285.5 2415 9769.5 4010.5 349.5 311.5 
TNFα 1732 7251 1612.5 574 599 900 5449.5 1078 202 230 516 3058 611 164 221 
IL-2 5417 20107 5096.5 16.5 18 1050 3623 640 54 45 79 45 43 139 120 
IL-4 4 6 4 4 3 3 4 3 3.5 3 3 3 3 3 3 
IL-5 107.5 1470 76 2 1 88 2769 144 3 4 93 1791.5 95 246 298.5 
IL-10 1660.5 3654 1072 530 540 466.5 745.5 330 117.5 92 153 70.5 28 79 40 
IL-17 225 2401 212.5 6 4 950.5 12426.5 1582 12 31 1843 9635 953 127 246 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 84 11497 144.5 138.5 133 3833 10789 207 195 167 3714.5 9372 823 541 339 
TNFα 643 6592 463 655.5 1236 615 4518 199.5 292 492.5 1156 2094.5 397 249 605 
IL-2 41 20845 5 8 15 387.5 2917.5 72 108.5 71.5 146.5 32 142 203 112 
IL-4 4 6 3 4 3 3 4 3 2.5 3 3 3 3 4 3 
IL-5 2 1455.5 1 1 2 40 1593.5 21 4 11 106 900.5 405 198.5 793 
IL-10 623.5 4052 419 824 753.5 156 469 94 170 123 95 36 62.5 97.5 52.5 






Patient 10 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 169 4509.5 246 214 186.5 95 8165 79.5 88.5 121 334 4746 35 29 207 
TNFα 6208.5 8069 4921 4968.5 4652 4397 7698.5 3425 3327 3055.5 2463 3918 1682.5 1735 1808 
IL-2 26 15558 22.5 9 9 94 114 32.5 35 212 78 151.5 55 63 117 
IL-5 2 334 1 1 1 2 1736 1 1 5 15 1201.5 1 1 267.5 
IL-17 45.5 1385 20 25 17 79 6355.5 58.5 24 246 484 4112.5 236 74 1348 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 75 4473 86 159.5 202 80 4869.5 113.5 84 118 151.5 2399.5 93 42 168 
TNFα 5684 10281 4158.5 7326 5149 3878 6537 3445 3655 3269 2359 4166 2187.5 2057 1936 
IL-2 10 22893 10 15 12 72 111 280 72 76 133 27 61.5 150 138.5 
IL-5 0 796 1 1 2 1 1506 100 7 16 683 927.5 957 320 215.5 








Patient 11 – Raw Cytokine MFI Results. 
Class I 
               
 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 30.5 3898 84 96 68.5 22 8736 50.5 45.5 39 13 5767 25 24 20 
TNFα 1753.5 3832.5 1926 2680.5 2278 1434.5 4029 1387.5 1339 1480.5 1013 2303 783 1249 1131 
IL-2 5 10333 4 4 4 4.5 4012.5 14 4.5 4 33 481 43 8 9 
IL-4 12 12 11 12 12 8 10 8 10.5 10 8 9 8 9 9 
IL-5 1 41 1 1 2 2 75 2 1 1 1 47 1 1 1 
IL-10 848 1592 1218.5 2078 1649 395 401.5 469 360.5 384 62 73 32 132.5 141.5 
IL-17 9.5 593.5 8 7 4.5 10 882 14 8 6 25 818.5 50 23 18 
                Class II 
               
 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 50.5 2999 67 107.5 82 35 6464.5 39 45 52.5 17 3839.5 17 23 24 
TNFα 1813.5 4081 1877.5 2223.5 2395 1620 3368.5 1178.5 1383.5 1537.5 1032 1916.5 605 987 994 
IL-2 4 7112 3 3 3 4 3109 6 7 9 43 449 18.5 15 52 
IL-4 9 12.5 12 11 12.5 8 10 8 9 8 10 9 8 7.5 10 
IL-5 1 25 1 1 1 1 45 1 2 1 1 29.5 1 1 2 
IL-10 734.5 1276.5 1321 1698 1748.5 446 234 451.5 399 469 48 50 24.5 36 49 





Patient 12 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 142 6315.5 10 6 6 1662 14104.5 10 7 7 425 11917.5 8 7 6 
TNFα 1825 10010.5 3477.5 720 606 3011 17205 2109 390.5 334 1415 15208 820.5 145.5 139 
IL-2 1703 24233 52 12 6 351 26268.5 107.5 18 12 17 26760.5 63 16 10 
IL-5 1 77 1 1 1 11 4406 1 1 1 7 3088.5 1 1 1 
IL-17 390.5 2386 10 9 9 4151.5 19241.5 12 10 10 2747 18099 10 8 9.5 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 7 5905 7 8 8 8 13131 8 7 7 7 12263.5 7 6 7 
TNFα 663.5 9243 1207 2055 2642 506 15402.5 792 1138 1737.5 171 12614 292 546 658.5 
IL-2 61.5 24705 24.5 8 5 96.5 26483 30 13 12 58 26138 56 15 15 
IL-5 1 36.5 1 1 0 2 8364 1 1 1 2 7833 1 1 1 








Patient 13 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 7 30 6 6 6 8 17 8 6 7 8 11 8 8 7 
TNFα 351 499.5 560.5 272 431.5 218.5 369 340.5 146.5 285 132 201 207 144 189 
IL-2 114.5 587.5 62 61 56 49 28 165 75 114 35 42 119.5 78 68.5 
IL-5 1 43 1 2 2 1 74.5 9 2 7 1 38 9.5 3 32 
IL-17 48 550.5 14.5 20 29 216 586 111 197 79 135 479 183 357 147 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 7 13 7 7 7 7.5 10 7 8 11 7 8 7 7 11 
TNFα 549 646.5 658 432 521 734 497 391.5 243 319 523 318 226 197.5 241 
IL-2 87 91 19 53 85 113 104 139 131 132 91 51 67 47 102 
IL-5 2 8 0 1 1 4 14 1 12 4 3.5 9 1 10 7 








Patient 14 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 308.5 8823 109.5 263 209.5 135 8640 54 122 140 125 5531 63 79 71 
TNFα 2657 3666 673.5 987 2591.5 1506 3164 363 552.5 1284 1089 1621 355.5 466.5 961.5 
IL-2 4 11927.5 11 4 5 42 60.5 30 23 68.5 118 6 97.5 51.5 93 
IL-4 3 4 3 3 4 3 3 2 3 2.5 3 3 3 3 2 
IL-5 1 189.5 1 1 1 1 328 1 1 2 6 192.5 1 5 38 
IL-10 1933 3406.5 388 584 771.5 177 261.5 74 63 95 32 15 33 77 27.5 
IL-17 21 1322.5 13 14 9 135 4343 69 20 38 245 1938 165.5 94 141 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 84 9835.5 146 120 70.5 51 9456.5 173 84 35.5 55 7516 59.5 45 63 
TNFα 2213 4600 1079 1148 1849.5 1513 3486 488.5 692 960 960.5 2147.5 330 538 858 
IL-2 3 11884.5 21 4 5 52 51 23 20 43 243 5 41 66 91 
IL-4 3 4 3 3 3 3 4 3 4 3 3.5 3 3 2 3 
IL-5 1 75.5 1 1 1 0 104.5 0.5 1 0.5 16 62 1 6 3 
IL-10 1163 2156.5 441 439 436 133.5 128.5 89 82 46 83 12.5 107 23.5 13 






Patient 15 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 6 23 7 8 13 18 37 14 11 9.5 20.5 40 42 13.5 11 
TNFα 576 603 612.5 793.5 1428 333.5 342 273 306.5 576.5 198.5 242.5 230 235 464 
IL-2 7 133 10 8.5 8 206 185 250 260 68 174 211 523.5 392.5 112 
IL-5 1 7 1 1 2 2 5 14 3 2 2 5 14 3 2 
IL-17 8 74 17 7.5 6 736.5 1261 735 750.5 204 866.5 2729 1956.5 1258 442.5 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 8 48 8 6 8 8 20 12 10 9 9 14 13 15 12 
TNFα 1167 1314 592 636 699 555 426 271 259 289.5 357.5 371 184.5 168 201 
IL-2 10 111 10 9 15 136.5 21 207 119 114 208 32 147 182.5 296 
IL-5 1 5 1 1 1 9 4 3 9.5 7.5 38 3 15 55 276 








Patient 16 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 190.5 6794 63 36 45.5 481 10125 111 39 42 160 9928 49.5 17 17 
TNFα 1175 7990 936 923 967.5 528.5 11152 515 563 488 304 7334.5 305 323 291.5 
IL-2 18.5 22151.5 3 2 2 14 16913 9 2 2 6 651.5 9 8 3 
IL-4 4 265 3 3 3 3 242 3 3 3 3 15 2.5 3 4 
IL-5 2 6005.5 1 1 1 7 13738.5 2 1 1 5 10599 1 1 1 
IL-10 463 9428.5 364 375 277.5 116 1683 126 114.5 79 30 99.5 27 26 18 
IL-17 7 6222 3 3 3 99 21077 5 2 3 77 20713.5 12 3 2 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 46 5155 154 91.5 56.5 38 9634 130 147 54 133 8403 70 151 28 
TNFα 1073.5 5830 1608 985 1386.5 566.5 10181 851 532.5 652.5 383.5 6292 532 389 349 
IL-2 2 21038 4 3 4 3 8254 3 23 7 22 136 9 12 10 
IL-4 4 143 4 3 3 3 108 2 2 2 3 9 3 2 3 
IL-5 2 3769 2 1 2 1.5 8468 2 1 2 24 6211 2 1 2 
IL-10 375 6583 671 325 481 83 1584.5 227.5 86.5 97 18.5 71.5 58 20 15.5 






Patient 17 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 7 9 7.5 11.5 11.5 8.5 10 8 7 7 8 7 8 8 8 
TNFα 656 525 589 1205 527 454 282 351.5 661 238 251.5 158 182.5 364 132 
IL-2 6 31 5 7 6 15 10 6 5 6 13 8 7 6 6 
IL-5 1 1 1 1 1 0 1 1 1 1 0 1 1 1 1 
IL-17 18 28 19 21 17.5 18 23.5 14 16 14 18 20 17 14 14 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 9 8 13 9.5 14 10 11 9 11 10 8 8 8 8 8 
TNFα 619.5 717 505 441 540.5 364.5 384 243 220 253 199 221.5 128.5 121 140 
IL-2 7 21 5 7 5 12 22 7 6 5 17 14 13 6 4.5 
IL-5 1 1 1 1 1 0 1 1 1 1 0 1 0 1 1 








Patient 18 – Raw Cytokine MFI Results 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 27.5 3523 185 94 109 70 3688 158.5 110 170 43 1720 415 238 234 
TNFα 1271 4006 4392.5 4004 3274 1042 3183 2445 2909 1920.5 953 2493.5 1806 1714 1245.5 
IL-2 15 837.5 15.5 9.5 14 81 257 40.5 22 61 130 15 201 297 192 
IL-4 12.5 11 12 10 11 9 10 9 9 10 8 7 8 7 8 
IL-5 1 5 1 2 1 2 7 6 1 1 24.5 4 518 2 359.5 
IL-10 527 1168 907 1643 583 158 1065.5 404 984 135.5 5 28 40 15.5 5.5 
IL-17 16.5 100.5 22 28.5 25 72 240 66 96 55.5 322.5 233.5 429 414 292.5 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 146 7476.5 111 98 106 343 8281 90.5 115.5 129 144.5 4907.5 153 119 51.5 
TNFα 3864 9131 3195 4524 3078 2574 6788.5 1706 2439 2163.5 1627.5 4797 1316.5 1596 1283 
IL-2 15 2011 21 20 20 35 417.5 54.5 58 45 98 29 100.5 92 70.5 
IL-4 10 12 12 10 12 11 10 12 10 11 8 8 8 8 11 
IL-5 1 11 1 1 2 2 101.5 3 1 26 2 74.5 79.5 41.5 72 
IL-10 1010.5 868 560 737 512 308 422 181 293 165 5 17 5 9.5 6 






Patient 19 – Raw Cytokine MFI Results 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 114 6025 352.5 679 221 379.5 12209 1325 1911 2208 233.5 10704.5 443 1164 1477 
TNFα 6845 7573.5 6489 6760.5 6626 5903 11544 5850.5 5353 5078 3422 8411.5 2972 3508 3519 
IL-2 6 16447 10 4 4 10 19823 12.5 8 53.5 14 275 13 18 18 
IL-4 4 113 4 3 4 3 549 4 3 3 3 17 3 3 2 
IL-5 28 6291.5 8 10.5 6 28 20426.5 7 7 4 15.5 17972 4 4 4 
IL-10 3289 1423 755.5 851 609 2209.5 2924 276 284 240 533 40 42 44.5 52 
IL-17 12 363 5 4 4 50.5 4274 25 11 8 75.5 4033.5 13 13 15 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 115.5 5089 211.5 501 242 998 10589 534 2637 2809 562.5 9860 261 1103.5 1368 
TNFα 5553 8070 7681 7158 7989 4272 9485 5760 5022.5 5717 3188 6901 3482 3110 3210 
IL-2 8 15900 4 7 4 21 9466.5 21 16 100 12.5 139 46 18 26 
IL-4 5 131 3 3 3 4 311 2 4 3 2.5 12 3 2.5 3 
IL-5 9 5909.5 7 10 13 16 17663.5 16 7 8.5 10 15149.5 14 6 8 
IL-10 518 1474.5 671.5 587.5 586.5 182 2819.5 257 206.5 209 45 45 43 25.5 26 






Patient 20 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 45 1959 94.5 39 23 1000 3332 859 1403 1976 3956.5 3538 5021 3487.5 3701.5 
TNFα 3326 3501 1676.5 1510 1742 1681.5 2522.5 919 1000.5 1251 2705.5 2150 2156.5 1805.5 1712 
IL-2 45.5 378 41 40 54 42 43.5 54 100 72 26 31 14 17.5 21 
IL-4 4 4 3 3 3.5 3 3 3.5 3 3 3 3 2 3 3 
IL-5 7 56.5 3 3 3 6 303.5 3 4 25.5 6.5 243 10 10 180 
IL-10 127 179 89.5 80 64 48.5 71 71.5 124 153 17 18 106 64 63 
IL-17 29 81 12.5 10 5.5 167 300.5 102.5 212 61 154.5 242 227 341 61.5 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 14 2757 14 13 21 593.5 4515.5 2278 514 1334 3618.5 4243 4631 3764.5 4978 
TNFα 2265 3617 1491 784.5 1710 1257 2721.5 916.5 613 1492 2764 2515 2786 2086.5 3154 
IL-2 20.5 1175 22 37 65 59.5 226 68 85 80.5 17 25 27 18 22 
IL-4 3 2 3 2 3 3 3 3 2 2 4 3 2 2 2 
IL-5 2 62 1 2 1 18 221 2.5 2 68 56 195 4 9 130 
IL-10 124 100.5 109 62.5 100 70 70.5 151 55 67 57 60 90.5 54.5 19 






Patient  21 – Raw Cytokine MFI Results. 
Class I 
               
 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 10 155 19 23 13 10 92 19.5 58 13 10 34 32 112 16.5 
TNFα 891.5 1349 1857 2851 1123 669 642 1434 1551 754 744 620 968 1489 688 
IL-2 10 1236 21.5 34 47 40 531 207 111.5 33 199.5 216 139 134 145 
IL-4 11 11 12 12 12 8 7 8 8 7 8 8.5 8 7 6 
IL-5 1 48 1 1 1 1 42 2 1 1 3 26 3 3 1 
IL-10 1126 2014 2082 2057 1376 51 30 90 95.5 75 18 33 8 12 18.5 
IL-17 8 50 24.5 24 53 17 52 194 307 33 45 57 261.5 754 88 
                Class II 
               
 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 9 565 12 16 14 23 488 15 12 12 59 323.5 12 10 14 
TNFα 1346 1236 3916 2065.5 1982 966 1036 742 1190 1136 808 960 505 862.5 936 
IL-2 6 1520.5 20 17 27 346 248 141.5 14 69 404.5 64 393 16 139 
IL-4 11 11 11 10.5 11 9 8 7 7 8 7 8 6 7 7 
IL-5 1 52.5 1 1 1 5 46 2 1 2 12 31.5 7 1 1 
IL-10 1086 1417 2209.5 2790.5 2411 67 80 39 103 103 11 32 5 25 13 





Patient 22 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 16 435 66.5 103 104.5 168.5 915 115 344 698 121 547 150 234 328 
TNFα 5108.5 6679 4773 4376.5 7718.5 2520 4772 2712.5 2338.5 5090 1781.5 2458.5 1574 1483 2943 
IL-2 18 104 3 11 25 11 23.5 21.5 34 18.5 29 14 47 45.5 6 
IL-4 2 3 3 3 2.5 2 3 3 2 2.5 2 2 3 2 2 
IL-5 1.5 2 1 1.5 1 1 2 0 0 1 1 1 1 1 1 
IL-10 853.5 504 385.5 282.5 356.5 173.5 120 65.5 54.5 91 73 34 35 33 21 
IL-17 4 30 8 3 6 55 251 32 24 23 60 291.5 154 36 14 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 11 324 162.5 222.5 284 44 721 141 241 677.5 35.5 306 47 92 296 
TNFα 3957 6408.5 4639 5835.5 7639 2122 3903 2599 3280 5080 1183.5 2092 1412 1955 3285.5 
IL-2 5.5 93 7 16 8.5 11 42 16 24.5 17 43.5 69.5 18.5 25 11.5 
IL-4 2 3 3 3 3 2 2.5 3 2 2 3 2 3 2 3 
IL-5 1 5 1 1 0 0 4 1 1 1 1 3 1 1 1 
IL-10 352.5 330 130 250 316.5 72 81.5 48 65 118.5 19 19 12.5 14 29 






Patient 23 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 17 4121.5 17.5 31 11 16.5 7726 135.5 27 12 13 5582 61 26 9 
TNFα 808 5056.5 521.5 526 503 443 4424 347 317 243.5 303 2303.5 202 175 111 
IL-2 10 6142.5 5 3 4 112 193 221.5 47 17 38 7 251 52 16.5 
IL-4 4 8 4 4.5 3 3 5 3 3 3 3 2.5 2.5 2.5 2 
IL-5 1 677 1 1 1 41 2701 54 5 7.5 464 1579.5 98 107 8 
IL-10 529 878 520 458 300.5 91 358 89 99.5 50.5 45 19 35.5 31.5 11 
IL-17 5 318.5 4 3 3 72 3419 37 7 5 195 1984 98 9 6 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 78 4478 33 61 159 345 7788 16 217.5 2630 356.5 4877.5 11 430.5 5033 
TNFα 1558 4443 825.5 2088 968 957.5 3545 348 1566 1032 614 2051 159 1347 2490 
IL-2 329.5 5066 122 7 131 240 152 36 235.5 3038.5 54 10 90 270.5 110.5 
IL-4 5 7 3 4 4 2 4 3 3 4 2 4 2.5 3 5 
IL-5 21 605 8 3 4 217 2017.5 6 10 383.5 484 1287.5 7 490 3192.5 
IL-10 352 588.5 515 2601.5 441.5 50 276.5 99 930.5 290 15.5 24 41 86.5 277.5 






Patient 24 – Raw Cytokine MFI Results. 
Class I 
               
 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 386 5487.5 192.5 231 271.5 179 3692.5 106 143.5 159 48 1538 32 41 45 
TNFα 3951 6867 3650 3549 3618 2269 3567 2307.5 2383 2349.5 1232.5 1981 1357 1246 1564.5 
IL-2 28 2102.5 8 18 13 23.5 444 7 9 11 16 124.5 5 13 6 
IL-4 13 14 14 12.5 14 9 8 9 10 9 9 6.5 5 9 9 
IL-5 2 8 1 2 1 2 8 1 3 1 1.5 6 1 2 1 
IL-10 6233.5 10319 6871 6491 6601 102 130 131.5 123 176 21 90 79.5 63 51 
IL-17 264 640.5 95 117 99.5 171 288.5 58 83 88.5 138 149 33 52 57.5 
                Class II 
               
 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 177 9168 213.5 219 233.5 78.5 7304 111 133 136 28 3681 39 36 33.5 
TNFα 2838.5 5271 3532.5 3396 3407 1775 3770 1957 2120 2045.5 1051 1844 1188 1280 1272 
IL-2 19 2119 9 11 9.5 14.5 94 9 10 10 12 22 8 7 9 
IL-4 13 13 15 12.5 15 8 9 9 6 9 9 10 8.5 8.5 9 
IL-5 9 38 1 2 2 9.5 33 1 1 3 10 26 1 2 1 
IL-10 3768 6385 7196 5874 5578 52 354 114 64.5 68.5 16 47.5 69 55.5 63.5 





Patient 25 – Raw Cytokine MFI results 
Class I 
               
 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 9 5287 19.5 11 20 25 5732 13 10.5 20.5 33.5 3971 8 9.5 18 
TNFα 2034 2012 1381 644 696 717 1667 716.5 239 464 417 1398 522 100.5 244.5 
IL-2 6 13656 6 6 17 47.5 3202 18 35 27 97.5 72.5 141 50 148 
IL-4 13 11 11 10 10 7 8 8 8 8 8 5 5 5 5 
IL-5 0 104 1 0 1 1 100 2 1 1 1 65 2 1 3 
IL-10 2127.5 1902 2059 1047.5 1045 553 245.5 378 109.5 173 37.5 60 9 8 24 
IL-17 10 971 8.5 18 19 37 852.5 32 47.5 55 174.5 624 40 49.5 161 
                Class II 
               
 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 9 7000.5 15 13 392 43 7259 18 9 101 42 4702.5 97 24 30 
TNFα 328 1462 371 321 3937 263 2131 219 168 1148 130 976 142 155 382 
IL-2 10 14808 19 9 34 30 3562.5 32 14 23 218 198 209 155 203 
IL-4 13 10 11 10 11 8 7 7 7 6 5.5 4 5 5 4 
IL-5 1 91.5 0 1 1 1 104 0.5 2 1 1 59 1 2 0 
IL-10 428 1611 720 731 7516 68 235 87 79 823 32 43 67 39 21 





Patient 26 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 155.5 1140 48 60 24 497 6814 41 394 16 161 4160 20 113.5 9 
TNFα 4195 6402 4875 4247 4085 2567 8825 2450 2200 2780 1231.5 5033.5 1503.5 1155 1512 
IL-2 45 11048 5 22 3 42.5 4480 9 113 3 7.5 28 41 36 11 
IL-4 3 49 3 2 3 3 70 3 3 3.5 2 5 3 3 3 
IL-5 1 1601 1 2 2 4 10048.5 2 3.5 1 2 7339 1 6 1 
IL-10 1582 1518 1417 869 906 319 909 375.5 250 240 53 25 47 46 34 
IL-17 31 658 4 3.5 8 292 7045.5 6 8 17 150 5132 14 8 19 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 95 3549 32 244 107 579 7635 216 257 317.5 291 5450.5 111 153 275 
TNFα 5899.5 7011 4632 3873 4552.5 3342 6594.5 2728.5 2185 2792 2195 3792 1644 1356 1686 
IL-2 112.5 9976 3.5 2 5 46 386 86 48 34.5 19 14 121 53 76 
IL-4 4 27.5 4 3 3 2 11 3 2 2 3 3 3 4 3 
IL-5 5 827 1 1 1 4 4973.5 3 2 2 3 3602 4 1 7 
IL-10 1416 1053.5 1182 1133.5 1367.5 277 946.5 248 230.5 324.5 41 22 31 55.5 46 






Patient 27 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 446 7608 47.5 70 31 7076 11477.5 46 957 29 4829 9849 17.5 243 9 
TNFα 3217 8380 2070 2358 2391 2351 12550 1190 1306.5 1222 1356 10852 530 607.5 495.5 
IL-2 226 24653.5 9 4 7 200 23444 27 6 4 11 23034 52 8 6 
IL-4 10 82.5 11 10 13 10 452.5 8 7 7 6 37 6 5 7 
IL-5 1 210 1 1 2 101.5 1748 1 1 1 102 2917.5 1 1 1 
IL-10 139 1866 25.5 39 31.5 389.5 4949.5 9.5 13 11 29 54 3 3 3 
IL-17 39 1271.5 6 7 7 918 9121.5 6 5.5 6 621 11414.5 7 6.5 6 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 51.5 6035 51 46.5 40.5 85 11714.5 220 30.5 27 17 10925.5 55 9 10 
TNFα 3601 8446.5 1912 1770 1507.5 2491 12884.5 1283 1066 842 1045 10151 542 494 388 
IL-2 6 23864 6 8 6 6 23330 250 6 5 5.5 22895.5 36 6 5 
IL-4 11 60 11.5 10 11 8 339.5 7 8 8 6 57 7 7 7 
IL-5 1 127.5 2 1 1 1 2302.5 2 1 1 1 3591.5 1 1 1 
IL-10 99.5 2171 33 20.5 31.5 51 5594 21 8 13 9 67.5 3 2.5 3 






Patient 28 – Raw Cytokine MFI Results. 
Class I 
               
 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 44 1276 276.5 185 123 21 686.5 97 57 52 13 380.5 53 33.5 23 
TNFα 2090.5 3441 3956 4083 4264 1474 1475 2284 2429 2563 1036.5 941 1599.5 1630 1740 
IL-2 10 4908 13 9 12 36 3200 45 8 14 13 1487.5 107 61.5 15 
IL-4 12 16 13 13 13 9 9 9 8 9 8 10 8 8 7 
IL-5 1 4.5 2 1 2 1 5 1 1 1 1 5 1 1 1 
IL-10 1886 2029 2386 3108 3650 59 48 144 182.5 238 29 127 13.5 28.5 101.5 
IL-17 22.5 466 59 29 17 33.5 325 188 49 17 34 228 683 184 26 
                Class II 
               
 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 139.5 12294 111 135 421 61 11317.5 47 60 168 37.5 8524 26 25 92 
TNFα 2779 3886 3712 4069 4598 1853 3331 2069.5 2324 2821 1182.5 2313 1351 1488 1802.5 
IL-2 13 16683 7 12 42 38 649 11 10 70.5 92 28 7 6 44 
IL-4 12 13 13 12 12 8 8 8 8 8 7 8 8 9 8 
IL-5 2 45 1 1 1 2 53.5 1 1.5 1 2 31 1 1 2 
IL-10 888 3955.5 3048.5 3512 2155 64 99 124 192 195 7 30 47.5 41 21.5 





Patient 29 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 822 10523 513 210 128.5 4294 10353 2234.5 131 68 2457.5 9909.5 870.5 34 29.5 
TNFα 4372 12203 5672 5755.5 5987 4025 9994 3853 3565 3224.5 2720 9047 2325 1995 1974 
IL-2 2585.5 23504.5 847.5 12 3 427 6369 247 4.5 2 15 82 8.5 6 9 
IL-4 3 378 3 3 3 4 116 3 3 2 2 6 3 3.5 3 
IL-5 105 8983 49 2 3 402.5 18381.5 40 2 2 334.5 16648.5 27 1 2 
IL-10 680.5 4766.5 786 555.5 610 221 782 194.5 152 120 34.5 47 28 21 29 
IL-17 130 3693 42.5 5 5 1266 10039 205.5 32.5 7 949 7806 213.5 12 6 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 352 10131 152 77 136.5 949 10731 402 51 78.5 949 8215 93.5 17 22.5 
TNFα 5391 10590 6588 6756 6607.5 3272 9170 4004 3583.5 3879.5 3272 6657 2010 1689.5 2234 
IL-2 2532.5 23037 4 3 3 536 659 7 2 2 536 36 4 2 5 
IL-4 4 246 3 3 3 3 44 4 3 3 3 4 2 3 2 
IL-5 126 7841 3 5 5 89.5 17020.5 2.5 4 4 89.5 11882 2 3.5 2 
IL-10 2426 5018 478 446 388.5 927 544 121 109 107.5 927 109 19 21 17 






Patient 30 – Raw Cytokine MFI Results. 
Class I 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 29 4402 129 98.5 65.5 19 5361 173 122 71 93.5 2480.5 322 526 332 
TNFα 2939 6195.5 2772 2812 2618.5 1630 4086 1779 1638 1746 861 2088 1038 1008.5 1028.5 
IL-2 14 12742 21 8 8 64 587 71 73 55 189 26 325 238 145 
IL-5 1 350.5 2 1 2 1 643 2 16 2 107 391 61 95 4 
IL-17 15 661 15 30 23 121.5 2545 97 79 99.5 631 1492 360 556.5 811.5 
Class II 
Day 1 Day 3 Day 5 
Cytokine Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 Neg Pos Test 1 Test 2 Test 3 
IFNγ 44 5647 109 97 74 29 7738 91 99.5 97 69 4549 104 150 228 
TNFα 3910 7720.5 2921 3959 2576 2538 5747 1882 2716 1394 1815 3231 971 1924 839.5 
IL-2 5 17829 16 12 8 52 540 87 30 65 131 27 150 158 138 
IL-5 2 752 2 2 1 3 1614 3 3 1 3 1117.5 3 2 2 
IL-17 15 1294.5 18 17 22 170 4402 233 139 74 833.5 2672 868.5 322.5 564 
 
 
 
